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A b s t r a c t
The thesis work presented evaluated the potential for use of disabled herpes simplex 
virus-1 (HSV-1) as gene delivery vectors for neural precursor cells and studied the 
effects of delivered recombinant factors on the de novo development of dopaminergic 
neurons from neural precursor cells.
Highly and less disabled HSV-1 has been studied with respect to gene delivery 
efficiency and effects on cellular integrity in primary neural progenitor cells, neural 
stem cells grown as neurospheres, and in endogenous neural stem cell niches in the 
adult rat. Data from autografts of virally transduced neurospheres into the striatum of 
rats were also presented. The characteristics of virally transduced neural precursor 
cells were compared to other viral vector systems reported in literature.
With respect to the study of differentiation factors, work has concentrated on 
fibroblast growth factor 8b (FGF8b). This has demonstrated that FGF8b is a mitogen 
for neural precursor cells in vitro. The study showed that neural stem cells isolated 
from different regions of the developing brain can be expanded in FGF8b alone and 
retain their stem cell characteristics, e.g. the capacity of self-renewal and 
multipotentiality. Growth curves and dose responses of neural precursor cells 
expanded in FGF8b further confirmed these findings. The study also showed survival 
effects of FGF8b on dopaminergic neurons derived from mesencephalic precursor 
cells. Further the effects of FGF8b on proliferation and differentiation of endogenous 
stem cells were also investigated.
Finally, the thesis work involved the construction and generation of highly and less 
disabled viruses expressing FGF8b, sonic hedgehog, basic fibroblast growth factor, 
and the transcription factor nurrl. Expression and bioactivity of the various constructs 
was confirmed. The effects of these factors on dopamine neuron development were 
then studied in vitro using neural progenitors and neural precursor cells for which 
gene delivery had been optimized in the first part of this thesis.
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C h a p t e r  1: 
I n t r o d u c t i o n
1.1 Hype and hope of stem cells
“IfDNA is the software, than stem cells are its hardware. ” [Stephen Hawking, 2004]
On an almost daily basis we are bombarded with public and scientific news released 
about stem cells. Most recently the opening of the world’s first stem cell bank in 
Hertfordshire (Pincock, 2004) and the construction of a pluripotent embryonic stem 
cell line from a cloned human blastocyst (Hwang et al., 2004) have caused quite a 
sensation. Stem cells not only raise the interest of scientists but also politicians, 
philosophers, lawyers, economists, human right activists and clergy. Often stem cells 
are mentioned in the same sentence with “curing” diseases, as replacements for worn 
out body parts, or for the cloning of humans reminiscent of Aldous Huxley’s “Brave 
new world”. In any discussion of the potential use of stem cells it is important to 
evaluate the realistic scientific and therapeutic potential, as well as the involved 
ethical concerns and to distinguish between the ‘hype’ and the ‘hope’.
Human stem cells exist from the very beginning to the end of life. During this time 
stem cells are unique as they have the capacity for unlimited self-renewal along with 
the ability to produce multiple different types of terminally differentiated descendants. 
The fertilized egg is a totipotent (Latin totus, meaning entire) stem cell and generates 
all the cells of a human. As development proceeds, stem cells become channelled into 
distinct pathways of differentiation. During a restricted period in development 
pluripotent (Latin plures, meaning several) embryonic stem (ES) cells exist and can 
be isolated from the inner cell mass of the embryonic blastula comprising a small 
group of cells (13 at the 64 cell stage embryo) (Hynes and Rosenthal, 2000). ES cells 
also exist in humans and it has become possible to grow them in vitro (Thomson et 
al., 1998). Development continues and cells become more specialised to give rise to a 
limited number of cell types, e.g. neuroepithelial stem cells generate all neural cell 
types, producing neurons first, and glia at later stages (reviewed by Kintner, 2002). 
The existence of stem cells is not limited to embryonic stages, but also occurs in adult 
tissue. Mammals appear to possess about 20 major types of somatic stem cells, e.g. in 
liver, pancreas, bone, cartilage, muscle or blood (reviewed by McKay, 2000). Most
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fascinatingly stem cells even persist in regions of the body that have historically been 
thought of as unable to give rise to new cells or to have a capacity for self-renewal, 
such as the adult mammalian central nervous system (CNS) (see below).
Reports suggesting that stem cells are not restricted to the generation of cell types 
specific to the tissue of origin have caused great excitement. This phenomenon, 
termed “transdifferentiation” (Anderson et al., 2001), proposes that adult stem cells 
retain sufficient plasticity to be able to cross lineage boundaries. Thus, for example, 
brain derived stem cells can give rise to blood and muscle cells, muscle derived stem 
cells to blood, blood derived stem cells to neurons etc. (Bjorklund and Svendsen, 
2001; Paul et al., 2002). The method of analysis used and the interpretation of the 
results obtained have often been controversial (Weissman et al., 2001; Anderson et 
al., 2001; Bjorklund and Svendsen, 2001; Wurmser and Gage, 2002), and some of the 
results of the earlier experiments have been later proved to result from cell fusion 
rather than transdifferentiation (Ying et al., 2002; Terada et al., 2002; Medvinsky and 
Smith, 2003).
A plethora of clinical applications have been proposed for the use of stem cells 
including for the treatment of leukaemia, diabetes, spinal cord injuries and ischemic 
heart diseases (reviewed by McKay, 2000; Paul et al., 2002). However, most 
prominent is the potential use of stem cells for the development of novel therapies to 
treat neurodegenerative diseases, such as Parkinson’s disease (PD), Huntington’s 
disease (HD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) or stroke 
(reviewed by Shihabuddin et al., 1999; Snyder et al., 2004). ES cells particularly have 
been credited with promise for therapeutic use. For example a report from the 
National Institutes of Health (NIH; Bethesda) has stated: “This class of human cell 
holds the promise of being able to repair or replace cells or tissues that are damaged 
or destroyed by many of our most devastating diseases and disabilities” (NIH, July 
2001; http://www.nih.gov/news/stemcell/scireport.htm). However, the current state of 
scientific and clinical knowledge means that the controlled generation of specific cell 
types from ES cells and proof of therapeutic function is still in its infancy. Although, 
for example, insulin releasing cells have been generated from ES cells (Lumelsky et 
al., 2001; Assady et al., 2001), such insulin production is low, and glucose
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responsiveness to the insulin produced has not been well characterized. Another 
example of the potential use of stem cells is the application to demyelination 
disorders. Here ES cell-derived oligodendrocyte precursors have been shown to 
myelinate axons in the brain and spinal cord after transplantation into a rat model of 
myelin disease (Brustle et al., 1999), and adult neurospheres (see later) injected 
intravenously or intracerebroventricularly into a mouse model of multiple sclerosis 
were shown to induce remyelination and functional recovery (Pluchino et al., 2003). 
However, clinical applications of such findings in human disease are not 
straightforward since demyelinating diseases such as MS are multifocal. It is therefore 
difficult to develop surgical procedures to target the multiple sites to which delivery 
of the cells would be required (Paul et al., 2002). Both of the examples also 
demonstrated another possible pitfall of the use of stem cells. As both juvenile 
diabetes and MS are possibly autoimmune diseases (Atkinson and Eisenbarth, 2001; 
Davidson and Diamond, 2001), rejection of transplanted and differentiated cells could 
prove problematic. From this point of view transplantation of cells into the CNS may 
have advantages as the CNS is, to at least some extend, immune privileged.
1.2 Defining stem cells
For the purpose of this study, it is important to clearly distinguish between the terms 
neural stem cell, neural progenitor cell and neural precursor cell. The working 
definitions for this study therefore were:
• Neural stem cells fNSCsT A multipotent cell population that have the ability 
to self-renew over long time periods and are able to generate progenitors 
capable of producing neurons, astrocytes and oligodendrocytes. Self-renewal 
and multipotency are maintained for the entire life of the neural stem cell.
• Neural progenitor cells. A cell population with a limited self-renewal capacity 
that is fate restricted to give rise to either neurons, astrocytes or 
oligodendrocytes, respectively.
• Neural precursor cells (NPCs). These encompass both populations as a 
mixture of neural stem cell and neural progenitor cells.
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These terms are often loosely used in the literature and the definitions used in this 
thesis are based on common considerations of what constitutes these cell populations 
(McKay, 1997; Morrison et al., 1997; Gage, 2000; Svendsen et al., 2001; Seaberg and 
van der, 2003).
1.3 Adult neurogenesis
“We are bom with a certain number of brain cells which decrease with age. 
Everything must die in the brain or spinal cord -  nothing can regenerate” (y Cajal, 
1902). The existence of stem cells in the adult central nervous system has historically 
remained unnoticed, the brain being considered as a structure incapable of 
regeneration. The first evidence for neurogenesis in the adult CNS was published 40 
years ago (Altman and Das, 1965; Lewis, 1968; Privat and Leblond, 1972), but the 
idea that new neurons are generated has found acceptance only in the last decade. 
This is mainly due to use of proliferating markers such as tritiated thymidine, 5- 
bromo-2’-deoxyuridine (BrdU), and retroviral labelling demonstrating de novo 
development of neurons in the adult mammalian brain (reviewed by Kuhn et al., 
2001; Rakic, 2002; Picard-Riera et al., 2004). In mammals, including humans, 
proliferating precursor cells can be isolated from various regions of the adult brain, 
including human subcortical white matter (Nunes et al., 2003), cortex (Arsenijevic et 
al., 2001), hippocampus (Eriksson et al., 1998; Roy et al., 2000), subventricular zone 
(Kirschenbaum et al., 1994; Kukekov et al., 1999; Palmer et al., 2001) and cerebellum 
(Jain et al., 2003). However, new neurons are only added into restricted regions of the 
mammalian brain these being intemeurons in the olfactory bulb and granule neurons 
in the hippocampus (for review see Doetsch, 2003). Other regions of the adult 
mammalian brain, such as the neocortex, have also been reported to generate new 
neurons (Gould et al., 1999; Magavi et al., 2000), but this has remained controversial 
(Komack and Rakic, 2001; Koketsu et al., 2003). Functionality of new neurons has 
also been confirmed (van Praag et al., 2002; Carlen et al., 2002; Carleton et al., 2003). 
The new neurons derive from neural stem cells originating at two sites, the 
subventricular zone (SVZ) of the lateral ventricle wall and the dentate gyrus 
subgranular zone (SGZ) of the hippocampus.
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1.3.1 Neurogenesis in the subventricular zone (SVZ)
The SVZ is the largest germinal zone of the adult mammalian CNS and comprises a 
layer of dividing cells extending along the lateral walls of the lateral ventricle (Figure 
1-1). Throughout the SVZ new neurons are produced and feed cells into a stream of 
dividing cells forming the rostral migratory stream (RMS) that leads to the olfactory 
bulb where the cells mature and differentiate into granule and periglomerular cells 
(for references see Alvarez-Buylla and Garcia-Verdugo, 2002). While neurogenesis 
has been shown to occur in the olfactory bulb (OB) of mammalian species (Lois and 
Alvarez-Buylla, 1994; Bonfanti et al., 1997), including primates (Komack and Rakic,
2001), its relevance still needs to be elucidated for the human OB considering that no 
signs of chain migration have so far been found (Sanai et al., 2004).
The SVZ from rodent species contains at least four distinct cell types based on 
morphology, ultrastructure, and molecular markers (Doetsch et al., 1997). A scaffold 
of astrocytes formed by slowly dividing type B cells allows young neuroblasts (type 
A cells) to migrate as homotypic chains (Lois and Alvarez-Buylla, 1994; Wichterle et 
al., 1997). Close to the chains of neuroblasts, clusters of rapidly dividing transit- 
amplifying type C cells are distributed that give rise to type A cells. The SVZ is 
separated from the lumen of the ventricle by a layer of multiciliated ependymal cells. 
Type B astrocytes occasionally contact the ventricle lumen by extending a short single 
cilium (Doetsch et al., 1999) between these ependymal cells that is similar to those 
found on embryonic neuroepithelial progenitor cells (Cohen and Meininger, 1987). 
Recently, the human SVZ was shown to contain a ribbon of astrocytes lining the 
lateral ventricle and separated by a gap from the ependymal cell layer (Sanai et al., 
2004).
The origin and nature of the stem cell has remained a matter of controversy. Two cell 
types have been reported as the source for neural stem cell in the SVZ-ependymal 
region: a subpopulation of ependymal cells (Johansson et al., 1999), or type B 
astrocyte-like cells in the subventricular zone (SVZ) (Morshead et al., 1994; Garcia- 
Verdugo et al., 1998; Chiasson et al., 1999; Doetsch et al., 1999; Alvarez-Buylla et 
al., 2001). These insights have resulted from the ablation of faster dividing type A and
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C cells using the antimitotic drug cytosine-b-D-arabinofuranoside (Ara-C), leaving 
exclusively type B cells proliferating (Doetsch et al., 1999). SVZ astrocytes were the 
only cells to divide after AraC treatment and started generating new type C cells, 
which in turn divided to give rise to type A cells. Labelling specifically SVZ 
astrocytes with an avian retrovirus further showed generation, migration and 
differentiation of labelled cells in the OB, as well as these cells showing self-renewal 
and multipotency in vitro. This has further been supported by studies showing that 
although ependymal and sub-ependymal cells can divide in vitro, only the 
subependyma-derived cells could self-renew and give rise to neurons and glia 
(Chiasson et al., 1999). This has lead to the suggestion that SVZ astrocytes are the in 
vivo primary precursor cells and act as stem cells in vitro (Doetsch, 2003).
Astrocytes outside the SVZ do not appear to be neurogenic in vivo under normal 
conditions, but astrocytes isolated from various brain regions before postnatal day 10 
have chacteristics of neural stem cells in vitro (Laywell et al., 2000). However, the 
differences between them remain unclear. The precise mechanisms of controlled 
proliferation and restricted neurogenesis in the adult mammalian brain are still 
unknown, but it seems that the microenvironment in which these neural stem cells 
reside has an important impact on their behaviour. It is intriguing that classical 
developmental signals and morphogens, such as Notch, BMPs, Eph/ephrins, Noggin 
and sonic hedgehog have been suggested to play a role as maintaining and instructive 
factors in determining the particular “stem cell niche” (reviewed by Alvarez-Buylla 
and Lim, 2004; Fuchs et al., 2004).
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Figure 1-1: The SVZ as a germ inal layer. Coronal section o f a rodent brain indicating the 
location of the SVZ in the lateral wall of the lateral ventricle (LV). The magnification shows the 
cellular composition of the SVZ as type A cells (young neurons), type B cells (slowly dividing 
astrocytes), and type C cells (rapidly dividing transit-am plifying cell). (Adapted from Alvarez- 
Buylla and Garcia-Verdugo, 2002).
1.3.2 Neurogenesis in the subgranular zone (SGZ)
Neural precursor cells in the hippocampus were suggested to originate from the 
subgranular zone (SGZ) of the dentate gyrus (DG) and migrate only a short distance 
into the granule cell layer (GCL), where they differentiate into granule neurons that 
extend axons to the CA3 region (Altman and Das, 1965; Bayer et al., 1982; Kaplan 
and Bell, 1984; Kuhn et al., 1996). Although neural precursors were isolated from the 
adult hippocampus that exhibit neural stem cell characteristics in vitro (Gage et al, 
1995; Palmer et al., 1995; Palmer et a l, 1997), it has recently been shown that stem 
cell characteristics are limited to cells isolated from the hippocampus-adjacent regions 
o f subependyma, but not of the adult DG that only contains neural progenitor cells 
(Seaberg and van der Kooy, 2002). Similar to the adult SVZ, astrocytes also play a 
role as neural precursor cells in the adult SGZ in vivo (Seri et al., 2001). Interestingly, 
astrocytes generated from the adult rat hippocampus are sufficient to instruct stem 
cells from newborn animals to convert into neurons (Song et al., 2002; Svendsen,
2002), an activity that seems to depend on the region the astrocytes were derived 
from. Future experiments might reveal the factors responsible for this.
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1.3.3 The function of adult neurogenesis
The question arises of the function of the newly generated neurons in the olfactory 
bulb and hippocampus. An extensively studied, and indeed system par excellence for 
studying functional adult neurogenesis, is the song system of songbirds where neurons 
are continuously replaced and new neurons participate in plasticity and song learning 
(for review see Nottebohm, 2002). Nevertheless, hippocampal neurogenesis has also 
been observed in rodents (Kuhn et al., 1996), non-human primates such as macaques 
(Gould et al., 1999; Komack and Rakic, 1999), marmosets (Gould et al., 1998), and 
humans (Eriksson et al., 1998). Potential roles in cognition and memory function are 
likely, and indeed it has been shown that neurogenesis increases in an enriched 
environment (Kempermann et al., 1997) and with exercise (van Praag et al., 1999) in 
the rodent brain. An interesting example suggesting that plasticity might have 
relevance for the human brain involved a study of London taxi drivers which showed 
increased hippocampal size in these subjects (Maguire et al., 2000). However, 
studying the function of hippocampal neurogenesis is not straightforward and 
although the hippocampus can be characterized as the “gateway to memory”, it 
appears to be more involved in information processing rather than storage 
(Kempermann, 2002). Although the loss of hippocampal-dependent memories has 
been correlated with ablation of dividing cells and neurogenesis (Shors et al., 2001), 
the techniques employed leave the results open to interpretation (Macklis, 2001; 
Kempermann, 2002).
Much less is known about the function of new neurons in the OB of adult mammals. 
A continuous replacement of neurons in the OB may represent a refinement of 
existing olfactory circuitry with a changing environment, changing odours or a 
changing of their relevance. It has been shown that newly generated neurons in the 
OB responded to odorants as a physical stimulant by the upregulation of c-Fos 
expression demonstrating functionality of the cells (Carlen et al., 2002). Therefore, 
olfactory neurogenesis could be a form of adaptation to the environment, but might be 
species dependent considering the absence of the RMS in humans (Sanai et al., 2004), 
and that neurogenesis in the human olfactory bulb has not yet been shown.
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Adult neurogenesis could also represent a mechanism of cell replacement or self­
repair of the CNS. Such a prospective function could be stimulated by insults such as 
disease, as described for acute animal models in the following section.
1.3.4 Reactivation of precursors in the adult CNS
It has been demonstrated in several animal models that after inducing an acute or 
chronic insult of the CNS neural stem cells retain the capacity to be re-activated. 
Proliferation of neural precursor cells is increased after seizure (Parent et al., 2002), 
ischemia (Zhang et al., 2001; Nakatomi et al., 2002; Arvidsson et al., 2002), 
transection (Weinstein et al., 1996), nigrostriatal lesioning (Lie et al., 2002; Zhao et 
al., 2003) and also demyelination (Calza et al., 1998; Nait-Oumesmar et al., 1999; 
Picard-Riera et al., 2002). An increased cell proliferation has also been reported in the 
brains of patients affected with Huntington’s disease (Curtis et al., 2003) and in non­
human primates exposed to ischemia (Tonchev et al., 2003). Reactivation is often 
demonstrated by an increased number of BrdU labelled cells. However, BrdU 
labelling is not a unique marker for cell proliferation but rather incorporates into any 
cell with DNA synthesis including those undergoing DNA-repair and must therefore 
be carefully considered when it is to be used as marker for de novo developed cells 
(see Rakic, 2002). Some of the studies refered to confirmed maturation of the 
reactivated cells into post-mitotic differentiated neural cell types (Nait-Oumesmar et 
al., 1999; Arvidsson et al., 2002), but functional replacement has only rarely been 
demonstrated (Nakatomi et al., 2002). Although it is intriguing to suggest that the 
injured CNS has the potential to reactivate, and possibly even has a limited capacity 
for self-repair, these events must be rare considering the impact of CNS insults on 
human diseases. Nevertheless, one of the most promising therapeutic targets for 
neural stem cells has been the treatment of neurodegenerative diseases such as 
Parkinson’s disease.
35
1.4 Fundamentals of Parkinson’s disease and its therapy
Parkinson’s disease is, after Alzheimer’s disease, the second most common age- 
related neurodegenerative disease. It is a progressive disease with a mean onset age of 
55. The rate of incidence markedly increases with age (reviewed by Dauer and 
Przedborski, 2003) and as such affects about 1% of the population over the age of 65 
(Shastry, 2001). The disease was first described by James Parkinson (1817) in his 
classic paper “An essay on the shaking Palsy” where he describes his observations of 
six patients. It took another century before any further relevant information was added 
to this work.
1.4.1 Clinical characteristics of Parkinson’s disease
SHAKING PALSY (Paralysis agitans) Involuntary tremulous motion, with lessened 
muscular power, in parts not in action and even when supported; with a propensity to 
bend the trunk forward and to pass from a walking to a running pace: the senses and 
intellects are being uninjured (Parkinson, 1817).
The major symptoms of PD -  tremor, bradkinesia (slowness of movement), muscle 
rigidity, postural defects and freezing (the inability to begin a voluntary movement), 
significantly decrease the quality of life of patients. Often these cardinal symptoms 
are accompanied by the inability to communicate with the environment due to paucity 
of normal facial expression (hypomimia), decreased voice volume (hypophonia), 
drooling (failure to swallow without thinking about it), decreased size and speed of 
handwriting as well as abnormalities of affect and cognition (reviewed by Dauer and 
Przedborski, 2003). Depressions are common, and often, particularly older patients, 
develop dementia. Over time, symptoms worsen and prior to availability of treatment 
the mortality rate among PD patients was three times higher compared to normal age- 
mached subjects.
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1.4.2 Neuropathology of PD
The main neuropathological features of PD are the formation of fibrillar cytoplasmic 
inclusions in the substantia nigra, so called Lewy bodies (Lewy, 1912; Tretiakoff, 
1912), and the profound depletion of dopaminergic neurons in the nigrostriatal system 
(Bemheimer et al., 1973; McGeer et al., 1988).
A crucial role of a-synuclein in the pathogenesis of PD has not just come from the 
discovery of mutations in the gene in some familial syndromes (see below), but that 
a-synuclein is also a prominent constitutent of Lewy bodies in idiopathic PD (Goedert 
and Spillantini, 1998; Mezey et al., 1998). a -synuclein is widely expressed in the 
nervous system and its normal physiological role is just beginning to be elucidated, 
but it appears to play a role in modulation of synaptic vesicle function (reviewed by 
Kahle et al., 2002). Although it is normally a soluble unfolded protein, it can 
aggregate into insoluble amyloid fibrils which then form Lewy bodies, followed by 
subsequent ubiquitination and accumulation of neurofilaments (Goedert and 
Spillantini, 1998; Mezey et al., 1998). The presence of Lewy bodies is not exclusive 
to PD, and is also relevant to other neurodegenerative diseases. However, the 
presence of Lewy bodies in the substantia nigra in conjunction with the nigral cell loss 
is the common hallmark of sporadic PD (Dunnett and Bjorklund, 1999) and suggests a 
neurotoxic role contributing to neurodegeneration in PD. Overexpression of wild-type 
Q'-synuclein by a genomic triplication causes the disease in a pedrigree of familial PD 
(Singleton et al., 2003). A number of cellular and transgenic animal models of wild- 
type a-synuclein-induced neurodegeneration have been developed (reviewed by 
Dawson et al., 2002) and have started to shed light on the pathogenic mechanisms that 
underly the formation of prospective neurotoxic fibrils in idiopathic PD. It has been 
suggested that inhibition of mitochondrial complex I creates an environment of 
oxidative stress that ultimately leads to aggregation of a-synuclein. It is thought that 
aggregated a-synuclein would then bind to proteasomes, inhibit ubiquitin-dependent 
proteasomal function preventing clearance of proteins that were destined for 
degradation, and ultimatively induce dopamine neuron cell death (Dawson and 
Dawson, 2003).
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At the onset of symptoms, around 70-80% of the striatal dopamine (Bemheimer et al., 
1973) and about 50% of nigral dopamine neurons (Feamley and Lees, 1991) have 
already been lost. Therefore, it appears that a threshold of dopamine neuron loss has 
to be passed before symptoms become apparent. Different models have been proposed 
to explain the progressive cell death in PD (see Dunnett and Bjorklund, 1999). In the 
accelerated “ageing model”, an elevated rate of cell death occurs where cell loss starts 
early and progresses more rapidly so that the critical level of dopamine loss is reached 
during the normal life span. In the “assault model” an acute insult causes an 
immediate but partial loss of dopaminergic neurons, followed by the normal age- 
dependent rate of degeneration. Nigral cell loss is not exclusive to the diseased brain 
but is a process that also happens during normal ageing at a rate of about 5% per 
decade (Feamley and Lees, 1991). However, in PD patients there is from the onset of 
symptoms an exponential progress of cell death at a tenfold higher rate (45% per 
decade) (Feamley and Lees, 1991). Hence, cell loss is likely to start 4-5 years before 
symptoms appear and considering that most cases of sporadic PD begin at middle age, 
an exponential degeneration has been favoured (Dunnett and Bjorklund, 1999). It has 
also been hypothesised that individuals bom with a smaller number of nigral neurons, 
e.g. due to exposure to environmental factors, might be more, susceptible to reaching 
the critical level of neuronal loss during the normal lifespan (Di Monte, 2003; Barzilai 
and Melamed, 2003).
Neuropathalogical studies have shown that PD-associated loss of dopaminergic 
neurons is distinct from the pattern seen in normal ageing and cell loss is concentrated 
in ventrolateral and caudal portions of the substantia nigra pars compacta (SNpc), 
whereas during normal ageing the dorsomedial aspect of SNpc is affected (Feamley 
and Lees, 1991). It has also been suggested that striatal dopaminergic nerve terminals 
are the primary target of the degenerative process (Dauer and Przedborski, 2003) 
which is accompanied by the accumulation of aggregated proteins in nigral processes 
known as Lewy neurites (Lotharius and Brundin, 2002). In this hypothesis dopamine 
neurons are “dying backwards” in a retrograde degeneration, followed by further 
accumulation of aggregated proteins in nigral cell bodies (Lewy bodies), and, finally 
culminating in cell death (Lotharius and Brundin, 2002; Dauer and Przedborski,
2003). Interestingly, dopamine itself might play a role in neurodegeneration in this
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model. Toxic forms of a-synuclein can permeabilze vesicles and thereby cause 
leakage of small molecules, such as dopamine, out into the cytoplasm. Subsequently 
this could lead to oxidative stress primarily at nigrostriatal terminals, where most of 
the neurotransmitter is produced and stored (Lotharius and Brundin, 2002).
1.4.3 Etiology of Parkinson’s disease
The causes of PD are unknown, although it is believed that a combination of genetic 
(Muenter et al., 1998; Gasser, 2001; Valente et al., 2001) and environmental factors 
(Langston and Ballard, Jr., 1983; Betarbet et al., 2000) may be responsible for the 
majority of PD cases. Therefore, a combination of genetic predisposition and 
exposure to environmental factors may implicate differences in the individual 
susceptibility to metabolise dopamine-related neurotoxins. In about 95% of PD cases 
no apparent genetic linkage exists and the disease is referred to as “sporadic” PD 
(Dauer and Przedborski, 2003).
1.4.3.1 Environmental hypothesis for PD
The environmental hypothesis postulates that PD-related neurodegeneration is a result 
from exposure to dopaminergic neurotoxins. A compelling prototypic example that 
exogenous toxins can induce PD was demonstrated by the discovery that the protoxin 
«-methyl-4-ohenyl-l,2,3,6-tetrahydropyridine (MPTP) causes PD-like syndromes in 
humans (Langston and Ballard, Jr., 1983). Other environmental toxins have been 
shown to induce a parkinsonian state, such as the herbicide paraquat and the 
insecticide rotenone (reviewed by Di Monte, 2003). All of the toxins have in common 
that they induce oxidative stress and/or inhibit mitochondrial function and have been 
used to induce parkinsonism in rodent and primate to model the human disease (Beal, 
2001).
Since MPTP is highly lipophilic it can easily cross the blood-brain barrier (Markey et 
al., 1984) and is then converted by monoamine oxidase B into its active form 1- 
methyl-4-phenylpyridinium (MPP+) (Di Monte et al., 1996). Glial cells and 
serotonergic neurons play a role in this activation step as they catalyse this oxidation.
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A selective function on degeneration of dopaminergic neurons might be due to its 
high affinity for the plasma-membrane dopamine transporter (Javitch et al., 1985) by 
which it is taken up into the cell soma. MPP+ also has affinity for the vesicular 
monoamine transporter (VMAT2) (Liu et al., 1992). This decreases vulnerability to
Alternatively, MPP+ can be taken up and concentrated in mitochondria where it is an 
inhibitor of mitochondrial complex I (Nicklas et al., 1985; Ramsay and Singer, 1986) 
which might increase free radical production (Chan et al., 1991). Although MPTP 
toxicity in primates and humans mimics the clinical signs of PD, including tremor, 
rigidity, akinesia and postural defects (Bloem et al., 1990), it does not induce the 
formation of Lewy bodies (Fomo et al., 1986) and its action is far more acute, causing 
PD within a few days after MPTP administration, rather than progressive. However, 
MPP+ toxicity has shown that mitochondrial dysfunction causes PD-like symptoms, 
which is supported by observations of complex I deficiency in the substantia nigra of 
PD patients (Schapira et al., 1990), an effect which is specific to PD, and not seen in 
any other diseases affecting the same neurons (Dunnett and Bjorklund, 1999). The 
primate MPTP model is the gold standard for the assessment of novel strategies and 
agents for the treatment of PD symptoms (Dauer and Przedborski, 2003).
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Figure 1-2: Neurotoxicity of M PTP metabolism. (Adapted from Dauer and Przedborski, 2003).
Similar to MPP+ is the effect of rotenone on inhibition of mitochondrial complex I. 
Continuous intravenous injections of rotenone into rats causes a progressive and 
selective degeneration of dopaminergic neurons (Betarbet et al., 2000) with PD-like 
symptoms such as bradykinesia, postural instability, disturbance of gait, some 
evidence of tremor and most interestingly cytoplasmic inclusions that stain with 
antibodies for ubiquitin and a-synuclein. However, the originally proposed selective 
toxicity of rotenone for dopaminergic neurons is in contrast to recent studies 
demonstrating significant reductions in striatal DARP-32-positive neurons, 
cholinergic, and NADPH diaphorase-positive neurons (Hoglinger et al., 2003). It has 
been suggested that dopaminergic neurons might be more susceptible to toxin-induced 
degeneration and particularly vulnerable to complex I inhibitors (Beal, 2001; Di 
Monte, 2003).
On the other hand environmental factors can also exhibit protective effects and in 
epidemiological studies, for example, it has been shown that caffeine consumption 
(Ross et al., 2000; Ascherio et al., 2001) and cigarette smoking (Morens et al., 1995; 
Sugita et al., 2001) can decrease the risk of PD.
Disruption of the normal cell metabolism might also contribute to neurodegeneration 
as an inadequate degradation of metabolic products could result in an accumulation of 
neurotoxic products. One source of endogenous toxins might even result from 
dopamine metabolism itself, in which harmful reactive oxygen species (ROS) are 
generated (Cohen, 1984). With respect to studies investigating the role of a-synuclein 
in neurodegeneration, evidence has implicated a role of a-synuclein, dopamine, and 
ROS in selective degeneration mechanism of nigral dopamine neurons in PD (Steece- 
Collier et al., 2002).
The study of environmental risk factors causing PD is difficult, since exposure to 
toxins may have occured long before onset of the disease. In addition, symptoms of 
PD may be the result of additive or synergistic effects of multiple exposures to 
environmental toxins. Although human epidemiological studies have implicated 
residence in a rural environment and related exposure to herbicides and pesticides
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with an elevated risk of PD (Tanner, 1992), there is as yet no convincing data to 
implicate any specific toxin causing PD (Dauer and Przedborski, 2003). However, 
toxins have been hypothesised to predispose to the development of PD rather than 
causing evident symptoms (Di Monte, 2003). Toxins may still cause a discrete loss of 
dopaminergic neurons and symptoms then becoming obvious after subsequent or 
additive exposure resulting in a synergistic damage of the nigrostriatal system 
(Thiruchelvam et al., 2000).
1.4.3.2 Genetic hypothesis for PD
A genetic component in PD has not generally thought likely since epidemiological 
studies examining twins suggested an absence of genetic factors (Tanner et al., 1999; 
Piccini et al., 1999), and also due to the fact that most patients had a sporadic disease. 
However, twin studies have been the cause of much debate as parkinsonian signs are 
not necessarily apparent in persons with partial nigrostriatal degeneration. Therefore, 
presymptomatic PD can only be assessed by positron-emission tomography with 
fluorodopa [18F], This revealed a significantly increased rate of concordance when 
abnormal striatal dopaminergic uptake was measured in the otherwise asymptomatic 
twin of a discordant pair (Morrish et al., 1998). Further evidence for potential genetic 
factors has come from the discovery of inherited cases of PD (Payami et al., 1994; 
Marder et al., 1996; Piccini et al., 1997) and by the observation that monozygotic 
twins with an onset of disease before the age of 50 years do have a very high rate of 
concordance (Tanner et al., 1999). However, the real advance has occurred with the 
discovery that the rare monogenetically inherited forms of the disease are linked to 
mutations in the a-synuclein gene (Polymeropoulos et al., 1997; Kruger et al., 1998), 
parkin gene (Ishikawa and Tsuji, 1996), the gene for ubiquitin hydrolyase LI (Leroy 
et al., 1998) and the gene for DJ-1 (Bonifati et al., 2002). Interestingly, all of the PD 
genes identified have in common that they appear to participate in the ubiquitin- 
proteasome pathway which is particularly compelling with respect to Lewy body 
aggregates that are pathologically defining for sporadic forms of the disease.
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1.4.3.3 Neurodegeneration as a lack of adult neurogenesis?
A hypothesis has been postulated that a primary deficit in neural stem cell 
proliferation, migration and differentiation might contribute to net cell loss and 
neuronal circuit disruption in neurodegenerative diseases (Armstrong and Barker,
2001). Here, the failure of endogenous neural stem cells to respond normally and 
appropriately to cell loss in neurodegenerative diseases, and thereby to replace 
neurons that die, would contribute to progression and thus pathogenesis of e.g. 
Parkinson’s disease. Recent findings suggested neurogenesis in the adult rodent 
substantia nigra (Zhao et al., 2003), where the absolute number of dopaminergic 
neurons remained constant throughout the lifetime of the animals thus implying that 
new neurons are delivered to this region to replace those that are lost. Is 
neurodegeneration simply a disruption of this normal homeostasis in some 
predisposed patients? Would disruption of neural stem cell genesis otherwise cause 
neurodegeneration? It is noteworthy to mention anecdotal reports of several patients 
developing parkinsonism with radiographic evidence of basal ganglia atrophy after 
whole body irradiation and high dose antimitotic chemotherapy (Mott et al., 1995). 
Considering recent findings demonstrating the lack of neuronal turnover and/or 
replacement of injured neurons in the human brain (Sanai et al., 2004), it has shown 
that species differences are an important issue to be considered in finding the right 
model to test this hypothesis. However, the identification of the cellular and molecular 
mechanisms that prevent neural stem cells from becoming integrated into functional 
neuronal networks could indeed be a major achievement (Rakic, 2004).
1.4.4 Therapeutic approaches for Parkinson’s disease
Since the cause of PD still needs to be elucidated and most cases of the disease are 
sporadic, therapies for PD are symptomatic. However, with recent progress in 
neuroimaging a decline in striatal dopamine function can be detected before clinical 
symptoms appear (Sanchez-Pemaute et al., 2002), which may open the way to novel 
neuroprotective therapies to block or slow down the degenerative process.
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The major breakthrough in the treatment of PD was the discovery that administration 
of the dopamine precursor L-DOPA alleviates symptoms of akinesia (Carlsson et al., 
1957; Birkmayer and Homykiewicz, 1961) and improves the daily life of patients in 
the early stages of the disease significantly. However, these benefits in the early 
phases were set back by a decline in the efficacy of the drug (“wearing-off effect”) as 
the disease progresses, and severe site effects occur, most importantly dyskinesia, 
within 5 years with beginning of the treatment (Duvoisin and Marsden, 1974; Rascol 
et al., 2000; Bezard et al., 2001). Although, the main treatment of PD is still the oral 
administration of levopoda (Djaldetti and Melamed, 2001), the problems 
accompanied with the use of this drug have led to the development of neurosurgical 
approaches (Follett, 2000), neuroprotective therapies (Dunnett and Bjorklund, 1999), 
cell replacement therapies (Bjorklund and Lindvall, 2000), and gene therapeutic 
approaches (Bohn, 2000).
1.4.4.1 Neurosurgical therapies
Surgical treatments for PD include ablative techniques (thalamotomy and 
pallidotomy), augmentative techniques (deep brain stimulation), and restorative 
techniques (tissue transplantation and gene therapy) (Follett, 2000). Restorative 
techniques will be considered separately.
Surgical treatment for the relief of symptoms in PD patients was historically used as 
early as 1912 (Guridi and Lozano, 1997; Speelman and Bosch, 1998) and intensified 
as pallidal and thalamic lesioning in the 1940s and 1950s (Laitinen et al., 1992) but 
lost interest with the introduction of L-DOPA in the 1960s. With advances in 
neurosurgical procedures accompanied by lower morbidity rates and with the 
awareness of site effects involved with L-DOPA treatment, surgical procedures have 
now experienced a renaissance. However, functional neurosurgery is purely 
symptomatic and only given in patients with severe motor fluctuations or L-DOPA- 
induced dyskinesias where no further improvement can be achieved with adjustments 
in medications (Betchen and Kaplitt, 2003).
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Based on the anatomy and physiology of the basal ganglia and motor systems, 
neurosurgical interference targets the ventral intermediate nucleus of the thalamus, the 
globus pallidus (GPi) and the subthalamic nucleus (STN). Due to the loss of inhibition 
from the putamen, an increased activity of neurons in the STN causes an overactivity 
of neurons in the GPi and substantia nigra reticular in PD patients. Overactivity from 
these regions subsequently exert inhibitory influences on thalamic and brainstem 
nuclei that are responsible for hypokinetic symptoms of PD (rigidity and 
bradykinesia). Therefore, pallidal interventions are aiming to reduce GPi activity and 
to restore normal thalamocortical and brainstem activity. Pallidotomy has 
significantly improved L-DOPA-induced on-dyskinesias with improvements in the 
UPDRS dyskinesia scale (Follett, 2000) but are usually performed unilaterally due to 
the risk of complications. Alternatively to pallidal procedures non-destructive 
techniques, such as deep brain stimulation (DBS), have been developed that produce 
adjustable and reversible functional lesion. The STN has become a popular target for 
DBS in patients who have severe motor fluctuations, dose-limiting dyskinesias or 
tremors (see Betchen and Kaplitt, 2003).
1.4.4.2 Neuroprotective therapies
The progressive cell death in PD involves a cascade of events, such as oxidative 
stress, mitochondrial dysfunction, excitotoxicity, and inflammatory changes, that all 
lead to apoptotic and necrotic cell death (for reviews see Olanow and Tatton, 1999; 
Dunnett and Bjorklund, 1999). Neuroprotective therapies aim to delay this cell death 
in order to maintain functional neurons as long as possible.
Clinical trials have been performed using antioxidants, such as selegiline 
hydrochloride (Shoulson, 1998) and dopamine receptor agonists (for review see 
Shults, 2003), the latter stimulates dopamine autoreceptors and thereby reduces 
dopamine synthesis, turnover and release, so that less L-DOPA is needed.
A hallmark for neuroprotective therapies was the discovery of neurotrophic factors, 
and their survival and rescue effects on injured neurons after damage in the adult 
brain. A promising candidate in neuroprotection and regeneration is glial cell-line
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derived neurotrophic factor GDNF (Engele and Bohn, 1991), which facilitates strong 
survival effects on dopaminergic neurons in vitro (Lin et al., 1993) and in vivo after 
mechanical (Beck et al., 1995) or toxic (Hoffer et al., 1994) insult. Several studies 
have shown behavioural improvement after intrastriatal, intranigral or 
intracerebroventricular injections of recombinant GDNF protein in rodent (Rosenblad 
et al., 1999; Kirik et al., 2000) and primate (Gash et al., 1996; Kordower et al., 2000) 
models of PD. GDNF has three different effects on dopaminergic neurons: (i) it 
rescues damaged neurons when given before or shortly after the insult; (ii) it promotes 
axonal sprouting or regeneration in lesioned animals; (iii) it stimulates dopamine 
turnover and function in dopaminergic neurons (Dunnett and Bjorklund, 1999; Kirik 
et al., 2004). In the first double-blind placebo controlled clinical study, PD patients 
received monthly intracerebroventricular injections of recombinant GDNF (Kordower 
et al., 1999). However, the study failed to improve clinical symptoms or to prevent 
nigrostriatal degeneration due to an ineffective delivery system. The poor penetration 
of the blood-brain barrier, as well as limited passage of recombinant proteins from the 
cerebrospinal fluid into the brain tissue, requires other routes of administration 
directly to the receptive target sites. Animal models have already demonstrated that 
beneficial effects of GDNF strongly depend on where it is administrated (Kirik et al.,
2004). In rodent and primate models it has been demonstrated that GDNF is not only 
neuroprotective to residual dopamine neurons but can also restore neurochemical 
function by increased dopamine turnover and/or release and also induces aberrant 
most likely functional sprouting (Kirik et al., 2004). Recently, new studies 
administrating recombinant GDNF protein continuously in the caudate putamen of PD 
patients have promising results (Gill et al., 2003). The data indicated significant 
improvement in off-medication motor sub-score of the UPDRS and daily living sub­
score without any serious side effects. The early onset of symptomatic improvement
1 8and the small increase in [ FJ-DOPA uptake around the injection site indicate a 
functional upregulation in residual dopaminergic neurons, rather than a regenerative 
response. Although this open-label trial was based only on a small number of subjects 
(5 patients) and monitored over a relatively short follow-up period (1 year) it is very 
promising for future clinical trials and those that are underway (Svendsen, personal 
communication).
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Continuous delivery of recombinant GDNF has potential problems, including 
complications associated with the chronically implanted infusion pump (Gill et al.,
2003) and alternative routes of delivery have been considered. Other approaches for 
the efficient delivery of GDNF are using encapsulated genetically engineered cells 
(Tseng et al., 1997), viral vectors (for review see Kirik et al., 2004) or engineered 
neural stem cells (Akerud et al., 2001). In a non-human primate model of the disease, 
lentiviral delivered GDNF showed significant improvement in functional recovery 
and a complete prevention of nigrostriatal degeneration (Kordower et al., 2000). 
Neurotrophic effects on dopaminergic neurons were also shown for other factors 
belonging to the GDNF family, such as neurturin (Horger et al., 1998), artemin 
(Masure et al., 1999), and persephin (Milbrandt et al., 1998).
1.4.4.3 (Stem) Cell based replacement strategies for Parkinson’s disease
Cell replacement strategies for Parkinson’s disease are based on the idea that neural 
grafts restore dopamine neurotransmission in the striatum and lead to substantial and 
long-lasting functional recovery. Therefore, the success of cell replacement therapies 
for Parkinson’s disease relies on two hypotheses: (1) the predominant symptoms of 
PD are dependent on the dysfunction or loss of dopaminergic neurons in the 
nigrostriatal pathway; and (2) dopaminergic neurons grafted into the dopamine- 
deficient striatum can replace those neurons lost as a result of the disease and can 
reverse some of the major symptoms of the disease (Bjorklund et al., 2003). 
Considering the complexity of brain circuitry the functional and structural integration 
of the graft into the depleted system appears a remote possibility. Functional 
integration of neuronal cells involving the establishment of reciprocal connectivity 
and formation of axonal connections are mainly restricted to the developing brain. 
However, functional integration of grafted neurons have been demonstrated in the 
adult brain of rodents and the capacity is increased after damage suggesting that 
mechanisms regulating neuronal differentiation and connectivity during development 
may be reactivated by lesions or degenerative changes (reviewed by Bjorklund and 
Lindvall, 2000). However, it can only be speculated if this is also relevant for the 
human adult brain. On the other hand, reconstruction of neural circuitry is not 
necessarily a prerequisite for functional recovery: transplated cells may release the
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missing neurotransmitter dopamine in a tonic manner, or they may produce 
neurotrophic or neuroprotective factors that can counteract degeneration or promote 
regeneration.
The basic proof of principle for cell replacement therapies has been provided by 
extensive animal experiments. Although these rodent and primate models of PD have 
a different etiology from the human disease (the lesion is acute rather than 
progressive), they still mimic its cardinal features, the depletion of dopaminergic 
neurons in the substantia nigra. Such experiments have shown that immature 
dopamine neuroblasts survive and re-establish dopaminergic innervation when 
transplanted into the denervated striatum, and restore baseline dopamine synthesis and 
release in the reinnervated area (reviewed by Bjorklund and Lindvall, 2000). Most of 
these studies have used ectopic locations of the graft (transplanted cells were placed 
into the striatum rather than into the substantia nigra) and are therefore unlikely to 
receive normal afferent inputs. This ectopic placement is necessary for extensive 
reinnervation of the striatum by the transplanted cells and they function by tonic 
release of dopamine at both synaptic and non-synaptic sites.
The successful functional recovery by foetal transplants in animal models of PD was 
justification for a series of clinical trial in humans since 1987. The first phase of 
clinical trial comprised small open-labelled trials that gave evidence that foetal 
transplants can survive and function for more than 10 years in PD patients and 
revealed therapeutic benefits, such as an increased time in the “on” phase (that is the 
time with a few or no motor symptoms), improvements in speed and accuracy of 
movement in defined “off’-phase (after drug withdrawal) and significant increase in 
striatal [18F]-DOPA uptake (reviewed by Dunnett et al., 2001). However, the main 
issues with these open-labelled studies is a high variability of the results and clinical 
improvements may be due to investigator bias or placebo effects that are well known 
to occur in PD and can be long lasting (at least up to six months) (Kordower et al., 
1995).
Based on the encouraging results from these open-labelled trials, the National Institute 
of Health (NIH) supported two double-blinded sham-surgery controlled trials in the
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early 1990s. The outcome has been published and revealed rather disappointing 
results (Freed et al., 2001; Olanow et al., 2003). Two major concerns have been 
raised: only modest benefits in patients under the age of 60 (no improvement in 
patients over the age of 60 years) and a significant number of patients developed 
severe off-state dyskinesias. In the study of Freed et al. (2001) patients received 
mesencephalic tissue from aborted human embryos (age 7-8 weeks after conception) 
that was prepared as 200/mi large strands and was stored for up to four weeks before 
use. Four needle passes were made through the forehead and projected through the 
long axis of the putamen. Patients did not receive immunosuppression. One year after 
transplant [18F]-DOPA PET scans showed survival of grafts in 85% of patients. Two 
post-mortem cases revealed that a rather low amount of 7,000-40,000 tyrosine 
hydroxylase-positive cells had survived. Only some of the younger patients showed 
improvements in UPDRS motor scores, but no change in older patients or in the 
sham-surgery group was observed. 15% of the patients developed severe dyskinesias, 
which persisted despite substantial reductions in levopoda doses. Similar results were 
obtained by the study from Olanow et al. (2002) showing no significant overall 
improvement in UPDRS motor scores, dyskinesias in more than half of the patients 
but some improvement in patients with less severe disease. Major criticism has been 
expressed about the conceptualization and conduct of these double-blinded studies, 
such as patient selection, preparation, storage and location of graft, lack of 
immunosuppression, surgical procedure and clinical assessment (Dunnett et al., 2001; 
Bjorklund et al., 2003). In the light of these studies the value of foetal transplants 
needs to be reassessed, methods improved and therapies tailored more individually to 
patients. A main technical problem and ethical concern is the availability of primary 
dopaminergic neurons. Considering the large amount of foetal tissue required for 
transplantation, this method will never be available as therapy for all patients with 
advanced PD and therefore, cannot meet its social goal.
For this reason neural stem cells and neural precursor cells, which potentially provide 
an unlimited supply of cells for regenerative therapies, have attracted great interest. 
This potential is based on their defining characteristics of self-renewal and 
multipotency. As stem cells by definition can be expanded over unlimited periods and 
retain the capacity to differentiate into different neural cell types, the challenge is to
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guide their maturation into dopamine releasing cells or dopaminergic cell types that 
would be available for transplantation as required. This has the additional advantage 
that such cells can be standardized, screened and manipulated in ways that could 
never be possible with foetal tissue. Stem cells can principally be predifferentiated in 
vitro to dopaminergic neurons prior to transplantation or alternatively transplanted as 
undifferentiated neuroblasts that differentiate in vivo to dopaminergic neurons. The 
latter approach may have the advantage that the cells integrate better as compared to 
differentiated dopaminergic neurons and, in the ideal scenario, reconstruct the 
nigrostriatal pathway. However, this would require that the cues to instruct the 
immature precursor cell to differentiate into the missing dopaminergic neuron are 
available in the PD patient’s brain. Transplantation of naive precursor cells to the 
adult striatum leads to predominantly glial differentiation (reviewed by Perrier and 
Studer, 2003), while “priming” prior to transplantation might allow precursor cells to 
adopt region-specific differentiation in the forebrain (Wu et al., 2002).
Potential cell sources for the generation of dopaminergic neurons are embryonic stem 
cells, neural stem cells from the embryonic or adult brain, or stem cells derived from 
other non-neural cells (Figure 1-3). Although the major goal is to generate a large 
number of functional dopaminergic neurons from these different sources, it is still an 
unresolved issue whether non-dopaminergic neurons and glial cells, that are normally 
present in the grafts used for transplantation so far, are important for the 
differentiation, survival and function of the grafted dopaminergic neurons. Therefore, 
a pure population of predifferentiated dopaminergic neurons may not necessarily give 
the optimal therapeutic benefit.
Recent excitement in the field suggested generation of neuronal cell types from other 
tissue sources by transdifferentiation (Woodbury et al., 2000; Brazelton et al., 2000; 
Mezey et al., 2000; Kohyama et al., 2001). Reports have suggested generation of 
dopaminergic neurons from dermis (Toma et al., 2001), bone marrow stromal cells 
(Li et al., 2001) and mesenchymal cells (Jiang et al., 2002). However, significant 
doubts about the neuronal identity and function of transdifferentiated cells have been 
raised (Anderson et al., 2001). Such easily accessible stem cell populations would
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provide an ideal source for transplantation therapy, as the cells could be harvested 
from the patients own tissue and be used to generate neurons for transplantation.
With the discovery that neural stem cells exist in the mammalian brain and with the 
knowledge that we have acquired over the past two decades about their isolation and 
propagation, a hypothetical approach is to remove the cells from the patient, to 
expand and predifferentiate them in vitro, followed by reimplantation to replace the 
lost dopaminergic neurons. Thereby the risk of an immune reaction would be avoided. 
However, several problems require to be overcome: (i) it has not been shown that 
adult human stem cells can be expanded and converted in sufficient numbers; (ii) it is 
not known if cells from patients with neurodegenerative disease function similar to 
cells from an unimpaired brain. Similar problems have also to be considered in 
alternative approaches to stimulate endogenous stem cells. Injury of the CNS has been 
shown to recruit endogenous stem cells in a model of stroke (Nakatomi et al., 2002; 
Arvidsson et al., 2002), and recently evidence for neurogenesis in the adult substantia 
nigra has been suggested (Zhao et al., 2003) that is further increased after lesion. 
These findings will be discussed in more detail in later chapters.
As an alternative source to human foetal dopaminergic neurons, xenografting has 
been considered involving transplantation of tissue from one species into another. 
Although the use of porcine cells has advantages, such as big litters and the potential 
for greater cell migration and axonal outgrowth in the adult CNS (Hurelbrink et al.,
2002), there exist disadvantages limiting its therapeutic application. Such major 
disadvantages are the risk of zoonotic infection involving the transmission of porcine 
endogenous retroviruses, rejection of xenografts by cellular and humoral processes, 
and limited data on functional capacity and capabilities of xenografts (reviewed by 
Bjorklund et al., 2003). Despite these concerns clinical trials using porcine xenografts 
for the treatment of PD have been undertaken (Schumacher et al., 2000).
Immunological problems accompanying transplantation of allogenic and xenogenic 
tissues and cells are in theory less of a concern for cells derived from somatic cell 
suclear transfer (SCNT). The concept, known as “therapeutic cloning”, refers to the 
transfer of the nucleus of a somatic cell into an enucleated donor oocyte (Lanza et al.,
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1999) and has been shown for different species (Cibelli et al., 1998; Munsie et al., 
2000; Wakayama et al., 2001), including most recently the derivation of human ES 
cells (Hwang et al., 2004) from SCNT. Functional dopaminergic neurons were 
obtained from mouse ES cells via SCNT from adult tail tip or cumulus cells 
(Wakayama et al., 2001) and have recently been shown to improve impairment after 
transplantation into hemiparkinsonian mice (Barberi et al., 2003).
Figure 1-3: Cell sources for the generation of dopaminergic neurons. (Adapted from Lindvall, 
2003).
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1.5 Generation of dopaminergic neurons from neural precursor 
cells in vivo and in vitro
The following section will describe the signals known to be involved in the 
embryonic development of dopaminergic neurons and their relevance as instructive 
cues for the generation of dopaminergic neurons from neural precursor cells and 
embryonic stem cells.
1.5.1 Characterization of the dopaminergic system
Dopaminergic neurons belong to the group of catecholaminergic neurons that are 
characterized by the synthesis of the neurotransmitter dopamine. Dopamine is 
synthesised in two enzymatic steps from the amino acid tyrosine (Figure 1-4). 
Tyrosine hydroxylase (TH) catalyses the rate-limiting step in dopamine biosynthesis, 
the conversion of tyrosine to L-DOPA. Subsequently L-DOPA is decarboxylated to 
dopamine by aromatic L-amino acid decarboxylase (AADC). Dopamine is also used 
as a precursor for other catecholaminergic neurons, i.e. noradrenergic and adrenergic 
neurons, that all share the first two steps of the catecholamine-synthesis pathway 
leading to dopamine. Functional dopamine neurotransmission further depends on 
transport, synaptic packaging, re-uptake and degradation of dopamine (Figure 1-4) 
(Goridis and Rohrer, 2002; Lin and Rosenthal, 2003; Perrier and Studer, 2003). 
Characterization of neurons solely by the expression of TH does not therefore 
necessarily identify dopaminergic neurons, and other markers that are unique for 
midbrain dopaminergic neurons, such as dopamine transporter (DAT), aldehyde 
dehydrogenase-2, Nurrl, Lmxlb, Ptx3 and engrailed-1 (see all below), as well as 
morphological criteria and exclusion of the expression of dopamine /3-hydroxylase 
characterizing adrenergic and noradrenergic neurons, are required (Arenas, 2002).
Dopaminergic neurons are organised in distinct groups and are found in the olfactory 
bulb, the retina, the diencephalon, but most prominently in the ventral midbrain where 
they are located in the substantia nigra (SN), the ventral tegmental area (VTA) and the 
retrorubral field (Nelson et al., 1996). They define topographically well-defined
53
projections: in rodents dopaminergic neurons from the SN project via the nigrostriatal 
system to the striatum (caudate-putamen in primates) and degeneration of this 
pathway is directly involved with motor symptoms in Parkinson’s disease patients, 
while neurons from the VTA connect via the mesolimbic pathway to the limbic 
system and cortex and are implicated in obsessive-compulsive disorders, 
schizophrenia and substance abuse (Egan et al., 1996; Swanson et al., 1998).
Figure 1-4: Simplified picture of dopamine metabolism. Plasma mem brane dopamine 
transporter (DAT), vesicular monoamine transporter (VM AT). DAT terminates action of 
dopamine by rapidly removing it from the synapse. VM AT loads cytoplasmatic dopamine into 
vesicles for storage and subsequent release. (Adapted from Cooper et al., 1996).
1.5.2 Dopamine neuron development in vivo
Dopaminergic neurons are generated in the ventral mesencephalon as a result of a 
well-coordinated expression of morphogens, transcription factors and survival factors 
involving a cascade of steps (Figure 1-5):
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1. Induction of an immature dopamine phenotype
2. Specification into differentiated dopaminergic neurons
3. Maturation and maintenance of dopaminergic neurons
4. Survival of fully differentiated dopaminergic in the neural circuitry
Characterized by the expression of TH the first dopaminergic neurons can be detected 
in the mouse at E10 when TH expressing cells appear in close proximity to two 
important signalling centers, the isthmus and the floor plate (Di Porzio et al., 1990), 
that pattern the neural plate and early neural tube along its dorsoventral and anterior- 
posterior axes (for review see Wurst and Bally-Cuif, 2001). Explant cultures have 
revealed two morphogens as molecular entities underlying the activity of these 
organizers: Sonic hedgehog (Shh) secreted by the floor plate and fibroblast growth 
factor 8 (FGF8) as mediator of the isthmus (Hynes et al., 1995; Hynes et al., 1995; Ye 
et al., 1998). While Shh is sufficient to induce dopaminergic phenotypes in vitro 
(Hynes et al., 1995; Wang et al., 1995), in vivo it defines the location of dopaminergic 
neurons in the dorsal-ventral (D-V) axis. FGF8 determines the position along the 
anterior-posterior (A-P) axis and dopaminergic neurons develop at the intersection 
within this Cartesian grid (Ye et al., 1998). Shh binds to its receptor patched (Ptc) 
thereby activating the co-receptor smoothened (Smo) that in its inactive form inhibits 
Shh signalling. Within the cells activated Smo initiates a signalling cascade leading to 
the expression of Gli proteins, a family of zinc finger transcription factors (Marti and 
Bovolenta, 2002). Forced Gli-1 expression in transgenic mice induces ectopic 
mesencephalic dopaminergic neurons (Hynes et al., 1997), while Gli-2 deficient mice 
fail to develop mesencephalic dopaminergic neurons (Matise et al., 1998). Once 
synergistic effects of Shh and FGF8 have induced an early commitment into a 
dopaminergic fate, regulatory genes are required for initiating and maintaining 
dopaminergic specific genes.
Specification and maintenance of midbrain dopaminergic neurons has been found to 
depend on the activity of the transcription factors Lmxlb, Nurrl and Ptx3. The first 
transcription factor for correct specification of midbrain dopaminergic neurons that is 
expressed in the midbrain is Lmxlb. Lmxlb expression commences at E9.5 when
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dopamine neuroblasts are still dividing and its expression is maintained in the SN and 
VTA throughout life (Smidt et al., 2000). Due to its early expression pattern it has 
been suggested that Lmxlb acts genetically as an upstream activator of the other 
specifying genes and may be involved in preparing the region for genesis and 
differentiation of the mesencephalic dopaminergic system (Smidt et al., 2003). Lmxlb 
deficient mice fail to express Ptx3 but exhibit initial expression of TH and Nurrl, 
indicating that Ptx3 is not necessary for TH expression (Smidt et al., 2000). However, 
this set of TH expressing cells is lost during embryonic maturation and it has been 
concluded that Lmxlb is essential for the proper specification of mesencephalic 
dopaminergic neurons (Smidt et al., 2003).
Nurrl and Ptx3 are not expressed in dopamine progenitors and appear only after cell- 
cycle exit (Smidt et al., 1997; Wallen et al., 1999). Nurrl is an orphan receptor of the 
nuclear receptor superfamily widely expressed in the brain of developing and adult 
rodents (Backman et al., 1999). Nurrl expression commences at E10.5 in early post­
mitotic neurons and continues throughout the lifespan of the cell (Backman et al., 
1999). In Nurrl deficient mice neuroepithelium cells give rise to midbrain 
dopaminergic neurons of an apparent normal phenotype characterized by the 
expression of specific markers such as Ptx3 and Lmxlb (Saucedo-Cardenas et al., 
1998). However, these dopaminergic precursors fail to differentiate into mature 
dopaminergic neurons as demonstrated by the lack of TH expression (Zetterstrom et 
al., 1997; Castillo et al., 1998). The prospective dopaminergic neurons eventually 
degenerate and disappear resulting in an extensive cell death and the complete lack of 
mature dopaminergic neurons (Wallen et al., 1999). In line with this the expression of 
the neurotrophic factor receptor Ret is deregulated in Nurrl deficient mice (Wallen et 
al., 2001). Although it has been shown that Nurrl directly induces TH expression by 
binding to cis-acting sites within the TH promoter (Iwawaki et al., 2000; Kim et al.,
2003), the pure lack of TH expression is probably not sufficient to explain the 
phenotype of Nurrl-deficient mice since dopaminergic neurons develop normally in 
TH deficient mice (Zhou and Palmiter, 1995). Although the function of Nurrl on 
dopamine neuron differentiation remains unclear, it appears that it is involved in 
modulating the expression of TH (Sakurada et al., 1999), ret (Wallen et al., 2001) as 
well as DAT and VMAT (Sacchetti et al., 2001; Smits et al., 2003).
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The last factor expressed in this temporal cascade is the homedomain transcription 
factor Ptx-3 that can be found from El 1.5 in rats (Smidt et al., 1997). Its neural 
distribution is exclusive for midbrain dopaminergic neurons although it can also be 
found in the developing lens (Semina et al., 1997). Ptx3 responsive elements have 
been described in the TH promoter (Cazorla et al., 2000; Lebel et al., 2001), but data 
from Lmblx deficient mice have already suggested that Ptx3 is not required for TH 
induction (see above). Indeed TH expression is not affected in the Aphakia (ak) 
mouse that is mutated for the Ptx3 gene (Semina et al., 2000; Rieger et al., 2001) 
resulting in a loss of Ptx3 expression in mesencephalic dopaminergic neurons (Smidt 
et al., 2003). However, anatomical studies revealed that the ventral substantia nigra 
pars compacta (vSNc) was diminished in these animals (van den Munckhof et al., 
2003; Smidt et al., 2003). This selective degeneration of vSNc and about half of the 
dopaminergic neurons in the VTA was also accompanied by a significant decrease in 
striatal innervations causing a reduction in spontaneous locomotor activity (van den 
Munckhof et al., 2003). Since no alteration in the number of dopaminergic neurons 
was observed at E12.5, but a progressive degeneration at later developmental and 
postnatal stages caused the observed depletion, it has been suggested that Ptx3 has an 
involvement in the survival and maintenance of dopaminergic neurons (van den 
Munckhof et al., 2003).
Maintenance of the dopaminergic phenotype appears to depend on the expression of 
the homeodomain transcription factors engrailed 1 (Enl) and engrailed 2 (En2) that 
are expressed in proliferating dopamine neuroblasts and post-mitotic dopaminergic 
neurons (Lin and Rosenthal, 2003). While mutants for Enl or En2 contain SN and 
VTA, double mutants initially specify these areas but completely lack TH positive 
cells at birth (Simon et al., 2001) suggesting that survival of dopaminergic neurons 
requires the Enl and En2 genes.
Neurotrophic factors play an important role in the long-term survival of dopaminergic 
neurons during development and throughout the lifespan of dopamine neurons in 
adulthood. Most notably for the survival of dopaminergic neurons are neurotrophic 
factors of the GDNF family comprising GDNF itself (Lin et al., 1993), as well as
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neurturin (Kotzbauer et al., 1996), persephin (Milbrandt et al., 1998) and artemin 
(Baloh et al., 1998). Despite their crucial role for continued survival of dopaminergic 
neurons and their high potential in therapeutic approaches for the treatment of 
Parkinson’s disease, they seem to have no direct effect on the development of 
dopaminergic neurons and from this perspective are not discussed further here.
1. InductionFGF2 (bFGF)
Shh
FGF8
2. Specification
GDNF
NRT
Enl
Lmxlb
Nurrl
Ptx3
En2
3. Maintenance
ART
PSP
4. Survival
Figure 1-5: Cascade of factors involved in the embryonic developm ent of dopam inergic neurons.
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1.5.3 In vitro dopamine neuron derivation
As shown in Figure 1-3 various cell sources have been tested for the in vitro 
generation of dopaminergic neurons. The following section focuses on findings for 
the potential conversion of neural precursors and embryonic stem cells into 
dopaminergic phenotypes.
Based on the fact that studies of developmental dopaminergic neuron specification 
have revealed some of the key factors, it would conceptually seem straightforward 
that these factors are also sufficient for the generation of dopaminergic neurons from 
neural precursor cells. However, so far such research has contributed little to finding a 
method for efficiently generating dopaminergic neurons from long term expanded 
neural precursor cells in vitro. Most studies describing the generation of dopaminergic 
neurons from embryonic or adult derived tissue have in fact used neural progenitor 
cultures and generally have not considered the long term expansion of generated 
dopaminergic neurons after multiple passages (Table 1-1).
Progenitor cells isolated from rat E14 ventral mesencephalon and maintained in 
serum-free conditions give rise to only a small proportion (around 5%) of TH 
expressing dopaminergic neurons (Cheung et al., 1997). Propagation in the presence 
of FGF2 can extend dopamine neuron proliferation and differentiation (Bouvier and 
Mytilineou, 1995) when maintained as primary culture on coated tissue culture plastic 
ware. In a first approach to increase the yield of dopaminergic neurons, committed 
dopamine neuroblasts were expanded in FGF2 and differentiated by growth factor 
withdrawal in the presence of foetal calf serum (FCS) (Studer et al., 1998). Upon 
transplantation into Parkinsonian rats the precursor cells survived and led to 
functional recovery. Additional improvement of the basic protocol has also been 
achieved by reducing the oxygen level to more physiological concentrations (Studer 
et al., 2000), whereas addition of ascorbic acid promoted dopaminergic differentiation 
after prolonged expansion (Yan et al., 2001). Similar short-term expansion 
approaches have also been applied to human midbrain precursors (Sanchez-Pemaute 
et al., 2001).
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However, continuous expansion of the neural progenitor cells as so called 
neurospheres (neural precursor cells grown as spherical aggregates in suspension 
cultures) followed by subsequent passaging, rapidly decreases the number of TH 
expressing cells and efficient generation of dopaminergic neurons from rodent and 
particularly human tissue has proven difficult (Svendsen and Rosser, 1995; Svendsen 
et al., 1997; Yan et al., 2001; Storch et al., 2001). In an approach to induce 
dopaminergic neurons, neurospheres were differentiated into the desired phenotype by 
a combination of soluble (cytokines, GDNF, FCS and striatal conditioned media) and 
insoluble (mesencephalic membrane fragments) molecules (Ling et al., 1998; Potter et 
al., 1999; Carvey et al., 2001). The generated cells survived transplantation into the 
striatum of hemiparkinsonian rats and ameliorated behavioural impairment (Carvey et 
al., 2001). Expanded midbrain neurons also exhibit functional properties of 
dopaminergic neurons in vitro (Storch et al., 2003). The same in vitro approach 
combined with low oxygen has also been used to generate dopaminergic neurons from 
human embryonic mesencephalic precursors (Storch et al., 2001). Although some of 
these studies report impressive yields of TH expressing cells, there have been 
concerns about their neuronal identity (Perrier and Studer, 2003). Further, the TH 
inductive effects depend on the presence of undefined soluble and membrane-bound 
factors. The observation of TH expressing cells in expanded human mesencephalic 
neurospheres under defined culture conditions (Riaz et al., 2002) may be the result of 
surviving dopamine neuroblasts due to the low number of passages performed.
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Species Age Origin Expansion Passaged Differentiation condition %TH Refererence
Rat E12 VM plated N o - no data (Bouvier and Mytilineou,
Rat E14.5 Mes suspension Yes IL-1, IL-11, LIF, GDNF, mesencephalic 
membrane fragments, striatal CM, FCS
20-25% (Ling et al., 1998) 
(Potter et al., 1999)
Rat E14.5 VM suspension Yes IL-1, 10%FCS 98% (Carvey et al., 2001)
Rat E12 VM plated N o 10%FCS 14% (Studer et al., 1998)
Rat E12 VM plated No 3% 0 2 only, AA 56% (Studer et al., 2000)
Human 5 - l lw Mes suspension Yes 3% 0 2, IL -lb , IL-11, LIF, GDNF, 
striatal co-culture
1% (Storch et al., 2001)
Mouse E14 STR suspension Yes B 49C M 5% (Daadi and W eiss, 1999)
Human 7-8w Mes suspension Y es (3x only) BDNF, DA, forskolin 60% (Riaz et al., 2002)
Rat E14 VM suspension N o 10%FCS no data (Sawamoto et al., 2001)
Table 1-1: In vitro d ifferentiation o f dopam inergic neurons. Abbreviations: ventral m esencephalon (VM ), striatum  (STR), conditioned m edia (CM ), ascorbic acid (AA).
In alternative approaches, non-mesencephalic precursor cells (Sakurada et al., 1999; 
Daadi and Weiss, 1999) and neural stem cell lines (Wagner et al., 1999) have been the 
target for conversion into a dopaminergic phenotype. Cortical and striatal progenitors 
produced a rather small number of TH positive cells when expanded in FGF2, but the 
yield could be increased in the presence of glial cell conditioned media (Daadi and 
Weiss, 1999). However, the majority of induced TH expressing cells co-labelled with 
GABA and therefore the phenotype is more similar to that of striatal and olfactory 
neurons than to that of midbrain dopaminergic neurons. Overexpression of Nurrl in 
adult rat hippocampal progenitor cells induced TH expression but did not alter the 
expression of other midbrain dopaminergic markers (Sakurada et al., 1999) indicating 
an unspecific action on the TH promoter in neuronal and non-neuronal cell types. 
Further the study showed that overexpression of Ptx3 in the same system did not 
cause an increase in the number of TH positive cells, while Shh increased TH 
expression when it was present during the expansion phase but conversely had 
repressive effects during the differentiation phase. The presence of FGF8 during the 
terminal differentiation stages also did not alter TH expression (Sakurada et al.,
1999). Interestingly, overexpression of Nurrl in a mouse neural stem cell, that was 
previously derived from postnatal cerebellum (Snyder et al., 1992), induced TH 
expression in combination with as yet unidentified factors derived from type-1 
astrocytes (Wagner et al., 1999). The TH positive cells expressed several midbrain 
dopaminergic markers and released dopamine suggesting that Nurrl might induce 
neuronal differentiation in multipotent precursors and provides a competence signal to 
respond to other soluble factors derived from astrocytes. However, after 
transplantation the cells survived poorly as compared to fetal mesencephalic neurons 
indicating that other signals are required for functional integration into the circuitry 
(Arenas, 2002).
Treatment of primary progenitor cultures from rat and human cortex (Zhou et al., 
1994; Zhou et al., 1998; Theofilopoulos et al., 2001) or mouse striatum (Stull and 
Iacovitti, 2001; Stull et al., 2001) with dopamine and protein kinase-A (PKA) 
activators (forskolin and isobutylmethylxantine) also induce ectopic expression of 
TH. An increased number of TH positive cells as well as elevated dopamine release
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indicate that BDNF and GDNF have beneficial synergistic effects on the generation of 
dopaminergic cells from cortical progenitors (Theofilopoulos et al., 2001).
The mechanisms leading to dopamine neuron generation during embryonic 
development have successfully contributed to improved protocols for the controlled 
conversion of embryonic stem cells to dopaminergic neurons. Two main strategies 
have evolved for the efficient generation of dopaminergic neurons.
The first strategy (Lee et al., 2000; Kim et al., 2002) uses the classical 
approach based on the formation of embryoid bodies in a five step protocol: 
expansion of undifferentiated ES cells, formation of embryoid bodies, selection of 
embryoid bodies, expansion of nestin-positive NSCs with FGF2 and finally 
differentiation into midbrain dopaminergic neurons by withdrawal of FGF2 and in the 
presence of the morphogens Shh and FGF8 (Lee et al., 2000). Although Shh and 
FGF8 are not essential for generation of dopaminergic neurons from ES cells, they 
significantly increase the yield. Further improvements in dopamine neuron yield were 
obtained in ES cell lines genetically engineered to overexpress Nurrl (Kim et al., 
2002; Chung et al., 2002). The disadvantage of this traditional protocol is the 
extended in vitro culture periods required, and recently a more rapid protocol for the 
selective generation of neural cell types including dopaminergic neurons has been 
developed (Barberi et al., 2003). The dopaminergic neurons derived from this 
protocol express several midbrain specific dopaminergic markers, release dopamine, 
exert electrophysiological properties of dopaminergic neurons and most notably 
survive, integrate and ameliorate impairment after intrastriatal grafting into 
hemiparkinsonian rats (Kim et al., 2002). Interestingly, some of the generated neurons 
are serotonergic, which are normally induced by Shh and FGF8 in the hindbrain 
region (Ye et al., 1998), suggesting that by mimicking the midbrain-hindbrain 
expression pattern in vitro, a similar cellular diversity can be induced to that of the 
isthmus and floor plate in vivo. Dopaminergic and serotonergic neurons can also be 
generated with clonal ES cell lines derived from nuclear transplantation of adult donor 
cells (Wakayama et al., 2001). The protocols have also been the basis for generation 
of ES cell derived dopamine neurons from non human-primates (Perrier and Studer, 
2003), but a direct adaptation to generate dopaminergic neurons from human ES cells 
has proved difficult (Zhang SC, personal communication). It has recently been
63
suggested that BDNF and TGFa are inductive for the production of dopaminergic 
cells from human ES cells (Park et al., 2004).
The other reported strategy relies on the inductive activity of co-culture 
with a bone marrow-derived stromal cell line, so-called stromal cell derived inducing 
activity (SDIA) (Kawasaki et al., 2000; Kawasaki et al., 2002). The method rapidly 
induces dopaminergic neurons independent of morphogenetic factors such as Shh or 
FGF8. However, the molecular identity of the factors within the SDIA has remained 
unknown. Interestingly, the inductive activity is retained after fixation or without any 
physical contact but could not be exerted by conditioned media (Kawasaki et al.,
2000). The prospective dopaminergic neurons produced, survived and integrated after 
grafting into 6-OHDA depleted striatum. However, functional recovery has not yet 
been demonstrated. The midbrain fate can be altered by sequential exposure of mouse 
ES cells to SDIA, retinoic acid (as caudalizing inducer) and Shh (here as ventralising 
factor) to differentiation into a spinal motor neuronal cell type (Wichterle et al., 2002) 
suggesting that SDIA supports a general neural promoting factor rather than being a 
specific dopaminergic neuron inducer.
The major drawback of ES cell derived dopaminergic neurons is, apart from ethical 
concerns, the possible generation of teratomas upon transplantation. With 20% of 
animals received ES transplants developing teratomas (Bjorklund et al., 2002) this is a 
serious safety issue to be overcome before clinical trials could be considered.
Summarising the previous studies, it has been shown that although neural progenitors 
derived from the developing ventral mesencephalon can be expanded for a short time, 
their long term expansion and controlled induction into a dopaminergic phenotype 
under defined conditions has proven difficult. Morphogenetic and inductive factors 
which are required for embryonic development in vivo also have effects on the 
generation of dopaminergic neurons from ES cells. However, they have not been 
demonstrated to sufficiently induce a dopamine phenotype in foetal or adult precursor 
cells. By definition all stem cells are multipotent, but practically, the distinct stem cell 
systems exhibit intriguing differences in their responsiveness to developmentally 
relevant signals. This leads to questions concerning the identity of different stem cells. 
Do stem cells change throughout development, and are neuroepethilium stem cells the
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same as a prospective adult stem cell? The inability of long-term expanded 
neurospheres to give rise to dopaminergic neurons is described as the “dopamine 
problem” (Svendsen, personal communication), and it will be the challenge of future 
studies to identify factors that are capable of inducing the desired neural phenotype 
from neural stem cells of this type.
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1.6 Viral vectors for gene delivery to neural precursor cells
With the discovery that neural stem cells exist in the mammalian brain and with the 
knowledge that we have acquired over the past two decades about their isolation and 
propagation, together with advances in molecular biology, virology and the 
understanding of neurodevelopment, the genetic manipulation of NSCs for both basic 
research and therapeutic applications has become feasible. The introduction of 
exogenous genetic material into neural stem cells can accomplish different purposes: 
to label and monitor neural stem cells, to guide their development into a specific cell 
type, to release therapeutic factors, to target specific genes or to study human 
diseases. The commonly used viral vectors for gene targeting to neural stem cells are 
adenoviruses, adeno-associated viruses, retroviruses, and lentiviruses (Asahara et al.,
2000). However, it is the aim of the study that defines which vector system is most 
appropriate. If for instance the aim is to label exclusively dividing cells, a method 
frequently used to monitor stem cells in vivo, a vector is required that only transduces 
proliferating cells and the vector choice is limited to retroviruses. In cases that only a 
transient transgene expression over a limited number of cell divisions is desired, non­
regulated integrating viral vectors are inappropriate and non-integrative vectors such 
as adenoviruses or HSV-1 should be considered. For the purpose of gene therapeutic 
applications, integrative vectors have another major disadvantage. Due to random 
integration into the cellular genome, proto-oncogenes may be activated causing 
cancer. Recent gene therapy clinical trials for severe combined immunodeficiencies 
(SCID) have shown that this is indeed a very serious problem. Here, bone-marrow 
stem cells were isolated from the patients, infected with retroviruses delivering the 
therapeutic gene to replace the genetic deficit and were then re-implanted into the 
patient, where they were hoped to multiply to normal immune cells to reconstitute the 
patients immune function. Although the majority of patients benefited from the 
treatment, some developed leukaemia-like conditions (Hacein-Bey-Abina et al., 
2003). Genetic analysis showed that the retroviral vectors had integrated into, and 
activated, an oncogene called LM02 that is associated with childhood leukaemia. 
Further development of safer vectors is needed to avoid such risks in future trials.
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General requirements that can be defined for all vector systems for gene delivery to 
neural stem cells are high transduction efficiency, low viral cytotoxicity and no 
effects on the intrinsic cellular function and stem cell character of the transduced 
neural precursor cell. Other properties to consider are the production of the vector as 
it should be easy to be generated and grown to high titre, it should be 
immunologically inert to avoid immunological clearance, and have the appropriate 
size capacity to accommodate the foreign genetic material.
The following section aims to give an overview of the most commonly used viral 
vectors for gene delivery to neural stem cells. Non-viral vectors give too low 
transduction efficiency to neural stem cells and will not therefore be further 
considered.
1.6.1 Adenoviruses
Adenoviruses (Ads) are non-enveloped double stranded DNA viruses with genomes 
of approximately 36kb in length, which usually remain as episomal elements within 
the host cell nucleus. In humans there are 50 different serotypes, which are classified 
into six groups termed A-F (reviewed in Horwitz, 2001). Members of the subgroup C 
are generally thought to be the most suitable for gene therapy vectors, due to low 
pathogenicity, and of this subgroup, Adi, Ad2, Ad5 and Ad6 are regarded as endemic 
within the population (Murphy, 1999).
The genome is functionally divided into two major regions, termed late and early, 
according to their time of transcription after infection. These two regions contain 
overlapping transcriptional units and in total encode for 50 polypeptides (Kay et al.,
2001). Ads exert a broad cell tropism and can infect both dividing and non-dividing 
cells (Benihoud et al., 1999). They can easily be genetically modified and purified to 
high titres (Lundstrom, 2003).
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Figure 1-6: Schematic of the adenoviral genome. ^  = packaging signal, E = early gene expression, 
L = late gene expression.
First-generation recombinant Ads are generated by deleting the parts of the vims 
genome that are required for replication (El region), and replacing them with a 
transgene expression cassette. In addition to express the transgenes of interest, some 
of these vectors still produce low-level expression of capsid and other vims proteins. 
This residual viral gene expression is responsible for transient transgene expression 
since early cytokine responses, followed by antigen-dependent immune responses 
lead to a cell-mediated destmction of transduced cells. Newer second- and third- 
generation vectors with many of the genes deleted, have demonstrated significant 
improvements (Schiedner et al., 1998). Gutless vectors, in which all adenovims 
genomic sequences have been deleted except for the non-coding inverted terminal 
repeats and packaging signal, have an increased transgene capacity (up to 36kb total), 
diminished immune activation, and the ability to confer long-term gene expression 
(reviewed by Davidson and Breakefield, 2003). The helper vims contains all of the 
necessary Ad replication and packaging signals that act in trans on a vector 
containing the necessary cis acting elements and the foreign gene. The helper vims is 
unable to package itself but aids the production of recombinant virions that lack all 
the Ad genes except for the cis acting elements. However, production of these gutless 
vectors require a helper-packaging vims, is labour intense and difficult to scale up to 
pharmaceutical levels. Moreover, current methods of vector preparations still contain 
helper vims contamination.
Adenovimses efficiently transduce primary rodent (Caillaud et al., 1993) and human 
neural progenitor cells (Sabate et al., 1995; Corti et al., 1999), as well as neural
precursor cells generated from the developing and adult rodent CNS (Gage et al., 
1995; Hughes et al., 2002; Falk et al., 2002) and the developing human brain 
(Keyoung et al., 2001). Other studies also showed the efficient gene delivery to 
postmitotic neurons and embryonic stem cells with low cytotoxicity using gutless 
vectors compared to first generation vectors (Cregan et al., 2000; Smith-Arica et al., 
2003). While neuronal physiology is disrupted upon infection with first generation 
viruses, normal physiological responses were seen with helper-dependent Ads with 
adverse effects only at high titres (Cregan et al., 2000). Efficient gene delivery has 
also been demonstrated to other neural cell types, such as astrocytes (Smith et al., 
1996) and oligodendrocytes (Le Gal et al., 1993), as well as ependymal cells 
(Bajocchi et al., 1993), and microglia (Bhat and Fan, 2002). Targeted gene expression 
to neurons has been achieved by construction of Ads with neuron-specific enolase 
(NSE) promoters (Navarro et al., 1999).
Infection of EGF expanded neurospheres with adenovirus expressing EGFP under an 
RSV promoter resulted in a reasonable transgene expression 16hr post transduction 
and could be maintained for one month in vitro (Hughes et al., 2002). However, 
adenoviral transduction induced a premature differentiation of progenitors into GFAP 
positive astrocytes, even when maintained in the presence of the mitogen EGF. This 
occasional differentiation is accompanied by a decrease in nestin expression. It was 
thaught that this premature differentiation may result from G1 progression due to 
adenoviral gene expression (Hughes et al., 2002). Removal of the growth factor 
induced differentiation of the transduced population into predominantly astrocytes, 
only about 2% of the infected cells being positive for the neuronal marker MAP2. 
Altered differentiation has also been observed upon adenoviral transduction of adult 
mouse neural precursor cells (Falk et al., 2002). Precursors derived from the ventricle 
were expanded as neurospheres in the presence of EGF and transduced with 
adenovirus expressing GFP under CMV promoter control resulting in a gene delivery 
efficiency of about 68%1(Falk et al., 2002). However, this phenomenon was not 
observed when transgene expression was targeted to a selective population of neural 
stem cells derived from human fetal tissue expanded as neurospheres in EGF and
1 N o m.o.i. provided in this reference.
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bFGF (Keyoung et al., 2001). This study uses adenoviruses expressing GFP under cell 
specific promoters to selectively label a subpopulation of uncommitted, dividing 
progenitor cells. Using EGFP under the nestin enhancer, a primitive population of 
nestin positive cells was selected of which only 3% were positive for /3III-tubulin and 
9% for GFAP. No predifferentiated progenitors were noted when hGFP was driven by 
the musashi promoter (Keyoung et al., 2001), an RNA binding protein expressed by 
neural progenitors (Sakakibara et al., 1996). This discrepancy may be the result of 
species differences or reflect the diversity of progenitor subpopulations within 
neurospheres. The premature differentiation of virally infected cells described by 
Hughes et al. may only occur in a subpopulation of already fate committed progenitor 
cells, but not in uncommitted precursor cells as shown by Keyoung et al. Further 
Keyoung et al. showed by retroviral lineage analysis that the selected adenoviral 
infected precursor cells retain their multipotent character even at multiple passages 
(Keyoung et al., 2001).
A strong and controlled transgene expression could also been observed upon 
transduction of human progenitors expanded in bFGF with an adenovirus expressing 
tyrosine hydroxylase under a CMV promoter (Corti et al., 1999). The adenoviral 
construct used in this study takes advantage of a regulated transgene expression using 
the tet-off system for a controlled expression in vitro and in vivo (Corti et al., 1999).
Adenoviruses also deliver efficiently to endogenous stem cells in the SVZ as 
demonstrated by injections into the lateral ventricle of mice (Bajocchi et al., 1993; 
Yoon et al., 1996) and rats (Benraiss et al., 2001) without any significant cytotoxic 
effects occurring. A strong transgene expression in the lateral wall of the SVZ was 
observed for at least two months after injection of 1.2xl06PFU of the recombinant 
virus driving LacZ under a CMV promoter. The transduced progenitor cells retain 
their capacity to proliferate and migrate along the rostral migratory stream to the 
olfactory bulb where they differentiate into granular and periglomerular intemeurons 
(Yoon et al., 1996). As the migration of the neuroblast occurs as a result of a 
continuous event of cell divisions (Lois and Alvarez-Buylla, 1994), the high number
2 Only characterized by morphology and not by staining with cell specific markers.
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of transduced progenitors in the olfactory bulb is surprising due to the non-integrative 
nature of the adenovirus. One possible explanation is a continuous arrival of 
transduced neuroblasts from the SVZ, which is confirmed by the observation that the 
number of transduced cells in the olfactory bulb increases over time and a time 
dependent maturation of the neuroblasts into differentiated neurons with a distinct 
mature morphology (Yoon et al., 1996). Intraventricular injections of adenoviruses 
expressing hGFP under a CMV into adult rats also confirmed a high efficiency of 
gene delivery restricted to the ependymal and subependymal layer of the SVZ over a 
time course of at least three weeks (Benraiss et al., 2001).
1.6.2 Adeno-associated viruses
Adeno-associated viruses (AAV) is a member of the human parvovirus family, small 
single-stranded DNA viruses that require a helper virus, such as adenovirus or herpes- 
simplex virus, for replication (for review see Okada et al., 2002). Although the 
majority of the population is seropositive for AAV, no known disease is associated 
with AAV infection, making it an ideal candidate for gene therapy. There are six 
different human serotypes known that have shown different expression patterns 
because of differences in cell entry and intracellular activities. Wild type AAV 
preferentially integrates into a specific locus on human chromosome 19, facilitated by 
the rep gene products (Samulski, 1993), but this property is lost in vectors due to the 
absence of the rep gene. AAV vectors infect a wide variety of cell types that are both 
dividing and non-dividing and vectors have been shown to remain episomally (Duan 
et al., 1999) or to integrate randomly (Miao et al., 2000).
The virus contains two genes, rep and cap, encoding polypeptides important for 
replication and encapsidation, respectively.
5’ ITR \|f rep cap 3’ ITR
Figure 1-7: Schematic of the AAV genome. 'F = packaging signal.
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Creation of AAV vectors usually involves the replacement of the rep and cap genes 
with transgenes. These two genes can be supplied in trans with only the inverted 
terminal repeats (ITRs) required in cis for viral replication. Therapeutic genes can 
therefore be inserted between the two ITRs, and vectors produced by co-transfection 
with plasmids encoding rep and cap and subsequent infection with a helper virus 
(Rolling and Samulski, 1995). Methods have been described using a single herpes 
simplex virus providing both helper virus function and rep/cap genes in one single 
simple step, which avoids transfection (Booth et al., 2004). Since transfection is 
difficult to scale up, this has significant advantages in generation of large scale virus 
preparations. The main disadvantage concerning these vectors are related to the small 
cloning capacity (about 4.8kb), however, this can be overcome by infection of cells 
simultaneously with two AAV vectors, which can recombine to generate a larger 
genome (Duan et al., 2003).
Primary mesencephalic progenitor cells derived from E14 time-mated rats can be 
infected with AAV at high multiplicity (m.o.i. of 25,000) without obvious cytotoxic 
effects (Fan et al., 1998). Gene delivery to mesencephalic progenitors in vitro is rather 
low but can be enhanced by using HSV/AAV hybrid vectors (Costantini et al., 1999) 
containing elements of HSV-1 amplicons and recombinant AAV vectors (Johnston et 
al., 1997). However, long term gene expression in vitro and in vivo was only possible 
with hybrid vectors containing the AAV rep gene (Costantini et al., 1999).
AAV2 gave unsatisfying gene delivery to mouse neural progenitors expanded as 
neurospheres with EGF (0.01% reporter gene positive cells at an m.o.i. of 2), while no 
reporter gene expression was observed with serotypes 4 and 5 (Hughes et al., 2002) 
and it has been suggested that this may be due to the lack of required receptors or 
extracellular matrix proteins interfering with viral uptake (Hughes et al., 2002). 
However, other studies have shown that human derived forebrain progenitor cells 
expanded in EGF could efficiently be infected with recombinant AAV2 expressing 
EGFP with an onset of expression one day after infection (Wu et al., 2002). 
Significant differences between the vectors are only the choice of promoter, Hughes
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et al are using an RSV promoter while Wu et al. are using a CAG promoter3, which 
might explain this controversial result. Mouse and human ES stem cells infected with 
AAV expressing the reporter gene under an RSV promoter demonstrated moderate 
transgene expression when infected with AAV2, but no expression upon infection 
with AAV4 or AAV5 (Smith-Arica et al., 2003). Furthermore, reporter gene 
expression disappeared after differentiation of the AAV2 infected ES cells. On the 
other hand, ES cells differentiated before transduction retained susceptibility to 
infection with all three AAV serotypes and it has been suggested that the absence of 
infection in undifferentiated ES cells may reflect the lack of the required receptors 
known to be involved in their attachment and internalization (O- and N-linked sialic 
acid; (Kaludov et al., 2001). AAV2 infected human neural precursor cells have 
decreased proliferation rates but retain their capacity to differentiate into neurons and 
glia, and furthermore survive and express the reporter gene after transplantation (Wu 
et al., 2002).
In vivo AAV serotype 2 infects neurons preferentially (Bartlett et al., 1998), 
apparently through the interaction of AAV2 capsid proteins with heparan sulphate 
proteoglycan (HSPG) moieties on the cell surface (Davidson and Breakefield, 2003). 
High level transgene expression in neuronal cell types depends on the choice of 
promoter (Haberman and McCown, 2002), mammalian promoters generally achieving 
more sustained transgene expression than viral promoters. Other AAV serotypes have 
also been found useful in brain-directed gene transfer, showing that AAV4 transduces 
ependymal cells more efficiently than AAV2 and AAV5 infects neurons and 
astrocytes in vivo unlike AAV2 which only infects neurons (Davidson et al., 2000). 
Differences between serotypes are most likely due to the fact that the capsid proteins 
use different cellular receptors for entry. Intraventricular injections of AAV2 results 
in dispersed gene delivery throughout the CNS (Passini and Wolfe, 2001), however, 
many brain areas remained poorly transduced. In contrast, injection of AAV1 into the 
lateral ventricles of mice produced a robust and extensive pattern of transduction with 
transgene expression in the ventricle wall of the SVZ-ependymal region throughout
3 The CAG promoter is a chimeric promoter that consists o f  a CMV immediate-early enhancer, a chick 
/3-actin promoter, a chimeric intron, exon 1 and a part o f  exon 2 o f  a rabbit /3-globin gene and has been 
shown to have a higher activity than the CMV promoter in mammalian cells (Wu et al., 2002).
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the entire ventricle system and the olfactory bulb (Passini et al., 2003). 
Immunohistochemical staining revealed that the majority of infected cells co-labelled 
with neuronal marker, but not with astrocyte- or oligodendrocyte-specific markers 
(Passini et al., 2003) suggesting that neural precursor cells were not targeted. AAV 
vectors of different serotypes also efficiently and stably deliver reporter gene 
expression to retinal progenitor cells in vivo (Surace et al., 2003).
Recently it has been shown that AAV can successfully be used as gene targeting 
vectors in adult human stem cells derived from individuals with osteogenesis 
imperfecta (OI) (Chamberlain et al., 2004). OI is caused by mutations in collagen 
genes that result in severe skeletal abnormalities. Mesenchymal stem cells (MSCs) 
from OI patients were isolated and infected with AAV gene targeting vectors that 
disrupted the mutated gene in the MSCs. AAV gene targeting improved collagen 
processing, stability and structure. Furthermore, targeted MSCs retained the 
multipotent capacity to differentiate into bone and fat cells demonstrating that gene 
targeting is possible in nonembryonic human stem cells (Chamberlain et al., 2004).
1.6.3 Retroviruses
The utilization of viruses as efficient vehicles to transfer recombinant DNA into 
eukaryotic cells first used retrovirus vectors (Cepko et al., 1984). Retroviruses are 
lipid-enveloped single-stranded RNA viruses with genomes of 7 to 11 kilobases 
(reviewed by Kay et al., 2001). The retrovirus family includes mammalian and C-type 
retroviruses, lentiviruses and spumaviruses. The majority of clinical trials to date have 
used vectors based on the murine leukaemia virus (MLV) (reviewed in Robbins et al.,
1998).
Productive transduction by retroviral vectors is strictly dependent on target cell 
mitosis shortly after entry (Miller et al., 1990). Because only a fraction of cells pass 
through mitosis at any given time, this severely limits the applications of retroviral 
vectors in gene therapy. Following entry into target cells, the RNA genome is retro- 
transcribed into linear double-stranded DNA and integrated into the cell chromatin. 
Integration does not guarantee stable expression of the transduced gene, but it is an
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effective way to maintain the genetic information in a self-renewing cell source, such 
as neural precursor cells.
The retrovirus genome contains two long terminal repeat (LTR) sequences flanking 
the three viral genes gag, pol, env and the packaging signal (reviewed by Kay et al.,
2001). The viral genes encode for structural proteins, nucleic-acid 
polymerases/integrases and surface glycoproteins. The viral envelope glycoprotein 
determines the host range of retroviral particles through the interaction with receptors 
on target cells. To overcome limitations of host cell tropism, retrovirus vectors have 
been pseudotyped with envelope proteins from other viruses such as the G 
glycoprotein from vesicular stomatitis virus (VSV) (Bums et al., 1993). VSV G 
pseudotyped retroviruses are less labile, can be concentrated to higher titres and have 
a much broader host range.
LTR LTR
env
LTR
LTR
Figure 1-8: Generation of retrovirus based vectors.
Retroviral vectors are constructed by removal of all viral genes replaced by the 
transgene of interest (up to 8kb of foreign genetic material) and flanked by the 
remaining cis regulatory elements (Robbins et al., 1998). Packaging cell lines 
expressing the viral genes gap, pol, env are either stably or transiently transfected 
with the recombinant retroviral construct and because only the vector contains the 
packaging sequence and the two LTRs, only vector RNA is packaged into virions.
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Separation of the gag/pol genes from the env gene is required to avoid recombination 
resulting in the production of replication competent retroviruses (Donahue et al., 
1992).
Because of their inability to deliver genes to non-dividing cells, retroviral vectors 
have found only limited application as gene therapeutic vectors in the CNS. However, 
this feature has made them a unique tool to label the rare population of dividing 
neural stem/precursor cells in the adult brain and follow their differentiation into 
mature neural cell types and functional integration in the circuitry in many studies (for 
example Fields-Berry et al., 1992; Doetsch et al., 1999; van Praag et al., 2002; Suzuki 
and Goldman, 2003). The retro-viral gene transfer method has become a reliable way 
to monitor migration and neuronal differentiation of precursor cells in situ (Rakic, 
2002), even in live time-lapse videomicroscopy (Suzuki and Goldman, 2003). 
Furthermore, these vectors have extensively been used for ex vivo infection of 
cultured neural precursor cells followed by transplantation (Flax et al., 1998; 
Torchiana et al., 1998; Liu et al., 1999; Meng et al., 2003) and for clonal analysis in 
brain development (Turner et al., 1990; Fields-Berry et al., 1992; Williams and Price,
1995). Although retroviral vectors have found application in many gene therapeutic 
trials, the fact that integration occurs randomly, and thus may have adverse effects on 
normal cellular function (see above), requires the further development of safer 
vectors.
Originally with the aim of infecting embryonic stem cells, a murine embryonic stem 
cell virus (MESV) has been developed from a retroviral mutant by manipulation of 
the 5’ untranslated region that abolished viral gene expression in ES cells (Grez et al., 
1990). This MESV was further altered by removal of all potential start sites of 
translation in the 5’ leader and replacement of the gag gene sequences with a 
constitutive transport element from aevian leukaemia virus to promote nuclear export 
of viral RNA (Owens et al., 2002). The generated vectors have been referred to as 
MESV2 and were demonstrated to infect rat hippocampal precursors cells in vitro that 
retained their ability to differentiate into neurons and astrocytes upon differentiation 
(Owens et al., 2002).
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1.6.4 Lentiviruses
Unlike retroviruses, lentiviruses rely on the active transport of the preintegration 
complex through the target cell nucleopore (Lewis et al., 1992), a feature that enables 
them to transduce both dividing and non-dividing cells. The vector gives long-term 
expression through chromosomal integration. Pseudotyping with VSV-G glycoprotein 
has expanded the vector tropism (Naldini et al., 1996) and made lentiviral vectors a 
promising tool for gene therapy (Kay et al., 2001).
The lentiviral genome is more complex than that of retroviruses and contains two 
additional regulatory genes, tat and rev, essential for the expression of the genome 
and a variable set of accessory genes (Naldini, 1998). The accessory genes appear to 
have no obvious function in vitro, but are required for full virulence and pathogenesis 
in vivo and do not need to be complemented in culture (Naldini et al., 1996). The 
generation of “minimal” packaging constructs have been adopted to increase vector 
biosafety (Dull et al., 1998). The fact that many of the lentiviruses used in gene 
therapy are based on the human immunodeficiency virus (HIV) has raised safety 
concerns and lead to the development of self-inactivating transfer vectors (Zufferey et 
al., 1998; Miyoshi et al., 1998). The vectors contain a deletion in the downstream 
LTR that after transduction results in the transcriptional inactivation of the upstream 
LTR and thus diminishes the risk of vector mobilization and recombination 
(Bukovsky et al., 1999).
Lentiviral gene delivery to the CNS causes a minimal inflammatory response and 
produces long-term transgene expression when introduced into the brain parenchyma 
or ventricles (Naldini et al., 1996; Brooks et al., 2002). Lentiviral vectors have been 
used for the efficient transduction of rodent (Ostenfeld et al., 2002) and human 
(Englund et al., 2000) neural precursor cells grown as free floating neurospheres. 
Gene delivery rates were between 75% (Ostenfeld et al., 2002) and 90% (Englund et 
al., 2000) at an m.o.i. of 5. No obvious cytotoxic effects were observed (Buchet et al., 
2002), but lentiviral transduction slowed down cell proliferation in human precursor 
cells (Englund et al., 2000). After transplantation into the striatum of rats the infected 
precursor cells survive and express significant amounts of the transgene (Englund et
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al., 2000; Ostenfeld et al., 2002). The transduced precursors retain the ability to 
differentiate into different neural cell types after grafting in vivo (Buchet et al., 2002). 
Intraventricular injections of retroviral and lentiviral vectors result in an inefficient 
transduction of cells in the SVZ-ependymal region (Johansson et al., 1999; Falk et al.,
2002), and thus are not suitable for extensive delivery of therapeutic genes to this 
region.
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1.7 Herpes simplex virus
Members of the Herpesviridae form a large and diverse family that comprises alpha-, 
beta-, and gammaherpesviruses. Herpes simplex viruses (HSV) belong to the family 
of alphaviruses (Roizman and Pellet, 2001) and are among the most intensively 
studied of all viruses. HSV-1 and HSV-2 are natural pathogens in humans, and are 
responsible for mucocutaneous lesions, but can also rarely cause meningitis and 
encephalitis (Spear and Longnecker, 2003). HSV-1 is endemic within the human 
population, with 80% of individuals testing positive for antibodies to HSV-1, and 
commonly establishes latent infections in neurons with the potential of reactivation to 
cause recurrent or new episodes of the disease (Roizman and Knipe, 2001).
1.7.1 Potential of HSV-1 as a gene delivery vector for neural precursor cells
So far HSV-1 has received attention as a gene delivery vector for gene therapeutic 
applications for several reasons (reviewed in Glorioso et al., 1995; Burton et al., 2001; 
Davidson and Breakefield, 2003):
• Broad host cell range including infection of dividing and non-dividing 
cells. Although HSV-1 is neurotrophic in vivo it efficiently infects a broad 
range of cell types in vitro and in vivo. Wildtype HSV-1 is cytotoxic to the 
infected cell, but by deleting multiple viral genes replication deficient, non- 
cytotoxic vectors can be generated that persist in a latency like state 
(Samaniego et al., 1998) in neurons and non-neuronal tissue (Wolfe et al.,
1999). Repeated vector administration is possible even in immune hosts.
• Establishment of latency gives the potential for life-long sustained 
transgene expression. During latency HSV-1 remains episomal and infected 
neurons function normally and are not rejected by the host immune system. 
Furthermore, the latency active promoters can be exploited in heterologous 
expression cassettes for long-term transgene expression (Palmer et al., 2000; 
Lilley et al., 2001).
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• HSV-1 can accommodate a large amount of foreign genetic material. The
genome contains a large number of accessible genes that are not required for 
viral growth in culture and essential genes that can be provided in trans. This 
feature makes HSV-1 a large capacity vector capable of harbouring at least 
30kb of foreign gene sequences encompassing large single genes or multiple 
gene cassettes that may be coordinatively or simultaneously expressed (Krisky 
et al., 1998).
• Recombinant HSV-1 is easy to manipulate and propagate. Highly 
replication-deficient viruses can be grown on cell lines providing the deleted 
genes in trans in titres of up to 109 plaque forming units per ml (PFU/ml).
Several features make HSV-1 particularly interesting for the transduction of stem 
cells. Due to its capability of incorporating large DNA inserts, it may be possible to 
express multiple genes to induce differentiation to a specific cell lineage. As the viral 
genome persists episomally without disturbing host cell metabolism this avoids the 
risk of integration related mutagenesis and the potential activation of proto-oncogenes 
(Burton et al., 2001). However, because of the non-integrating nature of HSV-1 
vectors, transgene expression will only be maintained in the transduced stem cell or 
progenitor cell over a small number of cell divisions and will not occur in cells found 
many cell divisions away from the transduction event. For the induction of a specific 
phenotype, requiring only a transient expression of the differentiating signal, this may 
be advantageous.
On the other hand, due to its non-integrative nature, HSV-1 is not suitable for delivery 
to neural stem cells with the purpose of continuously expanding the transduced 
precursor cell population. For this purpose integrative vectors are more appropriate.
HSV-1 as a vector system for stem cells has primarily been described to 
hematopoietic stem cells (reviewed in Burton et al., 2001; Wolfe et al., 2004), 
showing efficient transduction of progenitor cells derived from human bone marrow 
(Dilloo et al., 1997) and human blood (Coffin et al., 1998). Although amplicon based
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HSV-1 viruses have been used to efficiently transduce embryonic stem cells 
(Anderson et al., 2001; Vicario and Schimmang, 2003), no thorough study has been 
described using HSV-1 as a gene delivery vector to neural stem cells of the central 
nervous system. Therefore, it will be challenging to study the potential application of 
HSV in other stem cell lineages, such as neural stem cells.
1.7.2 Fundamental biology of HSV-1
1.7.2.1 The HSV-1 genome and structure of the virion
HSV-1 is a double-stranded, enveloped DNA virus. Its genome size is about 152 kb 
and encodes more than 80 polypeptides (Roizman and Knipe, 2001). The HSV 
genome is arranged as long and short unique segments (Ul and Us) that are flanked 
by repeated regions, a, b and c (McGeoch et al., 1986; Perry and McGeoch, 1988; 
McGeoch et al., 1988). About half of the viral genes are non-essential and therefore 
not required for viral replication in a permissive tissue culture environment. Deletion 
or replacement of these genes does not require substitution in trans for virus growth, 
but they may play a role in specific virus-host interaction in vivo (Krisky et al., 1998).
The natural route of HSV-1 uptake is by infection of skin epithelial cells, where upon 
the virus undergoes a cycle of lytic gene expression and replication (Roizman and 
Knipe, 2001). Following lysis the released viral particles infect sensory nerve 
terminals and are retrogradely transported to the neuronal cell body. From there on, 
the virus can either undergo a further round of replication or alternatively, establish a 
latent infection. During latency the viral genome can persist episomally for the 
lifetime of the cell or be reactivated to re-enter the lytic cycle followed by anterograde 
axonal transport to skin or mucosal surfaces where it results in the production of 
infectious particles at or near the original site of the primary infection.
The mature HSV-1 virion contains four components: the core of double-stranded viral 
DNA within an icosahedral capsid, surrounded by a protein-rich layer, the tegument, 
which is finally embedded within the lipid envelope (Roizman and Knipe, 2001).
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Figure 1-9: The HSV-1 virion and genome.
1.7.2.2 Virus entry
The initial steps o f viral infection include the interaction between virion and target 
cells (attachment) followed by incorporation of the virion into the cell (entry). This is 
facilitated by interaction between the viral envelope containing at least 11 
glycoproteins (named gB to gM) and receptors on the cell surface o f the target cell.
Although different cell surface molecules can serve as receptors for viral attachment, 
it has been established that the initial contact of HSV-1 with cells is mediated by 
binding to glycoaminoglycans, usually heparan sulphate (HS), on cell surface 
proteoglycans (Shukla and Spear, 2001). HS are linear polysaccharides which are 
ubiquitously biosynthesized as a proteoglycan in mammalian cells (reviewed by 
Rabenstein, 2002) including neural precursor cells (reviewed by Ford-Perriss et al.,
2002). The particular role HS plays as portal of entry has been demonstrated in 
several experimental rationales: Heparinase treated cells and prevention of HS 
biosynthesis significantly reduce virus binding and infectivity (WuDunn and Spear, 
1989; Shieh et al., 1992); soluble heparin and forms of HS inhibit viral infection by 
binding of viral particles (Nahmias and Kibrick, 1964; WuDunn and Spear, 1989);
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soluble forms of glycoprotein B (gB) and glycoprotein C (gC) bind heparin and HS 
(Svennerholm et al., 1991; Tal-Singer et al., 1995; Williams and Straus, 1997; 
Trybala et al., 2000) and competitively inhibit attachment to cells (Svennerholm et al., 
1991; Tal-Singer et al., 1995). Therefore, binding of the virion to HS appears to be 
mediated by the viral glycoprotein gB and gC, although gC is dispensable but 
significantly increases the efficiency of virus binding (Spear and Longnecker, 2003). 
The binding to HS is not essential for virus infection, but the presence of HS increases 
the efficiency of viral entry, probably by concentrating virus on the cell surface for 
subsequent interaction with the viral entry receptors (Spear and Longnecker, 2003). 
While initial studies identified heparan sulphate as receptor for HSV-1 attachment in 
endothelial cells (Herold et al., 1994), Immergluck et al. showed that heparin sulphate 
is also required for HSV-1 entry into primary neural progenitor cells derived from the 
developing chick cortex (Immergluck et al., 1998). Although in endothelial cells the 
interaction with heparan sulphate is predominantly facilitated by HSV-1 gC as shown 
in several studies using either neutralising antibodies for gC (Fuller and Spear, 1985; 
Svennerholm et al., 1991) or mutational analysis of gC (Campadelli-Fiume et al., 
1990; Herold et al., 1991; Mardberg et al., 2001), gC has no significant effect on 
initial virus binding in neural progenitor cells (Immergluck et al., 1998), and gB may 
provide functional redundancy in neural cell types.
However, HS is not the only cell surface receptor mediating virus attachment. 
Another factor, noteworthy here due to its role in infecting neural stem cells, is basic 
fibroblast growth factor receptor. Although this receptor plays a role in virus 
attachment (Baird et al., 1990), its originally suggested essential function as the entry 
receptor (Kaner et al., 1990) has later been disproved (Mirda et al., 1992; Muggeridge 
et al., 1992).
The initial and reversible binding to HS is followed by a cascade of irreversible 
receptor-ligand interactions at the cell surface that trigger fusion between viral 
envelope and the plasma membrane and ultimatively results in virus entry (Spear and 
Longnecker, 2003). Four of the envelope glycoproteins are absolutely essential for 
entry of HSV-1, namely gB, gD, gH, and gL (reviewed by Spear and Longnecker,
2003). Three classes of HSV-1 entry receptors have been identified on the surface of 
cells: a member of the TNF-receptor family named HVEM (HveA) (Montgomery et
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al., 1996), members of the immunoglobulin family referred to as nectin-1 (HveC) 
(Geraghty et al., 1998) and nectin-2 (HveB) (Warner et al., 1998), and a modified 
form of HS that generates binding sites for gD (Shukla et al., 1999). Any of these cell 
surface entry receptors can bind to gD and the interaction triggers fusion between the 
viral envelope and the cell membrane, a process that requires the participation of gB 
and gH-gL (reviewed in Spear and Longnecker, 2003).
Following cell fusion, the capsid-tegument structure is released into the cytoplasm of 
the host cell. While some of the tegument proteins remain in the cytoplasm (US11 and 
vhs), the viral DNA and the other tegument proteins (VP 16, VP 1-2) are retrogradely 
transported to the nuclear membrane via microtubules (Sodeik et al., 1997). At the 
nuclear pore membrane, the viral DNA and associated tegument proteins are released 
into the nucleoplasm (Roizman and Knipe, 2001).
1.7.2.3 The lytic lifecycle
During lytic infection tight regulatory and organisational alterations occur within the 
host cell in order to manipulate the cell for viral gene expression and protein 
synthesis. Lytic gene expression has been classified according to temporal expression 
upon cell entry into immediate early (IE or a), early (E or /3) and late (L or y) 
(Roizman and Knipe, 2001) gene expression.
Tegumental proteins released into the cytoplasm act to convert cellular resources from 
host cell protein synthesis to viral protein synthesis. Early host protein synthesis 
occurs in the absence of viral gene expression and is facilitated by copies of the 
tegumental virion host shut-off protein (vhs) released into the cytoplasm (Kwong and 
Frenkel, 1987). This allows an immediate shutoff after viral entry, although the gene 
encoding for vhs, UL41, is actually expressed as a late gene. Vhs is an mRNA- 
specific RNase which accelerates mRNA degradation of both host and viral mRNA 
(Kwong and Frenkel, 1987; Oroskar and Read, 1987), triggers rapid shut off of host 
protein synthesis, disrupts preexisting polyribosomes (Smiley et al., 2001; Smiley,
2004), and as such helps to redirect the cell from host to viral gene expression (Feng 
et al., 2001).
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Transcription of the five IE genes, ICPO, ICP4, ICP22, ICP27, and ICP47, is 
regulated by promoters that are responsive to a viral structural protein, VP 16, which is 
part of the tegument and transported to the host cell nucleus with the viral DNA 
(Roizman and Knipe, 2001). VP 16 requires the presence of two host proteins, the 
octamer binding protein one (oct-1) and the host cell factor (HCF), to efficiently bind 
to cognate motifs within the IE promoter and to promote transcriptional activation of 
the IE genes (Mackem and Roizman, 1982; Campbell et al., 1984; Preston et al., 
1988). Apart from its activation effect, VP16 has been reported to downregulate vhs 
expression, thus rescuing viral mRNA degradation (Mossman et al., 2000).
IE gene expression commences in the absence of viral protein expression and all IE 
gene products (except ICP47) are involved for the regulation of E and L gene 
expression. Of the IE gene products, only ICP4 and ICP27 are essential for expression 
of E and L genes, and thus viral replication (DeLuca et al., 1985; Sacks et al., 1985).
ICP4 activates the subsequent expression of early and late genes, whilst down- 
regulating its own expression and that of ICPO (Dixon and Schaffer, 1980; DeLuca et 
al., 1985; Roberts et al., 1988). ICP4 can directly bind DNA (Kristie and Roizman, 
1986) as homodimers (Metzler and Wilcox, 1985) and is believed to activate 
transcription via interaction with cellular transcription factors, such as the TATA 
binding protein and TFIID (Smith et al., 1993; Carrozza and DeLuca, 1996; Grondin 
and DeLuca, 2000).
ICP27 exerts multiple functions (Sacks et al., 1985), including the transition from 
early to late gene expression. By interaction with ICP4 and ICPO IE and E gene 
expression is repressed, while late gene expression is activated (Sacks et al., 1985; 
McCarthy et al., 1989; Rice and Lam, 1994). ICP27 inhibits the nuclear localisation 
of ICP4 and modulates its DNA binding activity (Panagiotidis et al., 1997). ICP27 is 
also required for viral DNA synthesis (McCarthy et al., 1989; Uprichard and Knipe,
1996). On the post-translational level ICP27 inhibits pre-mRNA splicing and thus 
provides an advantage for viral mRNA that is predominantly unspliced (only four of 
the ca. 84 viral genes contain introns, and three of these are IE genes) (Hardy and
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Sandri-Goldin, 1994; Smiley, 2004). Therefore, ICP27 collaborates with vhs for 
efficient shutoff of host protein synthesis and contributes to loss of host mRNAs 
(reviewed in Smiley, 2004). Furthermore, it has been shown that ICP27 has potential 
anti-apoptotic effects in human (Aubert et al., 1999; Aubert and Blaho, 1999; Zachos 
et al., 2001) and BHK cells (Zachos et al., 2001), thereby escaping the host cell 
defence mechanism to eliminate infected cells. It has been suggested that this anti- 
apoptotic function of ICP27, as well as ICP4, is facilitated by stabilization of bcl-2 
RNA (Zachos et al., 2001).
The gene encoding for the nuclear phosphoprotein ICPO is embedded within the short 
repeat regions of the HSV-1 genome, and thus is present in two copies per genome 
(Pereira et al., 1977; Zhu et al., 1991). ICPO is a potent activator for all three classes 
of viral genes IE, E and L (Cai and Schaffer, 1992; Chen and Silverstein, 1992) and is 
considered as a promiscuous activator for viral and non-viral genes since it can induce 
expression of otherwise silent genes (Nabel et al., 1988; Samaniego et al., 1998). 
Multiple functions have been described for ICPO including interaction with the 
transcription machinery (Lees-Miller et al., 1996), protein degradation (Everett et al., 
1997; Everett et al., 1998; Everett, 2000), cell cyle arrest (Hobbs and DeLuca, 1999) 
and also the inhibition of histone deacetylation (Poon et al., 2003). Due to the fact that 
ICPO mRNA is anti-sense and partially complementary to LAT a potential role in 
latency has also been speculated (see later).
ICP22 is dispensable for virus replication and promotes late gene expression in a cell 
type specific manner (Sears et al., 1985). By modification of the phosphorylation state 
of host RNA polymerase II, ICP22 specifically represses host cell replication (Rice et 
al., 1995) and increases the stability and splicing of ICPO mRNA (Carter and 
Roizman, 1996).
ICP47 is non-essential for virus replication in most cell types (Mavromara-Nazos et 
al., 1986) and inhibits the transporters of antigen processing (TAP), thereby reducing 
the presentation of HSV-1 epitopes on the surface of infected cells by MHC class I 
complexes (York et al., 1994). It has been demonstrated that the ICP47 gene product 
binds to TAP and prevents peptide translocation into the endoplasmic reticulum (ER)
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(Hill et al., 1995). The empty MHC class I molecules remain in the ER and fail to 
present peptides on the surface of the infected cell (Bauer and Tampe, 2002).
With the expression of IE genes a cascade of viral gene expression is induced. Early 
gene products primarily encode for enzymes involved in DNA replication, followed 
by expression of late genes mainly encoding structural components of the virion 
(Honess and Watson, 1974; Honess and Roizman, 1975; Roizman and Knipe, 2001).
In the classic model of HSV-1 DNA replication, viral DNA synthesis occurs 
by a rolling circle producing head-to-tail concatamers of Ul and Us that are separated 
by the inverted repeats (Jacob et al., 1979). During replication, the Ul and Us 
segments can independently reverse their orientation by homologous recombination 
between the inverted repeat elements, forming four possible isomers (Jacob et al., 
1979; Mocarski and Roizman, 1982; Davison and Wilkie, 1983). However, this model 
has recently been challenged by data suggesting that genome circularisation does not 
occur during lytic infection but during latency (Jackson and DeLuca, 2003).
Late gene expression requires the activities of ICP27 and ICP4 as well viral 
DNA synthesis (Mavromara-Nazos and Roizman, 1987). Following L gene 
expression, the capsid is assembled within the nucleus, the viral DNA cleaved and 
packaged through recognition of the packaging sequence “a” within the internal 
repeat of the short segment, and finally the tegument proteins associated (reviewed in 
Glorioso et al., 1995). The capsid-tegument complex buds through a modified patch 
of the nuclear membrane containing the viral glycoproteins, and thus forms the viral 
envelope.
Two models have been suggested for trafficking and secretion of the budded viral 
particles: (i) the enveloped virions fuse with the outer nuclear membrane to be 
released as envelope-free capsids and are re-enveloped by passaging through the 
Golgi compartment and subsequent release through secretory vesicles (Skepper et al., 
2001; Granzow et al., 2001); (ii) the virions are released as enveloped particles from 
the nucleus and travel in the cytoplasm either in vesicles or in the lumen of the ER to 
the Golgi; after final glycoprotein maturation in the Golgi compartment they are 
released via a secretory pathway (Roizman and Knipe, 2001).
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1.7.2.4 The latent lifecycle
Following an initial lytic infection, HSV-1 can establish latency in sensory neurons, a 
state that can persist for the lifetime of the host (Mellerick and Fraser, 1987). The 
latency-reactivation cycle involves three major steps: establishment, maintenance, and 
reactivation (reviewed by Jones, 2003). However, the processes regulating the 
establishment or reactivation of latency are not well understood.
Establishment of latency includes viral entry followed by shutoff of viral 
genome expression, except of the transcription of the latency-associated transcript 
(LAT).
During maintenance of latency the viral genome persists as a stable episomal 
element and the viral genome is associated with cellular histones and adopts a 
chromatin-like structure (Deshmane and Fraser, 1989) that is probably not extensively 
methylated (Dressier et al., 1987). The LAT region is the only known transcript that is 
abundantly expressed during this stage of latency.
External stimuli (e.g. stress and immunosuppression) can initiate the 
reactivation from latency and stimulate viral gene expression followed by the lytic 
gene expression cascade.
The primary transcribed LAT is an 8.5 kb unstable product that is spliced into the 
most abundant 2 kb LAT transcript (Farrell et al., 1991; Krummenacher et al., 1997). 
In neurons the 2 kb LAT can also be spliced to yield 1.4 and 1.5 kb transcripts (Mador 
et al., 1995). The majority of LAT is not capped, lacks a consensus poly(A) addition 
site, and appears to be circular (Jones, 2003). Although the exact function of LAT has 
remained obscure, it is generally accepted that it is multifunctional, and that it plays 
an important but not essential role in latency (reviewed in Burton et al., 2001; Jones, 
2003). LAT is predominantly nuclear localized and associated with polyribosomes, 
suggesting that it can be translated or regulates translation (Goldenberg et al., 1997; 
Ahmed and Fraser, 2001). LAT contains small open reading frames (ORFs) 
(Wechsler et al., 1989; Coffin et al., 1998; Dolan et al., 1998) and it has been 
suggested that LAT encodes for a putative protein that is potentially involved in 
reactivation (Thomas et al., 1999; Thomas et al., 2002). LAT is complementary to 
ICPO and overlaps the ICPO transcript, suggesting that it inhibits ICPO expression by
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antisense mechanism. Finally, it has been suggested that LAT is anti-apoptotic and 
enhances neuronal survival (Pemg et al., 2000).
The expression of LAT is regulated by two promoters that are located upstream of the 
start site of LAT, latency-associated promoters 1 and 2 (LAP1 and LAP2). The 
promoter fragments can cis activate a reporter gene in transiently transfected cells 
(Goins et al., 1994; Chen et al., 1995). LAP1 is a TATA box containing promoter, 
located 28bp upstream of the primary LAT transcript, and critical for directing LAT 
expression in sensory neurons (Dobson et al., 1989; Mitchell et al., 1990; Deshmane 
et al., 1993; Chen et al., 1995). LAP2, located between LAP1 and the 5’end of the 2kb 
LAT, does not contain a TATA box, but includes regulatory elements frequently 
found in the promoters of housekeeping genes, and promotes the expression of the 
stable 2kb transcript under lytic conditions (Chen et al., 1995). LAP2 functions as a 
long-term enhancer in latently infected mice and is also required for maintaining 
LAP1 promoter activity (Lokensgard et al., 1994; Lokensgard et al., 1997; 
Berthomme et al., 2000). Within the LAT promoter region a high abundance of 
binding sites for cellular transcription factors can be found (reviewed in Jones, 2003) 
and since many of these factors can also been detected in non-neuronal cells it might 
explain that the LAT promoter elements can direct transgene expression in non­
neuronal cells (Batchelor and O'Hare, 1992; Batchelor et al., 1994; Berthomme et al., 
2000).
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Figure 1-11: The Latency Associated Transcript (LAT).
1.7.3 HSV-1 manipulations for gene delivery
Wild-type HSV-1 infection is toxic and inevitably leads to death of the infected cells. 
The potential use of HSV-1 as a gene delivery vector therefore requires the 
elimination of pathogenicity (except applications for the destruction of e.g. neoplastic 
tissue) without losing the advantageous features, such as broad host range, long-term 
gene expression or propagation to high titres. Vector development has focused on two 
main strategies: construction of defective and disabled vectors.
1.7.3.1 HSV-1 amplicons (defective HSV-1 vectors)
HSV-1 amplicons, also referred to as “defective HSV vectors” (Geller and 
Breakefield, 1988; Geller and Freese, 1990), were originially discovered as 
contaminating wild-type-sized (about 150 kb) defective genomes composed of 
multiple repetitions of a partial HSV sequence organized in concatamers (Spaete and 
Frenkel, 1982). The monomers contain at least one origin of viral DNA replication 
and a DNA cleavage/packaging sequence. Since these virions are unable to replicate
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in the absence of a helper virus, they offered a potential vector system for gene 
delivery. The reiterated sequence of one of these defective viruses was cloned into a 
plasmid vector and the generated amplicon was sufficient to direct concatameric 
packaging of the plasmid sequence into HSV-1 virions in the presence of a 
complementing helper virus (Spaete and Frenkel, 1982; Spaete and Frenkel, 1985). As 
multiple copies of the transgene can be inserted by this method, high level gene 
expression can be achieved, large sizes of foreign DNA inserted, and the construction 
of the amplicons is straightforward (Geller and Breakefield, 1988). However, a major 
drawback of this system was the use of helper virus, which physico-chemically is 
indistinguishable from amplicon vetors, and therefore difficult to remove (Hermens 
and Verhaagen, 1998). Contaminating replication-deficient helper virus can be 
responsible for the induction of cytopathic effects and immune responses (Johnson et 
al., 1992; Wood et al., 1994; Ho et al., 1995) and bears the risk of generating 
replication-competent virus. This has led to development of helper-virus free 
packaging systems by delivering the required HSV genomic DNA using cosmid 
(Fraefel et al., 1996) and bacterial artificial chromosome (BAC) systems (Saeki et al., 
1998). By additionally deleting EE genes from these complementing vectors (Saeki et 
al., 2001), the generation of replication-competent virions and cytotoxicity could be 
significantly reduced. To date, the application of amplicons is mainly limited by the 
rather short-term (days to months) gene expression, that may be the result of loss of 
transgene DNA due to degradation, downregulation of transgene expression, or 
immune rejection (Sena-Esteves et al., 2000).
Successful amplicon based gene delivery has been demonstrated in vitro (Battleman 
et al., 1993; Casaccia-Bonnefil et al., 1993; Geschwind et al., 1994; Geller et al., 
1995) and in vivo (Geller et al., 1997; Costantini et al., 1999; Sandler et al., 2002; 
Harvey et al., 2003; Oh et al., 2003). Geller demonstrated stable reporter gene 
expression in various primary neuronal cultures from the adult rat CNS using a pHSV 
amplicon vector driving LacZ under the immediate early 4/5 promoter (Geller and 
Freese, 1990). Other reports demonstrated gene delivery to cortical (Detrait et al., 
2002), striatal (Freese and Geller, 1991; Aboody-Guterman et al., 1997) and 
mesencephalic neuronal cultures (Costantini et al., 1999), as well as embryonic stem 
cells (Vicario and Schimmang, 2003).
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1.7.3.2 Disabled vectors
Disabled vectors have foreign genes directly inserted into the viral genome while 
genes involved in the production of cytopathic effects are deleted. The large size of 
the HSV-1 genome does not allow cloning of a restriction fragment directly into it. 
However, the foreign gene flanked by at least lkb of unaltered viral DNA can be 
inserted by co-transfection with viral DNA (Coffin et al., 1996). As the viral DNA 
remains infectious, a lytic cycle proceeds and by homologous recombination, the 
foreign DNA is introduced into the virus at a site in the viral genome dictated by the 
flanking region. A small percentage of the resulting viral plaques will be recombinant 
virus which can be selected due to phenotypic differences (marker gene acitivity or in 
case of an essential gene deletion, growth in a complementing cell line).
As an approach to eliminate cytotoxicity of HSV-1 either essential or non-essential 
genes can be deleted. Essential genes are absolutely required for growth and 
pathogenicity and thus, their deletion requires complementation in trans for 
propagation in culture. Non-essential genes are only required for growth in vivo and 
therefore do not need to be complemented for virus propagation in vitro. Elimination 
of pathogenicity aims not only to prevent viral replication in cells to which transgenes 
are to be delivered, but also to minimise the expression of cytotoxic gene products 
that may still be produced even in the absence of viral replication (Burton et al., 
2002).
The first generation of disabled HSV-1 vectors were deleted for non-essential genes, 
such as thymidine kinase (tk) gene (Ho and Mocarski, 1988) or the RL1 gene 
(encoding for ICP34.5) (Chou et al., 1990; McGeoch et al., 1991). ICP34.5 is thought 
to act by inhibiting the cessation of protein synthesis associated with apoptosis in 
some nonpermissive, dividing cells (Chou and Roizman, 1992; Chou and Roizman, 
1994; Chou et al., 1995) and thus, preventing programmed cell death in these cells to 
allow continued virus replication. ICP34.5 deleted viruses showed a significant 
decrease in neurovirulence (Chou et al., 1990) and were indeed replication-deficient 
in the CNS and sensory ganglia of mice (Chou et al., 1990; MacLean et al., 1991).
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However, at some primary sites of infection the mutant was still found capable of 
replication (e.g. footpad, ependymal cells) (Robertson et al., 1992; Kesari et al., 
1998), and it is believed that ICP34.5 null mutants permit viral replication in actively 
dividing cells but not in terminally differentiated cells (Brown et al., 1994). ICP34.5 
deleted vectors expressing LacZ under control of the LAT promoter gave transient 
transgene expression in neuronal tissue in vivo (Coffin et al., 1996). However, 
expression of viral antigens was not abolished and caused inflammatory responses in 
the CNS (McMenamin et al., 1998).
Considerable effort has been undertaken to construct disabled viruses that are blocked 
at a very early stage in the lytic regulatory cascade to establish a state that is similar to 
latency (Dobson et al., 1990; Katz et al., 1990). By elimination of IE genes 
proceeding E and L gene expression can efficiently be aborted, and of particularly 
interest is the deactivation of the essential genes products ICP4 and ICP27 (Burton et 
al., 2002). One of the first replication-deficient HSV-1 vectors developed was deleted 
for ICP4 (DeLuca et al., 1985) that is unable to replicate in noncomplementing cells 
in culture. However, this single manipulation was not adequate to completely prevent 
cytotoxicity, since expression of the remaining IE gene products (ICPO, ICP22, ICP27 
and ICP47) as well as ICP6 and ORF P were toxic to host cells (Johnson et al., 1994; 
Wu et al., 1996; Samaniego et al., 1998). As shown before (Figure 1-10) IE genes are 
negatively regulated by ICP4, such that infection with ICP4 disabled virus results in 
their overexpression causing an extensive cell death in the absence of viral replication 
(DeLuca et al., 1985; Krisky et al., 1998; Moriuchi et al., 2000). This has lead to 
development of vectors that were systematically deleted for other LE genes to reduce 
or eliminate the toxic effects of ICP4 deletion mutants (reviewed in Glorioso et al., 
1995). However, additional deletion of ICP22 and/or ICP47 did not result in reduced 
cytotoxicity (Johnson et al., 1992), nor did the deletion of Ul41 (Johnson et al., 1994).
With the construction of cell lines supplying ICP4 and ICP27 in trans the generation 
and propagation of ICP4/ICP27 double mutant viruses has become possible that could 
also be further impaired for other non-essential IE genes (Wu et al., 1996; Samaniego 
et al., 1998; Krisky et al., 1998). Characterization of these vectors showed that 
simultaneous deletion of genes encoding for ICP4, ICP27 and ICP22 improves vector
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cytotoxicity and primary neuronal cultures expressed delivered transgenes for more 
than 21 days in vitro (Krisky et al., 1998). However, in cells infected with these triple 
mutants, cellular DNA replication and cell division were impaired (Wu et al., 1996). 
Electron microscopy analysis revealed accumulation of ICPO inclusions in the nucleus 
of the infected cells (Wu et al., 1996). On the other hand, viruses deleted for ICP4, 
ICP27 and ICPO also showed reduced cytotoxicity but not arrest of cell division 
(Samaniego et al., 1997) suggesting that ICPO is responsible for cell cycle 
impairment.
Quintuple IE gene deleted vectors (ICP0':ICP4':ICP22':ICP27':ICP47') have also 
been constructed, and are entirely non-toxic to cells (Samaniego et al., 1998). 
Although the vector persists for extended periods in the cells (Samaniego et al., 1998) 
it only grows poorly in culture and gives low levels of transgene expression in the 
absence of ICPO (Samaniego et al., 1998). Therefore, this virus has little use as a 
vector in gene therapy. Cell lines engineered to supplement for all IE genes could 
improve the growth of these fully disabled vectors, but are difficult to generate due to 
toxic effects of the gene products (Krisky et al., 1998). It has been shown that post- 
translational processing of ICPO is different in neurons than from glia (Chen et al., 
2000), and it appears that ICPO undergoes proteolytic degradation in neurons. Thus, it 
is hypothesised that deletion of ICPO with the purpose of transgene delivery to 
neurons may not be required.
Another approach that has been undertaken to reduce vector cytotoxicity involves the 
inactivation of the gene encoding for VP 16, the transactivator of IE promoters 
following virus infection (Johnson et al., 1994; Preston and Nicholl, 1997; Thomas et 
al., 1999; Palmer et al., 2000; Marshall et al., 2000; Lilley et al., 2001). Since IE gene 
expression relies on VP 16 its inactivation potentially reduces the expression of the IE 
genes without the need to delete individually all the IE genes and construction of 
complementing cell lines. Since VP 16 is an essential structural component of the 
virion, it cannot be deleted, and providing the gene product in trans would result in 
the assembly of virions containing fully functional VP 16. As alternative approach, a 
mutation has been inserted in the VP 16 gene that disrupts a domain of the protein 
responsible for the interaction with with Oct-1 and HCF but allows it to retain its
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structural role (Ace et al., 1989). The VP16 mutation was inserted into HSV-1 strain 
17+, and the resulting virus (in 1814) was unable to transinduce IE gene expression, 
expressed IE gene products at low levels and was avirulent in mice (Ace et al., 1989). 
Propagation of VP 16 deleted viruses does not require complementation in culture and 
the supplementation of hexamethylbisacetamide (HMBA) allows transactivation of IE 
gene expression and viral growth in vitro (McFarlane et al., 1992). The in 1814 
viruses have been used as backbone for further deletions and inactivations of IE genes 
to reduce basal expression of the encoded cytopathic proteins (Preston and Nicholl, 
1997; Marshall et al., 2000). Ultimately, this has led to the development of a vector 
combining the VP 16 mutation with deletions in ICP4, ICP27 and ICP34.5 (Lilley et 
al., 2001). In non-complementing cell lines this vector expressed only minimal 
amounts of the IE gene products ICPO, ICP22 and ICP47. It can easily been 
propagated to high titre stocks, allows high gene delivery to neuronal cells in vitro 
and in vivo, and maintains expression for extended periods depending on the chosen 
promoter (Lilley et al., 2001).
1.7.3.3 Using LAT elements for transgene expression
The fact that HSV-1 can establish a latent state during which no lytic genes are 
expressed, but a region of its genome remains transcriptionaly active (LAT), makes it 
very attractive for development of vectors exploiting the LAT region for potential 
long-term transgene expression. Since the LAT genes are not essential for 
establishment, maintenance, or reactivation from latency (see above), it is possible to 
insert transgenes within the LAT loci, disrupting the LAT genes and using the LAT 
cis-acting regulatory sequences to drive transgene expression (Burton et al., 2001).
Several studies have shown that the LAP promoter region can be used for long-term 
transgene expression in the peripheral nervous system (PNS) (Goins et al., 1994; 
Lachmann and Efstathiou, 1997; Goins et al., 1999; Palmer et al., 2000). In summary, 
these studies have shown that the LAP1 seems to drive high-level short-term reporter 
gene expression when placed within the LAT region or ectopically from another 
region in the genome. LAP2, on the other hand, allows extended transgene 
expression, but only at low levels. Combining the high-level expression features of
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LAP1 with the long-term activity associated with LAP2 by placing a lacZ gene 
downstream of an internal ribosome entry site (IRES), did indeed allow increased and 
long-term transgene expression (Lachmann and Efstathiou, 1997; Marshall et al., 
2000). Transgene expression could further be improved with the use of heterologous 
promoters by inserting CMV or MMLV promoters adjacent to the LAP1 and LAT P2 
fragment (LAP2 plus 700bp at the 3’end) (Palmer et al., 2000).
While HSV-1 naturally establishes latency in sensory neurons, its activity within 
neurons of the CNS is less well understood. Following an acute infection, replication- 
competent and neuro-attenuated vectors persist in CNS neurons where they transcribe 
the LAT region (Drummond et al., 1994; Kesari et al., 1996; Smith et al., 2000) 
Although long-term expression using the latency promoter system has been 
demonstrated with a replication-competent attenuated vector (Smith et al., 2000), only 
transient gene expression was observed with replication-deficient viruses (Oligino et 
al., 1998). Intrastriatal injections of a vector deleted for ICPO and ICP4 that 
additionally contained an insertion in the VP 16 gene abolishing its transactivating 
activity, showed stable reporter gene expression from LAP for up to 4 weeks 
(Scarpini et al., 2001). Cells expressing the reporter gene were found around the 
injection site and in distal regions to it, such as cortex, thalamus, and substantia nigra. 
However, transgene expression dramatically dropped after 7 weeks post injection, 
which could not be explained with the death of the infected cells since viral genomes 
were detected for up to 24 weeks in the CNS (Scarpini et al., 2001). Strong reporter 
gene expression was also detected in a highly disabled vector (ICP27‘:ICP4:ICP34.5' 
:VP16mutated) driving the lacZ gene under a LAP1/LATP2/CMV heterologous 
promoter (Lilley et al., 2001). After intrastriatal injection the vector undergoes 
retrograde transport to cell bodies located in the substantia nigra and exerts significant 
transgene expression for up to 1 month in vivo. In conclusion, the studies have shown 
that using the latency promoters extended transgene expression can be achieved not 
only in the PNS but also in neuronal tissue of the CNS.
Viral promoters other than the latency promoters give only short-term transgene 
expression in CNS neurons (Bloom et al., 1995; Howard et al., 1998; Yamada et al., 
1999; Marconi et al., 1999).
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1.8 Gene therapeutic approaches for PD
Gene therapy can be defined as the delivery of engineered genetic material into a host 
cell such that it can perpetuate the production of the desired gene product. In the case 
of PD most gene therapeutic approaches have focused on either the delivery of 
enzymes involved in biosynthesis of dopamine or the expression of neurotrophic 
factors. Other gene products considered for use have roles in the protection against 
apoptosis or exhibit anti-oxidative properties. The first gene therapeutic trial for PD 
has been launched in August 2003 using a combination of gene delivery approach and 
surgical treatment. Preliminary results are expected at the end of 2004 (see below). 
Depending on the route of administration gene therapy for PD can be divided into ex 
vivo gene therapy or in vivo gene therapy. In ex vivo approaches the patients cells are 
manipulated in vitro prior to being transplanted into the host, while in vivo approaches 
involve direct gene transfer into the host somatic cell in situ (Le and Frim, 2002). The 
fact that the depletion of a single, well defined group of neurons causes PD, along 
with the availability of well characterized animal models, makes PD potentially 
amenable to gene therapy.
1.8.1 Ex vivo gene therapy strategies
The advantage of ex vivo approaches is that gene expression can be assessed and 
manipulated prior to implantation. Genetically manipulated cells can be considered as 
biological “minipumps” releasing therapeutic factors at the grafting site. However, a 
frequent occurrence and significant limitation is the low level of cell viability that is 
found after grafting.
Attempts have been described using immortalised cell lines expressing L-DOPA and 
TH (Freed et al., 1986; Horellou et al., 1990; Date et al., 2000), encapsulated tumor 
cell lines (Lindner et al., 1995) or GDNF expressing neural stem cell lines (Akerud et 
al., 2001). However, major concerns regarding cell lines arise due to the possibilities 
of oncogenic spread, and the use of tumor cell lines in human clinical gene therapy 
seems unlikely.
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Other cell sources with potential therapeutic value after genetic modification are 
primary fibroblasts, astrocytes and neural precursor cells. Fibroblasts have been 
engineered to express neurotrophic factors such as BDNF (Frim et al., 1994; Levivier 
et al., 1995) and GDNF (Perez-Navarro et al., 1996), as well as enzymes involved in 
dopamine synthesis (Wolff et al., 1989). The advantage of using fibroblasts is that 
they can easily be harvested from the patient, e.g. by skin biopsy, and transplanted 
autologously after modification in vitro, thereby reducing the risk of graft rejection.
In similar approaches astrocytes have successfully been modified and transplanted 
(Lundberg et al., 1996; Ridet et al., 1999). Astrocytes play an important role as 
supportive neural cell type and their long lifespan and efficient secretory system make 
them attractive candidates for gene delivery (Lin et al., 1997; Ridet et al., 1999; 
Serguera et al., 2001). Gene expression can be targeted by using the promoter for glial 
fibrillary acidic protein (GFAP) as it has for instance been shown for the long term 
expression of TH in a rat model of PD (Cortez et al., 2000). Other examples using 
astrocytes as cell vehicle have demonstrated expression of neurotrophic factors, such 
as GDNF (Ericson et al., 2002) or BDNF (Yoshimoto et al., 1995). However, it has 
been suggested that astrocyte maturation in vitro might be accompanied by 
biochemical and functional changes that limit their capacity to support axon growth 
(Ostenfeld et al., 2002).
Neural precursor cells have also been engineered to express therapeutic transgenes. 
For instance, neurospheres derived from rat embryonic striatal tissue have been 
transduced with GDNF expressing lentivirus and were grafted into hemiparkinsonian 
rats where GDNF increased the survival and neurite outgrowth of precursor cells, 
however, an approach that did not improve behavioural impairment (Ostenfeld et al., 
2002). An advantage of using precursor cells is that they retain their migratory 
potential and hence, spread through a larger region and often move towards the area 
of damage (Hoehn et al., 2002). Furthermore, it might become possible to generate 
precursor cells from the patients themselves to be genetically manipulated, thereby 
reducing the risk of immune rejection. As discussed elsewhere in this study, neural 
precursor cells could ultimatively been engineered to predifferentiate into an 
immature dopamine phenotype and fully mature post implantation. In this model
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precursor cells would terminally differentiate and integrate as dopaminergic neurons 
in situ, thereby increasing survival and functional implementation into the existing 
circuitry. However, the factors required to induce an immature dopamine phenotype 
still need to be elucidated and it is not known if in the adult, damaged brain the clues 
are present that are required for a terminal differentiation into a dopaminergic 
neuronal phenotype.
1.8.2 In vivo gene therapy strategies
For a direct gene transfer of genetic to the host somatic cell, viral vectors have 
become the prefered tool due to higher gene delivery efficiency compared to non-viral 
system. Although many viral vectors are in common use, the optimal viral vectors 
needs to be assessed for each specific application. Vector choice is determined by 
efficiency and specificity for the the target cell, the duration of required transgene 
expression, whether regulation of the transgene expression is required, and the level 
of toxicity that is tolerated. Similar to ex vivo approaches, current in vivo strategies 
focus on prevention of cell death and delivery of genes involved in dopamine 
biosynthesis.
Local expression of apoptotic inhibitors prevents the loss of toxic induced 
dopaminergic cell loss as shown by HSV-1 delivered bcl-2 (Yamada et al., 1999), 
adenovirus delivered human neuronal apoptosis inhibitor protein (NAIP) (Crocker et 
al., 2001) or AAV delivered apoptotic protease-activating factor-1 (apaf-1) 
(Mochizuki et al., 2001). Although apopotosis has been reported as one possible 
mechanism of cell death in the SN of PD (reviewed by Vila and Przedborski, 2003) its 
role is still controversial. Furthermore, prolonged expression of anti-apoptotic factors 
has not been fully explored and as some of these factors are proto-oncogenes, their 
therapeutic use provides safety concerns (Burton et al., 2003).
The most promising neurotrophic factor to prevent neurodegeneration and restore 
functionality is GDNF (see before) and its therapeutic value has been demonstrated by 
direct delivery to rodents and primates using lentiviruses, adenoviruses, adeno- 
associated virus (for review on these vectors see Bjorklund et al., 2000) and HSV-1
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(Natsume et al., 2001). The studies showed robust GDNF expression after direct gene 
transfer into the striatum or substantia nigra, trophic effects in various animal models 
of PD, and restorative effects even after the toxic insult has occurred. However, long­
term expression of lentivirus delivered GDNF induced aberrant sprouting 
accompanied by spontaneous abnormal motor behaviour (Georgievska et al., 2002) 
raising safety concerns over the long-term effects of GDNF. In other studies 
combined expression of GDNF with anti-apoptotic factors, such as X-linked inhibitor 
of apoptosis (XIAP) (Eberhardt et al., 2000), or bcl-2 (Natsume et al., 2001) showed 
synergistic effects on cell survival and functional recovery.
Early gene therapy studies for PD focused on the delivery of enzymes involved in the 
metabolism of dopamine, such as tyrosine hydroxylase, aromatic acid decarboxylase 
(AADC) or GTP-cyclohydrolase I (GCH1) that synthesises a cofactor required for 
AADC. Multiple vector systems have been constructed to express either of these 
factors or combinations (Burton et al., 2003), with the best result obtained from 
simultaneous expression of all three enzymes. Although enhanced dopamine 
production can be achieved accompanied by behavioural improvement, it is unclear 
whether the non-physiological sustained delivery of dopamine will alleviate the 
problems of adverse effects, similar to those experienced with the use of levopoda.
Surprisingly, the first clinical phase I trial for PD that has been approved by the US 
Food and Drug Administration that will try to reduce the overstimulation of the 
globus pallidus interna through production of the inhibitory neurotransmitter gamma- 
amino butyric acid (GABA) using AAV (During et al., 2001). AAV expressing 
glutamic acid decarboxylase (GAD), a key enzyme in the synthesis of GABA, will be 
injected into the STN. Since the STN is disinhibited in PD leading to symptoms such 
as tremor, rigidity and bradykinesia, GABA expression is expected to re-inhibit the 
STN and thus, to ameliorate the symptoms. Virus injection will be performed together 
with unilateral STN stimulator implantation. In case that GAD expression has an 
unanticipated deleterious effect, then the STN can be either electrically silenced or 
ablated using the stimulator without additional surgery being required. Significant 
setbacks have been experienced in recent gene therapy clinical trials due to the death 
of a patient treated for a partial deficiency of the liver enzyme ornithine
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transcarbamylase (Lehrman, 1999) using adenoviral vectors and two children 
developing vector induced leukaemia after treatment for severe combined 
immunodeficiencies (SCID) (Hacein-Bey-Abina et al., 2003) with disabled 
retroviruses. Therefore, it seems that safety issues will play a particularly important 
role in the described trial for PD. Viruses are injected into a region of the brain that is 
sometimes surgically removed as standard treatment and thus offers a fallback 
position should the safety of the gene transfer become an issue (Howard, 2003). 
However, by using AAV the risk of viral integration into proto-oncogenes and other 
host genes still remains, although at a very low level considering the limited degree of 
AAV integration and that a non-dividing cell population is transduced.
102
1.9 Thesis aims
The previous sections have shown that the cause of Parkinson’s disease is still 
unknown, and so far all available therapies aim to treat the major symptoms of the 
disease rather than the cause. Since the most prominent characteristic of the disease is 
the almost complete loss of midbrain dopaminergic neurons, a main focus has been 
the replacement of these cells. Various cell sources have been suggested, but the 
diverse developmental potential and self-renewal capacity make stem cells 
particularly interesting.
Foetal and adult neural precursor cells have become a promising cell source for the 
generation of dopaminergic neurons since they generally do not involve ethical 
concerns or form teratoma, the main disadvantages of embryonic stem cells. 
However, signals required for the conversion of multipotent precursor cells into 
dopaminergic neurons have remained obscure. Several viral vector systems have been 
described to deliver genetic material to neural precursor cells. To date no thorough 
studies have been published describing the use of replication-deficient HSV-1 as a 
vector system for neural precursor cells.
The work presented in this thesis aims to evaluate the potential of replication-disabled 
HSV-1 as a gene delivery vector for neural precursor cells. The main focus will be the 
study of gene delivery efficiency and cellular integrity of the transduced precursor 
cell. Optimised vectors will be modified to deliver instructive genes (ShhN, FGF2, 
FGF8, Nurrl). These factors have been chosen since they are known to be required 
for the embryonic development of dopaminergic neurons, as well as playing an 
important role in the generation of dopamine neurons from embryonic stem cells. The 
effects of the virally delivered transgenes on neural precursor cells will be studied 
with respect to dopamine genesis aimed at providing techniques for converting neural 
precursors into fully functional dopaminergic neurons either prior to 
transplantation/implantation or directly in vivo.
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C h a p t e r  2:  
M a t e r i a l s  a n d  M e t h o d s
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2.1 Materials
Unless otherwise stated, all chemicals were purchased from Merck Ltd. (Poole, 
Dorset, UK), Boehringer Mannheim (Lewes, East Sussex, UK) or Sigma Chemical 
Company Ltd. (Poole, Dorset, UK) and were of analytical grade.
General disposable plasticware was purchased from Sterilin (Stone, Staffordshire, 
UK) or Greiner (Stonehouse, Gloucester, UK).
Additional laboratory materials and reagents were supplied from one of the following: 
Insight Biotechnology Ltd. (London, UK); Nunc (Roskilde, Denmark); Amersham 
International pic. (Little Chalfont, UK); Qiagen (Chatsworth, USA); Difco 
Laboratories (Detroit, USA); Gibco-BRL Life Technologies Ltd. (Paisley, 
Renfrewshire, UK); Bio-Rad (Hemel Hempstead, UK); Promega Corporation 
(Madison, Wisconsin, USA); Whatman International Ltd. (Maidstone, Kent, UK); 
Pharmacia Biotechnology Ltd. (St Albans, UK); Millipore Ltd. (Watford, UK); 
Stratagene Ltd. (Cambridge, UK); Marligen Bioscience Inc. (USA); New England 
Biolabs Inc. (Hitchin, Hertfordshire, UK), Molecular Probes (Leiden, Netherlands), 
Chemicon (Temecula, USA), TCS Cell Works (Buckinghamshire, UK), DAKO 
(glostrup, Denmark).
All oligonucleotide primers were constructed by Genosys (Pampisford, Cambs, UK).
2.1.1 Standard buffers and solutions
PBS: NaCl (137mM), KC1 (2.7mM), Na2HP04.7H20  (4.3mM), KH2P04
(1.4mM)
PB: Na2HP04 (72mM), NaH2P04 (28mM), pH 7.2
TE: Tris-HCl (lOmM), EDTA (ImM), pH8.0
TAE: Tris base (400mM), sodium acetate (200mM), EDTA (20mM), pH8.3
TBE: Tris base (89mM), boric acid (89mM), EDTA (2mM), pH8.0
Luria Bertani (LB) media: 1% (w/v) Bacto®-tryptone
1% (w/v) NaCl
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0.5% Bacto®-yeast extract
2.1.2 Bacterial strains
The XLl-Blue (XL1-B) (Stratagene Ltd.) strain of Escherichia coli of genotype 
recAl endAl gyrA96 thi-1 hsdR17 supE44 rel Al lac [F’proAB Laclq ZAM15, TN 19 
(Tet)r] was used for all plasmid clonings.
2.1.3 Materials for Molecular Biology
Restriction and modifying enzymes and buffers (Promega, Madison, Wisconsin, 
USA)
Bacto®-agar, Bacto®-tryptone, yeast extract (Difco Laboratories, Basingstoke, UK) 
Ammonium persulfate, TEMED (Bio-Rad, Hemel Hempstead, UK)
Concert™ “midi-prep” plasmid extraction kit, 1Kb DNA ladder (Gibco-BRL- 
Lifetechnologies Ltd., Renfrewshire, Scotland, UK)
Gel band extraction kit, Rainbow™ couloured protein full range molecular weight 
markers, Hybond-C and Hybond-N membranes (Amersham International pic., Little 
Chalfont, UK)
Thermocyler (Eppendorf, Hamburg, Germany)
2.1.4 Recombinant proteins
All recombinant proteins were purchased from R&D and reconstituted in PBS 
containing 0.1% bovine albumin serum and stored in aliquots at -80°C. Mouse 
recombinant fibroblast growth factor 8b (FGF8b, #423-F8) was prepared at a stock 
concentration of 50/ig/ml; human recombinant basic fibroblast growth factor (FGF2, 
#233-FB) at a stock concentration of 20/xg/ml; mouse recombinant sonic hedgehog N- 
terminal (ShhN, #461-SH-025) at a stock concentration of 50/xg/ml.
Heparin (Sigma, H3149) was prepared in DMEM/F12 media at a stock 
concentration of 5mg/ml and stored in aliquots at -80°C.
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2.1.5 Materials for surgery and dissection
Halothane (Rhone Merieux Ltd., Harlow, Essex, UK)
Dissecting microscope (Olympus SZ40)
Hamilton microliter syringe (Hamilton Bonaduz AG, Bonaduz, Switzerland)
Micro 1 syringe pump controller Ultra micropump 1 (World Precision Instruments, 
USA)
Ultra micropump 1 (World Precision Instruments, USA)
Foredom Micro Motor MH1 45 (MHC, USA)
Surgical instruments (Fine Science Tools, Heidelberg, Germany)
Expiral (Sanofi Animal Health, Watford, UK)
Paraformaldehyde (Sigma, UK)
Michelle clips (Biological Services, UCL, UK)
Tissue chopper (McIIwan, USA)
2.1.6 Materials for tissue preparation
Cryostat, Leica CM1900 (Leica Instruments, Nusloch, Germany)
Microscope slides and coverslips (BDH Labaratory supplies, Poole, Dorset, UK) 
Antifade mounting media (Molecular Probes, Leiden, Netherlands)
2.1.7 Materials for neural progenitor culture
Dulbecco’s modified Eagle medium (DMEM) (11965-118; Gibco-BRL, USA) 
Neurobasal® medium (21103-049, Invitrogen, UK)
Ham’s F-12 (lx  solution) without L-glutamine (12422; ICN, Ohio, USA)
Accutase™ (TCS Cell works, Buckinghamshire, UK)
Poly-L-lysine (PLL) (P5899; Sigma, UK)
Poly (2-hydroxyethyl methacrylate) (Poly-HEMA) (P-3932; Sigma, UK)
0.1% Trypsin (T4424; Sigma, UK)
Trypsin inhibitor (T6522; Sigma, UK)
DNAse (D4527; Sigma, UK)
Laminin (L2020; Sigma, UK)
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B27 supplement (15420-062; Gibco-BRL, UK)
Human basic fibroblast growth factor 2 (FGF2) (233-FB; R&D Systems, UK)
Heparin (H3149; Sigma, UK)
Bellco German glass round coverslips (Bellco, Germany)
2.1.8 Materials for Immunolabelling
Rabbit Anti-Tyrosine Hydroxylase polyclonal (P40101-0; Pel-Freez, Arkansas, USA) 
Rabbit Anti-Glial Fibrillary Acidic Protein (GFAP) polyclonal IgG (Z0334; Dako, 
Glostrup, Denmark)
Mouse Anti-Neuronal Nuclei (NeuN) monoclonal IgGl (MAB377; Chemicon, USA) 
Rabbit Anti-Nurrl/Notl polyclonal (AB5778; Chemicon, USA)
Mouse Anti-/3-Tubulin Isotype HI (TuJl) monoclonal IgG2b (T8660; Sigma, UK) 
Rabbit Anti-FGF-2 polyclonal (sc-79; Santa Cruz Biotechnology, USA)
Mouse Anti-Oligodendrocyte marker 04 monoclonal IgM (MAB345; Chemicon, 
USA)
Mouse Anti-galactocerebroside GalC monoclonal IgG3 (MAB342; Chemicon, USA) 
Alexa Fluor® 350 goat anti-mouse IgM (A31552; Molecular Probes, Netherlands) 
Alexa Fluor® 546 goat anti-rabbit IgG (Al 1010; Molecular Probes, Netherlands) 
Alexa Fluor® 488 goat anti-rat IgG (Al 1006; Molecular Probes, Netherlands)
Alexa Fluor® 546 goat anti-mouse IgGl (A21123; Molecular Probes, Netherlands) 
Alexa Fluor® 488 goat anti-mouse IgG2b (A21141; Molecular Probes, Netherlands) 
Goat Anti-Rabbit IgM+IgG rhodamine conjugated (4010-03; Southern 
Biotechnology, Birmingham, USA)
Goat Anti-Mouse IgG rhodamine conjugated (1031-03; Southern Biotechnology, 
Birmingham, USA)
Goat Anti-Mouse IgG fluorescine conjugated (1031-02; Southern Biotechnology, 
Birmingham, USA)
Mouse Anti-Nestin monoclonal IgGl (MAB353; Chemicon, USA)
Rat Anti-BrdU monoclonal IgG2a (ab6326; abeam, Camebridge, UK)
Goat Anti-FGF8 (N18) polyclonal (sc-6958; Santa Cruz Biotechnolgy, USA)
Goat Anti-ShhN (N19) polyclonal (sc-1194; Santa Cruz Biotechnolgy, USA)
Mouse Anti-GAPDH IgGl (#4200, Ambion, UK)
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Anti-goat IgG horseradish peroxidase (P0160, Dako, High Wycombe, Bucks, UK) 
Anti-rabbit IgG horseradish peroxidase (P0217, Dako, High Wycombe, Bucks, UK) 
Anti-mouse IgG horseradish peroxidase (P0260, Dako, High Wycombe, Bucks, UK) 
Antifade mounting media (P7481, Molecular Probes, Leiden, Netherlands) 
4',6-Diamidino-2-phenyindole (DAPI) (D9564, Sigma, UK)
Hoechst 33258 (B1155, Sigma, UK)
2.2 Molecular Biology methods
2.2.1 Bacterial growth conditions
XLl-Blue cells were grown in sterile Luria Bertani (LB) (1% w/v Bacto®-tryptone, 
1% w/v NaCl, 0.5% w/v Bacto®-yeast extract) media (autoclaved at 120°C for 20 
mins at 10 lb square inch-1) containing either no antibiotic or 50 pg/ml of tetracycline 
overnight (O/N) in a Gallenkamp™ orbital shaker at 200 rpm. Stocks of tetracycline 
were made at 5 mg/ml in ethanol and stored at -20°C. Colonies of XL1-B were 
isolated by growing on LB plates containing 2% Bacto®-agar and 12.5 pg/ml of 
tetracycline.
2.2.2 Transformation of bacteria
Competent E. coli cells were prepared using a standard calcium chloride technique 
(Sambrook et al., 1989). Single bacterial colonies were selected and grown O/N in 10 
ml of LB containing no antibiotic. 100 pi of this starter culture was used to inoculate 
100 ml of LB containing no antibiotic up to an ODsgo of approximately 0.5 units. The 
bacteria were then pelleted by centrifugation at 3500 rpm for 10 mins at 4°C and any 
excess LB was discarded. The cells were resuspended in 10 ml of ice-cold 100 mM 
CaCl2 and incubated on ice for 30min. The cells were then pelleted by centrifugation 
as before and resuspended in 4 ml of ice-cold CaCl2 . The cells were then left on ice 
until required and used within 48 hours.
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200 pi of competent cells were transformed upon addition of DNA and subsequent 
incubation on ice for 30 min. The cells were then heat shocked for 90 seconds at 42°C 
and returned to ice for a further 2 min. 800 pi of LB was added to the cells and the 
suspension was incubated in the orbital shaker for 1 hour at 37°C/200 rpm. The cells 
were pelleted (10 min/3500 rpm), resuspended in 100 pi of LB and subsequently 
plated onto LB agar plates containing the appropriate antibiotic selection, either 50 
pg/ml of ampicillin. If detection of /2-galactosidase was required, the plates used 
contained 50pl of a 20mg/ml stock of 4-chloro, 5-bromo, 3-indolyl-/?-galactosidase 
(X-Gal) dissolved in dimethyl formamide.
2.2.3 Small scale plasmid DNA extraction (mini-prep)
The ‘mini-prep’ DNA extraction method used is based on an alkaline lysis method 
previously described (Bimboim and Doly, 1979). Single colonies of transformed cells 
were used to inoculate 3 ml of LB containing the appropriate antibiotic selection, and 
were incubated O/N in an orbital shaker (37°C/200 rpm). The cells from 1.5 ml of 
O/N culture were pelleted by centrifugation in a bench top microcentrifuge at 13000 
rpm for 2 min and resuspended in 100 pi of resuspension buffer (50 mM Tris-HCL 
pH 7.5, 10 mM EDTA pH8). Bacteria were then lysed by addition of 200 pi of lysis 
buffer (200 mM NaOH, 1% (v/v) Triton X-100) and neutralised by the addition of 
150 pi of neutralisation buffer (3 M sodium acetate pH5.5). The cell lysate was then 
centrifuged for 3 min at 13000 rpm and the pelleted precipitate was removed and 
discarded. 500 pi of isopropanol was then added to the supernatant, which was 
vortexed and centrifuged for 20 min at 13000 rpm to pellet the DNA. The supernatant 
was discarded and the DNA was washed with 70% ethanol, pelleted (5min at 
13000rpm), dried under vacuum and resuspended in 50 pi of double-distilled water 
(ddH2<D) containing 20 pg/ml RNase A. Plasmid DNA was stored at -20°C.
2.2.4 Large scale plasmid DNA preparation (midi-prep)
Single colonies from a bacterial plate or approximately 100 pi of a suspension 
bacterial culture were used to inoculate 400 ml of LB containing the appropriate
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antibiotic selection. The inoculated medium was incubated O/N in an orbital shaker at 
37°C/200 rpm. 100 ml of the O/N culture were spun down at 3000 rpm for 10 min. 
Plasmid DNA was then extracted using the Midi-Prep Kit (Gibco-BRL) following the 
manufacturer’s instructions. A typical yield of DNA using this method was 100 pg, 
which was resuspended in 100 pi of ddPkO.
2.2.5 Viral DNA preparation
A well of a 6 well plate of virally infected cells at complete cytopathic effect (CPE) 
was harvested by adding 1ml of DNAzol (Helena Biosciences, Sunderland, UK). The 
DNA was precipitated by adding 0.5 volumes of absolute ethanol and washed twice in 
75% ethanol. Ethanol was removed and the DNA pellet dried for 5min at RT. The 
DNA was resuspended in 200/zl of 8mM NaOH and incubated O/N at 4°C on a 
rotating wheel. For neutralization 23pi of 0.1M HEPES were added and the DNA 
stored at -20°C.
2.2.6 Restriction enzyme digestion
Plasmid DNA was enzymatically digested for analysis or isolation of DNA fragments. 
Analytical digests were performed in a total volume of 20pl, containing 5pi of mini- 
prep DNA or lpl of midi-prep DNA. 10 units of each enzyme were added and the 
appropriate buffer used at lx concentration. The volume was made up to a final of 
20pl with ddH20. Digests were incubated for 1 hour at the appropriate temperature. 
Depending on the size of the fragments of interest the digested DNA was run on a 
0.5-1.5% agarose gel and the bands visualized on a UV transilluminator.
Restriction digests required for isolation of DNA fragments were carried out in a total 
volume of 100 pi containing approximately 5 pg of midi-prep DNA, lOunits of each 
enzyme and the recommended buffer at lx concentration. Digests were incubated O/N 
at the appropriate temperature and then run on a 0.5-1.5% agarose gel. DNA bands 
were visualised on a UV transilluminator and the bands of interest were carefully 
excised using a scalpel. As required DNA was extracted from the agarose using the
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GFX™ PCR and Gel Band Purification Kit (Amersham) according to manufacturer’s 
instructions. The DNA was then eluted in a final volume of 15 jul.
2.2.7 Agarose gel electrophoresis
0.5-1.5% (w/v) agarose gels were made using lx TAE (0.4 M Tris base, 0.2 M 
sodium acetate, 20 mM EDTA pH8.3). Ethidium bromide was added to a final 
concentration of 0.5 pg/ml. Approximately 0.1 volume of lOx loading buffer (lx 
TAE, 50% v/v glycerol, 0.025% bromophenol blue) was added to DNA samples prior 
to loading. 1 kilobase (kb) ladder DNA marker was used size marker. DNA was 
electrophoresed at 80-120mA mA until the fragments were well separated. Bands 
were visualised on a UV transilluminator and photographed with Polaroid film.
2.2.8 Blunt-end reactions
For blunt ending, overhangs were treated with T4 DNA polymerase. After restriction 
digest, 1 pi of a 25 mM stock of dNTPs (dATP, dCTP, dTTP, dGTP) and 15 units of 
T4 DNA polymerase were added directly to the reaction. The reaction was incubated 
for 30 min at 37°C. T4 DNA polymerase was heat inactivated at 80°C for 20 min and 
then cooled on ice prior to the addition of further enzymes.
2.2.9 Phosphatase treatment
To prevent possible religation of vector ends, the vector DNA was dephosphorylated 
using calf intestinal alkaline phosphatase (CLAP). Vector DNA was extracted using 
the GFX™ PCR and Gel Band Purification Kit (Amersham) according to 
manufacturer’s instructions. DNA was resuspended in a total volume of 50pl ddt^O 
containing lx phosphatase buffer and 5 units CLAP. The reaction was incubated for 
45min at 37°C, DNA again extracted as before and resuspended in 10/d ddf^O.
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2.2.10 DNA ligations
Ligations were performed in a total volume of 30/d. Purified fragments of vector and 
insert were usually used in a ration of 1:3 (vector:insert) measured according to its 
approximate amount from a small sample run on an agarose gel. The liagtion mix was 
made up with lx ligase buffer and 3units of T4 DNA ligase in ddtbO. The ligation
mix was incubated for 1.5 hours at RT (cohesive ligation) or O/N at 16°C (blunt
ligation). The ligation reaction was transformed into XL1-1B cells (2.2.2).
2.2.11 DNA sequencing
For sequencing of PCR amplified inserts cloned into the pGemT easy vector 
(Promega) T7 and SP6 primers were used. Plasmid DNA was prepared at a 
concentration of lOOng/ml in ddFkO and the sequencing performed at external 
facilities (DNA Sequencing Facility of the Biochemistry Department at the University 
of Camebridge, UK).
For sequencing of the Nurrl gene internal primers were required. The following 
primer sequences were used:
Primer 1: 5 ’ CCAGATGCGCTTTGACGG
Primer 2: 5’ CCGTCAAAGCGCATCTGG
Primer 3: 5 ’ CCACGCACGCATTGCAAC
Primer 4: 5’ GTTGCAATGCGTGCGTGG
2.2.12 RNA extraction
All plastic tissue ware and equipment was pretreated with RNA ZAP (Sigma) or 
soaked in 0.1N NaOH. Tissue was dissected and immediately frozen in liquid 
nitrogen and stored at -80°C until RNA was prepared. Neurospheres were settled 
down, medium removed and immediately resuspended in TRIzol (Invitrogen). 
Resuspended neurospheres were stored at -80°C as required.
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Tissue or neurospheres were resuspended and homogenated in 1ml TRIzol 
(Invitrogen) by pipetting. Homogenate was incubated for 5min at RT, 200/d 
chloroform added and mixed by inverting for 15sec. Samples were incubated for 3min 
at RT, centrifuged for 15min at 12,000 rpm at 4°C and the upper aqueous phase 
transferred into a new tube. RNA was precipitated by adding 500/d isopropanol, 
incubation for lOmin at RT and subsequent centrifugation for lOmin at 12,000 rpm at 
4°C. The RNA pellet was washed with 75% EtOH, centrifuged for 5min at 7500g at 
4°C, the ethanol removed and the pellet air dried for lOmin at RT. The RNA was 
resuspended in 30/d DEPEC ddfkO and incubated for lOmin at 55-60°C. The RNA 
concentration and quality was assessed by measuring the A260/A280 ratio which was 
expected to be between 1.7 and 2.0. The RNA concentration was calculated based on 
the assumption that 1 OD260 equals 40/xg/ml RNA. RNA was stored in aliquots at - 
80°C.
2.2.13 DNAse treatment
For RT-PCR reaction the extracted RNA was DNAse treated in order to remove 
genomic DNA contaminations. 5/xg RNA were prepared with DEPEC ddl^O in a 
total volume of 20/d DNAsel mix containing lx reaction buffer and 2/d amplification 
grade DNasel (Invitrogen). The DNAse mix was incubated at RT for 15min and 
DNAse treatment stopped by adding 1/d of 25mM EDTA and incubation for 15min at 
65°C. The mixture was cooled down, collected by brief centrifugation and was 
directly used for reverse transcription.
2.2.14 First strand cDNA synthesis
Neurosphere RNA was reverse transcribed and subsequently amplified in two 
separate reactions. Tissue RNA was reverse transcribed and amplified with gene 
specific primers using One-Step RT-PCR kit (Qiagen).
First strand cDNA synthesis of 1/xg neurosphere RNA was performed using the 
Superscript First Strand Synthesis System™ (Invitrogen). The RT-PCR reaction was 
set up and carried out according to manufacturer’s instructions.
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2.2.15 PCR amplification
PCR amplifications for semi-quantitative RNA analysis were performed using 
Platinum Taq DNA Polymerase (Invitrogen). PCR reactions were set up using 2/d of 
prepared cDNA (2.2.14) in a total volume of 50/d according to manufacturer’s 
instructions. The PCR mix was gently mixed and transferred to the thermocycler. The 
standard PCR program used included a hot start at 94°C for 2min, denaturation at 94 
for 15 sec, annealing at the indicated temperature for 30sec and extension at 72°C for 
1 min. The number of PCR cycles was chosen as indicated. A final extension step at 
72°C for lOmin was performed. The PCR products were analysed on 1-2% agarose 
gels.
2.3 Cell culture methods
All tissue culture preparations were carried out under sterile conditions in a laminar 
flow safety cabinet. All viral preparations were performed under Health and Safety 
Category 2 Conditions.
All cell lines and viruses were stored long term in liquid nitrogen and during 
culture were maintained at 37°C in a 5% CO2 incubator in a humidified atmosphere.
2.3.1 Baby Hamster Kidney Cells
Baby Hamster Kidney cells (BHKs) Clone 13 (Macpherson and Stoker, 1962) were 
provided by Imperial Cancer Research Fund (ICRF), London, UK. BHK cells were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) containing 100 units/ml 
penicillin/streptomycin (also refered to as serum free medium, SFM) supplemented 
with 10% Fetal Calf Serum (FCS) and is referred to as full growth media (FGM). 
BHK cells were passaged by washing in Hank’s Balanced Salt Solution (HBSS) at 
room temperature (RT) and then incubated with a minimal volume (enough to cover 
the area of flask) of 10% (v/v) trypsin in versene. An appropriate volume of FGM was 
added to neutralise the trypsin/versene and the cells were then divided accordingly.
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2.3.2 27/12/M:4 (M49)
M49 is a stable cell line derived from BHK cells expressing the HSV-1 genes ICP4 
and ICP27 (Thomas et al., 1999b). Cells were cultured in FGM containing 5% (v/v) 
tryptose phosphate broth, 800/xg/ml of neomycin and 750/xg/ml of zeocin. Cells were 
passaged as described before for BHKs (2.3.1).
2.3.3 C3H10T1/2 mouse fibroblasts
Mouse Fibroblast C3H/10T1/2 cells Clone 8 (ATCC #CCL-226) were maintained in 
DMEM medium containing 10% FCS. Cells were passaged as described in (2.3.1).
2.3.4 PCI 2 cells
Rat PC 12 cells (ATCC #CRL-1721) were maintained in DMEM containing penicillin 
(lOOunits/ml), streptomycin (100/ig/ml), 10% horse serum (Gibco) and 5% foetal 
bovine serum (Gibco) on poly-L-lysine coated (O.lmg/ml) tissue flasks. Cells were 
passaged as described in (2.3.1).
2.3.5 293 cells
293-T cells were obtained from the European Collection of Animal Cell Cultures. 
Cells were cultured in full growth medium containing 10% FCS and passaged as 
described in (2.3.1).
2.3.6 Preparation of primary dissociated neural progenitor cultures
Time-mated rats were terminated by CO2 asphyxiation followed by cervical 
dislocation. Following abdominal laparotomy, uterine horns were removed and 
collected in Hanks’ balanced salt solution (HBSS, w/o Ca++ and Mg++, Gibco). The 
embryos were removed under aseptic conditions, collected in HBSS at room
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temperature and crown-rump lengths measured to verify age. The heads were 
separated from the embryos and the skull and meninges removed using dissections 
scissors (number 5, DuMont). The CNS was exposed and the brainstem isolated. The 
mesencephalic flexure is deeply curved at this stage of development. To remove the 
mesencephalon a cut was made at the junction of the diencephalon and 
mesencephalon using the prominent diencephalic protuberance as a point of reference 
and another cut at the mesencephalic/metencephalic boundary. Using microscissors 
the ventral part of the mesencephalon was released by cutting along the tegumental 
midline through the ventricular opening. The dissected ventral mesencephalic tissue 
has a butterfly similar shape and the comers comprising tegmental tissue were 
trimmed off. Any attached meninges was removed and the explants pooled in HBSS 
on ice. The telencephalon was used to excise cortex by cutting through the ventricle 
from caudal to rostral and removing the cortical tissue from the ganglionic eminence. 
The striatum comprising medial and lateral ganglionic eminence was excised and 
cortical tissue trimmed off. Cortical and striatal explants were separately pooled in 
HBSS and stored on ice.
The HBSS was removed and the pooled explants were then incubated in 1.5ml 
trypsin (0.1% trypsin solution, Sigma) for lOmin at 37°C. The excess trypsin was 
removed and the explants incubated in 1.5ml soyabean trypsin inhibitor (0.1% in 
HBSS, Sigma) for 5min at 37°C, prior to rinsing in DNAse (0.1%DNAseI in HBSS, 
Sigma). Any excess buffers were removed and the explants were resuspended in 
culture media (Neurobasal based media for primary neural progenitor cultures or 
DMEM/F12 based media for neurosphere cultures; 50/d per dissected embryo). 
Explants were then dissociated into a quasi-single cell suspension by gentle 
tritutration using 1000/d Eppendorf pipette tips. Viability was estimated using the 
trypan blue exclusion method and cell density calculated.
2.3.7 Neural progenitor cultures
Dissociated neural precursor cells (2.3.6) were plated at a density of lxlO5 viable 
cells/well on PLL/Laminin coated glass coverslips (2.3.10) in a total volume of 30/d. 
After attachment cells were overlayed with 500/d Neurobasal® medium containing 
B27 supplement (2% v/v), L-Glutamine (500/dVl), penicillin (lOOunits/ml) and
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streptomycin (100/ig/ml). The medium in primary neural progenitor cultures was 
changed daily.
2.3.8 Neurosphere cultures
Dissociated rodent cortical and striatal cells were seeded at clonal density (20 viable 
cells/jul) into T75 flasks initially in a total volume of 10ml of defined serum-free 
proliferation medium (DMEM:HAMS-F12 at 3:1) supplemented with B27 (2% v/v), 
penicillin (lOOunits/ml), streptomycin (100/ig/ml) and fibroblast growth factor 
(20ng/ml, R&D). Dissociated mesencephalic rodent cells were plated at a density of 
100 viable cells//d in a total of 10ml proliferation medium. Only cultures to study the 
effects of heparin on viral transduction contained heparin (5/xg/ml). Two days after 
seeding 10ml fresh proliferation medium were added to the neurosphere cultures. The 
medium of neurosphere cultures was changed every three days by replacing half of 
the medium with fresh proliferation medium. Neurospheres were passaged after 7-10 
days by preparation of a quasi single cell suspension (2.3.6).
2.3.9 Preparation of a quasi-single cell suspension using Accutase™
Neurospheres were collected by brief centrifugation (lOOOrpm for 3min) and 
resuspended in 500/d Accutase™ followed by incubation at 37°C for 15min. 
Accutase™ was removed and neurospheres washed once in DMEM/F12 media and 
resuspended in 500/d differentiation medium. Neurospheres were triturated using a 
1000/d pipette tip, the cell density determined by the trypan blue exclusion method 
(2.3.12) and plated on PLL/Laminin coated glass coverslips. After attachment 
dissociated neural precursor cells were overlaid with 500/d differentiation media.
2.3.10 Coating of glass cover slips
Sterile glass coverslips (Bellco) were placed into the wells of a 24 well plate and 
overlayed with 500/d of 0.1 mg/ml Poly-L-Lysine (PLL) prepared in ddH20. After 
incubation for more than lhour at RT the PLL was removed and the coverslips rinsed 
with ddH20 three times. The plates were dried under sterile environment and stored at
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RT. Prior to use the coverslips were coated with laminin by placing 40/xl of 50/xg/ml 
laminin into the centre of the coverslip and incubation at 37°C for 30min. The laminin 
was removed and the spot washed three times with DMEM. For plating of cells the 
last wash was removed and the cells added in a total volume of 30/d. Cells were 
allowed to attach in a tissue culture incubator and subsequently overlaid with the 
appropriate medium.
2.3.11 Poly-HEMA coating of tissue culture plastic ware
For some neurosphere cultures tissue culture ware was coated with Poly-HEMA as 
required to prevent attachment to the tissue culture surface. Poly-HEMA is prepared 
at a final concentration of 12mg/ml in 95% ethanol. The tissue culture flasks were 
coated with 0.1 ml/cm of surface and allowed to dry O/N in a sterile environment.
2.3.12 Trypan blue cell exclusion method
Dissociated cells were diluted as required (1/10 to 1/100) in 0.4% Trypan 
blue/DEMEM (1:1) (T8154, Sigma). 10/ri of the dilution was prepared in an improved 
Neubauer chamber (Hausser, USA) and four groups counted under a bright light 
microscope. Cells that did not include the dye were counted as viable cells. The cell 
concentration was determined accordingly.
2.3.13 Cell Line Storage
Cell stocks for long term storage were prepared by suspending the cells from one 175 
cm2 flask in freezing media A (DMEM supplemented with 20% FCS) followed by 
addition of an equal volume of freezing media B (DMEM supplemented with 40% 
FCS and 16% dimethylsulphoxide (DMSO)) and aliquoted into 1.5 ml cryovials. 
These were slowly cooled to -70°C, and then immersed in liquid nitrogen. The cells 
were recovered by rapidly thawing the contents of one cryovial and then transferred to 
a 25 cm flask of pre-warmed medium. The medium was changed or the cells 
passaged the following day.
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2.4 Virus construction and propagation
Hexamethylene 6/s-acetamide (HMBA) was added to the growth media at a final 
concentration of 3mM in order to induce immediate early gene expression in HSV-1 
mutants with a mutated VP 16 gene (McFarlane et al., 1992). M49 cells were used in 
all cases for virus generation and propagation.
2.4.1 Homologous recombination transfections
M49 cells were co-transfected with 5-10pg of linearised plasmid DNA and 10-30/xg 
of purified viral DNA per transfection. The transfections were based on the calcium 
phosphate method as described previously (Stow and Wilkie, 1976). Cells were 
prepared to be 70-80% confluent. Two tubes were set up, A and B. Tube A contained 
31 pi 2 M CaCl2, 10 pg plasmid DNA and 20 pg herring sperm DNA. Tube B 
contained 400 pi HEBES transfection buffer. HEBES buffer contained 140 mM NaCl, 
5 mM KC1, 0.7 mM Na2HPC>4 , 5.5 mM D-glucose, 20 mM Hepes, pH 7.05 with 
NaOH and was filter sterilised with a 0.2 pm filter and stored at 4°C. The contents of 
tube A were carefully mixed by gentle pipetting and then added to tube B in a drop- 
wise manner with gently mixing. The mixture was then left for 20-40 min to allow the 
DNA to precipitate. Media was removed from the cell monolayer and the precipitated 
DNA mixture was then added (one transfection per well) and incubated for 7 hours 
prior to DMSO shocking. To DMSO shock, media was removed from the cells, and 
the cells were washed twice with 2 ml of FGM. 1 ml of ice-cold 20% (v/v) DMSO in 
HEBES transfection buffer was added to the cells and left for 90 seconds. The DMSO 
solution was removed and the cells were washed twice with 2 ml of FGM. A final 
volume of 2 ml of FGM was added to the cells and then these were incubated at 
37°C/5%C02 for 3-5 days until complete CPE was observed. The cells were then 
harvested and freeze-thawed. The harvested cells were titred (2.4.2) and the efficiency 
of the recombination determined by assaying for loss of reporter gene expression.
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2.4.2 Viral titration
Serial ten fold dilutions of a virus suspension (either harvested from homologous 
recombination or from a pure stock) were prepared in DMEM without FCS and plated 
onto 80% confluent wells of M49 cells in a total volume of 500/d. The virus was 
allowed to adsorb for 60 min at 37°C/5%CC>2 and then the monolayers were overlaid 
with 2 ml of a 1:2 (v/v) mixture of 1.6% carboxymethylcellulose (CMC):FGM 
supplemented with 3 mM HMBA. The cells were then incubated for a further 48 
hours at 37°C/5% CO2 and the number of plaques were counted in order to determine 
the titre of the virus in plaque forming units (pfu)/ml.
Cells expressing green fluorescent protein (GFP) required no pre-treatment and were 
visualised directly under an inverted fluorescent microscope at a wavelength of 
520nm.
2.4.3 Purification of viral recombinants by plaque selection
Titred transfection mixes were visualised under an epifluorescent microscope for viral 
plaques with the lack of GFP expression. The identified plaques were picked from the 
cell monolayer using a P20 Gilson micropipette (set at 3/d). Selected plaques were 
transferred into 100/d SFM and frozen at -80°C. The plaque suspension was thawed 
and 10/d and 90/d used to infect wells of a 6 well plate containing M49 cells at 80% 
confluency. Infection was performed as described in 2.4.2 and the cells were then 
incubated for a further 48 hours at 370C/5%CC>2. The plaque purification process was 
repeated until a pure population was obtained. When this was achieved a single 
plaque was used to infect one well of a 6 well plate and incubated until CPE was 
detected. The whole well was then harvested and its titre determined. This was then 
used as a master stock (MS) for large-scale propagation of the recombinant virus.
2.4.4 High titre stock production
Approximately 300/d of MS was used to infect 90% confluent M49 cells in 80cm2 
flasks. After incubation for lhour at 37°C/5%C02 cells were overlaid with FGM 
containing 3mM HMBA. Cells were harvested when complete CPE was observed.
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The virus was grown in 175cm2 flask until enough virus was obtained to infect 10 x 
224mm2 plates of M49 grown to 90% confluency. Each plate was infected with 
5xl06pfu of virus stock suspension in a total volume of 50ml FGM supplemented 
with HMBA. Cells were harvested by freezing at 80°C, followed by thawing and cell 
suspension of the plates was pooled. Cells were centrifuged at 3500rpm for 45min to 
remove cell debris. The supernatant was then sequentially filtered through a 5.0/mi 
and a 0.45/mi filter. To pellet the virus particles, the supernatant was spun at 
12000rpm for 2hr at 4°C. The supernatant was removed and a small volume of SFM 
media added (50/xl per 250ml cell suspension). The virus pellet was resuspended by 
shaking on an orbital shaker O/N at 4°C. 25/d and 50/xl aliquots of the resuspended 
virus were stored in liquid nitrogen. The titre of the resuspended virus was determined 
(2.4.2).
2.5 Immunolabelling
2.5.1 Western blotting
Cells were washed twice with lx PBS and harvested in 100/d protein loading buffer 
(7M Urea, 0.1% NaH2PO4H20,1% SDS, lOOmM DTT, 0.1% brombhenol blue pH7.2) 
and samples were frozen down at -20°C. Before loading on an SDS-polyacrylamide 
gel the samples were boiled at 95°C for 5min, cooled down on ice, briefly spun down 
and stored on ice until loading.
2.5.1.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-polyacrylamide gels were prepared and run in a vertical gel electrophoresis 
system according to the method of Laemmli (Laemmli, 1970). The composition of 
stacking and resolving gels can be seen in 2-1. The resolving gels used were of 15% 
for samples of FGF8, FGF2, ShhN and GFAP or 12% for Nurrl and TH. Resolving 
gels was overlaid with water saturated n-butanol, the solvent removed and 
subsequently the gel surface washed with CLH2O and dried before it was overlaid with
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the stacking gel. Gels were run at constant current (30mA/gel) with variable voltage 
in lx running buffer (25mM Tris, 250mM glycine and 0.1% (w/v) SDS, pH8.3). Gels 
were run until the protein of interest was approximately in the middle of the gel, as 
determined by the migration of the coloured molecular weught marker.
Resolving Gel 12% gel 15% gel
dH20 16.5 ml 11.5 ml
30% acrylamide mix* 20.0 ml 25.0 ml
1.5M Tris (pH 8.8) 12.5 ml 12.5 ml
10% SDS 0.5 ml 0.5 ml
10% ammonium persulfate 0.5 ml 0.5 ml
TEMED 0.02 ml 0.02 ml
Stacking Gel 5% gel
dH20 6.8 ml
30% acrylamide mix* 1.7 ml
1.0M Tris (pH 6.8) 1.25 ml
10% SDS 0.1 ml
10% ammonium persulfate 0.1 ml
TEMED 0.01 ml
Table 2-1: C om position o f  stacking and resolving gels used in SDS-PA G E . A crylam ide m ix =  
acrylam ide-bis acrylam ide (30:1.5).
2.5.1.2 Transfer of proteins to nitrocellulose membranes (western blot)
Proteins were transferred from the SDS-polyacrylamide gel to Hybond-C 
nitrocellulose membranes by a wet transfer method, based on that previously 
described. Briefly, the SDS-PAGE gel and the nitrocellulose membrane were pre­
soaked in transfer buffer (50mM Tris, 180mM glycine, 0.1% (w/v)SDS and 20% (v/v) 
methanol) and then sandwiched between sheets of 3MM Whatman paper and a Trans- 
Blot™ cell (BioRad) assembled according to the manufacturer’s instructions. Transfer 
was carried out at 10V O/N and 4°C.
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2.5.1.3 Immunodetection
Throughout the protocol the blots were shaken constantly on an orbital shaker. 
Following transfer, the membranes were rinsed three times for 5 min in T-PBS (lx 
PBS, 0.1% Tween-20) and blocked in 5% (w/v) skimmed milk powder in T-PBS for 
at least 1 hour. The membrane was then incubated in primary antibody diluted in 
blocking buffer containing 0.02% (w/v) Na-Azide for 1 hour at RT or O/N at 4°C. The 
primary antibody dilutions were as follows: FGF8 (1:400), FGF2 (1:200), ShhN 
(1:400), Nurrl (1:200), TH (1:150), GFAP (1:500), GAPDH (1:500). Unbound 
antibody was removed by washing the membranes for 3xl0min in T-PBS. The 
membrane was then incubated with secondary antibodies (all from DAKO horseradish 
peroxidase (HRP) conjugated; 1:1000 in blocking buffer) for 1 hour at RT. Unbound 
antibody was removed by washing as before. The bound HRP was then detected using 
an enhanced chemiluminescence system (ECL™) according to manufacturer’s 
instructions. The membrane was then exposed to X-ray film, from lsec to 15min, 
depending on the signal intensity.
2.5.2 Immunocytochemistry (ICC)
Immunocytochemical stainings were performed after fixation of cells on the glass 
coverlsips. All washing steps were carried out on an orbital shaker.
2.5.2.1 Fixation of cells
The medium was removed and the cells rinsed with lx PBS. 4% (w/v) 
paraformaldehyde (PFA) in lx PBS was freshly prepared, the pH adjusted to 7.4 and 
stored for up to one week at 4°C. Cells were fixed in ice-cold 4% PFA for 30min at 
RT. Coverslips were washed three times with lx PBS and stored in PBS at 4°C until 
the staining was performed.
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2.5.2.2 Immunocytochemical staining
Cells were blocked in 5% (v/v) normal goat serum (NGS) in 0.1% (v/v) TritonX-100 
in PBS for lh  at RT. Antibody incubations were carried out as “floating drop” 
technique: a small volume (60-100/d) of the appropriate antibody was placed as a 
drop on Parafilm™ in a humid chamber and the coverslip with the cells facing down 
carefully placed on this drop of antibody. Primary antibodies were prepared in 5% 
NGS at the appropriate dilution as decribed in Table 2-2 and the cells incubated for lh 
at RT. The coverslips were removed, placed into a 24 well plate and washed 3x lOmin 
with lx PBS. Appropriate secondary antibodies were made up according to Table 2-2 
in 5% NGS and cells incubated as described before as floating drop for lhr at RT. 
Coverslips were washed 3x for lOmin in lx PBS. As required cell nuclei were stained 
by incubation with Hoechst (1:10,000 in PBS) or DAPI (1:10,000 in PBS) for lOmin 
at RT and rinsed 3x with lx PBS. After the last wash, the coverslips were removed 
and mounted on a small drop (40/d) of Antifade™ Prolong mounting media. The 
edges of the coverslips were sealed with nail varnish and the specimen protected from 
light and stored at 4°C.
Alterations to this protocol were as follows: (i) in case that the secondary antibody 
was not raised in goat, all solutions were made up in serum of the same species as the 
secondary antibody was raised in. (ii) in case of immunolabelling for 
galactocerebroside (GalC) or oligodendrocyte marker 04  the detected epitopes are 
surface molecules and thus, cells were not permeabilsed with 0.1% TritonX-100. The 
incubation with the 04 primary antibody was carried out at 37°C according to 
manufacturer’s instructions, (iii) multiple labellings were performed sequentially to 
avoid cross-reactions between antibodies.
2.5.2.3 Sample preparation for BrdU staining
Immunolabelling for BrdU requires unraveling of the DNA since the antibody 
recognizes single stranded DNA. Fixed cells were incubated with 500/d 2N HCL per 
well for 20min at 37°C for acid denaturation. The acid was removed and 500/d 0.1M 
Na-Borate in ddlUO, pH8.5 added per well to neutralize for lOmin at RT. The
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neutralization step was repeated once and thereafter, the cells were washed 3x for 
lOmin in lx PBS at RT. Blocking and immunocytochemical staining were performed 
as described in 2.5.2.2. Double labelling of BrdU and an additional marker was 
performed sequentially with the staining for BrdU first.
2.5.3 Immunohistochemistry (1HC)
2.5.3.1 Tissue preparation
Animals were transcardially perfused with ice-cold 4% (w/v) paraformaldehyde 
(PFA) in 0.1M phosphate buffer pH 7.4, the brains removed and post-fixed for one 
hour or O/N depending on the quality of the perfusion. The brains were then protected 
in 30% (w/v) sucrose in 0.1M phosphate buffer pH 7.4 containing 0.02% sodium 
azide until they have sunk. Tissue was cut on a freezing microtome in sections 
between 20-100/mi and the sections stored in PBS containing 0.02% Na azide.
2.5.3.2 Immunohistochemical staining
Throughout the protocol incubations were performed free floating, shaking on an 
orbital platform. For BrdU IHC the tissue was prepared as described in 2.5.2.3. 
Sections were blocked in 5% NGS in PBS containing 0.3% TritonX-100 for 2h at RT. 
Tissue was transferred into primary antibodies made up in 5%NGS in PBS and 
incubated O/N at 4°C. The antibodies were diluted according to Table 2-2. Sections 
were washed 3x lOmin in PBS and transferred into the secondary antibody for lh at 
RT. Tissue was washed 3x lOmin in PBS and mounted on subbed slides (BDH, UK). 
All double labellings were performed sequentially. The specimen were air-dried and 
mounted in antifade mounting media.
2.5.3.3 X-Gal staining for detection of /3-galactosidase
Sections were incubated in X-gal solution (5 mM K3Fe(CN)6, 5 mM 
K4Fe(CN)6.6H20, 1 mM MgCl2, 150 pg/ml X-gal in DMSO in lx PBS) at 37°C for at 
least 2hr. The X-gal stain was then removed and sections washed three times in PBS.
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Primary antibody Corresponding secondary antibody
description class company ICC IHC description company ICC IHC
rabbit anti-tyrosine hydroxylase plgG Pel-Freez 1:150 1:150 Alexa Fluor 546 goat anti-rabbit Molecular Probes 1:1000 1:500
rabbit anti-GFAP plgG Dako 1:500 1:500 Alexa Fluor 546 goat anti-rabbit Molecular Probes 1:1000 1:500
mouse anti-NeuN m IgGl Chemicon n/a 1:500 Alexa Fluor 546 goat anti-mouse IgG (H+L) HC Molecular Probes n/a 1:500
mouse anti-TuJl m!gG2b Sigma 1:100 n/a Alexa Fluor 488 goat anti-mouse IgG2b Molecular Probes 1 1000 n/a
Alexa Fluor 546 goat anti-mouse IgG (H+L) HC Molecular Probes 1 1000 n/a
Rhodamine goat anti-mouse IgG (H+L) SB 1 200 n/a
mouse anti-04 m IgGM Chemicon 1:50-1:100 n/a Alexa Fluor 350 goat anti-mouse IgM Molecular Probes 1 500 n/a
mouse anti-GalC m!gG3 Chemicon 1:20 n/a Alexa Euor 350 goat anti-mouse IgG3 Molecular Probes 1 500 n/a
TRITC donkey anti-mouse IgG
rat anti BrdU mIgG2a abeam 1:100 1:100 Alexa 488 goat anti-rat IgG Molecular Probes 1 500 1:1000
mouse anti-nestin m lgG l Chemicon 1:200 1:200 Alexa 546 goat anti-mouse IgGl Molecular Probes 1 1000 1:500
Fluorescine goat anti-mouse IgG (H+L) SB 1 200 n/a
Alexa Fluor 546 goat anti-mouse IgG (H+L) HC Molecular Probes 1 500 1:500
Abbreviations: n/a not tested
SB Southern Biotechnology 
HC highly cross absorbed
Table 2-2: Antibody dilutions for ICC and IHC.
2.6 In vivo work
All experiments were carried out in accordance with the UK Animal Scientific 
Procedures Act 1986.
All animals were obtained from breeding colonies within the Department of 
Biological Services, UCL or from Harlan Labaratories (Oxon, UK and Madison, 
Wisconsin, USA). All animals were female Sprague-Dawley rats and weighed at least 
220g. The age of time-mated animals was assessed with the vaginal plug as E=0.
2.6.1 Stereotaxic injections
For all CNS injections a Kopf stereotaxic frame (dual small animal stereotaxic, Kopf 
Instruments, USA) was used and coordinates established according to a stereotaxic rat 
brain atlas (Paxinos and Watson, 1997). The head of the anaethetised rat was 
positioned into the frame, and a sagital incision was made to expose the skull. Tissue 
was removed and bregma and lambda points marked. Bregma was defined as the 
point of intersection of the sagittal suture with the curve of best fit along the coronal 
suture. When the two sides of the coronal suture met the sagittal suture at different 
points, bregma usually falls midway between the two junctions. The incisor bar 
adjusted until the heights of lambda and bregma were equal (flat-skull position). The 
tip of the needle was positioned at Bregma, the appropriate anterior-posterior and 
medial-lateral coordinates calculated and the injection site marked. A whole was 
drilled through the skull without damaging dura. The needle was lowered until the tip 
just touched the tissue surface. The dorsal-ventral coordinates were calculated and the 
needle accordingly lowered. Injections were carried out using an automatic 
microinjector (World Precision Instruments, USA) with a flow rate set at 0.5-1/d/min. 
Following injection, the needle was left in place for an additional 5min to allow the 
injectate to diffuse from the needle tip. The needle was then removed within 3min. 
The wound was closed using metal clips and the animals allowed to recover.
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2.6.2 In vivo BrdU injections
5-bromo-2’-deoxyuridine (BrdU) (B5002, Sigma, UK) was freshly prepared. BrdU 
was solubilised at 500mg/ml in DMSO and diluted in sterile 0.1M Tris/HCl pH7.4 to 
a final concentration of 50mg/ml. Animals were injected intra peritoneal (i.p.) with 
lOOmg/kg per day.
2.7 Detection of fluorescence
GFP expression was visualized under UV light (500nm). Alexa Fluor® 350 dye was 
visualised at an absorption of 350nm, Alexa Fluor® 546 and TRITC conjugated dyes 
at 560nm, Alexa Fluor® 488 and FITC conjugated dyes at an absorption of 500nm.
2.8 Statistic analysis
Every experiment was repeated at least two times in duplets cultures. For each 
experiment a minimum of 10 fields per 13mm coverslip were randomly selected. 
Statistic analysis was performed using the appropriate statitistical test. Statistical 
comparisons were made by ANOVA when more than three groups were involved and 
the data followed a Gaussian distribution. Data were expressed as means ± standard 
error of the means (SEM). All statistics were performed using the Prism software 
package Version 3.02 (Graphpad Software Inc, CA, USA).
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C h a p t e r  3:  
E v a l u a t i o n  o f  H e r p e s  
s i m p l e x  v i r u s  1 (HSV-1)
B A S E D  VECTORS FOR  
D E L I V E R I N G  R E C O M B I N A N T  
G E N ES  TO N E U R A L  P R E C U R S O R  
CELLS I N  VITRO A N D  IN VIVO
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3.1 Introduction
Multiple approaches have been unveiled for the use of neural precursor cells. Despite 
their therapeutic potential to replace various neural cell types lost or damaged in 
human diseases (Bjorklund and Lindvall, 2000), they offer a unique system to study 
neural development (Bhattacharyya and Svendsen, 2003), model neurological 
diseases (Jakel et al., 2004) or as assays to test pharmacological components (Calhoun 
et al., 2003). However, any of these studies may require ectopic gene expression 
involving the introduction of recombinant transgenes into neural precursor cells. 
Replication deficient viruses have become a powerful tool for gene targeting to neural 
stem cells and most commonly used vector systems are adenoviruses (Yoon et al., 
1996; Corti et al., 1999; Hughes et al., 2002; Falk et al., 2002), adeno-associated 
viruses (Davidson et al., 2000; Wu et al., 2002), retroviruses (Falk et al., 2002; 
Kageyama et al., 2003), and lentiviruses (Englund et al., 2000; Asahara et al., 2000; 
Buchet et al., 2002).
This chapter evaluates the potential use of disabled HSV-1 as a gene delivery vector 
to neural precursor cells in vitro and in vivo and emphasizes the effects of viral 
transduction on cellular integrity of the neural stem cell.
Neural precursor cells isolated from the developing CNS can be either maintained as a 
mixture of primary neurons and neural progenitor cells or expanded as neurosphere 
cultures (Gage et al., 1995). Based on these two in vitro models, we compared two 
replication-deficient HSV-1 viruses to find an adequate vector for ex vivo gene 
transfer approaches. The optimal vector system delivers recombinant genes efficiently 
at low viral doses and does not cause cytotoxic effects or interference with the 
function of the transduced precursor cell.
Previously our group has developed a multiple immediate-early gene deficient HSV-1 
vector deleted for ICP27, ICP4, and ICP34.5 with an inactivating mutation in VP 16 
(Lilley et al., 2001), termed 1764/27-/4-. This viral backbone was chosen as it 
efficiently transduces neurons of the CNS in vitro and in vivo without any cytotoxic 
site effects reported (Lilley et al., 2001). Further vector development has led to a
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vector containing ICP27, ICP34.5 and with a promoter cassette containing the 
woodchuck hepatitis virus posttranscriptional regulatory element (wpre). ICP27 and 
ICP34.5 were shown to be anti-apoptotic (Chou and Roizman, 1992; Aubert et al., 
1999; Zachos et al., 2001) and the woodchuck response element increases transgene 
expression through a combination of stabilisation of RNA transcripts and facilitation 
of their cytoplasmic export as demonstrated for retroviral (Zufferey et al., 1999) and 
adenoviral (Xu et al., 2003) constructs. In primary cortical neuronal cultures this less 
disabled vector, referred to as RL1+/27+/4-, showed increased transduction efficiency 
compared to previous vectors (Li, personal reference). However, these previous 
studies did not focus on gene delivery to primary neuronal cultures from other regions 
of the developing CNS and no data were available on transduction efficiency to 
mesencephalic or neurosphere cultures that are particularly relevant for this study.
Under the given rationale, the first part of this chapter compared gene delivery 
efficiency and cytotoxicity of these two viral backbones in primary cortical, striatal 
and mesencephalic progenitor cultures. A comparison to other HSV-1 based vectors is 
complicated by the use of different disablements of the viral constructs, and the 
preparation of tissue from different neurogenic regions at various gestational stages. 
In other reports e.g. gene delivery efficiency to cortical (Anderson et al., 2001), 
striatal (Freese and Geller, 1991; Aboody-Guterman et al., 1997) and mesencephalic 
neuronal cultures (Costantini et al., 1999) varied between 2% and 100%, indicating 
the variance in the experimental conditions.
In the second part of this chapter neurospheres were used as a model to study gene 
delivery and vector cytotoxicity to neural stem cells. Viral transduction may affect the 
cellular characteristic of the neural stem cell, aforementioned as self-renewal capacity 
and multipotency. Therefore, we characterized the antigenic identity of the transduced 
neural precursor cell and determined effects of HSV-1 infection on the differentiation 
potential into the different neural lineages.
In the third part of this chapter gene delivery to endogenous neural stem of the adult 
subventricular zone (SVZ) was studied. Other groups have shown before that 
replication-competent HSV-1 infects ependymal cells of the SVZ (Kesari et al.,
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1998), but did not further characterize the antigenic character of the transduced cells. 
As astrocytes were identified as the potential neural stem cells within the SVZ 
(Doetsch et al., 1999), the work presented here focused on the antigenic identity of the 
transduced ependymal and subependymal cells. Neuronal precursors bom in the SVZ 
migrate to the olfactory bulb where they differentiate into neurons (Lois and Alvarez- 
Buylla, 1994). Migration of transduced precursor cells was monitored by reporter 
gene expression in the olfactory bulb.
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3.2 M a ter ia ls  an d  M eth od s
3.2.1 Viral constructs and promoters used
Vectors tested were based on wild type HSV-1 strain 17syn+ (Brown et al., 1973). 
The term “ 1764” describes a virus with the m l814 mutation in the gene encoding 
VP 16 and with genes encoding ICP34.5 and ORF P completely deleted (between nt 
124945 and 125723). The vector 1764/27-/4- is deleted for ICP27 (nt 113273 and 
116869 comprising UL54, -55, and-56) and both copies of ICP4 (Lilley et al., 2001). 
The promoter cassettes pR19hGFP or pR19LacZ were recombined into the 
endogenous LAT regions between the two BstXI sites (nt 120220 and 120408) (Lilley 
et al., 2001). The resulting virus is referred to as 1764/27-/4-pR19hGFP or 1764/27- 
/4-pR19LacZ, respectively (Figure 3-1). Based on this vector the genes encoding for 
ICP27 and ICP34.5 were inserted back into the viral genome and a reporter gene 
cassette constructed containing the woodchuck hepatitis virus posttranscriptional 
regulatory element (wpre), resulting in the vector RLl+/27+/4-pR19hGFPwpre (Li, 
unpublished data).
1764/27-/4-/pRl9hGFP (Lilley et al., 2001)
ICP34.5 VP 16 ICP27 ICP34.5 ICP4 ICP4
LAP1 LATP2 CMV GFP
RLl+/27+/4-/pR19hGFPwpre
VP 16 ICP4 ICP4
GFPLAP1 LAT P2 CMV
Figure 3-1: Replication incom petent vector backbones and prom oter cassettes.
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3.2.2 Viral infection of primary neurons and neural progenitor cells
Primary neural progenitors (2.3.6) were cultured on substrate coated glass coverslips 
(2.3.10) in 24 well plates. For viral transduction the media was removed and cells 
were overlaid with 200/ri Neurobasal® media per well containing the appropriate 
amount of virus and incubated for one hour at 37°C/5%C02 in a standard tissue 
incubator. During infection the plate was tilted every 10-15min. Following infection
(fdthe virus containing media was removed and replaced by Neurobasal media 
containing B27 supplement (2% v/v, Gibco), L-glutamine (500/xM), penicillin 
(lOOunits/ml) and streptomycin (100jLtg/ml). The medium in primary neural progenitor 
cultures was changed daily.
3.2.3 Assessment of cell concentration and viral infection of rodent and human 
neurospheres
For gene delivery studies cell concentration was assessed by selecting 100 medium 
sized neurospheres (about 300/mi diameter) under a dissecting microscope in a flow 
hood. The neurospheres were pooled in a 1.5ml tube and settled by short 
centrifugation (lOOOrpm for 2 min). The supernatant was removed and the spheres 
resuspended in 500[il Accutase™ for cell dissociation. After incubation for 15min at 
37°C, spheres were briefly centrifuged (lOOOrpm for 3min) and the Accutase™ 
removed. Neurospheres were resuspended in 200/ri DMEM and triturated into a single 
cell suspension using a 200/zl pipette tip. The cells were counted using the trypan blue 
exclusion method (2.3.12) and the cell concentration determined as cells per 
neurosphere.
For viral infection neurospheres of the same size were selected and 
pooled in a 1.5ml test tube. Excess medium was removed and the neurospheres 
resuspended in 50/ri DMEM/F12 media containing the appropriate amount of virus. 
During infection the spheres were incubated for one hour at 37°C and the tubes finger 
vortexed every 15min. The neurospheres were briefly centrifuged (lOOOrpm for 
3min), the virus containing media removed, resuspended in appropriate media and 
transferred into T25 flasks containing 10ml of growth or differentiation medium
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(DMEM/F12 containing B27). Medium of infected neurospheres was changed every 
three days by replacing half of the medium by fresh medium.
For all other infections of neurospheres, cell concentration was determined by 
dissociation of an aliquot of the neurosphere suspension using Accutase™ and 
trituration as described above. After determination of the cell concentration using the 
trypan blue exclusion method (2.3.12), the virus amount required for infection of an 
appropriate number of neurospheres was calculated.
Human foetal tissue (8-12 weeks postconception) was used in this study collected 
following routine termination of pregnancy. The methods of collection conform to the 
arrangements set out by the Department of Health in the United Kingdom. Human 
neurospheres were expanded over long time in (DMEM:HAMS-F12 at 3:1) 
supplemented with N2 (1% v/v), penicillin (lOOunits/ml), streptomycin (100/zg/ml) 
containing EGF (20ng/ml, R&D) and LIF (lOng/ml, Chemicon). Human neurospheres 
require a cell-cell contact for long term expansion and were passaged using a unique 
chopping method as previously described (Svendsen et al., 1998). Assessment of cell 
concentration and viral infections of human neurospheres were performed as 
described for rodent neurospheres.
3.2.4 Cell migration assay
To monitor the migration and differentiation of single precursor cells, whole 
neurospheres were plated on poly-L-lysine/Laminin-coated glass cover slips in a total 
volume of 30/d in a 24 well plate. After one hour incubation in a humidified incubator 
(37°C, 5%CC>2), the neurospheres had attached to the surface and short processes 
emerged from the neurospheres. The cultures were overlaid with 500/xl appropriate 
proliferation or differentiation medium.
3.2.5 Stereotaxic injections
For intraventricular injections 5xl06 PFU of RL1 +/27+/4-pRl 9hGFPwpre in a 
volume of 5/d were injected bilaterally into each lateral ventricle of adult female
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Sprague-Dawley rats (250g-280g, Harlan, UK) (n=3). Using a Kopf Instruments 
stereotaxic frame, the rats were injected at the following coordinates relatively to 
Bregma: AP -0.3mm, ML ±1.2mm, DV -3.6mm (Paxinos and Watson, 1997). Three 
days after injection rats were transcardially perfused with 4% paraformaldehyde, the 
brains removed and conserved as described in 2.5.3.1. The brains were cut into 40/mi 
coronal sections. Immunohistochemical staining was performed as described in 2.5.3.
For injections into the SVZ 5x10s PFU of 1764/27-/4-/pR19LacZ in a 
total volume of 5/d were stereotaxically injected unilaterally into the dorsocaudal horn 
of the lateral ventricle of female adult Sprague-Dawley rats (250g-280g, Harlan UK) 
(n=3) at the following coordinates relatively to Bregma: AP -0.3mm, ML-2.0mm, DV 
-3.1mm (Paxinos and Watson, 1997). Three days after viral injection the animals were 
perfused, the brains removed containing the entire olfactory bulb and sliced into 60/mi 
coronal sections. The sections were stained for LacZ expression as described in
2.5.3.3.
3.2.6 Transplantation of neurospheres
Neurospheres derived from E14 ventral mesencephalon were expanded for 10 days as 
neurospheres. Neurospheres were infected with RLl+/27+/4-pR19hGFPwpre at an 
m.o.i. of 1 and maintained for another two days in differentiation conditions. An 
aliquot of the transduced neurospheres were plated on poly-L-lysine/laminin coated 
glass coverslips and stained for TH expression as described in 2.5.2. Before 
transplantation an aliquot of the neurosphere culture was removed and the cell 
concentration determined using trypan blue exclusion method. The neurospheres were 
diluted in DMEM/F12 media to a final concentration of 10,000 cells/5/d and aliquots 
of spheres were prepared individually for each animal prior to transplantation. Adult 
female Sprague Dawley rats (250-300g) (n=3) received unilaterally two grafts of 
10,000 cells into the left striatum. Using a stereotaxic frame the whole neurospheres 
were injected with a 28”gauge needle attached to a 25/xl Hamilton syringe at the 
following coordinates: AP +1.6mm, ML +2.4mm, and AP +0.2mm, ML +3.4mm, DV 
-4.5mm (Paxinos and Watson, 1997). The animals were perfused with 4% 
paraformaldehyde three days after injections, the brains removed and cut into 60/mi
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coronal sections. Immunohistochemical stainings were performed as described in
2.5.3.
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3.3 Results
3.3.1 HSV-1 as a gene delivery vector to primary neurons and neural 
progenitor cells of the CNS
The first part of this chapter considered gene delivery to primary neurons and neural 
progenitor cells using replication deficient HSV-1 vectors. The population of fate 
restricted primary cells was characterized and viral gene delivery validated in terms of
transduction efficiency and effects on neuronal cell loss.
3.3.1.1 Characterization of neural progenitor cells
Primary neurons and neural progenitor cells used in this study were isolated from
three distinct neurogenic regions within the neuroepithelium of the developing rat 
CNS: cortex, striatum (comprising medial and lateral ganglionic eminences) and 
ventral mesencephalon. The aim of this first section was to characterize the cultures 
regarding their neural cell types.
The tissue was prepared from time-mated E14 Sprague-Dawley embryos and 
dissections were performed as described before (Dunnett and Bjorklund, 1992) 
(Figure 3-2). The explants were dissociated into a quasi-single cell suspension by 
trypsin treatment and trituration. Cell suspension preparation is a crucial step for 
setting up primary neuronal and neurosphere cultures. The physical process of cell 
suspension preparation from termination of the animal, embryo removal, tissue 
dissection, through enzyme treatment and dissociation, causes cellular stress resulting 
in necrosis and apoptosis (Branton et al., 1998). This cell damage and neuronal loss, 
which is particular evident for mesencephalic cultures (Fawcett et al., 1995), was also 
observed in this study when cell viability was assessed by trypan blue exclusion assay 
of the trypsin treated and triturated cell suspension. About 10% of the cells 
incorporated the dye and these damaged cells were not included when the cell density 
was determined prior to plating of primary cells or seeding of neurosphere suspension 
cultures. However, these cells may bind viral particles and it has to be considered that 
this may effect determination of gene delivery efficiency.
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E14 Sprague Dawley
mesencephalontelencephalon
i
%
striatum cortex ventral mesencephalon
STR CTX VM
Figure 3-2: Isolation o f primary tissue. E14 time-mated (plague = EO) Sprague-Dawley rats 
(Harlan, UK) were sacrificed and the embryos removed. The CNS was exposed and the 
mesencephalon released by dissecting along the forebrain/midbrain boundary and the 
midbrain/hindbrain groove (the red lines indicate the rostral and caudal incisisons, and the 
dotted line the incision made to isolate the ventral m esencephalon). Striatal (medial and lateral 
ganglionic eminence) and cortical tissue were isolated from the telencephalon. The tissue shown 
here was fixed in 4% paraformaldehyde overnight prior to photography. D=dorsal, V=ventral, 
R=rostral, C=caudal. Scale bar represents 1mm.
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The dissociated cells were plated on poly-L-lysine (PLL)/laminin coated glass 
coverslips and maintained for seven days in serum-free Neurobasal™ media 
complemented with B27. Serum-free culture conditions were chosen to avoid any 
effects from undefined serum components. It has been reported previously that 
primary mesencephalic neurons can be maintained in Neurobasal™ media (Cheung et 
al., 1997) and neuronal survival increased by supplementing with B27 (Svendsen et 
al., 1995). The cultures followed a time dependent change regarding the amount of 
neurons and the morphology of the cells that also differed with the origin of the tissue 
(Figure 3-3). Generally, cells showed characteristics of immature neuroblasts on the 
first day in culture with a small oval cell body and two short processes. With 
continuous culture under serum-free conditions, the neural progenitors matured into 
neurons with a larger soma, longer and branched processes and distinctive phenotypes 
depending on the region the tissue was derived from. After three days in culture 
cortical neurons had predominantly large and polygonal cell bodies with multiple 
unbranched processes, while striatal neurons had smaller, oval shaped cell bodies with 
two to three long, unbranched processes. Striatal neural cells often formed spherical 
aggregates at later culture time points. Mesencephalic derived primary neurons can be 
classified as GABAergic and dopaminergic neurons (Hanaway et al., 1971; Altman 
and Bayer, 1981) with a large polygonal cell body. Dopaminergic neurons 
characterized by the expression of TH were found to be slightly larger than TH 
negative cells with a mostly pyramidal cell shape bearing typically two to five thick 
processes that gave rise to relatively sparse arborisation. Primary mesencephalic 
cultures contained a significant amount of cell debris on 1DIV compared to cortical 
and striatal cultures as a result from increased cell death during tissue preparation 
(Emgard et al., 2002), but appeared to recover within the first three days in culture. 
The cell density also affected the state of mesencephalic cultures. Low density 
cultures (less than 5xl04 cells per well) were difficult to maintain, a phenomenon that 
has also been described by other groups (Dal Toso et al., 1988).
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Cortex Striatum Ventral Mesencephalon
Figure 3-3: Distinct morphologies o f neurons derived from different regions o f the developing  
neuroepithelium. Neural progenitor cells from the developing cortex, striatum and ventral 
mesencephalon were plated on PLL/Laminin coated coverslips and maintained for three days 
in serum-free media. Cells were fixed with 4%PFA and stained for the neuronal marker 
T u Jl. Cortical neurons had a large, polygonal cell body, while striatal neurons were smaller 
and oval shaped with predominantly two long processes. M esencephalic neurons were often 
polygonal bearing three to four processes. Pictures were taken at lOOx magnification.
Cortex
DIV TuJl (%) nestin (%) TH (%)
3 58.96±5.21 42.26±2.73 n/a
7 67.52±3.80 20.10±2.08a n/a
Striatum
DIV TuJl (%) nestin (%) TH (%)
3 87.92±3.83 7.70±1.62 n/a
7 85.47±3.49 8.11±1.85 n/a
Ventral Mesencephalon
DIV TuJl (%) nestin (%) TH (%)
3 55.53±2.34 52.03±4.33 17.57±2.00
7 61.90±3.62 35.14±2.38a 10.60±2.88
Table 3-1: Composition o f neural progenitor cultures. Cortical, striatal and mesencephalic 
tissue from E14 rats was plated at a density o f lxlO scells per well on PLL/Laminin coated 
coverslips. The cultures were maintained in serum-free NeurobasaFM medium supplemented  
with B27 for 3 or 7 days in vitro. Cells were fixed with 4%PFA and stained for the neuronal 
marker T u Jl, the neurofilament marker nestin or the dopaminergic marker TH. Data are 
presented as percentage of total cell number.
* significant decrease in the amount of nestin positive cells in cortical (p<0.001 in two tailed t 
test, n=3 independent experiments) and mesencephalic progenitor cultures (p< 0.003, n=3 
independent experiments).
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The primary cultures were characterized on 1 and 3 DIV by cell lineage specific 
markers for TuJl positive neurons (Baneijee et al., 1990), GFAP positive astrocytes 
(Hansen et al., 1989), 04  positive oligodendrocytes (Sommer and Schachner, 1981) 
and nestin positive undifferentiated neural progenitor cells (Hockfield and McKay, 
1985) (Figure 3-4).
After three days in culture most of the striatal cells were identified as neurons, while 
only about half of the population of cortical and mesencephalic cells were positive for 
the neuronal marker TuJl. As shown in Table 3-1, cortical and mesencephalic 
cultures contained a high proportion of undifferentiated progenitor cells positive for 
the neurofilament marker nestin. Although the culture conditions were free of any 
exogenous growth factors and thus, support only differentiation but not proliferation 
of the progenitors, the data suggest that these cultures had not fully matured at this 
early stage yet. After 3DIV none of the cultures contained any GFAP positive 
astrocytes or 04 positive oligodendrocytes. Primary mesencephalic cultures contained 
a high proportion of TH positive neurons, presumably dopaminergic, that were rarely 
identified in cortical or striatal progenitor cultures.
With continuous culture in serum-free conditions, the progenitors mainly 
differentiated into post-mitotic neurons and for each region the majority of cells 
stained positive for TuJ after one week in culture. At this time point the onset of 
gliogenesis could be detected in striatal and mesencephalic cultures by a small 
number of astrocytes (Figure 3-4K) and oligodendrocytes (Figure 3-4G), a parallel 
development as shown in vivo (Williams et al., 1985). However, glial cells 
represented only an insignificant portion (less than 0.1%) of total cells and it was 
reported before that the chosen serum-free conditions do not support glial 
proliferation or differentiation (Walicke and Baird, 1988; Bouvier and Mytilineou, 
1995; Wood et al., 2003). The increase of neurons in cortical and mesencephalic 
cultures is accompanied by a significant decrease of nestin positive progenitors in 
these cultures, reflecting the differentiation of immature neuroblasts into mature post­
mitotic neurons. Although the number of total neurons in mesencephalic cultures had 
increased within seven days of culture, the proportion of TH positive neurons
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decreased, suggesting a limited proliferation of dopamine neuroblasts and an increase 
in cell death of particularly dopaminergic neurons under the chosen culture 
conditions. TH expressing cells showed signs of neuronal death after one week in 
culture visible by disintegrated processes.
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Figure 3-4. : Characterization o f neural progenitor cultures. Cortex (A-D), striatum (E-H) 
and ventral mesencephalon (I-L) from E14 Sprague-Dawley rats were dissected, trypsin  
treated and triturated into a single cell suspension. Cells were plated at a density o f 1x10s 
viable cells per well on PLL/Laminin coated glass coverslips and maintained in serum free 
Neurobasal media supplemented with B27. On 1 DIV and 3 DIV cells were fixed with  
4%PFA. Cells were either (A, E, I and C, G, K) triple-stained for the neuronal marker T uJl 
(Alexa 488: green), the astrocytic marker GFAP (Alexa 546: red) and the oligodendroglial 
marker 0 4  (Alexa 350: blue), or (B, F, J and D, H, L) stained for the neurofilament marker 
nestin (FITC: green), the dopaminergic marker TH (Alexa 546: red) and DAPI (blue). 40x 
magnification.
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3.3.1.2 Gene delivery to neural progenitors depends on the viral backbone
Primary neurons and neural progenitor cells derived from cortex, striatum and ventral 
mesencephalon were infected on 1DIV at increasing multiplicities of infection 
(m.o.i.), either with the highly disabled construct 1764/27-/4-/pR19hGFP or with the 
less disabled RLl+/27+/4-/pR19hGFPwpre. In order to determine transduction 
efficiency, cells were fixed three days after infection and GFP expression was 
visualised under an epifluorescent microscope (Figure 3-5 and Figure 3-6). 
Independent of the viral backbone, transduction efficiency increased, as expected, 
with higher multiplicity of infection. Recombinant gene expression significantly 
depended on the chosen viral backbone and the neurogenic region the progenitor cells 
were generated from.
Highly disabled virus only gave a reasonable gene delivery to mesencephalic neural 
progenitors when infected with a high viral dose (m.o.i. of 10). However, even at such 
high multiplicities cortical or striatal progenitor cells were only rarely transduced with 
1764/27-/4-/pR19hGFP. Infected mesencephalic cells showed different levels in the 
intensity of GFP expression. This suggests that single cells were infected with 
multiple virions resulting in stronger transgene expression, or alternatively, that cell 
type dependent differences affected transgene expression from the pR19 promoter 
cassette. GFP expressing cells did not show any signs of cytotoxicity due to viral 
infection compared to uninfected control cultures. Reporter gene expressing cells had 
large, flat cell bodies with long processes. Even at an m.o.i. of 10, only an 
insignificant number of transduced cells showed cytopathic effects, evident as 
rounded cells with retracted or without processes. GFP expression was localised in the 
cell body as well as in the processes of the progenitor cells. Infections of 
mesencephalic cultures at m.o.i.’s higher than 10, did not result in a proportional 
increase of transduction efficiency, suggesting that cells not expressing the transgene 
are either not susceptible to viral infection with this construct or expression from the 
promoter cassette is not supported in these cells.
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A significantly higher gene delivery to primary neural progenitor cells was achieved 
with the less disabled construct RLl+/27+/4-/pR19hGFPwpre (Figure 3-6). While 
low viral amounts (m.o.i. of 1) resulted in transduction of only a small number of 
progenitors, a high number of cells were expressing the reporter gene after infections 
at an m.o.i. of 5 and 10, independently of the neurogenic region the cells were isolated 
from. Reporter gene expression was observed as soon as one day post transduction 
and the expression levels were highest three days after infection. Although GFP 
expression was localised in the cell bodies and processes for the majority of 
progenitor cells, an increased number of rounded cells without or retracted processes 
were evident at high virus doses. As discussed in more detail later in this chapter, 
toxicity appeared to depend on the levels and the overall time of reporter gene 
expression in culture. Cytotoxic effects caused increased cell loss and became evident 
three days after transduction.
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Figure 3-5: Gene delivery to neural progenitor cells using highly disabled vector 1764/27-/4- 
/pR19hGFP. E14 neural progenitor cells derived from cortex (CTX), striatum (STR) or ventral 
mesencephalon (VM) were plated at a cell density o f l x l0 5cells/well on PLL/Laminin coated 
cover slips. On 1 DIV cells were infected with 1764/27-/4-/pR19hGFP at an m.o.i. o f 1, 5 or 10 
and fixed on 4DIV with 4% PFA. GFP expressing cells were visualized under a fluorescent 
microscope. Small insets are pictures taken with phase contrast. Scale bar represents 50pm.
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Figure 3-6: G ene delivery to neural progenitor cells using less disabled vector RL1+/27+/4- 
/pR19hGFPwpre. E14 neural progenitor cells derived from cortex (CTX), striatum (STR) or 
ventral mesencephalon (VM ) were plated at a cell density of lx l0 5cells/well on PLL/Laminin  
coated cover slips. On 1 DIV cells were infected with RLl+/27+/4-/pR19hG FPwpre at an m.o.i. 
of 1, 5 or 10 and fixed on 4DIV with 4% PFA. GFP expressing cells were visualized under a 
fluorescent microscope. Small insets are pictures taken with phase contrast. Scale bar 
represents 50pm.
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Gene delivery to cortical, striatal and mesencephalic derived neurons and neural 
progenitor cells was quantified for infections with RLl+/27+/4-/pR19hGFPwpre at an 
m.o.i. of 10 three days post-transduction (Figure 3-7). Although, the highest gene 
delivery was found in mesencephalic derived progenitor cells compared to cortical or 
striatal progenitor cells, the differences between the three neurogenic regions are 
statistically not significant (p>0.05 in One-way ANOVA, n=3 experiments). Under 
the chosen experimental conditions, the transduction efficiency to primary neural 
progenitor cells varied between 14% in cortical and 30% in mesencephalic cultures. 
Cell loss due to cytopathic effects within the first three days post-transduction 
contributed to the low gene delivery rate, as well as weak reporter gene expressing 
cells that were difficult to detect. Therefore, the calculated gene delivery efficiency 
only gives a rough approximation of the actual amount of transduced cells. As a 
quantification of reporter gene expressing cells does not reflect the levels of gene 
expression, the less disabled RLl+/27-/4-pR19wpre viral backbone may still give 
sufficient transgene expression to study e.g. biological functions of genes encoding 
for secreted proteins.
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Figure 3-7: Quantification o f gene delivery to cortical, striatal and mesencephalic derived neural 
progenitor cells. E14 prim ary neural progenitor cells derived from the different neurogenic regions 
were infected at an m.o.i. o f 10 on 1D1V with R Ll+/27+/4-/pR19hG FPwpre and Fixed on 4DIV. The 
percentage o f GFP expressing cells was determined from 10 different fields in duplicates under a 
fluorescent microscope. Data presented are the means of GFP positive cells as percentage of total 
cell number with SEM from three independent experiments.
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3.3.1.3 Gene delivery depends on the age o f the neuronal culture
As shown previously in this chapter, neural progenitor cells follow maturation in vitro 
noticeable by a change of cell morphology and cell fate towards a distinct post-mitotic 
neuronal character. The age of the neuronal culture may also affect gene delivery 
efficiency. Ventral mesencephalic progenitor cells were infected on 3 DIV and 5 DIV 
with either highly disabled 1764/27-/4-/pR19hGFP or less disabled RL1+/27+/4- 
pR19hGFPwpre. Reporter gene expression was monitored under the fluorescent 
microscope three days post-transduction (Figure 3-8). Gene delivery efficiency 
increased for both viral constructs in a time dependent course. Infection of neural 
progenitor cells at later culture times, when they had matured into more post-mitotic 
neurons, resulted in higher gene delivery efficiencies compared to earlier time points. 
Transduction of mesencephalic progenitors with RLl+/27+/4-pR19hGFPwpre that 
had been cultured for five days prior to infection, resulted in almost 100% 
transduction efficiency. Even with the highly disabled viral backbone 1764/27-/4- 
/pR19hGFP, that only gives a poor gene delivery rate after infection of immature 
progenitor cultures, a reasonable gene delivery was achieved when more mature 
neural progenitor cultures were infected. Strikingly, viral transduction at later culture 
time points also resulted in far less cytotoxic effects. The majority of infected cells 
showed healthy cell morphology with GFP expression in both soma and processes. 
The neurite processes were not disintegrated and far less cells were rounded up as 
observed after viral infection on 1 DIV. This result suggests that gene delivery 
efficiency not only depends on the dose of virus applied, but to a high degree to the 
maturation stage of the neural progenitor culture.
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Figure 3-8: Gene delivery efficiency depends on the age of the neural progenitor culture. E14 
primary ventral mesencephalic cells were plated at a cell density o f lx lO 5 cells per well on 
PLL/Laminin coated glass cover slips. Cells were infected at an m.o.i. o f 5 with highly disabled  
1764/27-/4-/pRl9hGFP or less disabled R Ll+/27+/4-/pR 19hG FPw pre on 3 DIV and 5 DIV, 
respectively. Three days post-transduction cells were fixed with 4% PFA and reporter gene 
expression monitored under a fluorescent microscope. Insets are pictures taken with phase 
contrast. Scale bar represents 50pm.
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3.3.1.4 Phenotypic identity o f the infected neural progenitor cell
In order to identify the antigenic character of the transduced neural progenitor cells, 
immunocytochemical staining was performed for neuronal, glial and neurofilamental 
markers. Neural progenitor cells from the three distinct neurogenic regions were 
infected with RL1+/27+/4-pR 19hGFPwpre on 1 DIV and fixed three days post­
transduction. The transduced progenitor cells were stained for TuJl as neuronal 
marker, GFAP as marker for astrocytes, nestin as marker for undifferentiated 
neuroepithelia and TH as marker for midbrain dopaminergic neurons (Figure 3-9).
In accordance with the previously described characterization of neural progenitors, 
only a very few astrocytes staining for GFAP were found in the cultures. The majority 
of transduced cells were of neuronal identity as demonstrated by GFP/TuJl double 
labelled cells. Despite of the growth factor free culture condition transduced 
progenitor cells were found that stained positive for nestin. Hence, some of the 
infected progenitors remained in an undifferentiated fate.
Progenitor cells derived from the ventral mesencephalon contained only a low number 
of TH/GFP double labelled neurons. Although a high number of GFP/TuJ double 
labelled cells were detected in these cultures, only less than approximately 1% of the 
total TH positive cells expressed the reporter gene. As the majority of dopaminergic 
neurons differentiated into mature dopaminergic neurons or neurons with a restricted 
dopamine fate prior to cell preparation in vivo, this may reflect a rather low 
susceptibility of post-mitotic primary dopaminergic neurons to viral transduction with 
HSV-1. As a high proportion of nestin positive cells were found in progenitor cultures 
on 1 DIV, the GFP/TuJl double labelled cells may have resulted from infection of 
these undifferentiated neuroblasts that fully differentiated into post-mitotic neurons 
after viral transduction. As cultures were prepared from E l4 embryos, differentiation 
of dopaminergic neurons had already been completed and the cultures contained 
under the chosen growth factor free conditions only a low number of dopamine 
neuroblasts available to viral transduction.
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Figure 3-9: Characterization o f transduced neural progenitor cells. Primary neural cells derived  
from E14 cortex, striatum and ventral m esencephalon were infected on 1DIV with RL1+/27+/4- 
pR19hGFP at an m.o.i. o f 10. On 4 DIV cells were fixed with 4% PFA and stained for the 
neuronal marker TuJ and the neurofilam ent m arker nestin. M esencephalic progenitors were also 
stained for tyrosine hydroxylase (TH). Scale bar represents 10 pm.
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3.3.1.5 Effects of viral transduction on neurogenesis and the number of 
dopaminergic neurons
Vector cytotoxicity was studied for the less disabled virus RL1+/27+/4- in primary 
neural progenitor culture derived from cortex, striatum and ventral mesencephalon. 
Cells infected with RL1+/27+/4-/pR 19hGFP at an m.o.i. of 1, 5 and 10 were fixed 
three days after infection and stained for the neuronal marker TuJl (Figure 3-10). 
Cytotoxic effects were examined by changes of cell morphology, noticeable by lost or 
disintegrated cells processes, resulting in rounded, often enlarged somas that easily 
detach from the cell culture surface and float in the cell culture supernatant. One day 
after infection GFP expression could be visualised in processes and cell bodies of 
transduced neuronal cells. At this time point cytotoxic effects were not apparent, the 
cells showed healthy morphology and no cells were floating in the supernatant.
With continuous culture and reporter gene expression the viability of transduced 
neural progenitor cells decreased on 3 and 4 DIV. An increased number of GFP 
expressing cells that co-labelled with the neuronal marker TuJl lost or retracted their 
neuronal processes. These cytotoxic effects were observed in cortical, striatal and 
mesencephalic derived neuronal cultures and increased with the viral dose added. 
However, control cultures that were incubated with serum free media hardly 
contained any neurons with an altered cell morphology which confirms that viral 
transduction and not the culture conditions caused the observed cytotoxic effects. 
Strikingly, GFP fluorescence was stronger in cells showing cytotoxic effects than in 
transduced cells with unaltered neuronal morphology. It cannot be concluded from 
these data, if the intense fluorescence is the result of increased reporter gene 
expression or the rounded cell shape compared to a polygonal cell shape in healthy 
neurons. However, Detrait et al. showed that toxicity of a given reporter gene product 
correlated with the level of expression of the gene (Detrait et al., 2002) suggesting 
that high level reporter gene expression contributed to the observed cytopathic effects. 
This is further confirmed by the observation that cytotoxic effects are time-dependent 
and increase with continuous GFP expression in the transduced neurons resulting in 
an accumulation of potentially toxic reporter gene product.
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Figure 3-10: Effects o f viral transduction on neurogenesis. Primary neural cultures were 
prepared from E14 cortex (CTX), striatum (STR) and ventral m esencephalon (VM ). Cells were 
plated at a cell density o f lx l0 5cells/well on PLL/laminin coated coverslips and infected on 1DIV 
with RLl+/27+/4-pR10hG FPwpre at the shown multiplicity o f infection or with serum-free media 
(SFM). On 4DIV cells were fixed with 4% PFA and stained for the neuronal marker T u Jl (Alexa 
546, red). GFP expression was visualized under the fluorescent m icroscope. Cytotoxic effects due 
to viral infection and/or reporter gene expression were observed with increasing viral amounts 
independent o f the neurogenic region. Transduced neurons showing cytopathic effects round up 
and have disintegrated or no processes (arrow heads). Scale bar represents 50pm.
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To quantify the observed cytotoxic effects and the impact of viral transduction on 
neurogenesis in primary neural cultures, the total amount of TuJl positive neurons 
and the proportion of neurons with cytopathic effects were determined (Table 3-2). 
Viral transduction with RL1 +27+/4-pRl9hGFPwpre at high m.o.i.’s significantly 
reduced the total number of TuJl positive neurons in cortical and mesencephalic 
cultures. The neuronal cell loss correlated with a significant increase in the number of 
neurons showing cytotoxic effects. While only about 1% of the neurons were rounded 
in control cultures, about 14% (striatum) to 20% (mesencephalon) of the neurons 
showed cytopathic effects in virally transduced progenitor cultures. About 40% of the 
TuJl positive neurons were transduced as demonstrated by GFP expression for 
mesencephalic derived cultures at the chosen multiplicity. These data confirmed that 
although RLl+27+/4-pR19hGFPwpre efficiently infected mesencephalic neurons and 
progenitor cells, gene delivery is accompanied by a decreased neuronal viability and 
profound neuronal cell loss in these cultures.
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Cortex
Total TuJl (%) rounded TuJl (%)
SFM 58.38+1.57 1.30+0.60
RLl+hGFPwpre 36.36+2.26 16.09+3.12
Striatum
Total TuJl (%) rounded TuJl (%)
SFM 61.29+1.04 1.02+0.11
RLl+hGFPwpre 51.44+2.56 14.02+2.99
Ventral Mesencephalon
Total TuJl (%) rounded TuJl (%) TuJl/GFP (%)
SFM 56.53+0.12 1.44+0.82 n/a
RLl+hGFPwpre 43.38+1.99 20.42+7.64 41.6+2.59
Table 3-2: N euronal loss due to viral transduction. £ 1 4  prim ary neural cultures from  cortex, 
striatum  and ventral m esencephalon w ere infected on 1DIV w ith R L l+/27+/4-pR 19hG FPw pre at 
an m .o.i. o f  10 and fixed on 4DIV. Cells were stained for the neuronal m arker TuJ. The num ber 
o f  total neurons as percentage o f  cells and the num ber o f  cells w ithout processes (rounded) as 
percentage o f  total neurons was counted from  10 different fields in duplicates. For mesencephalic 
derived neural p rogen itor cells the num ber o f G FP+ve infected neurons w as determ ined as 
percentage o f  total T u J l+ v e  neurons. Data are presented as m eans w ith standard error o f  the 
m eans (SE M ) from  three independent experim ents. V iral transduction causes a statistically  
significant loss o f  T uJ+ve neurons in cortical (a two-tailed t-test, p<0.01, n=3) and striatal (b two- 
tailed t-test, p<0.02, n=3) progenitor cultures. V iral transduction increases in all neuronal 
progenitor cu ltures the am ount o f  neurons showing cytotoxic effects characterized by the loss of 
neuronal processes.
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3.3.1.6 Effects o f viral transduction on the number o f dopaminergic neurons
As characterized earlier in this chapter only a proportion of the total neurons in 
mesencephalic cultures are dopaminergic, identified here by the expression of 
tyrosine hydroxylase. With the aim to use HSV-1 as vector for dopaminergic neurons, 
the effects of viral transuction on the number of TH expressing neurons was 
determined (Figure 3-11). Primary mesencephalic progenitor cells were infected with 
RLl+27+/4-pR19hGFPwpre at increasing multiplicities and the number of TH 
expressing cells was assessed three days post-transduction. Viral transduction with 
RLl+27+/4-pR19hGFPwpre does not appear to affect the number of dopaminergic 
neurons compared to control cultures. Even at high multiplicities no significant loss of 
dopaminergic neurons was observed. Similar results were also found after infection of 
mesencephalic neuronal progenitor cultures with the highly disabled 1764/27-/4- 
pR19hGFP after infection on 3 DIV (Figure 3-11). This result seems to be contrary to 
the profound neuronal loss in mesencephalic progenitors as described above. 
However, as shown earlier in this chapter RLl+27+/4-pR19hGFPwpre preferentially 
transduced immature neural progenitor cells that differentiate into post-mitotic TuJl 
positive neurons, but not necessarily dopaminergic neurons. Although some 
dopaminergic neurons were demonstrated to be infected by co-labelling of TH and 
GFP (Figure 3-9), the majority of dopaminergic neurons were not expressing the 
reporter gene suggesting a limited gene delivery to post-mitotic dopaminergic 
neurons. This lack of gene delivery to dopaminergic neurons explains the unaltered 
number of dopaminergic neurons in mesencephalic cultures. It also suggests that viral 
transduction and possibly expression of residual viral genes or reporter genes induced 
a cytopathic cascade in transduced neurons, but not contaminating components of the 
viral stock, such as non-infectious viral particles or cell debris from the producer cell 
line.
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Figure 3-11: Effects o f viral transduction on the amount o f dopaminergic neurons. Graph 
illustrates no significant loss o f dopam inergic neurons due to viral transduction. E14 
mesencephalic neural precursor cells were infected on 1 DIV with R Ll+/27+/4-/pR 19hG FP or 
1764/27-/4-pR19hGFP at the shown m.o.i. and fixed on 4DIV. Dopaminergic neurons were 
characterized by immunocytochemical staining for tyrosine hydroxylase (Alexa 546, red) and 
the cell nuclei were treated with DAPI (blue). Data represent the means o f TH +ve cells as 
percentage o f total cell num ber with SEM from three independent experiments. Scale bar 
represents 50pm.
SFM
m.o.i. 5
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3.3.2 HSV-1 as a gene delivery vector to neurospheres as model for neural stem 
cells
Neural stem cells (NSCs) isolated from the developing (Reynolds et al., 1992; Uchida 
et al., 2000) or adult (Reynolds and Weiss, 1992; Gritti et al., 1996; Palmer et al., 
1997; Palmer et al., 1999) CNS can be expanded as spherical aggregates, or 
‘neurospheres’, to a large number of cells that retain their multipotent neural 
characteristics (Reynolds et al., 1992; Vescovi et al., 1993; Gritti et al., 1996) and 
thus, are available for ex vivo gene transfer manipulations. Here it is reported for the 
first time that replication-deficient HSV-1 is also a promising gene delivery vector to 
rodent and human neurospheres as it efficiently transduces NSCs without causing 
major cytotoxic insults or interfering with the cellular metabolism of the NSC.
3.3.2.1 The effects of heparin on viral transduction
A prerequisite for viral transduction is that the target cells express the necessary 
cellular receptors for HSV-1 attachment. The proteoglycan heparin sulphate and the 
mitogen FGF2 are of significant importance in neurodevelopment (for review see 
Yamaguchi, 2001) and their interaction also plays a crucial role in the division and 
differentiation of neuronal precursor cells from the embryonic and adult CNS (for 
reviews see Vaccarino et al., 1999; Ford-Perriss et al., 2001). The evidence that 
heparin sulphate has been identified as a major factor in binding of HSV to the cell 
surface (WuDunn and Spear, 1989) and reports indicating that the basic fibroblast 
growth factor receptor itself plays a role in viral transduction (Kaner et al., 1990; 
Muggeridge et al., 1992) prompted us to the hypothesis that HSV-1 may be a potent 
candidate for efficient gene delivery to neural stem cells.
Further, heparin plays an important role for the stability and activity of FGF2 
(Gospodarowicz and Cheng, 1986; Saksela et al., 1988) and particularly potentiates 
the mitogenic effects of FGF2 in mesencephalic neurospheres (mesNS) (Caldwell and 
Svendsen, 1998). mesNS grow significantly slower than rodent neurospheres generated 
from cortex (ctxNS) or striatum (strNS) (Ostenfeld et al., 2002) and thus, their
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expansion to a high cell number required for experiments is limited in the absence of 
heparin. Therefore, neurospheres are routinely expanded in the presence of heparin at 
a final concentration of 5/rg/ml in the culture medium when FGF2 is used as mitogen. 
Although it has been shown by Immergluck et al. that the heparin concentration 
required to inhibit viral transduction in neuronal cells is far higher (IC50 ~30jng/ml) 
(Immergluck et al., 1998), we determined the potentially inhibiting effects of heparin 
on viral transduction of mesencephalic neurospheres.
mesNS expanded in FGF2 (20ng/ml) containing culture media in the presence or 
absence of heparin (5/xg/ml) were infected with highly disabled 1764/27-/4- 
/pR19hGFP either as whole neurosphere or after dissociation of neurospheres into 
single cells plated on PLL/Laminin coated cover slips. To minimize further cell 
division of transduced NSC, the infected cells were maintained for another two days 
in media without FGF2. GFP expression was visualized under a fluorescent 
microscope and could first be detected as soon as one day post-transduction, 
demonstrating that mesNS generally were susceptible to viral transduction with the 
highly disabled construct. Growth factor removal induces differentiation of expanded 
NSC (Gage, 2000) and transduced NSC within the neurosphere appear to extend long, 
branched processes (Figure 3-12).
The presence of heparin during the expansion phase of the mesNS significantly 
affected viral transduction. Heparin expanded cultures showed reduced gene delivery 
after infection of whole neurospheres or more prominently after transduction of 
dissociated mesNSCs. At the lower multiplicity chosen (m.o.i 5) hardly any reporter 
gene expressing NSCs were detected in dissociated cultures and only a low gene 
delivery was observed in whole neurospheres when heparin was present prior to 
infection. However, in the absence of heparin the majority of cells in dissociated and 
neurospheres cultures were expressing GFP at the same multiplicity. The inhibiting 
effects of heparin on viral transduction could be slightly overcome by increasing the 
multiplicity of infection. Heparin expanded mesNS infected at higher multiplicities 
(m.o.i. 10) contained more reporter gene expressing cells as is particularly evident for 
infections of dissociated cultures. However, doubling the viral amount did not
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accomplish the gene delivery efficiency observed for cultures expanded in the 
absence of the proteoglycan but infected at the lower multiplicity.
The inhibiting effects of heparin were not significantly decreased by rinsing the 
neurospheres (3x) in heparin-free media prior to viral infection. This suggests that 
residual heparin associated to the cells prevents viral attachment to the occupied 
receptors or alternatively, binds to the virion and thus, occupies virion sites necessary 
for attachment to cell surface heparan sulphates. This observation confirms previous 
studies showing that heparin inhibits attachment only when present during virion 
adsorption in endothelial cells (WuDunn and Spear, 1989), as well as in primary 
neuronal cultures (Immergluck et al., 1998).
Consequently, NSCs cannot be expanded in the presence of heparin in this study 
when viral transduction is anticipated. The significantly reduced proliferation rates of 
mesNS in the absence of heparin make clonal analysis of transduced mesNSC difficult 
for these studies. Therefore, mesNS cultures for gene delivery studies were seeded at 
non-clonal densities (100 cells//xl vs. 20 cells//d in clonal density experiments) in 
proliferation media without heparin. As cortical and striatal NSC have higher 
proliferation rates even in the absence of heparin, they were seeded at clonal density 
(20 viable cells//d) in heparin-free expansion medium for all further studies described. 
It has been demonstrated previously by mixing marked and unmarked cells that 
culturing cells at this density will result in clonal neurosphere colonies, as form in 
single-cell cultures, and that neurospheres do not arise as a result of cell aggregation 
at the cell culture densities used here (Morshead et al., 1998; Tropepe et al., 2000).
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Figure 3-12: Effects o f heparin on viral transduction o f mesencephalic neurospheres. Neural 
precursor cells derived from E14 ventral mesencephalon were expanded as neurosphere cultures 
in media containing FGF2 (20ng/ml) either in the presence or absence o f heparin (5pg/ml). Either 
the whole neurospheres (top pictures) or dissociated cultures (bottom pictures) generated from  
mesencephalic NSC were infected at an m.o.i. o f 5 and 10. Cells were maintained for another two 
days in the absence o f growth factors and heparin, then fixed with 4% PFA and reporter gene 
expression visualised under a fluorescent microscope. Scale bars represent 100pm in top pictures 
and 50pm in bottom pictures.
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3.3.2.2 Highly disabled HSV-1 efficiently transduces mesencephalic neural stem 
cells
To determine the approximate gene delivery rate to mesencephalic neurospheres, 
mesNS were infected at increasing multiplicities of 1, 10 and 30 with highly disabled 
1764/27-/4-pR19hGFP. In order to calculate the required viral amount for infection, 
the cell number of the neurospheres was assessed by selecting 100 medium sized 
neurospheres (about 300/xm diameter) for each treatment. The neurospheres of one 
representative group were dissociated into a single cell suspension and the number of 
viable cells determined by trypan blue exclusion method. The selected neurospheres 
contained about lxlO4 cells per sphere. Viral infection of the whole neurospheres was 
performed in a small volume (50/d) of serum-free media for one hour at 37°C. 
Following transduction the virus containing media was removed and the neurospheres 
were maintained for another two days in differentiation media to avoid continuous 
proliferation of infected cells. Three days post-transduction the neurospheres were 
dissociated into a single cell suspension and GFP expression was monitored under an 
epifluorescent microscope using a FITC filter. The number of GFP expressing cells as 
percentage of total cell number was determined from 10 different fields (more than 
200 cells per treatment) and the final mean calculated from three independent 
experiments (Figure 3-13).
GFP expression appeared evenly distributed throughout the entire neurosphere. It 
seemed that the virus did not only infect cells in the outer layer of the sphere surface, 
but also diffused inside the neurosphere to infect mesNSC even deep inside the core. 
Penetration of the virus may dependent on the size of the sphere and be limited by 
increasing diameter of the sphere. With higher viral doses the number of reporter gene 
expressing cells and the levels of GFP expression increased (Figure 3-13D). 
Infections at very high multiplicities showed a much stronger fluorescent signal than 
at lower m.o.i.’s or infections of larger neurospheres. Most likely, this was the effect 
of multiple infection events in the same neural precursor cell resulting in a transduced 
mesNSC harbouring the genetic information of more than one virion. The transduced 
neurospheres did not show obvious cytotoxic effects at the chosen multiplicities. The
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surface of the spheres remained smooth and only at higher multiplicities cells of the 
outer layer round up and detach from the cell context (Figure 3-13C).
Although penetration of the virus inside the spheres cannot be concluded from the 
fluorescent images due to the three dimensional nature of the sphere, dissociation of 
neurospheres infected at high m.o.i.’s showed that most of the mesNSC were infected. 
The highly disabled construct 1764/27-/4-/pR19GFP efficiently transduced mesNS 
even at low multiplicities (Figure 3-13). About 40% of the precursor cells were 
expressing the reporter gene at an m.o.i. of 1 and gene delivery efficiency could be 
increased to more than 80% at m.o.i.’s of 10 or higher. Therefore, an adequate gene 
transfer to mesNSC could be achieved with relatively low amounts of highly disabled 
replication deficient HSV-1. However, the gene delivery rate does not give any 
information about possible adverse effects of viral transduction on cellular integrity 
and thus must be seen in context with the following studies considering potential 
modifications of the stem cell characteristics.
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Figure 3-13: Highly disabled HSV-1 efficiently transduces m esencephalic neural precursor 
cells. Neurospheres derived from the ventral m esencephalon o f E14 rats were expanded in 
FGF2 (20ng/ml) containing proliferation media in the absence o f heparin. The neurospheres 
were infected either with SFM (A) or diluted 1764/27-/4-pR19hGFP at an m.o.i. o f 1 (B), 10 (C) 
or 30 (D). Following infection, the media was removed and the neurospheres maintained for 
another two days in differentiation media. GFP expression was visualised under an 
epifluorescent microscope with FITC filter. The neurospheres evenly express the reporter gene. 
Scale bar represents 100pm, 50pm in C. As illustrated in the graph the gene delivery rate at the 
different m .o.i.’s was determined by dissociating the infected neurospheres into single cells. 
The number o f GFP expressing cells presented as percentage o f total cells was determined  
under the fluorescent m icroscope from 10 different fields (>200 cells per treatm ent). Data show  
the means of three independent experiments with SEM.
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3.3.2.3 Gene delivery to cortical, striatal and mesencephalic neurospheres shows 
region specific differences
Neurospheres can be generated from various neurogenic regions of the developing 
CNS, including cortex, striatum and ventral mesencephalon (Svendsen and Smith, 
1999). A fundamental question in this field is: do neural stem cells of distinct regions 
behave in a similar fashion irrespective of their origin or are they regionally 
specified? Several studies have addressed this question and shown by morphological 
and molecular analysis that neurospheres are regionally specified (Zappone et al., 
2000; Ostenfeld et al., 2002; Parmar et al., 2002; Hitoshi et al., 2002). As 
demonstrated earlier in this chapter, primary neural progenitor cells from these 
distinct neurogenic regions showed differences in their susceptibility to viral 
transduction with disabled HSV-1. Gene delivery to striatal and mesencephalic 
primary neural cultures was much more efficient than to cortical neural progenitor 
cells. Here it was asked if transduction efficiency also depends on the region from 
which the neurospheres were generated.
Neurospheres were generated from E14 rat cortex (ctxNS), striatum (strNS) or ventral 
mesencephalon (mesNS) and expanded for 7 days in proliferation media without 
heparin. Medium sized neurospheres were selected and the cell concentration 
determined as described before (3.3.2.2). Neurospheres of the different regions were 
infected at the same multiplicity (m.o.i. of 3) with three different viral constructs: the 
highly disabled vector 1764/27-/4-pR19hGFP and the less disabled constructs either 
without the wood chuck response element (RLl+/27+/4-pRhGFP) or containing the 
wood chuck element (RLl+/27+/4-pRhGFPwpre). Reporter gene expression was 
monitored three days post-transduction under an epifluorescent microscope with FITC 
filter (Figure 3-14).
Gene delivery efficiency depended not only on the viral vector used but also varied 
with the neurogenic region the neurospheres were derived from. Infections with the 
less disabled construct containing the wood chuck response element resulted in the 
highest gene expression. GFP expression was significantly reduced using the same 
viral backbone but without the woodchuck response element, suggesting that the
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wood chuck element may have beneficial effects on transgene expression. For all 
three vector systems tested we found significant differences in the transduction 
efficiency depending on the neurogenic origin of the neurospheres. ctxNS were least 
susceptible to viral transduction with any of the constructs and a significaut gene 
delivery at the chosen m.o.i. was only achieved using RLl+/27+/4-pR19hGFPwpre. 
All three viral constructs delivered with much higher efficiency to mesNS with the 
strongest GFP expressing using RLl+/27+/4-pR19hGFPwpre. Surprisingly, the less 
disabled construct without wood chuck response element resulted in a lower 
transduction efficiency than the highly disabled construct. The same effect was 
obvious in strNS with a significant lower reporter gene expression after infection with 
the less disabled vector. This is contradictory to results obtained from studies in 
primary neuronal progenitor cells showing significantly higher gene delivery with 
RLl+/27+/4-pR19hGFP compared to 1764/27-/4-pR19hGFP and maybe the result of 
differences in the quality of the viral high titre stocks prepared. Infection of strNS with 
1764/27-/4-pR19hGFP and RLl+/27+/4-pR19hGFPwpre resulted in the strongest 
reporter gene expression. NSC’s of the entire neurosphere were expressing GFP at 
very high intensity suggesting multiple transduction events in striatal neural stem cells 
that are highly susceptible for infection with disabled HSV-1.
This finding has consequences for the choice of viral vector to infect neurospheres 
generated from distinct regions. Mesencephalic and striatal derived neurospheres can 
be efficiently transduced with either the highly disabled or the less disabled vector. 
However, where cortical neurospheres are the interest of study, RL1+/27+/4- 
pR19hGFPwpre may be the only choice for infections at low multiplicities.
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Figure 3-14: Region specific differences in the gene delivery efficiency to NSC generated from 
distinct neurogenic regions. Neurospheres were generated from E14 cortex (chtNSC), striatum  
(*trNSC) and ventral mesencephalon (mesNSC). Selected medium sized neurospheres were infected 
at an m.o.i. o f 5 with the highly disabled construct (1764/27-/4-pR19hGFP) or the less disabled 
viral vector either with the woodchuck response elem ent (RLl+/27+/4-pR19hG FPwpre) or 
without (RLl+/27+/4-pR19hG FP). Reporter gene expression was monitored three days post­
transduction under an epifluorescent microscope. Reporter gene expression was a function of 
viral construct and neurogenic region (triangle). For all constructs transduction efficiency was 
highest in strNSC, followed by mesNSC and lowest in ctlNSC. At the same multiplicity reporter 
gene expression was higher using R Ll+/27+/4-pR 19hG FPw pre than the highly disabled 1764/27- 
/4-pR19hGFP. Scale bars represent 100pm.
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3.3.2.4 Transduction of mesencephalic neurospheres does not impair cell migration 
or proliferation
Intact neurospheres plated on poly-L-lysine/Laminin coated surfaces, attach to the 
substrate and form radial processes already one hour after attachment that can be 
characterized by radial glial marker (Caldwell and Svendsen, 1998). In time-lapse 
microscopy it has been shown that TuJl-positive cells with long leading growth 
processes migrate along these radial fibers and onto the laminin (Caldwell and 
Svendsen, 1998). Individual transduced neural precursor cells are required to migrate 
from the plated neurosphere and onto the substrate to be analysed. Therefore, only 
those cells were considered that have actively migrated as progenitor cells out onto 
the substrate and subsequently undergone differentiation, rather than any remaining 
post migratory cells. This cell migration model was used to study if viral transduction 
inhibits formation of radial processes and migration of neuroblasts.
Mesencephalic derived neurospheres were infected with highly disabled 1764/27-/4- 
/pR19hGFP at increasing multiplicities. Following transduction, residual virus was 
removed and the neurospheres were plated on PLL/Laminin coated glass cover slips. 
Following transduction the mesNS were maintained in differentiation media. As soon 
as one hour after plating processes were visibly emerging from the neurosphere 
surface onto the substrate. As reporter gene expression is not apparent at this early 
time point, the processes may originate from transduced or untransduced mesNSC. One 
day after plating plenty of long processes had emerged from the neurosphere leading 
far distances onto the substrate. Reporter gene expression was visualised under an 
epifluorescent microscope showing that GFP was localised in a high number of the 
radial processes (Figure 3-15). Formation of processes was not obviously affected at 
low and medial viral amounts (m.o.i. of 1 and 10) and cells did not show any 
cytopathic effects. However, at high multiplicities (m.o.i. of 30) some of the plated 
neurospheres with strong reporter gene expression emerged significantly less 
processes (Figure 3-15). At this m.o.i. the processes were also shortened or 
disintegrated and cytopathic effects, detectable as rounded cells, became more 
evident. To study if neuroblasts can still evolve from the mesNSC and migrate along 
the radial processes, differentiated cultures were stained for the neuronal marker
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TuJl. Several TuJl-positive neurons were found far away from the neurosphere and 
must have resulted from migrating neuroblasts. As shown in Figure 3-15D transduced 
neuroblasts retain their ability to migrate along the processes of potentially radial glial 
cells. Thus, the cell migration assay showed that viral transduction at low and medial 
multiplicities did not affect the ability to form radial processes that build the scaffold 
for neuroblasts to migrate along at.
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Figure 3-15: Transduced mesNS retain capacity to migrate on substrate. Following transduction at 
an m.o.i. o f 1, 10 or 30, mesencephalic neurospheres were plated on PLL/Laminin coated glass 
cover slips and maintained for one day in differentiation media. Cells were fixed in 4% PFA and 
images were taken under an epifluorescent microscope w ith FITC filter. At all multiplicities 
tested transduced precursors formed long radial processes. Only at high viral amounts (m.o.i. 30) 
cytopathic effects became visible (arrow) and process form ation was inhibited. Transduced cells 
migrated sim ilar as untransduced precursor cells away from the neurosphere and differentiated  
into neural cell types in the absence o f mitogens. (D) Im munocytochem ical staining showing a 
high power magnification o f a transduced mesNS that differentiated into a T uJl positive neuron  
(Alexa 546, arrow) likely to be migrating along the process o f an infected radial glial process. 
Scale bar represents 100pm, 10pm in (D).
As shown for adeno-associated viruses, viral transduction may effect proliferation of 
the NSC, slowing or ceasing the continuous growth of transduced precursors even in 
the presence of growth factors (Wu et al., 2002). Due to the slow growth rate of 
mesNS, the proliferation effects were studied in cortical and striatal derived 
neurospheres that grow considerably faster and allow possible growth inhibiting 
effects to be observed more easily. However, as ctxNS were shown to be less 
susceptible to viral transduction with the highly disabled 1764/27-/4- vector, the less 
disabled construct RLl+/27+/4-pR19hGFPwpre was used for this study. Following 
transduction of ctxNS and strNS with RLl+/27+/4-pR19hGFPwpre at high multiplicity 
(m.o.i. 10) neurospheres were maintained in either proliferation or differentiation 
media. Reporter gene expression was detected three days post-transduction under an 
epifluorescent microscope (Figure 3-16). The reporter gene was stably expressed 
under proliferation and differentiation conditions. Under differentiation condition 
GFP expression appeared evenly distributed throughout the neurosphere and cells 
inside the sphere appeared to be infected at the same intensity as cells in outer cell 
layers. Maintaining infected neurospheres in the presence of FGF2 resulted in a 
graded gene expression within the spheres (Figure 3-16). While the centre of the 
sphere contained a high density of NSC strongly expressing the reporter gene, the 
outer cell layer contained less or no GFP expressing precursor cells. The intensity of 
GFP expression in the outer cell layer was also observed to be less strong compared to 
the core of the spheres. An explanation might be that the core of high GFP expression 
represented cells that were initially transduced. As infections were performed at high 
multiplicity the majority of NSC’s were infected most likely with more than one 
virion. As neurospheres continue to grow in the presence of the mitogen from inside 
to outside, the daughter cells formed the outer layers of the sphere. Since HSV-1 
remains episomal and does not integrate into the host genome only one daughter cell 
will inherit the genome in case that the mother cell was infected by a single viral 
particle, or the viral genomes are distributed on both daughter cells in case of multiple 
initial transduction events. With continuous proliferation of the NSC the viral genetic 
information will be further diluted and consequently, fewer cells in the outer cell 
layers will contain the recombinant episome. The result is the observed graded GFP 
expression under proliferating conditions. Indeed virally infected neurospheres further
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increased in diameter when FGF2 was present and no significant differences in the 
growth rates were observed compared to uninfected neurospheres.
Reporter gene expression was stable under differentiation conditions for at least two 
weeks, the longest time point tested. Over this time frame no decrease in the number 
of reporter gene expressing cells or in the intensity of GFP expression was observed. 
A continuous passaging of infected neurospheres has not been tested due to the 
episomal character of HSV-1.
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Figure 3-16: Viral transduction does not inhibit proliferation o f neurospheres in growth factor 
containing media. Overlay o f fluorescent and phase contrast images o f cortical and striatal 
neurospheres infected at an m.o.i. o f 10 with RLl+/27+/4-/pR19hG FPwpre. After transduction 
neurospheres were maintained for another two days in either proliferation media (containing 
20ng/ml FGF2) or differentiation media (no FGF2). In the presence o f FGF2 transduced 
neurosphere continued proliferating, but as HSV-1 remained episomal, not every daughter cell 
contained a viral genome. This resulted in a cell layer with reduced num ber o f reporter gene 
expressing NSCs surrounding a core of originally transduced cells (dotted line) und proliferating 
conditions. This layer o f reduced GFP expression was not evident under differentiation 
conditions. Scale bar represents 20pm.
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3.3.2.5 Transduction with HSV-1 does not impair differentiation into the different 
neural cell types
A defining characteristic of neural stem cells is their ability to give rise to neurons and 
glial cells (Gage, 2000). NSC’s grown as neurospheres remain multipotent even after 
continuous passaging. This makes them favourable as source for neural tissue 
(Svendsen et al., 1999). As viral transduction may affect this natural ability to 
differentiate into neuronal or glial cell types, whether infected NSC’s retained this 
capacity was studied, considering two aspects: can infected neurospheres give rise to 
neural cell types, and into which neural cell type do infected NSC’s differentiate upon 
serum withdrawal?
In order to address these questions cortical, striatal and mesencephalic derived 
neurospheres were infected with either the highly disabled construct 1764/27-/4- 
/pR19hGFP or the less disabled vector RLl+/27+/4-pR19hGFPwpre. Following 
transduction the neurospheres were plated on poly-L-lysine/laminin coated cover slips 
to take advantage of the cell migration assay. The transduced NSC’s were 
differentiated for five days prior to fixation in paraformaldehyde. Neurons were 
identified by immunocytochemical labelling with the post-mitotic marker TuJl and 
glia by staining for GFAP reactivity (Figure 3-17 and Figure 3-18). Infected NSC’s of 
all three neurogenic regions retained their ability to differentiate into neurons and glia. 
Virally infected NSCs preferentially differentiated into GFAP positive astrocytes, a 
phenomenon that appeared independent from the region of the NS or the disablement 
of the viral vector. Differentiation of transduced NSC into neurons was not 
completely abolished as several migrated TuJl positive cells expressing GFP were 
detected after infection with either construct in the three regions tested. However, the 
total number of transduced NSC’s differentiating into neurons was different for the 
two viral constructs. NSC’s infected with the highly disabled vector gave rise to more 
neurons than with the less disabled construct. This is particularly evident in strNS that 
naturally give rise to more neurons than cortical or mesencephalic neurospheres 
(Ostenfeld et al., 2002). This observation may reflect differences in vector 
cytotoxicity affecting neurogenesis of infected neural progenitor cells. The viral gene
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product ICP27 or ICP 34.5 maybe toxic in neuronal progenitor cells resulting in an 
early cell death of transduced progenitors determined to become neurons while it 
obviously is non-toxic in glial progenitor cells that retained the capacity to 
differentiate into mature GFAP positive astrocytes. This toxic effect was not evident 
in the 27- mutant giving rise to plenty TuJl/GFP double labelled neurons in striatal 
neurospheres. The low number of double labelled neurons in ctxNS was mainly due to 
the inefficient gene delivery to cortical precursor cells with 1764/27-/4-pR19hGFP as 
described earlier in this chapter. That transduced strNS mainly differentiate into 
astrocytes may reflect the predominance of glial progenitor cells in neurospheres 
expanded under the chosen culture conditions. Cytotoxic effects of viral transduction 
with 1764/27-/4-pR19hGFP on neuronal morphology became obvious at high 
multiplicities (m.o.i. 10). The somas of infected neurons were enlarged and neural 
processes often shortened or disintegrated. At the same multiplicity no cytopathic 
effects were observed in transduced NSC that had differentiated into GFAP positive 
glial cells (Figure 3-17).
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Figure 3-17: Neurospheres from different regions retain the ability to differentiate into astrocytes 
and neurons after transduction with 1764/27-/4-pR19hGFP. Cells were fixed and stained for TuJ or 
GFAP (Alexa 546, red), respectively. Independent of the neurogenic region, the transduced 
precursors predominantly differentiated into astrocytes. However, neurogenesis is not inhibited as 
shown by GFP/TuJ double labelled neurons (arrows). High multiplicities cause cytopathic effects in 
neurons visible in swollen cell bodies and disintegrated processes. Scale bars represent 50pm.
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Figure 3-18: Neurospheres from different regions retain the ability to differentiate into astrocytes 
and neurons after transduction with R Ll+/27+/4-pR19hG FPwpre. N SC’s derived from the 
different neurogenic regions mainly differentiate into GFAP positive astrocytes. Although  
neurogenesis is not abolished as shown by the occurrence o f T uJl positive neurons, viral 
transduction seems to have negative effects on neurogenesis o f transduced precursor cells as only 
a low num ber o f G FP/TuJ double labelled cells were detected. Scale bars represent 50pm.
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3.3.2.6 Viral transduction does not induce premature differentiation
The previous section has shown that neural stem cells infected with the less disabled 
vector RLl+/27+/4-pR19hGFPwpre predominantly differentiate into GFAP positive 
astrocytes. It was suggested that the viral gene product ICP27 may inhibit 
differentiation of neuronal progenitor cells into post-mitotic neurons, most likely due 
to cytotoxic effects. On the other hand no inhibiting effects on gliogenesis were 
observed dependent of the neurogenic region the neurospheres were generated from. 
However, this does not exclude the possibility that viral transduction with the less 
disabled construct or that the expression of viral genes induce a premature 
differentiation of a common precursor cell into a glial phenotype. That viral 
transduction of neurospheres can induce an unexpected differentiation into GFAP 
positive astrocytes accompanied by a decrease in nestin expression even under 
proliferation conditions has been reported for adenoviral vector systems (Hughes et 
al., 2002; Falk et al., 2002) and was also observed with adeno-associated vectors (Wu 
et al., 2002). To address this possibility induction of GFAP expression was considered 
after viral transduction of neurospheres under proliferating conditions.
In the presence of the mitogen FGF2 neurospheres remain in an undifferentiated state 
and the majority of neural stem cells were expected to be nestin positive. Striatal 
neurospheres infected with either the highly disabled vector 1764/27-/4-pR19hGFP or 
the less disabled vector RL1 +/27+/4-pRl 9hGFPwpre showed indeed strong 
immunoreactivity for nestin when maintained in proliferation media and fixed one 
day after viral transduction (Figure 3-19E and F). More than 90% of the radial fibers 
were nestin positive at this time point. Although the majority of GFP expressing cells 
(>80%) were co-localising with nestin, some transduced progenitor cells that migrated 
onto the substrate were not immunoreactive for the neurofilament marker. GFP 
expression was localised in the cell bodies and radial processes of the nestin positive 
cells.
In order to study if transduction with RLl+/27+/4-pR19hGFPwpre induces 
differentiation of neural progenitor cells into astrocytes even under the continuous
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presence of growth factors, the neurospheres were plated on PLL/Laminin coated 
cover slips and a cell migration assay performed as described before. Individual 
transduced precursors and cells derived from NSC’s migrated were characterized 
three days post-transduction for their antigenic identity. Control cultures were treated 
with serum-free media instead of diluted virus stock during infection. Following 
transduction the neurospheres were maintained in media containing FGF2 (20ng/ml). 
Surprisingly, a significant number of GFAP positive astrocytes (Figure 3-19 A and B) 
were found in both virus treated and control cultures, suggesting that some of the cells 
derived from migrating NSC’s have differentiated despite the continuous presence of 
FGF2. However, the majority of neural precursor cells in control and virally infected 
cultures stained positive for nestin. By immunocytochemical staining an increased 
number of GFP expressing cells co-localised with GFAP was not observed. Most of 
the transduced NSC’s remained undifferentiated as shown by co-localisation with 
nestin (Figure 3-19C). To quantify differences in GFAP expression from 
neurospheres transduced with RLl+/27+/4-pR19hGFPwpre or SFM and maintained 
under proliferation conditions, western blot analysis was performed (Figure 3-19 G). 
Although both neurosphere cultures express the astrocytic marker even under 
proliferation conditions, no differences in the expression levels were detected between 
virally and non-virally infected samples. Therefore, it was concluded that transduction 
with disabled HSV-1 did not induce a premature maturation of uncommitted NSC’s. 
The observation that some of the NSC’s differentiated under proliferation conditions 
independently of a viral transduction event, maybe the result of insufficient supply 
with growth factor over three days cultivation period.
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Figure 3-19: Viral infection does not induce prem ature differentiation o f N SC’s. strNSC w ere 
infected with RLl+/27+/4-pR19hG FPwpre (A to D , F) or 1764/27-/4-pR19hGFP (E) and 
maintained in the presence o f FGF2 for another one (E and F) or three days (A to D) prior to 
fixation with paraformaldehyde. (A) and (B) G FA P expressing cells (Alexa 546, red) were 
detected in control and virally infected cultures. Although som e transduced NSC’s have 
differentiated into GFAP positive astrocytes (arrow), the majority o f  GFP expressing cells did not 
co-localise with the astrocytic marker. (C) and (D) N estin (Alexa 546, red) was expressed in the 
majority o f control and virally infected cultures (arrows). (E) and (F) One day after infection  
most o f the GFP expression co-localised with nestin expression in the radial fibers emerged from  
the neurospheres. (G) W estern blot analysis confirm ing that GFAP expression was not 
upregulated in strNS that had been infected with R Ll+/27+/4-pR 19hG FPw pre and m aintained in 
the presence o f  FGF2 for three days after transduction.
184
3.3.2.7 Gene delivery to human neural stem cells
Although this study preliminarily focused on the use of rodent neurospheres, 
neurospheres derived from human tissue were also tested for transduction with 
replication-deficient HSV-1. Mesencephalic neurospheres derived from human tissue 
(meshNS) were previously prepared and had been passaged using a chopping method 
that allowed extended growth of otherwise senescent human neurospheres (Svendsen 
et al., 1998).
meshNS were infected as whole neurospheres with the highly disabled construct 
1764/27-/4-pR19hGFP at an m.o.i. of 10. Using the migration assay, transduced 
meshNS were subsequently plated on poly-L-lysine/laminin coated substrate and 
maintained in differentiation media. Reporter gene expression was visualised under an 
epifluorescence microscope (Figure 3-20) showing efficient gene delivery to meshNS. 
As described before for rodent NSC’s, the infected human NSC’s also retain the 
ability to emerge radial processes and neural precursor cells migrate onto the substrate 
to differentiate in distance of the neurosphere. As shown by immunocytochemical 
staining for the neuronal marker TuJl, infected human NSC’s can still differentiate 
into post-mitotic neurons with long neural processes without any evident cytopathic 
effects (Figure 3-20). Transgene expression in meshNS is stable and could be detected 
for up to 14 days, the longest time point tested.
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Figure 3-20: Transduction o f human neurospheres generated from embryonic m esencephalic 
tissue. M esencephalic derived neurospheres were previously isolated and prepared from human 
foetal tissue and passaged using a unique tissue chopping method. Neurospheres were infected  
with 1764/27-/4-pR19hGFP at an m.o.i. o f 10 and subsequently plated on PLL/Lam inin coated  
cover slips. Infected meshNS formed radial processes and precursor cells migrated onto the 
substrate in distance of the original sphere as shown in (A) a phase contrast image. (B) GFP  
expression three days post-transduction dem onstrating high gene delivery efficiency to hNSC ’s, 
(C), (D) Infected NSC’s retain their ability to differentiate into T u Jl positive neurons as 
confirmed by immunocytochemical staining. M erged images for T uJl (red) and GFP in the same 
neurons. Insets show unmerged images. Scale bars represent 100pm in (A) and (B), 10pm in (C) 
and (D).
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3.3.2.8 Transplantation o f virally infected neurospheres
Neurospheres have also emerged as promising cellular vehicle for ex vivo gene 
transfer approaches. The approach aims to expand and genetically manipulate neural 
stem cells in vitro, prior to transplantation to the CNS. Thus, safety concerns about 
direct administration of virus are diminished as the genetically modified cells could be 
tested for any remaining virus prior to transplantation. It has been well established 
that neural stem cells can survive, migrate and functionally integrate into the host 
circuitry after intracerebral transplantation (reviewed by Lindvall, 2003). Other 
groups have also demonstrated that neurospheres transduced a priori with adenoviral 
(Sabate et al., 1995; Corti et al., 1999) and lentiviral vectors (Ostenfeld et al., 2002) 
retain this ability. Here, the aim was to establish if rodent neurospheres transduced 
with replication-deficient HSV-1 survive and express the transgene after intracerebral 
transplantation.
The experimental rationale was to transplant mesNS that were transduced two days 
prior grafting with the less disabled vector RLl+/27+/4-pR19hGFPwpre into the 
striatum of adult rats and to determine reporter gene expression in the graft three days 
and three weeks after grafting (Figure 3-21A). mesNS were freshly prepared and 
expanded for ten days before infection with RLH727+/4-pR19hGFPwpre at an m.o.i. 
of 1. Strong reporter gene expression was confirmed two days after transduction 
(Figure 3-2IB) and an aliquot of the neurospheres was plated on PLL/Laminin coated 
cover slips to stain for the presence of TH expressing neurons (Figure 3-2IB). 
Unpassaged neurospheres were used in this study for optimal cell survival and a low 
number of TH expressing cells were identified, most likely residual primary 
dopaminergic neurons from tissue preparation. The transduced mesNS were 
transplanted as whole neurospheres (diameter about 200pm per sphere) at two 
injection sites unilateral into the striatum of rats. 10,000 viable cells were transplanted 
per injection site with three animals per group. As the same rat strain was used for 
preparation of neurospheres and as host for grafting, immunosuppression of the 
animals was not required. The animals were sacrificed three days or three weeks after 
transplantation, the brains removed and coronal sections prepared.
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Three days after grafting evidence was found of GFP expressing cells around the 
injection site (Figure 3-21C). Due to the surgical procedure, significant cell damage 
was observed around the grafting site. GFP expression was only observed in the 
vicinity of the graft at this time point in the form of spherical deposits. Only a few 
reporter gene expressing cells had migrated short distances from the injection site into 
the host tissue. A significant upregulation of GFAP (Figure 3-2ID) and nestin (Figure 
3-2IB) expression was found around the graft most likely due to microglia 
infiltration. Physical stress and damage caused by the surgical procedure may have 
caused this host response. Interestingly, evidence of cell bodies staining for TH within 
the graft and around the injection site (Figure 3-2IF) was found. These TH positive 
cells had the ability to migrate into the striatum of the host (Figure 3-21G) and also 
formed processes into the host tissue (inset in Figure 3-21G). As dopaminergic cell 
bodies are localised in the substantia nigra and only the processes project into the 
striatum, the detected TH positive cells probably originated from the graft. No TH 
positive cell bodies were found in the striatum contralateral to the injection site. 
However, the TH expressing cell bodies did not co-label with the reporter gene GFP 
suggesting that they were not virally transduced. As shown before in this chapter, 
primary dopaminergic neurons were generally rather difficult to transduce with 
disabled HSV-1 and it is likely that the detected TH positive cells in the host striatum 
were actually untransformed, residual primary dopaminergic neurons. Therefore, it 
cannot be concluded from these data if viral transduction affected the migration 
capacity of the NSC as no GFP expressing cells were detected at any further distance 
to the grafting site at this time point.
Under the tested conditions no long term GFP expression was observed in the grafted 
neurospheres. Three weeks after transplantation no GFP expression could be detected 
in the striatum of grafted animals (Figure 3-21H). This might be the result of poor 
survival of virally transduced neurospheres and/or due to rejection as result of the 
inflammatory response that was observed in the three day time point. A similar lack 
of long-term survival was also found in other studies (Svendsen et al., 1996).
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Figure 3-21: Transplantation of transduced neurospheres. mesNS were expanded for lOdays prior 
viral transduction with RLl+/27+/4-pR19hG FPwpre. (A) Infected neurosphere showed strong  
GFP expression prior to transplantation. 10,000 cells were transplanted into two sites o f the 
striatum of adult rats. Animals were terminated 3 days and 3 weeks after transplantation. (B) An 
aliquot o f the transduced neurospheres was plated on PLL/laminin coated glass coverslips and 
stained for TH expression (arrow). (C) Clusters o f GFP expressing cells were found around the 
injection site (IS). (D) GFAP and (E) nestin expression were upregulated around the injection site 
most likely due to surgical tissue damage. (F) TH staining revealed TH expressing cell bodies 
around the grafting site (arrowheads) and (G) som e o f the TH expressing cells were found in 
distant to the graft within the host striatum. Inset shows TH+ve process emerging into the tissue. 
(H) No GFP expression was detected 3 weeks after transplantation. Scale bars: 100pm in A, C, E, 
F; 50pm in B, D and inset o f F.
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3.3.3 HSV-1 as a gene delivery vector to endogenous neural stem cells in the 
subventricular zone of the CNS
In the adult mammalian forebrain new neurons are continuously generated from 
progenitor cells that are localised in the subventricular zone (SVZ) (Alvarez-Buylla 
and Garcia-Verdugo, 2002). Remarkably, neural progenitors can migrate long 
distances from the site of birth in the SVZ to the olfactory bulb, where they fully 
differentiate into mature neurons (Lois and Alvarez-Buylla, 1994). In order to study 
behaviour of endogenous neural stem cells or to deliver potentially therapeutic genes 
to the SVZ, viral vectors are particularly useful for in vivo gene delivery to neural 
stem cells in this region. Previously it has been demonstrated that cells of the SVZ can 
efficiently be transduced using adenoviruses (Yoon et al., 1996; Benraiss et al., 2001) 
and adeno-associated vectors (Davidson et al., 2000) after intraventricular injection. 
Here, replication defective HSV-1 was used to infect adult precursor cells in the 
subventricular zone and their migration followed to the olfactory bulb.
To test whether replication-deficient HSV-1 could label cells localised within the 
SVZ, the less disabled vector was injected into the lateral ventricles of adult rats 
(older than 6 months). 5xl06PFU of RLl+/27+/4-pR19hGFPwpre were injected 
bilaterally into three animals and the animals terminated four days after injection. The 
brains were removed, coronally sliced into 40/mi rostral-caudal sections on a freezing 
microtome and reporter gene expression monitored under an epifluorescent 
microscope (Figure 3-22). GFP expressing cells were found in the walls of the lateral 
ventricles around the injection site (Figure 3-22C), as well as in distant sections 
rostral (Figure 3-22A) and caudal (Figure 3-22B) of the injection site. Thus, the 
highly concentrated virus applied into the lateral ventricles, diluted in the 
cerebrospinal fluid (CSF) and was transported with it throughout the ventricle system 
to infect cells of the ventricle wall at a distance from the actual injection site. Little 
parenchymal reporter gene expression was noted. No GFP expression was observed at 
this time point in the striatum or septum, suggesting that viral penetration outside the 
subependyma was minimal. A significant higher number of labelled cells were found 
in the ventricle wall facing the striatum rather than septum.
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It has been shown before that adenoviral vectors injected directly into the SVZ of the 
lateral wall labelled precursor cells that retained the ability to migrate to the olfactory 
bulb where they expressed the reporter gene LacZ (Yoon et al., 1996). To study if a 
similar result can be obtained with HSV-1 vectors, highly disabled 1764/27-/4- 
pR19LacZ was injected directly into the SVZ rather than into the ventricle and LacZ 
expression observed in the olfactory bulb (Figure 3-22) three days after virus 
injection. In all animals (n=3) we found strong LacZ expression around the injection 
site around the dorsolateral horn of the ventricle and also detected LacZ expressing 
cells in the OB. In the OB LacZ expressing cells were mainly observed in chains that 
may reflect the migration of transduced progenitors within the olfactory stream. The 
reporter gene expressing cells showed a rather globular cell shape without visible 
processes, suggesting that a differentiation into mature neuronal cell types had not 
occurred at this time point. However, the lack of LacZ product localised in processes 
may be a problem related to the use of LacZ as reporter gene since it has been shown 
before that /8-gal was mostly defined to the cell perikaryon of these cells (Yoon et al.,
1996).
To further characterize the cellular identity of the transduced cells within the SVZ, 
immunohistochemical staining for GFAP and nestin was performed. The cellular 
composition and architecture of the adult mouse SVZ has been characterized before 
(Doetsch et al., 1997) and the SVZ-ependymal layer contains at least four different 
cell types (Alvarez-Buylla and Garcia-Verdugo, 2002). Most notable is the population 
of dividing astrocytes (B cells) that were identified as the in vivo primary precursors 
in this region and act as stem cells in vitro (Doetsch et al., 1999). B cells interact 
closely with ependymal cells which separate the SVZ from the lateral ventricle. 
Occasionally, an SVZ astrocyte extends a process between ependymal cells to contact 
the ventricle lumen. Whereas ependymal cells have long cilia, some B cells contain a 
single short cilium (Doetsch et al., 1999).
As shown in (Figure 3-22A) GFP expressing cells were found in the subependymal 
layer of the SVZ in a zone comprising about two to three cell layers of the lateral 
wall. Unfortunately, the ependymal layer came off during tissue processing and thus,
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no conclusion can be made regarding transduction efficiency of ependymal cells. 
However, sections containing the ependymal layer as ribbon floating within the 
ventricle showed strong reporter gene expression suggesting that both, ependymal and 
subependymal layers, were transduced. Immunohistochemical staining for GFAP 
revealed as expected a high number of astrocytes within the subependymal layer 
(Figure 3-23B and C). Some of the astrocytes were expressing the reporter gene and 
had globular (arrows in Figure 3-23B) or branched (arrow head in Figure 3-23B) cell 
morphologies. Interestingly, some of the virally transduced astrocytes had short single 
processes that emerged into the lumen of the ventricle (Figure 3-23D). As mentioned 
above, these may be the astrocytes giving rise to faster dividing neural progenitors 
that had been identified by others as the neural stem cells of the SVZ (Doetsch et al., 
1999). Immunohistochemical staining for the neurofilament marker nestin showed a 
ribbon of nestin positive cells along the wall of the lateral ventricle (Figure 3-23D and 
E). Within this layer of nestin positive cells GFP expressing cells were localised. As 
shown in Figure 3-23E some the transduced cells appear to co-label with the 
neurofilament marker.
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Figure 3-22: Disabled HSV-1 transduced cells o f the subventricular zone (SVZ). As shown in the 
illustration progenitor cells born in the SVZ migrate via the migratory stream to the olfactory 
bulb where they differentiate into neurons. I: Replication deficient HSV-1 RL1+/27+/4- 
/pR19EGFPwpre was injected into the lateral ventricles and gene expression monitored n  (A) 
rostral, (B) caudal and (C) sections to the injection site. GFP expressing cells were detected in the 
wall o f the SVZ throughout the entire lateral ventricle (LV), here shown in representative 
sections. No GFP expression was found in the septum (SEP) or striatum (STR). II: Direct 
injections o f 1764/27-/4-/pR19LacZ into the SVZ (IS). LacZ expression was detected ia the 
olfactory bulb (OB) three days after virus injection. D=dorsal, V=ventral, M =medial, L=lateral. 
Scale bar represents 100pm.
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Figure 3-23: Characterization o f transduced cells in the SVZ. (A) GFP expression was detected 
in cells o f the subependymal layer o f the ventricle wall. Inset in (A) is a phase image to confirm  
no cytotoxic effects o f viral infection in the wall o f the LV. (B) Merged im age of GFP  
expression and GFAP expression. Some o f the transduced cells in the SVZ co-labelled with 
GFAP (arrows). GFP/GFAP double labeled cells differed in cell size and morphology. Some of 
the double labelled cells were small and globular, others had a large cell body with processes 
(arrowhead). (C) Along the lateral nestin positive cells were found as a ribbon (about 150pm) 
along the wall o f the lateral ventricle. (D) Some of the nestin positive cells within this ribbon 
were expressing GFP (arrow). LV=lateral ventricle, STR=striatum , SVZ=subventricular zone, 
CC=corpus callosum. Scale bars represent 100pm in A and 50pm in B-D.
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3.4 Discussion
In this chapter it was demonstrated for the first time that replication-deficient HSV-1 
can efficiently deliver foreign genes to neural precursor cells of the CNS. Two 
different disabled viral vector systems with also different promoter cassettes were 
tested for their suitability as gene delivery systems to neural progenitor and neural 
stem cells in vitro and in vivo.
Neural progenitor cells follow phenotypic changes in vitro
Since the overall aim of this study focuses on dopamine neuron development, 
embryonic tissue was chosen at a developmental stage that corresponds to the 
beginning of dopamine neuron development. In the rat embryo, midbrain dopamine 
development occurs between embryonic day 11 (El l ) toE15 (Hanaway et al., 1971; 
Lauder and Bloom, 1974). Characterized by the expression of tyrosine hydroxylase it 
has been shown that mesencephalic dopamine neurons begin to differentiate at E l2.5 
(Specht et al., 1981). Dissections of embryos before the gestational stage E14 are 
technically difficult to perform and only a low number of mesencephalic progenitors 
can be obtained.
In the first section of this chapter the isolated neural progenitor cultures 
were characterized regarding their phenotypic identity. Of particular interest for this 
study were mesencephalic derived progenitor cells that give rise to dopaminergic 
neurons. Depending on the age of the culture about 62% of the cells were neuronal 
and 10% of the cells positive for the dopaminergic marker TH. The proportion of 
dopamine neurons is higher than in other studies reporting about 5% of TH positive 
cells from rat mesencephalic tissue cultured under similar conditions (Cheung et al.,
1997). However, this might be the result from variations in the gestational age, 
dissection methods, culture conditions, and possibly the use of different immunogenic 
reagents. Particularly primary mesencephalic progenitor cultures showed a high 
variability among the preparations regarding cell viability.
Although, growth factor free, differentiative culture conditions were used in this 
study, it was shown that the progenitor cells undergo a time dependent maturation in
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vitro. Particularly cortical and mesencephalic neural progenitors contained a high 
proportion of undifferentiated, nestin positive progenitors at early culture time points 
that later mainly gave rise to neurons since the culture conditions did not support glial 
differentiation. Whether these undifferentiated, nestin positive cells were neural stem 
cells or fate committed neuroblasts cannot be explained from these data. However, 
cells were observed with weak immunoreactivity for nestin that also had 
morphological characteristics of immature neurons suggesting that a commitment 
towards the neuronal lineage has already occurred.
Hence, these neurogenic progenitor cultures present a potential in vitro 
system to study the effects of exogenous factors on dopamine neuron development.
Less disabled HSV-1 vectors efficiently express in neural progenitor cells but on the 
expense o f neuronal cell loss
In order to establish the conditions determining transduction efficiency, effects of the 
maturation state of the neural progenitor culture on viral transduction were 
considered. Infection of more mature mesencephalic progenitor cultures resulted for 
both vector systems tested in significant higher gene delivery efficiency than 
transduction at earlier time points. Indeed, other studies have also shown that 
transduction efficiency with the highly disabled construct depends on the age of 
primary cultures (Lilley, 2000). However, for the overall aim of this study it was not 
practical to use fully differentiated neural cultures. In order to induce a dopaminergic 
phenotype from neural precursor cells, the developmental stage of the primary tissue 
used for preparation of progenitor cell cultures is important. As progenitor cells 
mature in culture, recombinant genes need to be delivered at early culture time points 
to progenitor cells which are still plastic and able to adapt different phenotypes. 
Therefore, transduction efficiency was studied in progenitor cells infected on 1 DIV 
although significantly higher gene delivery rates were found at later time points. At 
this early time point reasonable gene delivery was only achieved using the less 
disabled construct RLl+/27+/4-pR19hGFPwpre, while the highly disabled backbone 
1764/27-/4-pR19hGFP gave an inadequate transduction efficiency.
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In vitro gene transfer studies to neuronal cultures of the CNS using HSV-1 have 
previously been limited by vector cytotoxicity. Reduction of immediate early gene 
expression in replication-incompetent HSV mutants resulted in decreased cytotoxicity 
(Johnson et al., 1992; Johnson et al., 1994). Infectious viral particles may cause 
cytopathic effects in transduced neurons due to residual viral gene expression. 
However, non-infectious viral particles, as well as cell debris from the producer cell 
line present in the virus stock, may also contribute to cell death in primary neuronal 
cell cultures (Ho et al., 1995). To reduce the amount of components from the producer 
cell line and thus, to increase the quality of the viral stock, all viruses used in this 
study were clarified in two subsequent filtration steps. Virus cytotoxicity was assessed 
for the less disabled construct RLl+/27+/4-pR19hGFPwpre in neural progenitor cells. 
Virally induced cytopathic effects were concentration dependent and more evident 
upon infection of early cultures rather than more mature primary neuronal cells. It 
appeared contradictory that a significant loss in the total number of neurons was 
observed in mesencephalic progenitor cultures, but that the number of TH expressing 
dopaminergic neurons was unaffected by viral transduction. Neuronal cell loss may 
occur either after infection of post-mitotic differentiated neurons or alternatively, viral 
transduction of undifferentiated neuroblasts abolishes further differentiation into a 
mature phenotype. Considering minimal cytotoxic effects in more mature cultures and 
no effects on primary dopamine neurons, it appears that immature neuroblasts are 
more vulnerable to the viral insult. As shown in this study and by others (Bouvier and 
Mytilineou, 1995), not many undifferentiated dopamine neuroblasts were present at 
the chosen gestational stage, and the serum and growth factor free culture conditions 
did not support their proliferation. Hence, virally transduced neuroblasts are mostly of 
non-dopaminergic fate and due to the low susceptibility of mature dopaminergic 
neurons to infection with disabled HSV-1, the number of TH expressing cells 
remained unaltered even at high multiplicities. Nevertheless, the low transduction 
efficiency of mature dopaminergic neurons in vitro is surprising since high 
susceptibility of these neurons for this replication-deficient HSV-1 vector was 
demonstrated in vivo (Lilley et al., 2001).
Vector cytotoxicity and reporter gene expression may explain the neuronal cell loss 
observed in this study. HSV-1 amplicon vectors expressing enhanced green
197
fluorescent protein (EGFP) induce apoptosis in primary cortical neuronal progenitor 
cells (Detrait et al., 2002). In preliminary work comparing three different reporter 
genes, enhanced GFP, hr GFP and LacZ, we have found similar results regarding 
reporter gene toxicity in primary neuronal cultures. Primary cortical and 
mesencephalic neural progenitor cells infected at the same multiplicity with the 
RL1+/27+/4- backbone expressing either of the reporter genes in the same promoter 
cassette, showed reporter gene dependent cytotoxic effects: EGFP»hGFP ^ LacZ. At 
the same gene delivery rate, EGFP expressing neuronal cultures contained a 
significant higher number of rounded neurons without processes two days post­
transduction compared to hGFP or LacZ expressing cultures. Significantly more 
EGFP expressing cells detached from the cell culture surface and were lost prior to 
cell fixation resulting in a reduced number of transgene expressing cells. Cytotoxic 
effects between hGFP and LacZ expressing neuronal cultures were less evident. Since 
the antigenic identity of the transduced cell was to be determined in 
immunoyctochemical staining, it was decided to use hGFP expressing viral vectors 
for in vitro studies. However, cytotoxic effects of accumulated hGFP protein may 
contribute to neuronal cell loss in this study.
Highly and less disabled vectors efficiently deliver transgenes to neurospheres
In the next section of this chapter gene delivery to neural precursor cells expanded as 
neurospheres was considered. It was demonstrated that replication-deficient HSV-1 
vectors efficiently deliver to rodent and human neurospheres. Since work shown in 
following chapters is based on the delivery of recombinant genes of rodent origin, it 
was decided to perform all subsequent work with neurospheres derived from rats.
Significant differences in gene delivery efficiency were demonstrated for the highly 
disabled construct 1764/27-/4-pR19hGFP in neurospheres. Even at low multiplicities 
the vector delivered with high efficiency and most notably, without causing any 
obvious cytotoxic effects or interfering with the stem cell nature of the infected cells. 
Transduced precursor cells retain their ability to self-renew and to differentiate into 
glial or neuronal cell types. Although gene delivery was more efficient with the less 
disabled construct RLl+/27+/4-pR19hGFPwpre at low multiplicities, reduced
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neurogenesis after infection at higher multiplicities was found. Cytotoxic effects make 
this vector for this reason more favourable for infections with minimal virus 
concentrations.
Next it was asked if neuronal loss may partly be explained due to glial differentiation 
of transduced precursor cells. A premature differentiation of HSV-1 infected 
precursor cells into GFAP positive astrocytes was not observed as described by other 
groups using adenoviral vectors (Hughes et al., 2002; Falk et al., 2002). However, this 
phenomenon described for adenoviral vectors may only occur in a subpopulation of 
already fate committed progenitor cells and was not observed when transgene 
expression was targeted to a selective population of uncommitted neural stem cell 
(Keyoung et al., 2001).
Viral transduction could be blocked in the presence of heparin, most likely by 
competing for heparan sulphates as receptor for viral attachment. Other studies had 
identified heparan sulphate as receptor for HSV-1 attachment in endothelial cells 
(Herold et al., 1994), and primary neural progenitor cells (Immergluck et al., 1998) 
and virus adsorption could be inhibited in the presence of heparin or by enzymatic 
digestion of cell surface heparin sulphates (WuDunn and Spear, 1989; Immergluck et 
al., 1998). Heparan sulphate proteoglycans contain a plethora of members that are 
expressed in the developing and adult CNS (reviewed by Yamaguchi, 2001) and were 
also found on neural precursor cells expanded in vitro (Brickman et al., 1995; 
Hagihara et al., 2000). Hence, viral attachment is also in neurospheres most likely 
facilitated by heparan sulphates.
Interestingly, transduction with the vectors indicated region-specific differences 
between expanded precursor cells derived from distinct neurogenic regions. With the 
three viral backbones tested a similar region-specific increase in gene delivery 
efficiency was found: ^ N S ^ ^ N S ^ N S . These region specific differences were 
found in rodent neurospheres and also observed in neurospheres derived from 
different neurogenic regions of human tissue. It is noteworthy that a similar 
expression pattern was also observed with the highly disabled 1764/27-/4-pR19LacZ 
construct to neurons of the CNS in vivo: the virus gave strong transgene expression in
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striatal and nigral neurons, but no expression was observed in the cortex (Lilley et al., 
2001). Characterization of neurospheres derived from different neurogenic regions 
showed that neural precursors maintain region specific molecular identities of their in 
vivo counterparts even after continuous passaging (Parmar et al., 2002). The presented 
data extend these previous findings by showing that cellular differences between 
neurosphere cultures define their susceptibility for HSV-1 infection. Fate differences 
of neural precursor cells may restrict viral attachment due to altered expression of 
cellular receptors, such as heparan sulphates or FGF receptors, or alternatively, cause 
a region-specific promoter shut off.
Limited transgene expression after transplantation in vivo
Virally transduced neurospheres expressed the reporter gene after striatal 
transplantation for only a short time in vivo. Aggregates of GFP expressing cells were 
only found within three days after transplantation and transduced cells either ceased 
transgene expression or were eliminated due to a host immune response. Since it was 
decided to transplant whole neurospheres that were previously shown to have better 
survival rates after grafting than dissociated precursor cells (Ostenfeld et al., 2000), a 
steel needle with large diameter (28 gauge) was used that caused major cellular 
damage around the injection site. This damage resulted in a significant upregulation 
of GFAP and nestin expression around the injection site three days post-grafting 
suggesting microglia infiltration. Thus, microglia cells may have eliminated the graft 
and could be the reason for the lack of transduced precursor cells found at later time 
points. Cells expressing TH were detected in close proximity to the graft and may 
have resulted from either primary dopaminergic present within the transplanted 
precursor cells or from differentiation of uncommitted precursor cells after 
transplantation. Transient expression of TH positive neurons within intrastriatal grafts 
have also been found after transplantation of human progenitors into depleted striatum 
(Ostenfeld et al., 2000). It has been suggested that the adult rat striatum retains at least 
some of the endogenous cues required to support the development of dopaminergic 
neurons from undifferentiated NSCs. However, no TH positive cells were found in 
this study at later stages which is in agreement with the reported findings (Ostenfeld
200
et al., 2000). As grafting was not a major aim of this study, no attempt was made to 
further improve the technical difficulties associated with the surgical procedure.
Disabled HSV-1 deliver transgenes to cells within the stem cell niche in situ
In the last part of this chapter it was shown that replication-deficient HSV-1 
transduced cells of the SVZ-ependymal region, a region that has well been established 
to harbour neural stem cells giving rise to new neurons within the adult mammalian 
brain (Alvarez-Buylla et al., 2001; Alvarez-Buylla and Garcia-Verdugo, 2002; 
Alvarez-Buylla and Lim, 2004). Although an identification of neural stem cells within 
this region is difficult due to the lack of appropriate unique stem cell markers, it was 
demonstrated that HSV-1 can deliver recombinant genes to this microenvironment 
that can best be described as “stem cell niche” (Alvarez-Buylla and Lim, 2004; Fuchs 
et al., 2004). Ependymal and subependymal cell layers of the ventricle wall were 
transduced and can be used to deliver genes into the close neighbourhood of the actual 
stem cells. Hence, secreted factors can be applied to modify the stem cell niche in 
order to study proliferation or differentiation of endogenous precursor cells since 
‘‘...’sternness’ may be more related to competence of a group of early precursors 
within a lineage rather than to a specific cell type of cell” (Alvarez-Buylla and Lim, 
2004). Viral transduction of precursor cells within the SVZ did not inhibit their ability 
to migrate to their final destination, such as the olfactory bulb. Since these cells have 
been shown to divide during their migration (Lois and Alvarez-Buylla, 1994), cell 
division apparently did not affect the functional integrity of the viral genome. Similar 
results were shown for subependymal injections of adenoviral vectors, followed by 
stable expression of reporter genes in differentiated granular and periglomerular 
neurons in the olfactory bulb (Yoon et al., 1996). Viral leakage or retrograde transport 
were ruled out as these neurons do not project outside the olfactory bulb (Yoon et al., 
1996).
Characterization of the antigenic character of the transduced precursor cells within the 
SVZ showed no cell type specific reporter gene expression. Due to the use of an 
unspecific CMV promoter, reporter gene expression was observed in GFAP positive 
astrocytes and in nestin positive precursor cells. Some of the GFAP/GFP double
201
labelled cells showed characteristic cell morphologies of type B astrocytes that have 
been demonstrated to give rise to fast dividing precursor cells (type C cells) (Doetsch 
et al., 1999).
This chapter has shown that disabled HSV-1 transduces neural progenitor cells 
maintained as monolayer, neural stem cells expanded as neurosphere cultures and 
endogenous neural precursor cell. The optimal vector for each of these cell systems 
can be considered as function of gene delivery efficiency and adverse effects from 
viral transduction. For efficient delivery to progenitor cells at early time points, the 
less disabled backbone RL1+/27+/4- is the vector of choice. This is also the case for 
cortical rodent and human neurospheres that are otherwise only difficult to transduce 
with the highly disabled vector. However, this 1764/27-/4- based vector efficiently 
transduces striatal and mesencephalic neurospheres without any evident cytotoxic 
effects. Although the less disabled vector also delivers to these cells at high efficiency 
this is achieved on expense of neuronal cell loss most likely due to cytotoxic effects. 
No obvious differences between the two tested viral vectors were observed in vivo 
making both vectors equally useful for delivery to endogenous precursor cells.
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C h a p t e r  4:
FGF8b i s  a  m i t o g e n  f o r
N E U R A L  P R E C U R S O R  CELLS IN
VITRO
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4.1 Introduction
A plethora of growth factors have been studied regarding their effects on the 
proliferation and differentiation of neural precursor cells in vitro and in vivo 
(Kilpatrick and Bartlett, 1993; Ahmed et al., 1995; Caldwell and Svendsen, 1998; 
Erlandsson et al., 2001; Gallo et al., 2002; Farkas et al., 2003). Fibroblast growth 
factors (FGFs), a family of 23 known members, play a central role in nervous system 
development (Vaccarino et al., 1999; Ford-Perriss et al., 2001; Omitz and Itoh, 2001) 
and modulate a variety of biological activities including proliferation, migration and 
survival of neurons and glia (Vaccarino et al., 1999; Ford-Perriss et al., 2001). The 
function of FGF2 on the proliferation of embryonic precursor cells has been well 
established (Baird, 1994), but initial studies identified EGF as the first mitogen for the 
expansion of NSC’s isolated from adult tissue (Reynolds and Weiss, 1992; Vescovi et 
al., 1993). Later it has been shown that the forebrain germinal zone and its adult 
remnant, the subependyma, contain a small population of EGF and FGF2 responsive 
stem cells (Vescovi et al., 1993; Morshead et al., 1994; Palmer et al., 1995; Gritti et 
al., 1996), which display the definite characteristics of stem cells, i.e. self-renewal and 
multipotentiality. Indeed it has been shown that E14 striatal neural precursor cells 
initially respond only to FGF2 and acquire EGF responsiveness later during in vitro 
development (Ciccolini and Svendsen, 1998). This transition in growth factor 
responsiveness was also demonstrated to occur during CNS development in vivo 
(Tropepe et al., 1997; Ciccolini, 2001). EGF responsive precursor cells resulted from 
symmetric division and asymmetric division of FGF2 responsive stem cells (Martens 
et al., 2000). EGF and FGF2 are the most commonly used growth factors for the 
expansion of NSC’s as neurosphere cultures to date (for reviews see Weiss et al., 
1996b; McKay, 1997; Gage, 2000; Doetsch, 2003), and neurospheres generated with 
these mitogens retain the ability to produce neurons, astrocytes and oligodendrocytes 
conferring on them their stem cell identity (Reynolds et al., 1992; Weiss et al., 
1996a).
Recently other factors have also been identified which provide a mitogenic potential 
to neural precursor cells in vitro. It has been shown that sonic hedgehog (Shh) induces 
proliferation of adult hippocampal precursor cells (Lai et al., 2002). However, the
204
study did not address if the morphogen also has an effect on ventricular derived stem 
cells. PDGF has mitogenic effects on the expansion of immature neuronal progenitors 
(Erlandsson et al., 2001) and amphiregulin, an EGF related growth factor, can be used 
to grow adult neural stem cells derived from the SVZ or hippocampus as 
neurospheres without losing their multipotent character (Falk and Frisen, 2002).
Many of these growth factors have also been demonstrated to induce proliferation of 
endogenous neural stem cells. EGF injected into the lateral ventricle increased the 
proliferation of subependymal cells. However, most of the precursor cells generated 
differentiated into astrocytes (Craig et al., 1996; Kuhn et al., 1997) and it was later 
demonstrated that EGF actually acts on rapidly dividing transit-amplifying C cells 
(Doetsch et al., 2002). FGF2 delivered to the lateral ventricles also increased 
proliferation of endogenous precursor cells but resulted in an increased number of 
newly generated neurons migrating to the olfactory bulb (Kuhn et al., 1997). EGF and 
FGF2 delivered to the fourth ventricle only generated astrocytes and oligodendrocytes 
(Martens et al., 2002). Intrastriatal administration of TGFa induced a massive 
proliferation, migration and differentiation of neural precursor cells in animals that 
were lesioned with 6-hydroxydopamine in the substantia nigra (Fallon et al., 2000), 
whilst TGFg: knockouts have decreased SVZ proliferation and fewer neurons reaching 
the olfactory bulb (Tropepe et al., 1997). Overexpression of Shh in the SGZ induces 
proliferation and neurogenesis of hippocampal progenitors in vivo (Lai et al., 2002), 
while removal of the co-receptor for Shh reduced the number of progenitors in the 
postnatal subventricular zone and hippocampus (Machold et al., 2003). The notion 
that Shh may be a stem cell factor that functions during embryonic development and 
also continues to play a role in the “maintenance” of the adult stem cell niche is 
intriguing. On the other hand, increased numbers of dividing cells in the SVZ 
contributing to more neuroblasts migrating to the olfactory bulb may also be due to 
survival effects as shown after intraventricular delivery of BDNF (Zigova et al., 1998; 
Benraiss et al., 2001).
A member of the FGF family, FGF8b, plays a crucial role in forebrain (Storm et al., 
2003) and midbrain (Danielian and McMahon, 1996) development where it is 
particularly required for early commitment of dopaminergic neurons (Ye et al., 1998).
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FGFs exert their activity by activating a class of transmembrane tyrosine kinase FGF 
receptors (FGFRs) of which neural precursor cells express FGFR1 and FGFR3 
(Hajihosseini and Dickson, 1999; Lobo et al., 2003). While FGF2 transduces 
exclusively via FGFR1 (Brickman et al., 1995), FGF8 acts mainly through the FGFR3 
IIIc splice variant (MacArthur et al., 1995; Omitz et al., 1996) that is highly expressed 
in the ventricular zone (Fu et al., 2003). Blocking of FGF8 signalling by soluble 
FGFR3 IIIc antibodies inhibits dopamine neuron differentiation (Ye et al., 1998).
Using retrovirally tagged clonal analysis it was demonstrated that FGF8b has survival 
effects on primary cortical precursor cells, and that most of the generated clones 
acquired an astroglial cell fate (Hajihosseini and Dickson, 1999). Mesencephalic 
precursor cells maintained in lowered oxygen show a strong upregulation of FGF8 
expression accompanied by an increase in the number of dopaminergic neurons and 
addition of exogenous FGF8 prolonged precursor proliferation while it delayed 
neuronal differentiation (Studer et al., 2000). Ectopic expression of FGF8 in the 
mesencephalon continued neural precursor proliferation and prevented neurogenesis 
(Lee et al., 1997). However, previous studies indicating potential proliferative effects 
of FGF8 on precursor cells have not considered if FGF8b may be sufficient as the 
only source for the continuous expansion and passaging of neural stem cells.
The following chapter considered if foetal neural stem cells derived from different 
neurogenic regions can be expanded as neurosphere cultures with FGF8b as the only 
growth factor without losing stem cell identity. With respect to its role on defining 
dopaminergic phenotypes during development, possible inductive effects of FGF8 on 
de novo generation of dopaminergic neurons from mesencephalic precursor cells was 
also examined.
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4.2 Materials and Methods
4.2.1 Determination of primary neurospheres formed
The striatum (medial and lateral ganglionic eminence) was dissected from E14 
Sprague-Dawley rats and dissociated into a single cell suspension as described in 
2.3.6. Cells were seeded at 20 viable cells//xl into Poly-HEMA coated (2.3.11) 24 
multi well dishes in a total volume of 1ml DMEM/F12/B27 medium containing 
heparin (5/xg/ml) and either FGF8b (50ng/ml), FGF2 (20ng/ml) or BSA (20ng/ml). 
Three days after seeding 1ml fresh medium with recombinant protein was added per 
well. On 5 DIV the total number of formed neurospheres (>10cells per aggregate) 
were counted from six different wells. The means were calculated from three 
independent experiments.
4.2.2 Growth curves
E14 cortex, striatum and ventral mesencephalon were dissected as described in 2.3.6 
and seeded as single cell suspension at clonal density (20 viable cells//d) in 
DMEM/F12/B27 medium containing heparin (5jig/ml) and either FGF8b (50ng/ml) or 
FGF2 (20ng/ml). After 10 days expansion the neurospheres were collected and 
washed three times in DMEM/F12/B27 medium to remove traces of growth factors 
and heparin. For each region and growth factor condition 12 medium sized 
neurospheres were selected (about 120/mi diameter) and single spheres were 
transferred into each well of a Poly-HEMA coated 96 well plate containing 
proliferation media with FGF8 (50ng/ml) or FGF2 (20ng/ml) as solely mitogen either 
in the absence or presence of heparin (5/xg/ml). The diameter of each neurosphere was 
measured from two different angles under a standard light microscope with a 
reticulate ocular and the mean of the diameters calculated. Based on the assumption 
that neurospheres had the shape of a perfect sphere, the volume was calculated for 
each treatment every three days in a total period of 12 days.
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4.2.3 Dose response curves
Dissociated striatal E14 precursor cells were seeded at clonal density (20 viable 
cells/jLtl) in T75 tissue culture flasks (Nunclon) containing 5ml of DMEM/F12/B27 
medium with heparin (5/xg/ml) and the growth factors FGF2 or FGF8 at a final 
concentration of O.lng/ml, lng/ml, lOng/ml and lOOng/ml, respectively. Three days 
after plating 5ml fresh medium was added per treatment. On 6 DIV each culture was 
pulsed by adding BrdU to a final concentration of 0.2/xM. 14 hours later the 
neurospheres were collected dissociated into a single cell suspension as described in 
2.3.9 and plated at a density of lx l0 5 cells per well on poly-L-lysine/Laminin coated 
glass coverslips (2.3.10). One hour later cells had attached to the surface and were 
fixed with 4% paraformaldehyde. Immunocytochemical staining for BrdU was 
performed as described in 2.5.2.2 and cells were counterstained with DAPI to label 
cell nuclei. The percentage of BrdU labelled cells of the total cell number was 
determined from 10 different fields.
4.2.4 Characterization of FGF8 expanded neurospheres
E l4 cortical, striatal and mesencephalic precursor cells were seeded at clonal density 
(20 viable cells//xl) in media containing heparin (5/z/ml) and either FGF8 (50ng/ml) or 
FGF2 (20ng/ml). After 10 days expansion cells were dissociated into a single cell 
suspension (2.3.9) and plated at a cell density of 5xl04 cells per well on poly-L- 
lysine/Laminin coated glas cover slips (2.3.10). Cells were differentiated in the 
absence of exogenous growth factors for four days following fixation with 4% 
paraformaldehyde (w/v in PBS). Immunocytochemistry for TuJl, GFAP and GalC 
were performed as described in 2.5.2.2 and cell nuclei were counterstained with 
Hoechst. The number of astrocytes, neurons and oligodendrocytes was determined 
from 10 randomly chosen fields and the mean calculated from three independent 
experiments.
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4.2.5 Sectioning of E l2 ventral mesencephalic tissue
Ventral mesencephalon of time mated E l2 Sprague-Dawley rats were dissected as 
described in 2.3.6. E12 explants were mechanically dissociated by chopping into 
300/mi sections using a tissue-chopper as described for passaging of human 
neurospheres in 3.2.3. Cells were expanded in DMEM/F12/B27 media containing 
heparin (5 jLig/ml) and as indicated FGF8 (50 ng/ml), FGF2 (20ng/ml), ShhN 
(50ng/ml) or BSA (20ng/ml). At the indicated time points neurospheres were 
passaged by chopping into 200/mi sections as described before. For differentiation 
neurospheres were dissociated into a single cell suspension (2.3.9) and plated at a cell 
density of 5xl04 cells per well on poly-L-lysine/Laminin coated glass coverslips 
(2.3.10). During differentiation cells were maintained in DMEM/F12/B27 media in 
the absence of any growth factors. After 4 days cells were fixed with 4% 
paraformaldehyde (w/v in PBS) and immunocytochemical staining performed as 
described in 2.5.2.2.
4.2.6 RT-PCR analysis
Rat E l2 ventral mesencephalon and cortex was dissected as described in 2.3.6 and 
mechanically dissociated by chopping into 300/mi sections. Explants were expanded 
as neurosphere cultures with combinations of ShhN (lOOng/ml), FGF8 (200ng/ml), 
FGF2 (20ng/ml) or BSA (200ng/ml) in Poly-HEMA coated 12 well plates (2.3.11) as 
illustrated in Figure 4-10. Neurospheres were passaged by mechanical dissociation 
into 200/mi sections on 2 DIV, 10DIV, 14DIV and 21DIV. After 12DIV and 30DIV 
aliquots were taken for RNA preparation and differentiation by growth factor 
withdrawal for four days. RNA was extracted as described in 2.2.12, DNAse treated 
(2.2.13) and first strand cDNA synthesis was performed from 10/xg RNA per 
condition using the Superscript kit (Invitrogen) (2.2.14). cDNA was treated with 1/d 
RNAse H (Invitrogen) per reaction for 20min at 37°C. PCR conditions were 
optimized by varying MgCL concentration, annealing temperature and cycle number 
to determine linear amplification rate. MgCL concentration was 2.0mM for TH and 
1.5mM for all others. PCR was performed with Platinum Taq DNA Polymerase 
(Invitrogen) at the following program: 94°C for 2 min, cycles with denaturation at
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94°C for 15 sec, annealing for 30 sec, extension at 72°C for 1 min and final extension 
at 72°C for 10 min. Primer sequences, cycle numbers and annealing temperatures 
were as follows:
GAPDH (833-1137): 28 cycles, 59°C, 305 bp 
FW: 5’ CTCGTCTCATAGACAAGATGGTGAAG 
RW: 5’ AGACTCCACGACATACTCAGCACC
Nurrl (194-448): 30 cycles, 55°C, 255 bp 
FW: 5 ’TGAAGAGAGCGGAGAAGGAGATC 
RW: 5’TCTGGAGTTAAGAAATCGGAGCTG
Ptx3 (378-634): 35 cycles, 60°C, 257 bp with 5% DMSO 
FW: 5’ CGTGCGGGTGTGG TTCAAGAAC 
RW: 5’ GCGGTGAGAATACAGGTTGTGAAG
En-1 (1164-1544): 30 cycles, 60°C, 381 bp;
FW: 5 ’TCAAGACTGACTCACAGCAACCCC 
RW: 5 ’CTTTGTCCTGAACCGTGGTGGTAG
TH (1130-1428): 27cycles, 56°C, 300bp 
FW: 5’ CACTGTGGAATTCGGGCTATG
RW: 5’ GGCTGTCCAGTACGTCAATG
PCR products were analysed on 1-2% agarose gels containing ethidium bromide 
(l/tg/ml).
4.2.7 Proliferation of endogenous neural stem cells
Intraventricular injections were performed as described in 3.2.5 using 5xl06 PFU of 
RLH-/27+/4-pRl 9FGF8bwpre, RLl+/27+/4-pR19LacZwpre or 1764/27-/4- 
/pR19FGF2 per injection and delivered into both ventricles of adult female Sprague- 
Dawley rats (n=4 per group) (260-280g). The rats were injected daily with the mitotic
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marker bromodeoxyuridine (BrdU) (lOOmg/kg, i.p.) for a total period of 18 
consequtive days. The animals were perfused with 4% PFA two days after the last 
BrdU injection (day 20). The brains were removed including olfactory bulbs, post­
fixed for lh in 4%PFA and protected in 30% sucrose. After the brains had sunk they 
were cut as 20/mi sagittal (n=3) or coronal (n=l) sections on a freezing microtome. 
Immunohistochemistry for BrdU, NeuN, GFAP, nestin, TH was performed as 
described in 2.5.3.
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4.3 Results
In preliminary work it appeared that neurospheres expanded with FGF2 in the 
presence of FGF8 proliferated much faster than in the absence of FGF8 or in the 
presence of other morphogens such as sonic hedgehog. This prompted the idea that 
FGF8 itself may be a mitogen for neurospheres that could be used independently of 
other growth factors for the expansion of neural precursor cells.
4.3.1 Neural stem cells expanded in FGF8 retain their neural stem cell identity
To test if NSC’s can be proliferated in FGF8 as the only mitogen, precursor cells 
isolated from rat E l4 cortex, striatum and ventral mesencephalon were seeded at 
clonal density (20 viable cells//il) in DMEM/F12 media containing heparin (5jttg/ml) 
and recombinant mouse FGF8b (50ng/ml, R&D). Control cultures contained FGF2 
(20ng/ml) or no exogenous growth factors. The NSC’s were grown in suspension 
culture to obtain neurospheres that could subsequently be passaged. The cells seeded 
as a single cell suspension started forming multicellular clusters after one to two days 
in culture. Significantly more clusters were observed in growth factor containing 
cultures compared to cultures without exogenously added mitogens. The cells 
continued dividing rapidly and after about five days neurospheres were clearly visible 
in FGF8 and FGF2 containing cultures. Differences in the proliferation rate depending 
on the mitogen were evident (see below). FGF2 containing cultures formed larger 
neurospheres than those in the presence of FGF8 despite the lower concentration of 
FGF2. However, morphologically the neurospheres were indistinguishable (for 
pictures of FGF8 and FGF2 expanded neurospheres see Figure 4-5). FGF8 expanded 
neurospheres comprised a dense cluster of cells and the surface of the spheres 
appeared smooth with some cells in the outer layer projecting short processes into the 
medium. This morphology is identical to FGF2 expanded neurospheres and is 
considered the “healthy” appearance for a neurosphere. Formations of spherical 
aggregates under mitogen free conditions were also found. However, these 
neurospheres were much smaller and appeared as rather loose cell association without 
any visible cilia. After dissociation these spheres did not form any secondary spheres.
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They were considered as aggregates formed from residual cell division of mitotic 
active primary neural precursor cells or due to endogenous release of growth factors 
stimulating short term cell division.
After 10 days, mitogen containing cultures had formed large neurospheres that were 
dissociated into single cells and seeded under the same culture conditions as before. 
Secondary neurospheres appeared at about two days after dissociation from FGF2 and 
FGF8 containing cultures, but not from growth factor free controls. After one week 
these secondary spheres were dissociated again to seed cultures forming tertiary 
neurospheres that were plated onto poly-L-lysine/laminin coated glass coverslips. The 
neurospheres were differentiated by withdrawal of any exogenous growth factors and 
as shown in the previous chapter, cells started forming radial processes and migrated 
into the substrate. Process formation and migration of neural precursor cells was 
observed independent of the mitogen used for expansion. After four days of cell 
differentiation, cells were stained for markers identifying the three neural lineages: 
TuJ as neuronal marker, GFAP as marker for astrocytes and GalC for 
oligodendrocytes (Figure 4-1). Independent of the neurogenic region FGF8 expanded 
neurospheres generated neuronal, glial and oligodendroglial progenitor cells. Hence, it 
was concluded that FGF8 may be a mitogen for embryonic neural precursor cells that 
retain their stem cell identity even after subsequent passaging.
Neurospheres could be continuously expanded and passaged in FGF8 as the only 
available exogenous mitogen for a period of about four to five weeks without losing 
their multipotent character. After this period cells had significantly reduced growth 
rates and underwent senescence as has been shown for EGF and FGF2 expanded 
rodent neural stem cells (Svendsen et al., 1997b).
Effects of FGF8 on the formation of primary cell clones were determined for striatal 
precursor cells seeded at clonal density (Figure 4-2). Although in the presence of 
FGF8 slightly more primary neurospheres were generated than in FGF2, the 
differences were not statistically significant. In BSA alone a significantly smaller 
number of very small neurospheres were generated showing the growth of 
neurospheres is not favoured in the absence of exogenous mitogens.
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Figure 4-1: FGF8 expanded neurospheres retain the capacity to differentiate into the three 
neural lineages after multiple passaging. Neural precursor cells derived from E14 cortex 
(CTX), striatum (STR) and ventral mesencephalon (VM) were expanded as neurosphere 
cultures in medium (DM EM /F12) containing heparin (5pg/ml) and recom binant mouse 
FGF8b (50ng/ml, R&D) but in the absence of any other growth factors. Neurospheres were 
passaged twice by dissociation into a single cell suspension and seeding at clonal density (20 
viabh cells/pl) prior to plating and differentiation in the absence o f FGF8b. Shown is the 
triple immunolabelling for the neuronal marker TuJ (Alexa 488, green), the astrocytic 
mark«r GFAP (Alexa 546, red) and the oligodendroglial marker GalC (Alexa 350, blue). 
Scale bar represents 50pm.
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Figure 4-2: Num ber of prim ary formed neurospheres is unaltered between FGF8 and 
FGF2. E14 striatum  tissue was dissociated into a single cell suspension and cells seeded at 
clonal density (20viable cells/ml) into a 24well plate. Cells were expanded in DMEM/F12 
media with heparin (5/ig/m l) containing either FGF8b (50ng/m l), FGF2 (20ng/ml) or BSA  
(20ng/ml), respectively. The total number of prim ary neurospheres per well was counted 
after 5 DIV from 6 wells per treatment. Data illustrated represent the means of total 
neurospheres per well with SEM  from three independent experim ents. No statistical 
significant differences in the number of prim ary neurospheres were determined between 
FGF8 vs. FGF2 (p>0.05 in One-way ANOVA, n=3 experiments). However, striatal 
precursor cells maintained in BSA as control formed significantly less neurospheres 
(p<0.05 in One-way ANOVA, n=3 experim ents).
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4.3.2 Heparin increases the mitogenic effects o f FGF8
As discussed above, although the number of neurospheres generated from clones was 
unaltered between the use of FGF8 or FGF2, they appeared to grow much faster in the 
presence of FGF2. The previous chapter discussed, that heparin sulphates plays a 
crucial role in FGF signaling and the mitogenic effects of FGF2 on the expansion of 
particularly mesencephalic precursor cells (Caldwell and Svendsen, 1998). Heparin 
and heparin sulphate domains also play an important role in binding and signaling of 
FGF8b (Loo and Salmivirta, 2002) but their function on the proliferation of neural 
precursor cells induced by FGF8 has not been reported. Here, growth curves were 
performed for neural precursors expanded in FGF8 either in the presence or absence 
of heparin and the proliferative effects of FGF8 compared to those of FGF2.
Heparin significantly increased the mitogenic activity of FGF8 for the three 
neurogenic regions (cortex, striatum and ventral mesencephalon) (Figure 4-3). In the 
absence of heparin neural precursor cells grew very slowly with a 3-fold increase in 
the sphere volume after 12 days. No significant differences in the growth rates 
between the different regions were observed under these conditions. However, adding 
heparin to the medium considerably changed the growth pattern. Region specific 
differences were observed in the proliferation rates showing that striatal (12 days 
p<0.001, n=12 neurospheres) and cortical (12 days p<0.01, n=12 neurospheres) 
derived neurospheres proliferated significantly faster when compared to 
mesencephalic, while no significant differences were observed between striatal versus 
cortical NS (12 days p>0.05, n=12 neurospheres) under these conditions. In the 
presence of heparin mesencephalic neurospheres underwent an approximate 10- 
volume increase, cortical neurospheres a 20-fold increase and striatal neurospheres a 
more than 30-fold increase in the sphere volume after 12 days expansion. We 
conclude that, as for FGF2, supplementation of exogenous heparin is required for the 
mitogenic activity of FGF8 on neural precursor cells grown as neurospheres.
Comparing the mitogenic effects of FGF8 to those of FGF2 (Figure 4-4) showed a 
similar pattern for the expansion of NSC’s from different regions with either growth
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factor: mesencephalic neurospheres grew slower than those derived from the 
forebrain, an observation that conforms to other reports (Ostenfeld et al., 2002a). 
Furthermore, the growth curves showed that FGF2 was a more potent mitogen for the 
expansion of cortical and striatal neurospheres than FGF8. In the presence of heparin 
an 80-fold increase in the sphere volume was calculated for ctxNS after 12 days in 
culture and for strNS this increase was 100-fold. Post hoc comparisons with FGF8 
expanded neurospheres revealed significant differences (p<0.001 at 12 days, n=12 
neurospheres) for ctxNS and strNS, however, mesNS did not reveal increased 
proliferation rates in FGF2 compared to FGF8 (p>0.05 at 12 days for n=12 
neurospheres). This might reflect a relatively higher affinity of mesencephalic neural 
precursors to the mitogenic effects of FGF8 than those of FGF2.
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Figure 4-3: Heparin significantly increases the mitogenic effects o f FGF8. E14 derived NS were 
expanded for 10 days before medium sized neurospheres were selected. Diameters o f 12 
neurospheres were measured at the indicated time points in three independent experiments. One 
way ANOVA revealed significant differences in the growth rate of VM vs. STR/CTX (p<0.01;
n=12 neurospheres) and significant increase in the presence o f heparin (p<0.0001 for all). No
differences were detected for the different cell lines grown in the absence o f heparin.
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Figure 4-4: FGF8 expanded NS grow significantly slower than in FGF2. Neurospheres from the 
different neurogenic regions were expanded either in the presence of FGF8b (50ng/ml) or FGF2 
(20ng/ml). Medium sized NS were selected and the diameter measured over the indicated time 
period. One-way ANOVA with Tukey’s post hoc test shows significant differences in the growth  
rate for CTX and STR NSC’s expanded in FGF8 vs. FGF2 (p<0.001; n=12 neurospheres), but not 
for VM NSC’s.
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4.3.3 FGF8 dose response curve for strNS
To further confirm differences in the affinity for the two mitogens, dose response 
curves were carried out on striatal neural precursor cells for FGF8 and FGF2 (Figure 
4-5).
For both mitogens a sigmoid correlation between the number of BrdU incorporating 
cells and the growth factor concentration was found. However, at the same mitogen 
concentration more cells showed a mitotic response to FGF2 compared to FGF8 
suggesting higher proliferation rate of the precursor cells for FGF2. While at high 
FGF2 concentrations (lOOng/ml) about 90% of the cells were mitotic active, the same 
concentration of FGF8 stimulated cell division in only 67% of the striatal precursor 
cells. Although saturating mitogen concentration were not tested, the data suggest that 
the concentration of FGF8 required to stimulate 50% of the striatal precursors to 
divide is approximately about 60ng/ml, while it seems to be less than lOng/ml for 
FGF2.
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Figure 4-5: D ose response curves for FG F8. E14 striatal precursor cells w ere seeded at clonal 
density (20 cells/p l) in m edium  contain ing heparin (5pg/m l) and the indicated final 
concentration o f  either F G F 8b  or FG F2 as solely m itogen. O n 6 D IV  cultures w ere pulsed  w ith  
BrdU (0.2pM  final concentration ) and neurospheres d issociated 14 hours later and plated  on  
PLL /L am inin coated glass coverslips. Cells w ere fixed after attachm ent and stained for B rdU . 
BrdU  positive cells as a percen tage o f  total cell num ber w ere determ ined  and are presented as 
the m ean w ith SE M  from  th ree independent experim ents. I. S igm oid correlation  betw een B rdU  
incorporation  and m itogen  concentration  using a logarithm ic scale. II. A  linear scale illustrates  
a h igher concentration  is required  for FG F8 to induce proliferation in 50%  o f  the stria ta l 
precursor cells. S cale bar represents 100pm .
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4.3.4 Characterization of FGF8 expanded neural precursor cells
Multipotent precursor cells derived from embryonic tissue respond differently to EGF 
and FGF2 (Ciccolini and Svendsen, 1998), and different neurogenic regions produce 
distinct numbers of neural progenitors (Ostenfeld et al., 2002a). Growth factor 
concentration can also affect the outcome of neural differentiation (Qian et al., 1997). 
Further, it has been suggested that FGF8 promotes astroglial differentiation of cortical 
precursor cells (Hajihosseini and Dickson, 1999). In order to study if FGF8 expanded 
neurospheres give rise to a different population of progenitor cells than FGF2 
expanded spheres, the composition of forebrain and midbrain derived progenitor cells 
was characterized after differentiation (Figure 4-6).
ctxNS, strNS and mesNS were expanded for one week in either FGF8 or FGF2 and 
following dissociation the precursor cells were differentiated by growth factor 
withdrawal and exposure to a substrate. Neurons, astrocytes and oligodendrocytes 
were identified by immunocytochemical staining with cell-type specific markers 
TuJl, GFAP and Gal-C, respectively (Figure 4-6). No significant differences were 
observed in the proportion of the three neural cell types generated from neurospheres 
expanded in FGF8 compared to those expanded in FGF2. In all treatments a high 
proportion of cells that didn’t label with either of the immunogenic markers was 
detected and most likely these cells represent a population of undifferentiated neural 
precursors. Residual growth factors or endogenous mitogens released by the precursor 
cells may, therefore, maintain some cells in an uncommitted neural fate. In neither the 
forebrain nor midbrain cultures was an increase in GFAP positive astrocytes or a 
decrease in neuronal progenitor cells observed when expanded in FGF8 versus FGF2, 
as has been described for cortical precursor cells (Hajihosseini and Dickson, 1999). 
Rather a decreased number of astrocytes was found but more oligodendrocytes 
appeared when expanded in FGF8. However, these differences were marginal. The 
discrepancy may have resulted from different experimental conditions as the referred 
to study considered single clones formed in the presence of FGF8 while this study 
characterized the total cell population of neurospheres generated at clonal density. 
Therefore some of the neurospheres generated may give rise exclusively to astrocytes 
while others contain only neuronal progenitor cells. This study did not further
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distinguish between the antigenic characteristics of single neurospheres generated in 
FGF8 compared to those generated in FGF2.
Cortical neurospheres expanded in FGF8 and FGF2 tended to give rise to more 
neurons and oligodendrocytes but less astrocytes than striatal or mesencephalic 
neurospheres. In dissociated mesNS only an insignificant number of neurons was found 
that were not included in the results presented. Although Figure 4-1 showed that 
mesencephalic neurospheres expanded in either mitogen can give rise to neuronal 
progeny when plated as whole neurospheres, the experimental rationale chosen for 
this characterization resulted in a decreased number of surviving neurons. As 
dissociated neurospheres rather than a migration assay were used, the stress of 
enzyme treatment and trituration most likely caused an increased death of neural 
precursor cells. Therefore, the total number of neurons was lower than reported in 
other studies (Ostenfeld et al., 2002a) using cell migration assays.
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F igure 4-6: C haracterization  o f  E 14 neurospheres exp and ed  in FG F 8 versu s F G F 2. 
Im m unocytochem ical sta in ing for (A ) FG F2 and (B ) F G F 8b expan ded  ctIN S show ed for  
neurons (T u J l, green) or astrocytes (G FA P , red). W hile  F G F 8 expanded  m**NS contained  
plenty o f  neurons (C ) prior to d issociation , a fter trituration  (D ) m ainly G F A P  positive  
astrocytes and (E) an increased num ber o f  G alC  positive o ligod en d rocytes w ere  observed . C ell 
nuclei w ere counterstained w ith  H oechst (blue). Scale bar rep resen t 50pm . (F) Q uantification  
show ed no significant differences in the neural progeny gen erated  w hen  n eu rospheres from  
different neurogenic regions w ere  either expanded  in FG F 2 or F G F 8 as only m itogen. D ata  
represent m eans as percentage o f  total cells from  three in d ep en d en t experim ents.
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4.3.5 FGF8 increases the number of dopaminergic neurons generated from
mesN S .
While FGF8 did not significantly alter the amount of TuJl positive neurons in 
neurospheres generated from cortex and striatum, it was possible that there were 
effects on survival or de novo development of dopaminergic neurons from mesNS. It is 
known that although FGF2 can extend dopamine neuron progenitor proliferation in 
E l2 foetal mesencephalic cultures for a short period of time (a few days) (Bouvier 
and Mytilineou, 1995), further expansion results in a cell that can no longer generate 
DA neurons. Expansion of E l4 mesencephalic precursors in FGF2 as neurospheres is 
possible (see previous data). However, these cultures only give rise to an insignificant 
number of TH positive neurons (Caldwell and Svendsen, 1998; Ostenfeld et al., 
2002a), upon differentiation. Figure 4-7 shows that precursor cells generated from 
E l4 ventral mesencephalon and seeded at clonal density as a single cell suspension 
gave rise to neurospheres containing TuJl positive neurons when expanded in either 
FGF2 or FGF8. However, FGF8 expanded mesNS generated a significant increase in 
the number of dopaminergic neurons when compared to FGF2 expanded mesNS as 
characterized by the expression of TH. While FGF2 expanded mesNS rarely contained 
TH positive cells after one week expansion, several dopaminergic neurons were 
detected within FGF8 expanded mesNS. After dissociation of these E14 neurospheres, 
using trypsin or Accutase™, the dopaminergic neurons generated did not survive as 
only a very few TH positive cells were detected after plating on coverslips or 
subsequent generation of secondary neurospheres. The decrease in TH expressing 
cells was accompanied by a continuous loss of total neurons with each passage as has 
been described for rodent neurosphere cultures (Ostenfeld et al., 2002a). Possible 
explanations are that enzyme based dissociation methods do not support the survival 
of primary dopaminergic neurons or that dopamine precursors driven by FGF8 
undergo only a certain number of cell divisions and subsequently loose the ability to 
differentiate into dopaminergic neurons.
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FGF2 FGF8
F igure 4-7: E 14 mesN S give rise to m ore dopam inergic  neurons w hen  exp an d ed  in FG F8. R at 
E 14 V M  w as d issociated  into a single cell suspen sion  and seeded at c lonal den sity  (20 cells/p l) 
in either FGF2 (20ng/m l) or FG F 8 (50ng/m l). T he w hole neu rospheres w ere  sta ined  for T u J l  
(A lexa 488, green), T H  (A lexa 546, red) and cell nuclei cou ntersta in ed  w ith  H oech st (b lue). 
W h ile FG F2 expanded  mesN S g ive only rise to  a very  few  T H  p ositive  ce lls, neurospheres  
expanded  in F G F 8 generated  sign ificantly  m ore dopam inergic neurons.
FGF 2 expanded FGF8 expanded
F igure 4-8: FG F8 increases the num ber o f  T H +ve cells in E 12 expanded  m esencephalic  
neurosphere culture. V M  from  E 12 rat em b ryos w as isolated and m ech an ica lly  d issociated  by  
chop p in g  at 300pm . C ells w ere  expanded  fo r  tw o w eeks e ith er in F G F 8 (50ng/m l) or FG F2  
(20ng/m l) and heparin (5ug/m l) and passaged tw ice by ch opp ing  at 200pm  w ith in  this period . 
C ells w ere  d issociated  using A ccutase and plated  at 2x105 cells on P L L /L am in in  coated  glass  
cover slides. Subsequently  cells w ere d ifferentiated  for fou r days by grow th factor  
w ith d raw al, fixed and stained for tyrosine h ydroxylase (A lexa 546 , red). A: C ounting  o f  
T H + ve cells in 20 random ly chosen  fields per treatm ent. Illu strated  are  m eans and standard  
error o f  the m eans (SE M ). O ne w ay A N O V A  w ith  T u k ey’s p osth oc test sh ow s a statistically  
increased  num ber o f  T H + ve cells w hen  expanded w ith  F G F 8 (p<0.01). B: 
Im m unocytochem istry  o f  d issociated  neurospheres p reviously  exp and ed  in FG F 8 or FG F2  
for  T H  (red). Im age w as taken  at low  m agn ification  and does not rep resen t th e  m agnification  
for  the countings as show n in (A ). Scale bar 50 pm.
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In order to quantify the differences between the number of dopaminergic neurons 
generated after extended proliferation in FGF8 versus FGF2 and after multiple 
passaging, but to avoid adverse effects of enzymatic digestion, it was decided to 
mechanically dissociate primary ventral mesencephalic tissue and to passage the 
generated neurospheres by sectioning using a tissue chopper. As discussed in the 
previous chapter, at E14 rat dopaminergic neurons have almost completely 
differentiated and thus, to increase the amount of immature dopamine neuroblasts, 
ventral mesencephalic tissue was dissected from time mated E l2 rat embryos. E12 
mesNS grew rapidly in either FGF2 or FGF8 and were passaged twice by chopping 
prior to dissociation with Accutase™, which was found to be less cell damaging than 
trypsin. Dissociated, and at equal density on poly-L-lysine/Laminin coated glass 
coverslips, plated precursor cells were differentiated in the absence of any growth 
factors and subsequently stained for TH expressing neurons.
As shown in Figure 4-8 both growth factors show an increase in the number of 
dopaminergic neurons compared to E14 mesencephalic tissue. However, 
mesencephalic precursor cells expanded in the presence of FGF8 generated 
statistically more dopaminergic neurons (p<0.01) than FGF2 cultures even after 
subsequent passaging. At this time point the mesNS had been in culture for two weeks 
and had undergone three passages in total. Consequently, the number of dopaminergic 
neurons can be maintained over an extended period and taken through multiple 
passages as neurosphere cultures using the chopping method and mesencephalic tissue 
from E12 rather than E14. Thus, the overall yield can be further increased with FGF8 
as mitogen.
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4.3.6 Sonic hedgehog further increases the number o f TH positive neurons
Induction of dopaminergic neurons during neurodevelopment requires an interplay of 
the morphogens Shh and FGF8 in vivo (Ye et al., 1998). The same morphogens also 
play an important role for the generation of dopaminergic neurons from embryonic 
stem cells (Lee et al., 2000; Kim et al., 2002). However, they fail to induce a 
dopamine phenotype in rodent and human embryonic precursor cells expanded as 
neurosphere cultures with FGF2 as the mitogen (Ostenfeld et al., 1999; Svendsen et 
al., 1999), but seem to increase the number of TH expressing cells in a neural stem 
cell line overexpressing the transcription factor Nurrl (Kim et al., 2003c). Shh and 
FGF8 also play a role in induction of dopaminergic phenotypes in passaged adult rat 
hippocampal progenitors (Sakurada et al., 1999). ShhN is neurotrophic for 
dopaminergic neurons and also promotes the survival of other midbrain and striatal 
neurons in vitro (Miao et al., 1997). Here, whether ShhN has effects on dopaminergic 
neurons generated from neural precursor cells expanded as neurospheres in FGF8 as 
the mitogen was explored.
E l2 VM precursor cells were prepared as described in 4.3.5 and expanded as 
neurosphere cultures using FGF8 as the sole mitogen. After dissociation and plating 
as a single cell suspension on coated coverslips, cells were differentiated by FGF8 
withdrawal and exposure to substrate. Recombinant ShhN (50ng/ml) was added to the 
neurosphere cultures either during expansion and/or the differentiation phase. As 
illustrated in Figure 4-9 ShhN did increase the number of TH positive dopaminergic 
neurons generated in FGF8 expanded cultures. Addition of ShhN during the 
differentiation phase did not significantly increase the number of dopaminergic 
neurons. However, ShhN doubled the number of dopaminergic neurons when FGF8 
was simultaneously present during the expansion phase suggesting a synergistic effect 
of the two morphogens on dopamine neuron development from E l2 mesencephalic 
precursor cells. By immunocytochemical staining it was confirmed that the TH 
expressing cells generated did co-label with the neuronal marker TuJ, and thus likely 
represent bona fide dopaminergic neurons.
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FGF8 expanded E12 VM FGF8 & ShhN expanded E12 VM
ShhN
Differentiation
ShhN
Figure 4-9: ShhN further amplifies the FGF8 mediated generation o f dopaminergic 
neurons. E12 ventral mesencephalon was mechanically dissociated into 300pm  sections. 
Explants were grown as neurosphere cultures in FGF8 (50ng/ml) as the mitogen in the 
presence or absence o f ShhN (50ng/ml) during the expansion phase. After one week  
expansion the cells were dissociated into a single cell suspension and differentiated after 
plating on poly-L-lysine/Laminin coated glass cover slips for four days. During 
differentiation FGF8 was withdrawn but ShhN (50ng/ml) was present as indicated. Cells 
w ere fixed and stained for T u Jl (green), TH (red) and Hoechst (blue). TH expression co­
labelled with T u Jl confirming neuronal identity. The num ber o f dopam inergic neurons 
was determined from 20 different fields. One way ANOVA with Tukey’s post hoc revealed  
a statistically increased number o f TH expressing cells when ShhN was present during the 
expansion phase (p<0.001). No significant effect o f ShhN was detected when the morphogen  
was present during differentiation phase.
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To further characterize if ShhN only increases the number of dopaminergic neurons in 
the presence of FGF8 or if this effect was also accomplished with FGF2, 
mechanically dissociated E12 VM cultures were expanded in different growth factor 
combinations as shown in Figure 4-10. The neurospheres were passaged twice within 
two weeks before they were plated as a single cell suspension on laminin coated glass 
cover slips and allowed to differentiate for four days in the absence of mitogens. Even 
after passaging, FGF8 expanded neurospheres resulted in a significant increased 
number of dopaminergic neurons compared to when FGF2 was used as the mitogen 
(p<0.001). ShhN present during the expansion phase significantly increased the 
number of TH positive cells with either FGF8 (p<0.05 compared to FGF8 alone) or 
FGF2 (p<0.01 compared to FGF2 alone). Interestingly, when neurospheres were 
expanded simultaneously in both FGF2 and FGF8, either in presence or absence of 
ShhN, a significant drop in the number of dopaminergic neurons (p<0.001) was 
detected.
The data show that the possible inductive effect of ShhN on dopamine neuron 
generation from mesencephalic precursor cells is not limited to synergism with FGF8, 
but can also be facilitated with FGF2.
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FGF2 •  •  •  •
FGF8 •  •  •  •
ShhN •  •  •
Figure 4-10: Com parison o f E12 ventral mesencephalic neurosphere cultures expanded in 
different com binations o f growth factors. M echanically dissociated niesNS were continuously 
expanded by subsequent passaging in different growth factor com binations as indicated. (A) 
ShhN increased the num ber of dopam inergic neurons when present during the expansion 
phase, an effect that is not limited to the presence of FGF8 but was also observed with FGF2. 
A significantly decreased (*p<0.001) number of TH expressing cells was determined when 
neurospheres w ere expanded sim ultaneously in all three growth factors.
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4.3.7 The expression of midbrain specific markers decreases after extended 
passaging
Although dopaminergic neuron containing neurospheres could be passaged over three 
weeks, a significant loss in the total numbers of TH expressing cells with each 
passage was observed in either of the growth factor combinations tested. After about 
four passages TH expression was detected only rarely, even during expansion with 
FGF8 and ShhN. If these morphogens are indeed inductive on a common multipotent 
precursor cell, no loss of susceptibility to the signals after consecutive passaging 
would be expected. Based on the idea of a unique stem cell existing in different 
neurogenic regions of the developing brain, an induction of dopaminergic markers 
from precursor cells other than those derived from the mesencephalon may be 
expected. To study if dopaminergic markers are upregulated in cortical neurospheres 
and if the loss of TH expression in mesencephalic neurospheres is also accompanied 
by a loss in expression of other dopaminergic markers, semi-quantitative RT-PCR 
analysis were performed.
Explants from E12 cortices were initially mechanically dissociated and expanded in 
different growth factor combinations as illustrated in Figure 4-11 A. ctxNS were 
expanded for 9 days and passaged once within this period before they were 
differentiated by growth factor withdrawal. After 6 days differentiation, the RNA was 
isolated and RT-PCR performed on DNAse treated samples. None of the growth 
factor combinations induced the expression of TH in ctxNS showing that ShhN and 
FGF8 alone are not sufficient to convert cortical precursor cells into TH expressing 
neurons. Nurrl, which is strongly linked to the differentiation of midbrain 
dopaminergic neurons (Saucedo-Cardenas et al., 1998), was expressed in the 
expanded ctxNS at low levels. However, no significant upregulation was observed as a 
result of potential synergistic effects of ShhN and FGF8. Very low levels of Ptx3 
expression were detected. No differences in the expression levels of Ptx3 were 
evident for the various treatments. Overall, it was concluded that the morphogens 
ShhN and FGF8 did not induce an upregulation of dopamine neuron specific markers
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in E l2 cortical neurospheres and other midbrain specific factors may be required for 
their conversion into a dopaminergic phenotype.
mesNS were expanded over four weeks with continuous passaging by mechanical 
dissociation of the neurospheres and proliferation under the various growth factor 
combinations as illustrated in Figure 4-1 IB. After two weeks expansion the 
neurospheres had been passaged three times and aliquots were used for RNA 
extraction and differentiation. As shown in previous experiments by 
immunocyochemistry, RT-PCR (Figure 4-11C) revealed an upregulation of TH 
expression in FGF8 expanded mesNS. This upregulation was detectable in samples 
analysed from proliferating cultures as well as from differentiated samples. ShhN 
present during the expansion phase further augmented the effects of FGF8 on TH 
expression. Cultures expanded in FGF2 showed a decreased TH expression compared 
to FGF8 expanded cultures even in the presence of ShhN confirming that the 
previously detected increased number of dopaminergic neurons is FGF8 dependent. 
Strikingly, a drop in TH expression was detected when mesNS were simultaneously 
expanded in ShhN, FGF8 and FGF2 as has been observed previously by 
immunolabelling. Ptx3 expression had a similar pattern as TH during the proliferation 
phase with the strongest expression in cultures that were expanded with FGF8 and 
ShhN. This confirmed that these conditions promoted the specific midbrain 
dopaminergic phenotype and had not merely upregulated TH expression, while 
additional FGF2 decreased the expression of this dopaminergic marker. The midbrain 
marker Engrailed-1 (Enl), which acts in a pathway with wnt-1 signalling and FGF8 
(Joyner, 1996; Danielian and McMahon, 1996), showed no differences in the 
expression levels between the different treatments.
The precursor cells were expanded and passaged for another three 
weeks. RT-PCR analysis was performed after five passages, a time point when no TH 
positive cells could be detected by immunochemical approaches. Indeed none of the 
cultures expressed detectable levels of TH, although Nurrl expression appears to be 
upregulated in those conditions when ShhN and FGF8 were simultaneously present. 
Whether such an upregulation could reflect an inductive effect of the morphogens is 
speculative, particularly considering that these expression levels were not maintained
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during the differentiation phase. This pattern was also not reproduced by Ptx3 
expression showing decreased levels compared to samples prepared after 3 passages.
Overall, RT-PCR analysis revealed that after extended passaging of FGF8 expanded 
neurospheres, the mesencephalic precursors loose their ability to produce a 
dopaminergic phenotype. Morphogens such as FGF8 and ShhN that are beneficial for 
dopamine generation at early passages have no positive effects on the expression of 
dopaminergic markers at later passages. Under differentiation condition at later time 
points none of the midrain dopaminergic markers were expressed suggesting that 
under the chosen culture conditions no premature dopamine neuroblasts were 
generated that had only failed to differentiate into TH expressing dopaminergic 
neurons.
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Figure 4-11: Semi-quantitative RT-PCR analysis o f E12 neural precursors expanded in 
different growth factor combinations. (A) RT-PCR analysis o f E12 ctxNS did not show an 
upregulation of dopaminergic markers. (B) Experimental rationale for RT-PCR of 
mesencephalic expanded precursors. GF= growth factor. (C) RT-PCR analysis o f E12 mesNS for 
dopaminergic markers after long time expansion as described in the text.
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4.3.8 Is FGF8 a survival factor for primary dopaminergic neurons or a mitogen 
for a dopamine neuroblast?
Although the previous data suggested that FGF8 is not inductive to convert a 
multipotent precursor cell into a dopamine progenitor, FGF8 might be mitogenic for 
an existing dopamine neuroblast and as such driving its cell division resulting in an 
increased number of de novo developed dopamine neurons. Alternatively, FGF8 
might be a survival factor for existing primary dopaminergic neurons or fate restricted 
dopamine neuroblasts that undergo their terminal differentiation into mature 
dopaminergic neurons in vitro. To establish whether increased numbers of TH 
neurons arose from proliferating progenitors we designed a BrdU pulse experiment 
(Figure 4-12). FGF8 or FGF2 expanded mesNS were pulse labelled with BrdU and the 
number of BrdU/TH double labelled dopaminergic neurons determined after 
differentiation.
As shown in Figure 4-12, no statistically significant difference in the number of BrdU 
labelled dopaminergic neurons expanded in FGF8 or FGF2 was detected. At both 
time points the BrdU pulse resulted in a similar number of de novo developed 
dopaminergic neurons which lead to the suggestion that FGF8 is no more mitotic on 
dopamine precursor cells than FGF2. Thus, the increased number of dopaminergic 
neurons with FGF8 must have been generated from cell divisions before the cells 
were pulsed and most likely FGF8 increased their survival.
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FGF8
BrdU
Expansion of 
dopamine neuroblast?
% BrdU/TH double labeled cells
Survival effect on 
dopamine neurons?
3-4 DIV 6-7 DIV
FGF2 7.2±2.0 7.0±1.8
FGF8 8.3±1.2 8.6±1.9
Figure 4-12: FG F 8 is not a m itogen for a d opam ine neurob last but a survival factor. T o answ er  
the question  if  FG F8 is driv ing  proliferation  o f  a d opam ine neurob last or rather increases the  
survival o f  existing  prim ary dopam inergic neurons or neurob lasts, a B rdU  pulse experim ent 
w as perform ed. I f  FG F8 is a m itogen for dop am ine n eu rob last sign ificantly  m ore de novo 
developed dopam inergic neurons w ould  be expected  characterized  as B rdU /T H +ve cells than  
w ith  FG F2. H ow ever, the n um ber o f  double labelled  cells w ill be unchanged  betw een the tw o  
m itogens if  FG F8 increases the survival o f  post-m itotic d op am ine neuroblasts. FG F 8 or FG F 2  
expanded E12 mesN S w ere pu lse labelled at the ind icated  tim e points w ith  BrdU  (0 .2pM ) for  12h 
and follow ing d ifferentiation  sta ined  for B rdU  and T H . T he nu m ber o f  B rdU /T H  double  
labelled cells w as not sign ificantly  increased w hen  neurospheres w ere expanded in FG F8. 
Im m unocyotchem ical sta in ing  show s TH  expressing  cells (A lexa  546, red) that incorporated  
BrdU  (A lexa 488, green) (arrow ).
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4.3.9 Effects of FGF8 on proliferation of endogenous stem cells of the SVZ
Proliferation of endogenous neural stem cells can be stimulated by delivery of 
exogenous growth factors, such as EGF and FGF2, into the lateral ventricle resulting 
in an increased division of stem cells residing in the SVZ of the forebrain (Craig et al., 
1996; Kuhn et al., 1997). It was decided to use a similar approach to study the 
potential roles of FGF8 on proliferation of forebrain neural stem cells in vivo by 
delivering recombinant FGF8 with a replication-deficient HSV-1. Construction and 
expression of the vector RLl+/27+/4-pR19FGF8bwpre will be described in chapter 5.
The experimental rationale, as illustrated in Figure 4-13, comprised stereotaxic 
injections of FGF8 expressing virus (RLl+/27+/4-pR19FGF8bwpre) or control virus 
(RLl+/27+/4-pR19LacZ) into the lateral ventricle of adult Sprague-Dawley rats (n=4 
per group). To label dividing cells, these injections were followed with daily 
intraperitoneal injections of BrdU at lOOmg/kg for the next 18 days. On day 20, the 
animals were killed and the brains were fixed along with the olfactory bulbs. The 
brains were then sectioned and stained for BrdU in tandem with phenotype-specific 
markers (Figure 4-13).
The effects RLl+/27+/4-pR19FGF8bwpre on proliferation of endogenous NSC’s 
were first assessed within the SVZ around the injection site. No differences in the 
number of BrdU positive cells were evident in comparison with injections of the 
control virus. Within the subependymal layer only a low number of cells incorporated 
BrdU suggesting a slow and unaltered division of NSC’s within this area. Some BrdU 
positive cells had migrated into the adjacent striatal areas. No upregulation of GFAP 
or nestin expression could be detected confirming that FGF8 had no effect on the cell 
population within the stem cell niche of the SVZ.
Next it was determined if FGF8 had any effects in other areas, such as olfactory bulb, 
hippocampus and substantia nigra. Although plenty of BrdU labelled cells were 
detected in the olfactory bulb, resulting from unaltered migration of dividing cells 
from the SVZ, no differences in the total neuronal number or the amount of cells
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double labelled with the neuronal marker NeuN and BrdU were detected. Migration 
of BrdU incorporated cells was observed as a ridge leading from the caudal part of the 
lateral ventricle via the rostral migratory stream (RMS) to the olfactory bulb where 
cells radially dispersed (Figure 4-13H). Therefore, FGF8 did not appear to have any 
effects on survival, migration or differentiation of precursor cells from the SVZ to the 
olfactory bulb. Only a rare number of BrdU positive cells were found in the 
hippocampus and no evidence of cell division in the substantia nigra was apparent. A 
lack of dopamine neurogenesis in the substantia nigra is in agreement with a recent 
report (Frielingsdorf et al., 2004).
In order to confirm that the experimental rationale allowed studying the proliferation 
of endogenous stem cells after ventricular injections of growth factor expressing 
HSV-1, disabled HSV-1 expressing FGF2 was injected into the lateral ventricle. As 
shown in Figure 4-13 a massive proliferation within the subependymal layer of the 
SVZ was detected after injection of the FGF2 expressing virus compared to the 
control virus. In FGF2 injected animals “polyp-like” hyperplasia containing an 
increased number of BrdU positive cells were found. An accelerated number of BrdU 
positive cells were also observed in the olfactory bulb and striatum of FGF2 injected 
animals. This confirmed that the experimental rationale itself allowed induction of 
cell proliferation within the subependymal layer after viral delivery of recombinant 
FGF2. These observed proliferative effects after intraventricular delivery of FGF2 on 
endogenous precursor cells and their differentiation into neuronal cell types have been 
described elsewhere (Kuhn et al., 1997), and hence were not further investigated in 
this study.
Overall, it was concluded that under the chosen experimental rationale virally 
delivered FGF8 did not induce proliferation of endogenous neural stem cells 
generated from the SVZ and that it did not effect in any obvious way their migration 
or differentiation in the olfactory bulb.
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RL1+/27+/4-
I LAT P1/P2 CMV FGF8b WPRE LAT
LAT P1/P2 CMV LacZ WPRE ] LAT
1764/27-/4-
LAT ] P1/P2 CMV FGF2 LAT
Viral Injection Brdu (100mgdcg IPxl8 days) Sacrifice
FGF2FGF2
STR
Figure 4-13 continuation: Virally delivered FGF8 has no effect on proliferation o f endogenous 
precursor cells o f the SVZ. Effects o f virally delivered FGF8 were tested after (A) injections 
into both lateral ventricles o f adult rats (n=4). (B) Viral constructs used were the less disabled 
backbone expressing either FGF8 or LacZ and the highly disabled construct expressing FGF2 
as positive control. (C) Experim ental rationale was to inject 5 x l0 6 PFU per ventricle o f viral 
vector followed by 18 days o f BrdU injections (lOOmg/kg, i.p.) and sacrification o f the animals 
two days after the last BrdU injection. (D) to (H) im m unohistochem ical stainings for the group 
injected with FGF8 expressing virus showed no significant increase in the num ber o f BrdU  
positive cells. (D) No significant upregulation o f GFAP or nestin expression was found in the 
SVZ o f the lateral ventricle. O ther regions analysed were (E) hippocam pus, (F) olfactory bulb 
and (G) substantia nigra. No significant changes to the control group were observed. (H) BrdU  
labelled cells migrated from the SVZ of the lateral ventricle as rostral migratory stream (RM S) 
into the olfactory bulb (OB) w here they disperse to differentiate into neurons. (I) Animals 
injected with LacZ expressing virus showed a similar number o f BrdU positive cells around the 
lateral ventricle (LV). (J) and (K) animals injected with FGF2 expressing virus had a significant 
increased num ber o f BrdU positive cells within the SVZ and the surrounding striatal tissue. (K) 
shows massive proliferation in the LV in caudal positions o f the injection site and often 
hyperplasia (inset) were detected in FGF2 injected animals as “polyp-like” changes o f the 
lateral wall containing an increased num ber o f dividing cells. Scale bars represent 50pm in (D) 
and 100pm in (E) to (I).
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4.4 Discussion
This chapter has shown that another member of the fibroblast growth factor family, 
FGF8 b, is a potent mitogen for the expansion of neural stem cells derived from 
different regions of the developing CNS. The expanded NSC’s retain definite stem 
cell characteristics as demonstrated by differentiation into the three neural lineages 
after subsequent passaging. Heparan sulphates generally play an important role for the 
activity of FGFs (Yamaguchi, 2001) and this has also been proven for the mitogenic 
activity of FGF8 b (Loo and Salmivirta, 2002). Probably the lack of heparin in the 
culture conditions of other studies is the reason that the function of FGF8  on NSC’s 
has not so far been seen. The presence of heparin was absolutely required for efficient 
and long time expansion of mesNS in this study, as has also been shown for 
mesencephalic precursor cells using FGF2 (Caldwell and Svendsen, 1998). Other 
studies that suggested the potential mitogenic effects of FGF8  on cortical 
(Hajihosseini and Dickson, 1999) and mesencephalic (Studer et al., 2000) precursors 
did not use heparin. However, these studies used cultures grown attached to a 
substrate rather than free-floating spheres which may be less dependent on exogenous 
heparin due to a continual production of heparin-like molecules. Further more, these 
studies did not grow the precursor cells as continuous cultures with subsequent 
passaging, and could therefore be considered as primary neural progenitor cultures.
Growth curves and dose response analysis revealed that FGF8  has a significantly 
lower mitogenic activity than FGF2. An appropriate ED50 of 60ng/ml for FGF8  
compared to lOng/ml for FGF2 was calculated based on their ability to stimulate 
BrdU incorporation in striatal neural precursor cells. Lower activities may reflect 
differences in their affinities for FGFR as it has been shown that FGF8  preferably 
binds to FGFR3 IIIc (Omitz et al., 1996; Ford-Perriss et al., 2002), while FGF2 
facilitates its mitogenic functions in neuroepithelial cells via FGFR1 (Brickman et al., 
1995) but can also bind to FGFR3 in other cell lines (Omitz et al., 1996). FGFR1 and 
FGFR3 as mediators for FGF2 and FGF8  signaling, respectively, are expressed in the 
developing brain between E10 and E14 (Ford-Perriss et al., 2002), the embryonic ages 
used in this study.
241
Activation of distinct receptors did not appear to have an impact on the outcome of 
progenitors generated as no differences in the composition of the neural progeny 
produced were observed. Of interest is the marginal shift within the glial progeny for 
mesencephalic neurospheres since the increase of oligendrocytes in FGF8 expanded 
cultures is accompanied by an identical decrease in the number of astrocytes 
compared to FGF2 expanded cultures (Figure 4-6). This leads to the speculation that 
FGF8 actually drives a common mesencephalic precursor cell into the 
oligodendroglial lineage at the cost of differentiation into astrocytes. Indeed it has 
been shown that FGFR3 signaling regulates terminal differentiation of 
oligodendrocyte progenitors (Oh et al., 2003b), and increased activation of this 
receptor may contribute to an augmented generation of oligodendrocytes in FGF8 
expanded cultures.
Interestingly, mesencephalic neural precursor cells gave rise to significantly more 
dopaminergic neurons, characterized by the expression of TH, when expanded in 
FGF8 as compared to FGF2. The number of dopaminergic neurons could further be 
increased when ShhN was simultaneously present with FGF8 during the expansion 
phase of mesNS. That the upregulation of dopaminergic markers depends on the 
presence of ShhN during the expansion phase and that the morphogen may even 
depress TH expression when present during the differentiation phase has also been 
proven for dopaminergic neurons generated from adult hippocampal progenitors 
(Sakurada et al., 1999).
Three possible explanations for the augmented number of TH positive cells may be 
considered: a) FGF8 induces de novo development of dopaminergic neurons from 
multipotent precursor cells, which could collaboratively be increased by FGF8 and 
ShhN; b) FGF8 is a mitogen particularly for amplifying dopamine neuroblasts; c) 
FGF8 exerts survival effects on existing dopamine neuroblasts and/or differentiated 
primary dopaminergic neurons. Several observations disprove that FGF8 and ShhN 
were converting a multipotent neural stem cell into a dopaminergic progenitor cell as 
demonstrated during embryonic development (Ye et al., 1998) and for the generation 
of dopaminergic neurons from embryonic stem cells (Lee et al., 2000; Kim et al.,
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2002). A neural stem cell that exists within the neurosphere and is susceptible to the 
morphogens should give rise to TH expressing cells when isolated at different 
embryonic ages and not loose its susceptibility to the signals following passaging. A 
reduced number of dopaminergic neurons in E14 mesNS compared to E l2 mesNS were 
observed and a significant decline in the total number of TH positive cells with each 
passage. Further more, the morphogens did not induce upregulation of TH expression 
or other dopaminergic markers in cortical neural precursor cells or mesencephalic 
neurospheres that had been passaged over time. Other reports also confirmed that 
ShhN and FGF8 are not sufficient to induce a dopaminergic phenotype in mouse 
striatal precursor cells and in a human neural stem cell line (Stull and Iacovitti, 2001). 
It was also demonstrated that the effects of ShhN are not a unique phenomenon 
resulting from synergism with FGF8 but could also be mimicked with FGF2. 
However, the high concentration of FGF-2 used to propagate the NSC’s (20ng/ml) is 
known to activate all three FGF receptors (Omitz et al., 1996), suggesting that FGFR3 
may be activated under the chosen conditions by FGF2. The BrdU pulse experiments 
performed suggest that FGF8 is not a specific mitogen for the proliferation of 
dopamine neuroblasts when comparing the de novo generated dopaminergic neurons 
to those in FGF2 conditions. Therefore, the increased number of TH expressing cells 
in FGF8 conditions did not result from the de novo generation of dopaminergic 
neurons but most likely due to survival effects on existing primary dopaminergic 
neurons and post-mitotic dopamine neuroblasts. Neuroprotective effects of FGF8 
have also been reported for rat hippocampal neurons (Mark et al., 1999), PC 12 cells 
and human neural progenitor cells (Tanaka et al., 2001).
Interestingly, a depression of TH expression was detected by immunocytochemistry 
and RT-PCR analysis when mesNS were simultaneously expanded in ShhN, FGF8 and 
FGF2. Considering that these factors are mitogens, they determine cell fates in a 
concentration dependent pattern. Therefore, excessive activation of FGFR3 or other 
FGFRs via FGF8 and FGF2 could actually inhibit dopamine differentiation and 
favour differentiation into other neuronal cell types. It has been shown that FGF8 and 
ShhN also induce serotonergic neurons in collaboration with FGF4 and exposure of 
midbrain explants to FGF2 or FGF4 gave rise to serotonergic neurons at the expense 
of dopaminergic neurons (Ye et al., 1998), while blocking of FGF4 signalling
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increased the production of dopaminergic neurons on the cost of serotonergic neurons 
(Rodriguez-Pallares et al., 2003). Considering that different FGFs can transduce 
through the same cellular receptors (Omitz et al., 1996) it is possible that at the high 
concentration of the mitogens used, FGF4-mediated signalling pathways are activated 
that may inhibit differentiation into mature dopaminergic neurons. Further, it has 
recently been shown that the trophic effects of FGF8  are dose dependent and that 
accelerated FGF8  signalling actually inhibits the FGF8 -dependent cell-survival 
pathway (Storm et al., 2003). It was decided to use FGF8  at a concentration of 
50ng/ml corresponding to the calculated ED50 value. Whether different FGF8  
concentrations have effects on the number of dopaminergic neurons generated needs 
to be addressed in future studies.
Although FGF8  has mitogenic effects on precursor cells in vitro, no effects on 
proliferation of neural stem cells in vivo were observed after intraventricular delivery 
using disabled HSV-1. Several possibilities may explain this finding. Gene delivery 
with the chosen vector may be unsatisfactory either due to limited transduction 
efficiency of cells within the SVZ or low expression levels from the construct in vivo 
that are not sufficient for a biological effect. The previous chapter had shown that the 
selected viral backbone does infect cells of the SVZ. However, transgene expression 
was only observed in a limited number of subependymal cells. As shown by 
intraventricular injections of the FGF2 expressing vector, viral delivery is sufficient to 
induce a proliferative effect with FGF2. It should be considered that significantly 
higher concentrations of FGF8  may be required to induce a potential effect with FGF8  
in vivo, as in vitro analysis had already revealed that the ED50 of FGF8 is significantly 
higher than that of FGF2. However, the simplest explanation is that no FGF8 
responsive neural stem cell exists in the adult forebrain and that the mitogenic effects 
are limited to neural stem cells derived from the developing CNS. Expression of 
FGF8 (Tanaka et al., 2001) and its receptor FGFR3 (Belluardo et al., 1997) were 
confirmed in the adult rodent brain and FGFR3 expression was also localized in 
astrocytes within the postnatal ventricular zone (Pringle et al., 2003), but the function 
of FGF8 is likely to be very different from its mitogenic activity in the developing 
brain. Similarly, as has been shown for ShhN (Lai et al., 2002), FGF8 may effect 
proliferation or survival of hippocampal neural stem cells or be involved in
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“maintaining” the stem cell niche as was reported for smoothened (Machold et al.,
2003). In this study it was decided not to test if neural precursor cells derived from the 
adult SVZ or SGZ can be propagated as neurosphere cultures in vitro. However, it 
was found that neural stem cells isolated from human embryonic tissue (cortex, 
striatum, mesencephalon and spinal cord) could also be expanded in the presence of 
FGF8 as the sole mitogen (data not shown). It was also found that the presence of 
exogenous heparin is required to enhance the mitogenic effects of FGF8 and thus, 
insufficient amounts of heparin or heparin sulphates within the stem cell niche may 
further limit the function of FGF8 in vivo. As the identity and cellular properties of 
endogenous neural stem cells remain unclear, future studies will hopefully unveil 
information about the expression of the receptors and proteoglycans within this niche.
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C h a p t e r  5:  
C o n s t r u c t i o n  a n d  
C h a r a c t e r i z a t i o n  o f  HSV-1
VE CTORS FOR THE PO T E N T IA L  
I N D U C T I O N  OF A 
D OP A M IN E R G I C  P H E N O T Y P E
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5.1 Introduction
This chapter describes the construction of disabled HSV-1 for the delivery of 
modulatory genes to neural progenitor cells, neurospheres and for potential in vivo 
applications. The aim was to study the effects of expression of selected factors on the 
induction of dopaminergic phenotypes in these models.
As described in the general introduction embryonic dopamine neuron development 
involves synergistic function of mitogenic, morphogenic and transcription factors. 
This chapter focuses on the roles of the mitogen FGF2, the morphogens FGF8 and 
ShhN and the transcription factor Nurrl. These selected factors have been well 
established as playing crucial roles in the development of dopaminergic neurons 
during embryonic development (Perrone-Capano and Di Porzio, 2000; Perrone- 
Capano et al., 2000) and for the induction of a dopaminergic phenotype in embryonic 
stem cells (for review see Lin and Rosenthal, 2003). Since functional FGF2, FGF8 
and ShhN can be added to in vitro cell cultures as bacterially produced recombinant 
proteins, most studies have avoided the use of proteins produced in mammalian cell 
culture systems, or the construction of viral vectors expressing these factors. 
However, such bacterially produced recombinant factors have the disadvantage of the 
lack of posttranslational modification. The factors under study do undergo such 
modifications, e.g. FGF8 is glycosylated (Crossley and Martin, 1995) in mammalian 
cells and Shh is modified by cholesterol and palmitolyl attachment as well as forming 
disulfide bonds (see below). Further it has been shown that FGF2 and ShhN remain 
cell associated and that signalling pathways involve direct cell to cell contact (Omitz 
and Itoh, 2001; Marti and Bovolenta, 2002). Hence, the mitogenic or differentiation 
activity of bacterial produced factors may only reflect a limited function of these 
factors. Given the important role of the interaction with proteoglycans, as shown in 
the previous chapters, these modifications may have significant relevance for their 
biological function in vitro and in vivo. Therefore, replication deficient HSV-1 vectors 
were constructed to deliver these factors to cell and animal models which should 
overcome all the limitations of the artificial production of cell free protein.
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As established in chapter 3, the highly disabled 1764/27-/4- vector only gave low 
level gene expression in primary progenitor cells after infection at early time points. 
The less disabled backbone RL1+/27+/4- resulted in higher level gene delivery, 
although at the expense of increased neuronal cell loss. As it was intended to modify 
the function of progenitor cells at time points at which they still possess plasticity, i.e. 
when the cell population still contains immature precursor cells, gene delivery is 
required at early time points. Thus, the vector chosen was based on the RL1+/27+/4- 
backbone. The second model used in the study used neurospheres as the source for 
neural precursor cells. While striatal and mesencephalic derived neurospheres can be 
efficiently transduced with either viral vector, gene delivery to cortical neurospheres 
can only be achieved with RL1+/27+/4- viruses. However, infection with this 
construct at high multiplicities affected the differentiation capability of transduced 
precursor cells into neuronal cell types. Hence, for the delivery of genes encoding the 
selected factors to striatal and mesencephalic neurospheres the more highly disabled 
vector, 1764/27-/4-, may be more appropriate. Previous work has also shown that 
1764/27-/4- is particularly suitable for in vivo gene delivery to the substantia nigra 
(Lilley et al., 2001). Intrastriatal administration results in a retrograde transport of the 
virus to the substantia nigra giving strong transgene expression in this region and 
around the striatal injection site. Therefore, 1764/27-/4- based vectors will be used in 
this chapter for in vivo gene delivery studies.
The genes encoding the respective factors were cloned into the pR19 expression 
cassette and flanked by sequences of the LAT region. This allows the targeted 
insertion of the expression cassette into the LAT region by homologous 
recombination, thereby replacing the endogenous LAT region. The rationale for the 
use of this cassette was based on previous work in where the pR19 based viruses had 
been shown to direct high level, long term expression of reporter genes in vitro and in 
vivo (Palmer et al., 2000; Lilley et al., 2001).
In an attempt to study the pathogenesis and possible therapeutic strategies for 
Parkinson’s disease, several cell and animal models have been developed (Deumens 
et al., 2002; Dauer and Przedborski, 2003; Jakel et al., 2004). Animal models using 
rodents, primates and even drosophila (Feany and Bender, 2000) can be distinguished
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as “etiological models” using gene-based approaches and “pathological models” that 
induce a selective degeneration or depletion of dopaminergic neurons by 
administration of toxins (Dauer and Przedborski, 2003). Most commonly used animal 
models were based on acute or chronic exposure to such toxins as l-methyl-4-phenyl- 
1,2,3,6-tetrahydropyridinine (MPTP), 6-hydroxydopamine (6-OHDA), paraquat and 
rotenone that induce oxidative stress by formation of reactive oxygen species (ROS) 
and/or inhibition of mitochondrial function (Jakel et al., 2004). Although these models 
imitate some characteristics of the disease they do not reflect the progressive 
degeneration which is symptomatic for the human pathogenesis.
For the purpose of this study a toxin-based animal model of PD was used that is easy 
to establish in rats, induces a profound and selective depletion of dopaminergic 
neurons within a reasonable time, and allows quantification. Therefore, it was decided 
to induce acute dopaminergic cell death by administration of 6-OHDA. 6-OHDA is 
selectively taken up by catecholaminergic neurons (Luthman et al., 1989) and induces 
neuronal cell death within the first 24 hours when injected into the medial forebrain 
bundle (MFB), which carries ascending dopaminergic and serotonergic projections to 
the forebrain, or into the substantia nigra (Jeon et al., 1995). However, when injected 
into the striatum it induces retrograde loss of dopaminergic neurons which is slower 
and progressive and lasts for 1 to 3 weeks (Przedborski et al., 1995). In this study the 
MFB was lesioned by unilateral injections of 6-OHDA which resulted in an almost 
complete loss of dopaminergic neurons in the ipsilateral substantia nigra and TH 
reactive fibers in the striatum. The advantage of unilateral lesions is that they can 
easily be measured by drug-induced asymmetric circling behaviour, the magnitude of 
which depends on the degree of the nigrostriatal lesion (Ungerstedt, 1971b). The 
postsynaptic agonist apomorphine induces rotations contralateral to the lesioned side 
due to a stimulation of denervation-induced upregulated D2 receptors in the ipsilateral 
striatum (Ungerstedt, 1971a). Apomorphine induced rotations become detectable 
when more than 90% of dopaminergic fibers in the striatum and more than 50% of 
dopaminergic cell bodies in the substantia nigra have been depleted (Deumens et al., 
2002). This Parkinson model will be used to study the effects of selected virally 
delivered factors on the potential regeneration of the denervated nigrostriatal system.
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5.2 Materials and Methods
5.2.1 Construction of FGF8b expressing viral vectors
The cDNA encoding for mouse FGF8b (GeneBank accession number D12482) was 
obtained in pBluescript® SK and the construction of the plasmid has been described 
before (Crossley and Martin, 1995). FGF8b cDNA was removed by restriction digest 
with Smal and Xhol and then subcloned into the pR19 shuttle plasmid flanked by 
LAT sequences allowing insertion into the LAT region. Therefore, the reporter genes 
of the vector backbones pGEM-5 pR19LacZ LAT (Lilley et al., 2001) or pGEM-5 
pR19Nurrlwpre LAT (constructed by J. Palmer, unpublished data), were removed by 
enzymatic digest with HindHI followed by blunt ending with T4 DNA polymerase 
(2.2.8) and restriction digest with Xhol. After ligation FGF8b containing clones were 
characterized by multiple restriction digests.
For the generation of recombinant viruses (2.4.1) 1764/27-/4-pR19GFP 
or RLl+/27+/4-pR19GFPwpre viral DNA, respectively, were co-transfected with 
linearised pGEM-5 pR19FGF8b LAT and pGEM-5 pR19FGF8bwpre LAT plasmid 
DNA. Recombinant plaques were detected by the lack of GFP expression under a 
fluorescent microscope and selected until pure stock of virus was obtained generating 
the viruses 1764/27-/4-pR19FGF8b and RLl+/27+/4-pR19FGF8bwpre, respectively.
5.2.2 Construction of FGF2 (bFGF) expressing viral vectors
The cDNA encoding for rat basic fibroblast growth factor was amplified from rat 
brain mRNA (2.2.12) by RT-PCR using the One-step RT-PCR kit (Qiagen). 2/zg RNA 
were used as template in the RT-PCR reaction with the following primers nesting a 
HindHI restriction site in the 5’ and a Xhol restriction site in the 3* end encompassing 
the ORF from 533bp to 1024bp according to the GeneBank accession number 
M22427:
250
FW: 5’ CGTAX4GC77GATTCC ATGGCTGCCGGC AGC ATC A 
RV: 5’ CGTACrCG^GATTCCCTGAGAGTGACAGTGTCTA 
Restriction sites are indicated in Italic style.
The following RT-PCR program was used on a thermocycler (Eppendorf): reverse 
transcription for 30min at 50°C, PCR activation for 15min at 95°C, 34 cycles of 
denaturation for lmin at 95°C, annealing for lmin at 80°C, extension for lmin at 72°C 
followed by a final extension for lOmin at 72°C. The PCR product was separated on a 
1% agarose gel, the band of the expected molecular size (about 520bp) cut out and 
purified using a Gel band purification kit (Amersham). The PCR product was 
subloned into pgemT vector (Promega) resulting in pGemTbFGF. Insert containing 
clones were sequenced (2.2.11) and the sequence compared to the Genebank sequence 
of bFGF (M22427). The sequence is attached in the appendix.
The cDNA encoding for bFGF was removed from pGemTbFGF by 
restriction digest with Hindlll and Xhol and subloned into a shuttle vector to replace 
the transgene of pGEM-5pR19LacZLAT or pGEM-5pR19NurrlwpreLAT within the 
HindHI and Xhol sites. The plasmids generated were named pGEM-5pR19bFGFLAT 
and pGEM-5pR19bFGFwpreLAT and subsequently linearised with Sspl.
For generation of bFGF expressing viruses, the linearised plasmids were 
co-transfected with viral DNA generated from 1764/27-/4-pR19GFP and 
RLl+/27+/4-pR19GFPwpre, respectively. Recombinant plaques were detected by the 
lack of GFP expression under the fluorescence microscope, selected until pure and the 
constructed viruses named 1764/27-/4-pR19bFGF and RLl+/27+/4-pR19bFGFwpre.
5.2.3 Construction of ShhN expressing viral vectors
ShhN was amplified by PCR from rat embryonic cDNA (Quick clone, clontech) using 
0.1 ng of the template and the following program: hot start for 2min at 95°C, 34 cycles 
of denaturation for 1.3min at 95°C, annealing for 1.45min at 69.8°C, extension for 
2min at 72°C and final extension for lOmin at 72°C. The primers were designed to 
amplify the aminoterminal part of rat sonic hedgehog (amino acid residues 1-198 
according to Gene Bank accession number L27340). Therefore, a stop codon was
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inserted in the reverse primer after 908bp (according to #L27340) and is indicated 
(underlined) in the following sequence:
FW: 5’ CGTAGGATCCGAA7TCCGTACCAGCTCGCGCACAGA 
RV: 5’ CGTACTCGAGAA7TCTCAGCCGTCAGATTTGGCCGCCA
Further the primers contained restriction sites for BamHI and EcoRI (FW) or EcoRI 
and Xhol (RW) as indicated in italic style. The PCR reaction resulted in a 753bp large 
product that was subsequently cloned into pgemT vector (Promega) resulting in 
pgemTShhN. The sequence of correct clones was confirmed and is attached in the 
appendix.
The cDNA encoding for ShhN was removed by restriction digest with 
BamHI followed by blunt ending with T4 DNA polymerase (2.2.8) and Xhol digest. 
The fragment was cloned into a shuttle vector to replace the transgene of pGEM- 
5pR19LacZLAT or pGEM-5pR19NurrlwpreLAT. Therefore, the plasmid was 
HindHI digested, blunt ended with T4 DNA polymerase and the insert subsequently 
removed by Xhol digest. The plasmids generated were named pGEM- 
5pR19ShhNLAT and pGEM-5pR19ShhNwpreLAT and subsequently linearised with 
Sspl.
Recombinant viruses were generated by co-transfection of linearised 
plasmids with viral DNA from 1764/27-/4-pR19GFP (pGEM-5pR19ShhNwpreLAT) 
and RLl+/27+/4-pR19GFPwpre (pGEM-5pR19ShhNwpreLAT). Recombinant 
plaques were detected by the lack of GFP expression under the fluorescence 
microscope, selected until pure and the constructed viruses named 1764/27-/4- 
pR19ShhN and RLl+/27+/4-pR19ShhNwpre.
5.2.4 Construction of Nurrl expressing viral vectors
Nurrl was amplified by PCR from rat embryonic cDNA (Quick clone, clontech) 
using 0.1 ng of the template and the following program: hot start for 2min at 95°C, 34 
cycles of denaturation for 1.3min at 95°C, annealing for 1.45min at 69.8°C, extension 
for 2min at 72°C and final extension for lOmin at 72°C. Primers were designed 
inserting an additional HindHI restriction site in the 5’end and an Xhol site in the 
3’end with the following sequence (restriction sites in italic style):
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FW: 5’ CGTA^4GC7TTCGGCTGAAGCCATGCCTTG 
RV: 5’ CGT ACTCGAGACGTGCATGGGAGAAAGTC
The resulting PCR product of about 1.8kbp was cloned into the pgemTeasy vector 
(Promega) resulting in pGemTNurrl. The sequence of selected clones was determined 
and verified with the published entry (Gene Bank accession number U72345). Nurrl 
was subcloned into the expression cassette by using the Hind III and Xhol restriction 
sites available in the vector pGEM-5pR19LacZLAT and thereby replacing the LacZ 
gene. The resulting vector is referred to as pGEM-5pR19NurrlLAT. For generation 
of viruses expressing the transgene with the wood chuck hepatitis virus 
posttranscriptional regulatory element, the Nurrl gene was subcloned by others of our 
group into pGEM-5pR19hrGFPwpreLAT (Palmer J, personal reference). Therefore, 
the hrGFP gene was replaced by Nurrl using HindHI and Notl restriction sites 
generating pGEM-5pR19NurrlwpreLAT (Palmer J, personal reference).
Recombinant virus were generated by co-transfection of 1764/27-/4- 
pR19GFP and pGEM-5pRl 9Nurr 1 LAT, resulting in 1764/27-/4-pR19Nurrl, or 
RLl+/27+/4-pR19GFPwpre and pGEM-5pR19NurrlwpreLAT, resulting in 
RLl+/27+/4-pR19Nurrlwpre. Recombinant plaques were identified under a 
fluorescent microscope by the lack of GFP expression and subsequently selected until 
pure.
5.2.5 Western blot analysis
BHK cells, primary E14 cortical, striatal and mesencephalic neural progenitors and 
neurosphere cultures were infected with the indicated viral constructs at an 
approximate m.o.i. of 10. For secreted proteins infected BHK cells were maintained 
for two days in standard growth medium, then the media was removed and the cells 
washed three times with HBSS (Gibco). Cells were overlaid with 500/d DMEM 
medium (SFM) and incubated at 37°C/5%C02. After 2, 6 and 24h the supernatant was 
collected and centrifuged for 2min at 3000rpm. The supernatant was concentrated 
using Microcon columns (Millipore, cut off 10 kDa) and resuspended in a small 
volume (25-30/d) of western blotting loading buffer containing 0.1M DTT. BHK 
infected cell pellets as well as infected progenitor cells were harvested in 100/d
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loading buffer. Infected neurosphere cultures were maintained for five days after 
infection in differentiation media. Cells were settled and resuspended in 100/d loading 
buffer. All western blotting samples were stored at -20°C. SDS-PAGE, transfer and 
antibody incubations were performed as described in 2.5.1.
5.2.6 Neurite outgrowth assay
6000 viable PC 12 cells (2.3.4) were seeded per well into six-well multiwell plate 
(Nunclon) coated with poly-L-lysine. The next day cells were infected by removing 
growth media and incubation with 500/d DMEM containing 1.8xl06PFU of the 
respective viral construct for one hour at 37°C. The virus was removed and cells 
overlaid with maintenance medium. Positive control cultures (only for neurite assay 
of 1764/27-/4- constructs) were supplemented with recombinant FGF8 (R&D, 
50ng/ml) or FGF2 (R&D, 5ng/ml) and growth factors were freshly added every other 
days at the indicated final concentration. Three days after infection medium was 
removed and replaced by DMEM containing reduced serum (2%FCS only). Six days 
after infection the cells were fixed with 4% paraformaldehyde. For quantification cells 
were counted in 20 fields per treatment with processes of the length of the cell 
diameter or longer. The neurite outgrowth assay was repeated in three independent 
experiments.
5.2.7 Differentiation of C3H/10T1/2 cells
For the standard assay of ShhN activity lxlO4 viable mouse fibroblast C3H/10T1/2 
cells/cm2 were plated in 8-well chamber slides (Nunclon). The next day medium was 
removed and cells infected with 100/d of virus diluted in SFM. Cells were infected at 
an m.o.i. of 3 with 1764/27-/4-pR19ShhN and RLl+/27+/4-pR19ShhNwpre or the 
respective viral backbones expressing GFP. After one hour infection at 37°C /5%CC>2 
virus was removed and replaced by 250/d DMEM with reduced serum content 
(3%FCS). Cells were maintained for another five days and subsequently fixed with 
4% paraformaldehyde. Cells were washed three times with Hank’s balanced solution 
(HBSS, Gibco). Infected cells were assayed for alkaline phosphatase (AP) by adding 
200/d 5-Bromo-4-chloro-3-indolyl Phosphate (BCIP)/Nitroblue Tetrazolium (NBT)
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Liquid Substrate (BCIP/NBT) (B1911, Sigma) per well. Cells were incubated at room 
temperature and colour development monitored under a standard microscope. AP 
activity produced a blue-purple, stable precipitate in the cells. Colour development 
was stopped by rinsing three times with distilled water.
5.2.8 6-OHDA lesions
6-hydroxydopamine Hydrochloride (6-OHDA, Sigma 14381) was freshly prepared in 
0.9% saline solution containing 0.2% ascorbic acid at a concentration of 2.5/xg//xl. 
Aliquots were protected from exposure to light and kept on ice prior to injection. 
Adult female Sprague-Dawley rats (260-280g) were anaesthetised and fixed in a Kopf 
stereotaxic frame. Under standard surgical procedure (2.6.1) 12.5/xg (total volume of 
5id) of free base 6-OHDA were injected at a rate of 1/xl/min with a 32”gauge steel 
needle (Hamilton, #79628) attached to a 25/xl Hamilton syringe using an automatic 
microinjector (World Precision Instruments). Injections were performed into the left 
medial forebrain bundle at the following coordinates (Paxinos and Watson, 1997): 
AP-0.22, ML+0.15 from Bregma and DV -0.79 from dura with the incisor bar 
adjusted that bregma and lambda were positioned in a horizontal line (flat-skull 
position). After injection the needle was left in place for another 5min before slowly 
retracting it within 3min.
5.2.9 Behavioural analysis
At two weeks after lesion the drug-induced rotational behaviour was monitored for 
the first time in automated rotometer bowls (MedAssociates, USA). Apomorphine 
HCL (Sigma) was freshly prepared in distilled autoclaved water at a concentration of 
0.5mg/ml and protected from exposure to light. Animals were injected with 
apomorphine at 0.5mg/kg s.c., transfered into the rotational bowl and connected to the 
automatic counter (Rotorat™, MedAssociates, USA). 5min after apomorphine 
injection net rotational asymmetry was monitored over 30 min as full contralateral 
body tums/min. Animals showing 5 or more turns were selected and apomorphine 
induced rotation tests were repeated after 4 weeks and 6 weeks prior to virus injection 
and after virus delivery as indicated.
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5.2.10 Striatal virus injections
The GDNF expressing construct 1764/27-/4-pR19GDNF used in this study was 
previously constructed in our laboratory (Li XP, personal reference) and expresses the 
gene encoding for human GDNF in the pR19 cassette inserted in the LAT region of 
1764/27-/4-backbone.
4 weeks (GDNF experiment) to 6 weeks (ShhN/FGF2 experiment) after 
lesion, apopmorphine induced rotational behaviour was assessed and one day later 
virus injections performed. Using standard surgical procedure (2.6.1) 5x10s PFU of 
1764/27-/4-pRl9LacZ, 1764/27-/4-pR19FGF2, 1764/27-/4-pR19ShhN or 1764/27-/4- 
pR19GDNF were injected in a total volume of 5/xl into the left striatum ipsilateral to 
the 6-OHDA lesion at the following coordinates (Paxinos and Watson, 1997): 
AP+0.18, ML+0.3 from Bregma and DV-0.45mm from dura with the incisor bar at 
+4.5mm from interaural line. For injection a 33” gauge steel needle (Hamilton, 
#79628) was attached to a 25fi\ Hamilton syringe and virus continuously injected at a 
rate of 0.5/zl/min using an automated microinjector.
For BrdU labelling animals were injected i.p. with lOOmg/kg BrdU in 
O.IMTris/HCl pH7.4 daily for six consecutive days. Seven days after the last BrdU 
injection the animals were transcardially perfused with 4%PFA in 0.1M 
phosphatebuffer pH7.4, postfixed overnight and cryprotected in 30% sucrose until 
brains had sunk. Brains were cut in coronal sections at 30/xm and 
immunohistochemical staining performed for BrdU, TH and nestin as described in 
2.5.3.
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5.3 Results
5.3.1 Overview of the vectors constructed
HSV-1 vectors were constructed expressing FGF8b, FGF2, ShhN and Nurrl in either 
the highly disabled backbone 1764/27-/4- or the less disabled vector RL1+/27+/4- 
(Table 5-1 and Figure 5-1). While FGF8 expressing vectors were generated based on 
an existing plasmid encoding the mouse specific sequence of the gene (Crossley and 
Martin, 1995), all other genes were amplified using PCR methods from embryonic rat 
cDNA (Nurrl, ShhN) or adult tissue (FGF2) that was prepared for this purpose from 
rat brains. The correct sequences of all PCR based constructs were confirmed and are 
attached in the appendix.
Virus name Deletions/
Inactivations
Transgene Gene Bank
Accession
number
1764/27-/4-
/pR19FGF2
ICP34.5/ORF P, 
VP16, ICP27, ICP4
rat basic fibroblast 
growth factor
M22427
1764/27-/4-
/pR19FGF8
ICP34.5/ORF P,
VP 16, ICP27, ICP4
mouse fibroblast 
growth factor 8b
D12482
1764/27-/4-
/pR19ShhN
ICP34.5/ORF P, 
VP16, ICP27, ICP4
rat sonic hedgehog 
(residues 1-198)
L27340
1764/27-/4-
/pR19Nurrl
ICP34.5/ORF P, 
VP16, ICP27, ICP4
rat orphan nuclear 
receptor Nurrl
U72345
RL1+/27+/4-
pR19FGF2
VP16, ICP4 rat basic fibroblast 
growth factor
M22427
RL1+/27+/4-
pR19FGF8
VP16, ICP4 mouse fibroblast 
growth factor 8b
D12482
RL1+/27+/4-
pR19ShhN
VP 16, ICP4 rat sonic hedgehog 
(residues 1-198)
L27340
RL1+/27+/4-
pR19Nurrl
VP16, ICP4 rat orphan nuclear 
receptor Nurrl
U72345
T able 5-1: R ecom binant viruses constructed. All transgenes w ere cloned into the pR19
expression cassette and inserted into the LAT region.
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Highly disabled construct 1764/27-/4-
ICP34.5 VP 16 ICP27
E
ICP34.5 ICP4 ICP4
X  *
LAP1 LAT P2
FGF8b -
T31
T3a
Less disabled construct RL1+/27+/4-
VP16
-  FGF2 -
— Nurrl —
ShhN
LAP1 LAT P2 CMV
FGF8b -
FGF2
Nurrl -
ShhN -
Figure 5-1: Genome structure o f the viruses constructed. The cDNA encoding the respective 
factors were cloned into the pR19 expression cassette consisting o f a heterologous promoter 
encompassing the HSV-1 latency promoter LAP1 and LAT P2 region combined with CMV  
promoter driving the transgene. The expression cassette was inserted into the LAT region of 
the respective viral backbones replacing the endogenous LAT elements.
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5.3.2 The effects of virally delivered FGF8 and FGF2 in primary neuronal 
cultures and neurospheres
The effects of FGF8 and FGF2 on the generation and survival of dopaminergic 
neurons from neural precursor cells grown as neurospheres have been shown in the 
previous chapter. Here the effects of virally delivered FGF2 and FGF8 on primary 
neurons and neural progenitor cells were studied.
5.3.2.1 Construction of HSV-1 vectors expressing FGF8 and FGF2
Co-transfection of 1764/27-/4-pR19GFPLAT or RLl+/27+/4-pR19GFPwpreLAT 
viral DNA with linearised plasmid DNA containing FGF8b or FGF2 either with or 
without the woodchuck hepatitis virus post-transcriptional regulation element (wpre) 
resulted in replacement of the GFP expressing promoter cassette by FGF8 and FGF2 
encoding cassettes, respectively. Homologous recombination can either occur in one 
or both sites of the LAT region generating faint or no GFP expressing viral plaques. 
Therefore, generation of recombinant plaques replaced for both LAT regions are 
stochastically rarer than those with unilateral recombination. Indeed, only a small 
number of recombinant plaques with both LAT regions replaced were detected as 
characterized by the absence of GFP expression. Faint GFP expressing viral plaques 
were observed but not selected for further virus purification. Plaques based on the less 
disabled backbone, RL1+/27+/4-, were significantly larger than those generated from 
highly disabled vector, 1764/27-/4-, since the latter constructs have decreased growth 
rates due to the multiple viral gene deletions. Purified recombinant constructs that did 
not contain any GFP expressing particles were tested for their lack of growth on non­
complementing BHK cells.
To select positive recombinant vectors, purified clones were first tested for their 
expression of FGF8 or FGF2 on 27/12/M:4 (M49) cells (Thomas et al., 1999b), which 
allow virus growth. Most of the purified clones expressed FGF8b (Figure 5-2A), 
while some of the isolates did not express FGF2 (Figure 5-3A). This may have 
resulted from recombination events resulting in the loss of the recombinant gene,
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although this problem was not encountered in recombinant constructs based on the 
less disabled viral backbone. Positive clones were selected and propagated to produce 
high titre viral stocks.
To ensure that recombinant FGF8 and FGF2 were also expressed and secreted in non­
complementing cells, BHK cells were infected with the different constructs. Two days 
post infection the cells were overlaid with serum free media and the supernatant 
collected at different time points. After concentration using size exclusion 
chromatographic mini-columns the proteins were separated by SDS-PAGE and 
immunoblotted for FGF8 and FGF2, respectively. As shown for the highly disabled 
constructs, FGF8b (Figure 5-2B) and FGF2 (Figure 5-3B) were expressed in these 
non-complementing cells and secreted into the supernatant.
western blotting for FGF8 showed a ladder of bands of different molecular weights 
around the expected molecular size of 23kDa (Dorkin et al., 1999) which is probably 
the result of multiple N-linked glycosylation events (Crossley and Martin, 1995). A 
very strong signal was also observed from cell-associated and supernatant samples 
from infected BHK cells for RL1+/2 7+/4-pR 19FGF8bwpre (Figure 5-2C) confirming 
that a large amount of virally produced FGF8 was released from these cells.
Smaller amounts of FGF2 appeared to be secreted after infection of BHK cells with 
1764/27-/4-/pR19FGF2. The protein ran on the SDS-PAGE at a molecular weight of 
about 19kDa which conforms to the reported protein size of 18-20 kDa for FGF2 
(Brickman et al., 1995). Interestingly, unlike the other members of the FGF family, 
FGF2 lacks amino-terminal signal peptides and is apparently secreted by mechanisms 
other than the classical protein secretion pathway (Mignatti et al., 1992) and mainly 
remains cell-associated on the cell surface and within the extracellular matrix (Omitz 
and Itoh, 2001). This was also observed in western blot analysis after infection of 
BHK cells with RLl+/27+/4-pR19FGF2wpre (Figure 5-3C). Virally produced FGF2 
protein was strongly associated with the cell pellet but could also be detected in the 
supernatant. Some of the protein in the supernatant may also have resulted from the 
release from damaged cells.
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Expression was also confirmed after infection of primary neural progenitor cells and 
neurospheres. Cortical, striatal and mesencephalic progenitor cells as well as striatal 
neurospheres were infected with RLl+/27+/4-pR19FGF8bwpre, RL1+/27+/4- 
pR19FGF2wpre or control virus (RLl+/27+/4-pR19GFPwpre). No endogenous 
expression of FGF8 (Figure 5-2C) or FGF2 (Figure 5-3C) was detectable from control 
samples. Significant levels of recombinant FGF8 and FGF2 were detected after 
infection with the respective constructs. Strong transgene expression was observed in 
neurospheres, while expression in neural progenitor cells was lower due to limited 
transduction efficiency in this cell system as discussed in chapter 3. However, 
considering the low concentration required for achieving biological effects (FGF8 was 
used before at concentrations of 50ng/ml and FGF2 at 20ng/ml), the virally produced 
proteins may be sufficient to study effects in primary neural progenitor cells.
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SFM C #1 #2 #3 #4
A. Purified clones
1764/27-/4-pR19FGF8b « * < * ■ »
30 kDa 
21 kDa
SFM C #1 #2 #3 #4 #5
RL1 +/27+/4-pRl 9FGF8b
30 kDa
21 kDa
B. 1764/27/4-pR19FGF8b  j "------ “-------"------ "
30 kDa
21 kDa1
C. RLl+/27+/4-pR19FGF8bwpre
1 2 3 4 5 6 7 8 9 10 11 12
30 kDa —
21 kDa —
Figure 5-2: W estern blot analysis confirmed expression o f virally delivered FGF8b in various 
cell systems. (A) Purified clones were tested for their expression o f FGF8 in virus growth 
complementing M 49 cells. C=control virus (B) BHK cells were infected with (1) 1764/27-/4- 
pR19LacZ, (2) SFM , or (3) to (5) 1764/27-/4-pR19FGF8b at an m.o.i. o f 5 and overlaid with 
SFM three days post infection. Supernatant of the infected BH K ’s was collected (3) 2h, (4) 6h 
and (5) 24h later, concentrated, the proteins separated on a 15% SDS-PAGE and blotted on a 
nitrocellulose membrane. (C) Expression after infection with R Ll+/27+/4-pR 19FG F8bw pre was 
also confirmed in (1) cell pellet o f BHK cells, (3) collected supernatant o f infected BHK’s, (5) 
cortical neural progenitor cells, (7) striatal neural progenitor cells, (9) m esencephalic neural 
progenitor cells and (11) striatal neurospheres. (2), (4), (6), (8), (10) and (12) are the respective 
cells infected with 1764/27-/4-pR19GFPwpre where no FGF8 expression was detected.
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A. Purified clones
1764/27-/4-pRl 9FGF2
RL1 +/27+/4-pR 19FGF2
SFM C #1 #2 #3 #4 #5
SFM  C #1 #2 #3 #4 #5
B. 1764/27/4-pRl 9FGF2 1 2 3 4 5
21 kDa “
C. RLl+/27+/4-pR19FGF2bwpre
1 2 3 4 5 6 7 8 9 10 11 12
Figure 5-3: W estern blot analysis confirmed expression o f virally delivered FGF2 in various cell 
systems. (A) Different purified clones were tested for their expression o f FGF2 in M49 cells. 
C=control virus (B) BHK cells were infected with (1) 1764/27-/4-pR19LacZ, (2) SFM , or (3) to 
(5) 1764/27-/4-pR19FGF2 at an m.o.i. o f 5 and overlaid with SFM three days post infection. 
Supernatant o f the infected BH K ’s was collected (3) 2h, (4) 6h and (5) 24h later, concentrated, 
the proteins separated on a 15% SDS-PAGE and blotted on a nitrocellulose membrane. (C) 
Expression after infection with R Ll+/27+/4-pR 19FG F2w pre was also confirmed in (1) cell 
pellet o f BHK cells, (3) collected supernatant o f infected BH K ’s, (5) cortical neural progenitor 
cells, (7) striatal neural progenitor cells, (9) m esencephalic neural progenitor cells and (11) 
striatal neurospheres. (2), (4), (6), (8), (10) and (12) are respective cells infected with 1764/27-/4- 
pR19GFPwpre where no FGF2 expression was detected.
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5.3.2.2 Virally delivered FGF2 and FGF8 induce neurite outgrowth in PC12 cells
FGF2 and FGF8 not only have mitogenic effects as discussed in previous chapters, 
but can also induce neuronal differentiation in cultures of rat PC 12 cells (Rydel and 
Greene, 1987; Tanaka et al., 2001). Neuronal differentiation is detectable by the 
formation of long and branched processes. This neurite outgrowth assay was used to 
confirm the bioactivity of virally produced FGF2 and FGF8 (Figure 5-4).
Infection of PC 12 cells with the highly and less disabled viral constructs resulted in 
rather low gene delivery at m.o.i’s between 1 to 30. In order to transduce about 50- 
70% of the cells an m.o.i. of about 300 was required as measured by GFP expression. 
Reporter gene expression using 1764/27-/4-pR19GFP was faint and difficult to 
document with the available system. However, even at these high multiplicities no 
cytotoxic effects compared to uninfected PC 12 cells were observed.
PC 12 cells infected with FGF2 and FGF8 expressing constructs began to evolve 
neurite processes three days post infection. On the other hand, positive controls 
containing recombinant proteins from the day of transduction had already formed 
long neurites at this time point. Most likely a threshold concentration of virally 
produced proteins was required to induce differentiation. Neural process formation 
continued until the experiment was terminated six days post infection. At this time 
point PC 12 cells infected with viral constructs expressing FGF2 or FGF8 had long 
and branched neurite processes. Control cultures that were uninfected or transduced 
with reporter gene expressing vectors did not show significant signs of differentiation.
Quantification of the neurite outgrowth showed a significant increase in process 
formation for cultures infected with FGF8 or FGF2 expressing vectors (p<0.001 
compared to controls). No statistical difference between virally and bacterially 
produced recombinant FGF8 and FGF2 was observed suggesting similar biological 
effects. Small statistical differences (p<0.05) between virally produced FGF8 and 
FGF2 and between the vector backbones may reflect differences in the expression 
level of the respective viral constructs.
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Hence, the neurite outgrowth assay confirmed that virally produced FGF8 and FGF2 
were bioactive and induced neuronal differentiation in the chosen system.
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1764/27-/4- RL1+/27+/4-
vFGF8 vFGF2 vGFP SFM rFGF8 rFGF2 vFGF8 vFGF2 vGFP SFM
Figure 5-4: Virally delivered FGF2 and FGF8 induce neurite outgrowth in PC12 cells. PC12 cells 
were infected with 1764/27-/4-pR19FGF8b, 1764/27-/4-pR19FGF2 or RL1+/27+/4-
pR19FGF8bwpre, RLl+/27+/4-pR19FG F2wpre. Negative controls were 1764/27-/4-pR19GFP, 
R Ll+/27+/4-pR19G FPwpre and SFM. As positive controls recom binant FGF8 (50ng/m l) and 
FGF2 (5ng/ml) were added every other day from the day o f infection. 6 days after infection the 
percentage of cells with processes longer than the cell diam eter was counted. Data represent the 
means of cells with neurite processes as percentage o f total cell number with SEM from three 
independent experiments. Virally delivered FGF8 (vFGF8) and FGF2 (vFGF2) significantly 
induced neurite outgrowth compared to GFP and SFM controls (p<0.001, n=3 experim ents in 
One-way ANOVA). Lower statistical differences were detected between vFGF8 and vFGF2 
(p<0.05; n=3 experiments in One-way ANOVA). The phase contrast images show the 
morphological differences resulting from infection with FGF8 and FGF2 expressing highly 
disabled constructs. No morphological changes were detected after transduction with GFP 
expressing control virus. Scale bar represents 50pm.
266
5.3.2.3 Virally delivered FGF2 and FGF8 have mitogenic effects on primary cortical
and mesencephalic neural progenitor cells
The previous chapter has shown that FGF8 and FGF2 are mitogens for the expansion 
of neural precursor cells in neurosphere cultures. In chapter 3 the population of neural 
progenitor cells was characterized and it was found that at early time points these 
cultures contain a population of undifferentiated nestin positive cells. The population 
of undifferentiated cells decreased over time in culture due to differentiation into post­
mitotic neural cell types. In order to establish if progenitor cultures can be maintained 
in a proliferative state, the potential mitogenic effects of virally delivered FGF8 and 
FGF2 were explored.
Neural progenitor cells derived from E l4 cortex and mesencephalon were infected on 
1 DIV with the less disabled constructs expressing either FGF8 or FGF2. Negative 
controls were infected with reporter gene expressing virus or SFM instead. To label 
the proliferating cells on 3-4 DIV progenitor cells were pulse labelled with BrdU 
(0.2/iM) for 12 hours. Immunocytochemical staining for BrdU were performed to 
detect cells that have incorporated the thymidine substitute and hence, were 
characterized as cells with DNA synthesis. To quantify the effects on proliferation the 
number of BrdU positive cells as percentage of total cell number was determined 
(Figure 5-5).
Virally delivered FGF8 and FGF2 significantly increased the number of BrdU 
incorporating cortical (p<0.01 for all vs. SFM in One-way ANOVA; n=3 independent 
experiments) and mesencephalic (p<0.05 for FGF8 vs. SFM, p<0.001 for FGF2 vs. 
SFM in One-way ANOVA; n=3 independent experiments) progenitor cells. 
Surprisingly, in uninfected cortical cultures about 30% of the cells incorporated BrdU 
despite the lack of exogenous growth factors. However, after delivery of FGF8 and 
FGF2 about 83% of the cells incorporated BrdU. Proliferative effects were more 
prominent in cortical than mesencephalic progenitor cultures. In mesencephalic 
progenitor cultures only 10% of the control cells were BrdU positive, an amount that 
could be increased by viral delivery of FGF8 and FGF2 to 45% and 67% respectively.
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Proliferative effects of FGF8 and FGF2 on progenitor cells were not only observed by 
BrdU incorporation but also demonstrated by an increased cell number in those 
cultures.
To ensure that BrdU incorporation resulted mainly from cell division, mitosis was 
inhibited in FGF2 and FGF8 infected cells by administration of the anti-mitotic drug 
cytosine-/3-D-arabinofiiranoside (Ara-C) (Figure 5-6). In the absence of Ara-C 
mitogenic effects of virally delivered FGF8 and FGF2 were observed as shown above. 
Addition of Ara -C completely abolished BrdU incorporation in cultures infected with 
control virus as well as with FGF8 or FGF2 expressing vectors. As Ara-C inhibits 
DNA synthesis (Kufe and Major, 1982), BrdU incorporation resulted most likely from 
cell division. By reversing the mitogenic effects of virally delivered FGF8 and FGF2 
it was therefore confirmed that the expressed proteins did indeed induce proliferation 
of progenitor cells that would otherwise differentiate into post-mitotic neural cell 
types.
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Figure 5-5: Virally delivered FGF8 and FGF2 increased BrdU incorporation in cortical and 
mesencephalic progenitor cells. Progenitor cells were infected with RL1+/27+/4- constructs 
expressing FGF8, FGF2 or as controls LacZ and SFM. Cells were pulse labelled with BrdU  
(0.2pM) for 12 hours three days after infection. Cells were fixed and stained for BrdU (Alexa 488, 
green) and cell nuclei stained with DAPI (blue). Data represent means o f BrdU incorporated cells 
as percentage o f total cells from three independent experim ents. Virally delivered FGF8 and 
FGF2 significantly increase the number o f BrdU positive cells in cortical (p<0.01 for FGF8 and 
FGF2 vs. SFM; p<0.05 for both vs. LacZ) and m esencephalic (p<0.05 for FGF8 vs. LacZ and 
SFM, p<0.01 for FGF2 vs. LacZ and p<0.001 for FGF2 vs. SFM ) progenitor cells.
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without AraC with AraC
RL1 +/27+/4-pRl 9FGF2wpre
RL1 +/27+/4-pRl 9FGF8bwpre
RL 1 +/27+/4-pR 19LacZwpre
Figure 5-6: Treatm ent with cytosine-fi-D-arabinoturanoside (Ara-C) abolished the mitogenic 
effects o f FGF8 and FGF2. E14 cortical progenitor cells w ere infected on 1 DIV and maintained 
in Neuobasal™ /B27 media. On 3 DIV cells were pulse labelled with BrdU (0.2pM) for 12 hours 
in the presence or absence o f Ara-C (20pM ). The cells were fixed and stained for BrdU (Alexa 
488, green). In the absence o f the anti-m itotic drug an increased number o f progenitor cells 
incorporated BrdU when infected with FGF8 and FGF2 expressing vectors. In parallel cultures 
BrdU incorporation was almost completely inhibited when Ara-C was present. Hence, 
increased BrdU incorporation most likely resulted from proliferative effects o f virally delivered 
FGF8 and FGF2.
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5.3.2.4 Characterization o f proliferating cells
In order to establish the nature of the proliferating cells the antigenic character was 
identified. Therefore, cortical and mesencephalic progenitors infected with FGF8 and 
FGF2 expressing vectors were BrdU pulse labelled and maintained in differentiation 
conditions for another five days before fixation. Immunocytochemical double 
labelling for BrdU/nestin or BrdU/GFAP was performed (Figure 5-7).
Most of the BrdU positive cells double labelled with the neurofilament marker nestin. 
This was observed for cortical and mesencephalic progenitor cells infected with either 
FGF8 or FGF2 expressing viruses. None of the cultures contained a significant 
number of GFAP positive cells confirming that the dividing cells did not represent 
astrocytes. This is in agreement with results obtained in chapter 3 showing that the 
culture conditions do not support proliferation or differentiation of astrocytes.
Hence, virally delivered growth factors maintained primary neural progenitor cells in 
a proliferative and undifferentiated fate. As identified in chapter 3, neural progenitor 
cells undergo differentiation into post-mitotic neural cell types in the absence of 
additional growth factors accompanied by a decrease in the number of nestin positive 
cells. Here it was demonstrated that this differentiation pathway could be overcome 
by virally delivered FGF8 and FGF2 that maintain the precursor cell population over 
an extended time in vitro. It has yet to be confirmed if the generated cell population 
remained susceptible to other inductive signals that might allow their guided 
differentiation into specific neural cell types. As previously discussed, neural 
progenitor cultures have a very narrow time frame during which they remain plastic to 
alteration of their cell fate. By inhibiting early differentiation the progenitor cultures 
have therefore become more useful for testing other factors involving their conversion 
into a dopaminergic phenotype.
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Figure 5-7: Characterization o f progenitor cells stimulated by virally delivered FGF8 and 
FGF2. Cortical (A, B, E, F) and m esencephalic (C, D, G, H) progenitor cells were infected with 
the less disabled viral constructs expressing FGF8 or FGF2. Five days post transduction cells 
were fixed and double stained for BrdU (Alexa 488, green) and nestin (Alexa 546, red) or BrdU 
and GFAP (Alexa 546, red). Virtually all BrdU positive cells co-labelled with nestin. Only a 
small number o f GFAP positive astrocytes (arrows) was detected in the cultures. 40x 
m agnification.
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5.3.2.5 Virally delivered FGF8 increases the number o f TH+ve neurons in
mesencephalic progenitor cultures
In the previous chapter it was shown that recombinant FGF8b exerts neurotrophic 
effects on primary post-mitotic dopamine neuroblasts and dopaminergic neurons 
grown as neurosphere cultures. In order to establish if similar effects could also be 
accomplished in primary mesencephalic cultures, the effects of virally delivered 
FGF8 in this cell system were studied.
E l4 ventral mesencephalic progenitor cells were infected with the less disabled 
vectors expressing FGF8b or FGF2 on 1 DIV. As controls parallel cultures were 
transduced with LacZ expressing vims or SFM only. In order to label newly generated 
dopaminergic neurons the cultures were pulse labelled with BrdU (0.2/zM) for 12 
hours on 3-4 DIV. Cells were fixed five days post transduction and stained for BrdU 
and TH. The number of TH+ve cells was determined as the percentage of total cell 
number from 20 different fields and the means calculated from three independent 
experiments (Figure 5-8).
Virally delivered FGF8 significantly increased the number of TH positive cells in 
mesencephalic progenitor cultures compared to cultures infected with FGF2 
expressing vims or controls (p<0.05 for FGF8 vs. all other treatments using One-way 
ANOVA, n=3 experiments). However, only an insignificant number of BrdU/TH 
double labelled cells was detected in either FGF8 infected progenitor cultures or any 
of the parallel treatments. This suggests that during the BrdU pulse (3-4 DIV) no cell 
division of dopamine neuroblasts occured in FGF8 cultures and hence, the increase of 
TH expressing cells is not the result of de novo generated dopaminergic neurons or an 
extended proliferation of dopamine neuroblasts. As discussed in the previous chapter 
the increased number is most likely due to trophic effects of virally delivered FGF8 
on post-mitotic dopaminergic neurons.
Although an increased cell proliferation was detected in FGF2 infected progenitor 
cultures, only very few TH positive neurons were double labelled with BrdU
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demonstrating that FGF2 did not extend the time of proliferation of dopamine 
neuroblasts. Other groups have previously reported that recombinant FGF2 can 
extend such dopamine proliferation and delay differentiation of the dopamine 
neuroblast (Bouvier and Mytilineou, 1995). However, Bouvier and Mytilineou used 
E12 mesencephalic progenitor cultures while the study here used E l4 ventral 
mesencephalon. Different embryonic ages used in the studies may explain the 
discrepancy.
Thus, the increased precursor proliferation did not correlate with enhanced dopamine 
neuron expansion or differentiation.
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Figure 5-8: Virally delivered FGF8 increases the number of dopam inergic neurons in 
mesencephalic progenitor cultures. E14 ventral mesencephalic progenitor cells were infected 
with SFM  or R L1+/27+/4- vectors expressing FGF8, FGF2 and LacZ on 1DIV. The number of 
TH positive cells as percentage of total cell numbers was determined from 20 different fields on 
6 DIV. The data represent the means from three independent experim ents. One-way ANOVA  
with Tukey’s post-hoc analysis revealed a significant increased number o f TH positive cells in 
cultures that were infected with FGF8 expressing vectors (p<0.05 vs. all other groups, n=3 
experim ents).
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5.3.2.6 Effects o f virally delivered FGF2 and FGF8 in neurospheres
Mitogenic effects of virally delivered FGF8 and FGF2 were tested in a BrdU 
incorporation assay after transduction of mesencephalic neurospheres (Figure 5-9). 
Increased cell proliferation was confirmed after transduction with viral vectors 
expressing FGF8 and FGF2. As shown for recombinant FGF8b in chapter 4, virally 
delivered FGF8 also induced proliferation of mesencephalic precursor cells (p<0.01 
for vFGF8 vs. vLacZ in One-Way ANOVA, n=3 experiments). The rather small 
proliferative effect observed for virally delivered FGF8 was most likely due to the 
absence of heparin in the culture conditions. As discussed before, the mitogenic 
activity of FGF8 strongly depends on the presence of heparin. However, heparin 
inhibits viral transduction and was therefore omitted in this experiment. As FGF2 is a 
potent mitogen even in the absence of heparin, significantly more mesencephalic 
precursor cells responded after transduction with viral vectors expressing FGF2.
Interestingly, it was observed that dissociation of FGF8 infected neurospheres into 
single cells and maintenance under differentiation conditions gave rise to more GalC 
positive oligodendrocytes than FGF2 infected precursors or controls (Figure 5-9B). 
This observation corresponds to results from the previous chapter showing a shift 
towards the generation of more oligodendrocytes in FGF8 expanded mesencephalic 
neurosphere cultures. It has previously been shown that FGF8 mainly transduces via 
FGFR3IIIc in neural precursor cells (Hajihosseini and Dickson, 1999) and its 
activation also plays crucial roles in oligodendrocyte development (Oh et al., 2003b). 
Thus, it is possible that virally delivered FGF8 did indeed support development of 
oligodendroglial progenitor cells. However, as this observation was not relevant to 
the study, such effects remained unquantified, although they could be of interest in the 
future.
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Figure 5-9: Effects o f virally delivered FGF8 and FGF2 in m esencephalic neurospheres. (A) E14 
mesencephalic neurospheres were infected with SFM or highly disabled backbone 1764/27-/4- 
expressing FGF8, FGF2 or LacZ. Three days post transduction neurospheres were pulse labelled 
with BrdU (0.2pM ) for 12 hours, dissociated and plated on substrate coated glass cover slips. 
Cells were fixed after attachment and stained for BrdU. The num ber o f BrdU positive cells as 
percentage o f total cell number was determined from 20 different fields. Data represent means 
with SEM from three independent experiments. Significant increase o f cell proliferation was 
detected for vFGF8 (p<0.01 vs. LacZ and p<0.05 vs. SFM ) and vFGF2 (p<0.001 vs. LacZ and 
SFM). (B) Neurospheres infected and dissociated as described above were stained for GalC  
(Alexa 546, red) and cell nuclei stained with Hoechst (blue). A high number o f oligodendrocytes 
was detected in FGF8 infected me*NS. lOx m agnification.
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5.3.3 The effects of virally delivered ShhN in primary neuronal cultures and 
neurospheres
5.3.3.1 Construction of HSV-1 vectors expressing ShhN
Conversion of Shh into an active form requires multiple posttranslational modification 
steps and distinct secretion pathways (Figure 5-10A). Shh (45kDa) is produced as an 
inactive precursor protein which converts itself by autocatalytic internal cleavage 
(Porter et al., 1995; Bumcrot et al., 1995; Lee, 1998) into an active aminoterminal 
molecule, the 19kDa NH2-terminal domain of sonic hedgehog (ShhN, residue 25-198) 
mediating all signaling activities in vertebrates and invertebrates (reviewed by 
Hammerschmidt, 1997), and a 25kDa C-terminal protein (ShhC) that possesses 
protease activity (Porter et al., 1995; Porter et al., 1996a). ShhN is further modified by 
cholesterol attachment at its COOH-terminal (Porter et al., 1996a; Porter et al., 1996b) 
and addition of a palmitolyl group to the N-terminal of the processed ShhN (Porter et 
al., 1996a; Pepinsky et al., 1998; Chamoun et al., 2001). These posttranslational 
modifications play critical roles in Shh signaling and increase the inductive potency of 
ShhN (Marti and Bovolenta, 2002). Processed ShhN can remain in the cell membrane 
in bound form, with affinity to extracellular matrix glycoproteins such as vitronectin 
enhancing Shh activity (Pons and Marti, 2000), or secreted in a soluble form (Porter et 
al., 1996a). Secreted ShhN can form disulfide bonds that also affect its biological 
activity (Saeki et al., 2000) and due to its lipophilic modifications soluble ShhN can 
multimerize with itself (Zeng et al., 2001). The distinct biological functions reported 
for ShhN as morphogen, mitogen, survival factor or axonal guidance factor (reviewed 
by Marti and Bovolenta, 2002) may likely resemble those different forms available 
during development and adulthood.
Viral vectors were generated expressing the bioactive aminoterminal part of rat Shh 
(ShhN). Therefore, PCR primers were designed amplifying the openreading frame to 
produce a protein encompassing the first 198 amino acids of rat ShhN (Gene Bank 
accession number AF162915) by introducing an artifical stop codon after nucleotides
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908. The sequence of the generated cDNA including the introduced stop codon was 
confirmed by sequencing and is attached in the appendix. After subcloning into the 
pR19 expression cassettes the generated plasmids, pGEM-5pR19ShhNLAT and 
pGEM-5pR19ShhNwpreLAT, were co-transfected with viral DNA from 1764/27-/4- 
pR19GFPLAT or RLl+/27+/4-pR19GFPwpreLAT, respectively. Recombinant 
plaques were visualised under the fluorescent microscope by the absence of GFP 
expression, purified and were named 1764/27-/4-pR19ShhN or RL1+/27+/4- 
pR19ShhNwpre, respectively. Expression of ShhN from different clones was 
confirmed by western blotting on virus growth complementing 27/12/M:4 cells as 
described above for FGF8 and FGF2 expressing vectors. Selected clones were 
propagated to high titer stocks.
Expression and secretion of virally delivered ShhN was tested on non-complementing 
BHK cells (Figure 5-1 OB) after infection with ShhN expressing constructs. As 
described above, the expression of ShhN was analysed from cell-associated and 
supernatant samples on denaturating SDS-PAGE. Western blotting confirmed that 
ShhN was expressed in BHK cells and released into the supernatant. Soluble ShhN 
accumulated in the supernatant as increased amounts of protein were detected over 
time. The virally produced ShhN ran at about 21 kDa, slightly larger than the 
predicted molecular weight of 19kDa. However, this was in agreement with 
observations from other groups showing a molecular weight of 20 to 24 kDa on SDS 
PAGE under reducing conditions (Katsuura et al., 1999; Saeki et al., 2000).
The western blotting revealed an interesting finding. Supernatant samples contained 
two additional bands of ShhN protein, one that ran slightly faster than the main band 
and another that ran significantly slower at about 44 kDa. These additional bands 
were only found for secreted ShhN but not in samples generated from the respective 
cell pellet suggesting that ShhN must have been further modified after secretion. The 
smaller protein band was detected at all time points taken, while the larger protein 
band only appeared at the latest time point when a large amount of recombinant 
protein had accumulated in the supernatant. The faster running band was unlikely the 
result from cholesterol addition as it was not detected in cell-associated samples. It 
has been reported that soluble ShhN can form disulfide bonds between the three
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cysteine residues (Cys-25, Cys-103, Cys-184) within its N-terminal form that result in 
a pattern of shifted bands (Saeki et al., 2000). Although denaturing conditions were 
used, insufficient reduction may explain the small amount of this faster migrating 
protein band. The larger band is most likely due to multimerisation of ShhN as has 
previously been shown for soluble ShhN (Zeng et al., 2001). Despite its two lipophilic 
modifications ShhN is soluble in an aqueous environment and this is most likely to be 
possible by binding additional proteins to bury its hydrophobic moieties. This could 
also explain why agglomerates of ShhN were only found at high protein 
concentrations.
The expression of ShhN from the less disabled RL1+/27+/4- constructs was also 
confirmed in non-complementing cell systems. ShhN was expressed and secreted by 
RLl+/27+/4-pR19ShhNwpre in BHK cells showing the same additional bands in 
samples generated from concentrated supernatant as mentioned above. Infection of 
primary ventral mesencephalic neural progenitor cells with RL1+/27+/4- 
pR19ShhNwpre also confirmed expression while no detectable ShhN was found in 
control infected cultures. Strong expression of ShhN was also demonstrated in 
mesencephalic neurospheres after infection with the construct.
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Figure 5-10: Western blot analysis confirmed expression of virally delivered ShhN in various cell 
systems. (A) Shh processing as described in text. (B) BHK cells were infected with (1) 1764/27-/4- 
pR19LacZ, (2) SFM , or (3) to (5) 1764/27-/4-pR19ShhN at an m.o.i. o f 5 and overlaid with SFM  
three days post infection. Supernatant of the infected BH K’s was collected (3) 2h, (4) 6h and (5) 
24h later. ShhN was found to be expressed in the cell pellet and supernatant. W estern blotting of 
supernatant protein contained two additional bands. The sm aller band (arrow) represents most 
likely secreted forms o f protein that formed disulfide bonds, while the larger band (45kDa) 
contained agglomerated multimers. (C) Expression after infection with RL1+/27+/4- 
pR19ShhNwpre was also confirmed in the supernatant of infected BH K ’s, m esencephalic neural 
progenitor cells and m esencephalic neurospheres. C=infection with control virus RL1+/27+/4- 
pR19GFPwpre.
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5.3.3.2 Virally delivered ShhN induces differentiation of C3H10T1/2 fibroblasts into 
osteoblasts
Bioactivity of produced ShhN has often been assessed by the activity of alkaline 
phosphotase (AP) in the mouse fibroblast cell line C3H10T1/2 (Kinto et al., 1997; 
Howard et al., 1998; Williams et al., 1999; Saeki et al., 2000; Zeng et al., 2001). The 
cell line provides a simple system for determining ShhN function without the 
complication of having to work with primary cell cultures or organ explants. 
C3H10T1/2 cells are ShhN-responsive as assessed by induction of alkaline 
phosphatase (AP), a marker of mature, differentiated osteoblasts (Williams et al., 
1999).
C3H10T1/2 cells were infected with ShhN or GFP expressing viral constructs based 
on 1764/27-/4- or RL1+27+4- backbone and differentiated in reduced serum 
conditions for five days. The AP assay was performed resulting in a deep purple stain 
in cells with AP activity (Figure 5-11).
Strong AP activity was determined in C3H10T1/2 cells with ShhN expressing 
constructs, while no activity was observed in the control cultures. The purple 
precipitate was mainly localised throughout the cytoplasm of the cells and 
significantly less abundant in the nucleus.
The experiment has confirmed that virally delivered ShhN is bioactive by inducing 
differentiation of C3H10T1/2 cells into osteoblasts, characterized by the activity of 
alkaline phosphatase.
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Figure 5-11: Assay for alkaline phosphatase (AP) confirm ing bioactivity o f virally delivered  
ShhN. M ouse fibroblast C3H10T1/2 cells were infected at an m.o.i. o f 3 with 1764/27-/4- 
pR19ShhN, RLl+/27+/4-pR19ShhNwpre or the respective control viruses expressing GFP. 
Cells were maintained for five days in DM EM /3%  FCS and AP activity determined using a 
histochemical AP kit (Sigma). AP activity is visible as a deep purple precipitate. Cells infected  
with ShhN expressing vectors showed AP activity, while no activity was found in control 
cultures. Inset shows localisation o f the stain predom inantly in the cytoplasm o f ShhN treated  
cells. Consequently, virally delivered ShhN did induce differentiation o f C3H10T1/2 cells into 
AP positive osteoblast and thus, is bioactive. Scale bar represents 50pm.
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5.3.3.3 Virally delivered ShhN has no significant effects in primary neuronal 
cultures and neurospheres
The previous chapter has shown that recombinant ShhN is neurotrophic for midbrain 
dopaminergic neurons cultured as neurospheres when present during the expansion 
phase. The work presented here tried to investigate if virally delivered ShhN exerts 
similar effects in primary midbrain dopaminergic neurons.
E14 midbrain dopaminergic neurons were infected with either SFM or less disabled 
vectors expressing ShhN or LacZ. Five days post-transduction the number of 
dopaminergic neurons was determined (Figure 5-12A) for the different treatments. No 
significant difference in the number of TH expressing cells was determined in the 
presence of virally expressed ShhN. This is surprising and opposed to findings of 
other groups clearly showing trophic effects of ShhN on TH survival of primary 
midbrain dopaminergic neurons generated from the same gestational age (Miao et al., 
1997b). That study showed that ShhN concentrations of above 25ng/ml significantly 
delayed dopaminergic cell death and rescued an increased amount of TH expressing 
cells after one week in culture. However, lower concentrations of ShhN did not have 
this trophic effect and apparently a threshold of protein needs to be present to 
facilitate the effect. For this reason it is possible that the expression levels from the 
vector were not sufficient to achieve the desired survival effect on dopaminergic 
neurons.
As potential roles of ShhN on dopamine development from neural precursor cells 
were studied in the previous chapter, it was now determined if virally delivered ShhN 
alters the cell fate of precursor cells grown as neurospheres. Since the role of Shh on 
oligodendrocyte specification has been well established (Marti and Bovolenta, 2002), 
the amount of 04 positive cells was quantified after infection of cortical neurospheres 
(Figure 5-12B). No significant differences in the percentage of 04 positive 
oligodendrocytes could be detected compared to controls. The total cell number also 
seemed unaffected by virally delivered ShhN suggesting that it did not have obvious 
mitogenic effects on neural precursor cells as has been found for embryonic
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development (Britto et al., 2000), and also reported for adult hippocampal neural 
precursor cells (Lai et al., 2002). The previous chapter also suggested that 
recombinant ShhN had no significant proliferative effects on forebrain or midbrain 
neural precursor cells under the culture conditions used. No apparent changes in the 
amount of GFAP positive astrocytes or TuJl positive neurons were observed when 
ShhN was delivered to mesencephalic neurospheres (Figure 5-12).
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Figure 5-12: Effects o f virally delivered ShhN in neural progenitor cells and neurospheres. (A) 
TH survival in primary E14 mesencephalic cultures after infection with R Ll+/27+/4-pR 19ShhN  
or the respective control virus expressing LacZ. No significance differences in the number of 
TH positive cells were noted in One-way ANOVA. (B) Cortical neurospheres were infected 
with RLl+/27+/4-pR19ShhN and differentiated for five days in the absence of growth factors. 
The number o f 0 4  positive cells was determined in a m igration assay. One-way ANOVA did 
not reveal significant differences in the num ber o f 0 4  positive cells (p>0.05). (C) Infection of 
mesNS with 1764/27-/4- based vectors expressing ShhN, FGF2 or LacZ. Infected neurospheres 
were dissociated after infection, plated on poly-L-lysine/Lam inin coated glass coverslips and 
differentiated for five days. Im munocytochem ical staining for GFAP (Alexa 546, red) and TuJ 
(Alexa 488, green) did not show obvious differences in the am ount of astrocytes or neurons 
generated after infection with viral vectors expressing ShhN, FGF2 or LacZ. Cell nuclei were 
stained for DAPI (blue).
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5.3.4 The effects of virally delivered Nurrl in primary neuronal cultures and 
neurospheres
5.3.4.1 Construction of HSV-1 vectors expressing Nurrl
The gene encoding for Nurrl was amplified from rat cDNA by PCR and subcloned 
into the viral expression cassettes generating the plasmid pGEM-5pR19NurrlLAT or 
pGEM-5pR19NurrlwpreLAT. Recombinant viruses were generated by insertion of 
the respective cassettes into the LAT region of highly disabled vectors, generating 
1764/27-/4-pR19Nurrl, or the less disabled backbone, creating RL1+/27+/4- 
pR19Nurrlwpre.
The expression of Nurrl was confirmed by western blot analysis (Figure 5-13). The 
Nurrl protein ran on 15%SDS PAGE with an approximate molecular weight of 
66kDa which is in agreement with the predicted molecular weight (Law et al., 1992). 
As expected Nurrl proteins remained cell-associated and were not secreted into the 
supernatant of infected non-complementing BHK cells. Nurrl expression was also 
confirmed in neurosphere cultures derived from mesencephalic, cortical or striatal 
regions after transduction with RLl+/27+/4-pR19Nurrlwpre. Control infections did 
not express Nurrl.
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Figure 5-13: W estern blot analysis confirmed expression o f virally delivered N urrl in various 
cell systems after infection with R L l+/27+/4-pR 19N urrlw pre. (A) Purified clones of 
R L l+/27+/4-pR 19N urrlw pre were tested for their expression o f N urrl in virus growth 
complementing M49 cells. C=control virus. (B) Infection of BH K cells detected N urrl protein  
exclusively in the cell pellet but not in the supernatant. Expression could also be confirmed 
after infection of cortical, striatal and mesencephalic neurospheres. Arrows indicate protein 
band of N urrl.
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5.3.4.2 Nurrl does not induce TH expression in primary neuronal cultures
As characterized by immunogenic markers in chapter 3 neural progenitor cells 
derived from E14 cortex and striatum do not express TH. It has previously been 
shown that retrovirally delivered Nurrl could induce TH expression in hippocampal 
derived progenitor cells independent of proliferation, survival or differentiation 
effects, but most likely due to direct activation of the TH gene by binding to cis-acting 
response elements within the TH promoter (Sakurada et al., 1999). Indeed it has been 
confirmed that three binding sites are responsible for induction of TH expression by 
Nurrl, but that TH activation remains cell type dependent (Kim et al., 2003b). This 
seems to be in agreement with earlier studies demonstrating that although Nurrl is 
sufficient to induce TH expression in a neural stem cell line, other factors most likely 
secreted by co-cultured type 1 astrocytes are required for this function (Wagner et al., 
1999). In order to establish if Nurrl can induce ectopic TH expression the effects of 
virally delivered Nurrl in primary neural progenitor cultures were examined.
Here neural progenitors from cortex, striatum and mesencephalon were used at early 
stages as they previously had been identified as containing undifferentiated nestin 
positive cells. Progenitor cells were infected on 1 DIV with the less disabled construct 
expressing Nurrl and fixed five days post transduction. Immunocytochemical staining 
for TH was performed and the number of TH positive cells determined for 
mesencephalic cultures (Figure 5-14).
Neither control cultures nor Nurrl infected cortical or striatal progenitor cells 
contained any TH expressing cells. Thus, virally delivered Nurrl did not induce any 
TH expression in these cell types under the chosen conditions. No evident changes in 
the number of TuJl positive neurons were observed. No significant number of GFAP 
positive astrocytes was detected in any of the cultures which is in agreement with 
previous findings discussed in chapter 3.
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Quantification of TH positive cells in mesencephalic cultures also did not reveal a 
significant increase in the number of dopaminergic neurons in Nurrl infected 
treatments compared to controls.
The experiment has therefore shown that virally delivered Nurrl does not result in a 
gain-of-function, i.e. TH expression, in neural progenitor cultures. As under the 
chosen conditions these cultures are neuron enriched and contain virtually no 
astrocytes, other factors that are required for the function of Nurrl may be missing 
under these culture conditions. For this reason, Nurrl mediated TH induction was 
next studied in a culture system that contains a large number of astrocytes and 
oligodendrocytes, i.e. neurospheres.
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Figure 5-14: Effects o f virally delivered N urrl in neural progenitor cultures. E14 cortical, striatal 
and mesencephalic progenitors were infected with R L l+/27+/4-pR 19N urrl or the LacZ version, 
respectively. Five days post transduction cells were fixed and stained for TH (Alexa 546, red). (A) 
Quantification of the number o f TH positive cells did not show significant differences (p>0.05 in 
One-way ANOVA; n=3 experiments). (B) Infection with R Ll+/27+/4-pR 19N urrl did not induce 
TH expression in cortical and striatal progenitor cells. 40x magnification.
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5.3.4.3 Nurrl induces TH expression in neurospheres generated from different 
regions of the CNS
As discussed previously, neurospheres generated from cortical and striatal precursor 
cells do not generate TH positive cells and only an insignificant number of 
dopaminergic neurons can be maintained from mesencephalic neurosphere cultures 
expanded in FGF2. Therefore, neurospheres represent an ideal system to perform 
gain-of-function studies. In order to establish if Nurrl can induce TH expression in 
the presence of glial cell types the effects of virally delivered Nurrl in neurospheres 
was examined.
Neurospheres generated from E l4 cortex, striatum and ventral mesencephalon were 
expanded in FGF2 prior to transduction with RL1+/27 +/4-pR 19Nurr 1 wpre or 
controls. As proliferation of neural progenitor cells has been demonstrated to be 
important for the generation of TH expressing cells (Wagner et al., 1999), Nurrl 
infected neurospheres were maintained in growth factor containing media for one day 
post transduction. Thereafter neurospheres were induced to differentiate by 
withdrawal of FGF2 for five days. Cells were characterized for TH expression by 
immunocytochemistry or western blot analysis performed as shown in Figure 5-15.
No TH expression was detected by immunocytochemistry or immunoblotting in 
uninfected neurospheres or after infection with control virus RL1+/27+/4- 
pR19GFPwpre. However, a significant number of TH expressing cells was detected in 
cortical and striatal neurospheres infected with Nurrl expressing virus. As 
mesencephalic neurospheres can contain TH expressing dopaminergic neurons an 
increase of induction was difficult to assess by immunocytochemical staining. Since 
enzyme treatment and trituration may cause cell death and hence, loss of TH 
expressing cells, it was decided not to dissociate the neurospheres into single cells for 
quantification. Instead western blot analysis was performed confirming an 
upregulation of TH expression in cortical, striatal and mesencephalic neurospheres 
when infected with the Nurrl expressing virus.
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Figure 5-15: Virally delivered N urrl induces TH expression in neurospheres. (A) E14 derived and 
in FGF2 expanded neurospheres from cortex, striatum and ventral mesencephalon were infected 
with RLl+/27+/4-pR 19Nurrl or RLl+/27+/4-pR 19LacZ. One day post infection growth factors 
were withdrawn and neurospheres were plated on PLL/Laminin coated coverslips and 
differentiated for five days. Cells were stained for TH (Alexa546, red). Neurospheres infected with 
N urrl expressing virus induced TH expression in neurospheres of all three neurogenic regions 
while controls did not contain TH expressing cells. Quantification by western blotting confirmed 
N urrl mediated TH induction in neurospheres. Scale bar represents 50pm. (B) TH induction is cell- 
context dependent as N urrl infection did not induce TH expression in BHK or 293 cells.
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Since the data had not yet confirmed if TH upregulation is cell type dependent or if 
Nurrl unspecifically upregulates TH expression independent from the cell context, 
BHK cells and 293 cells were infected with Nurrl expressing virus or control virus. 
Western blotting for TH (Figure 5-15B) did not reveal an induction of TH expression 
in these cell types.
This gain-of-function study has demonstrated that virally delivered Nurrl can 
significantly induce TH expression in a culture system containing a mixture of neural 
precursor cells, including neurons, astrocytes and oligodendrocytes. The induction of 
TH seems to be restricted to the tested neural precursor cells and hence, likely 
depends on the cell-context. Since ectopic TH expression does not necessarily imply 
that bona fide dopaminergic neurons have been generated, the nature of the TH 
expressing cell was characterized next.
5.3.4.4 Characterization of TH expressing cells
It was observed that Nurrl mediated TH upregulation depended on the presence of 
proliferating conditions during infection as transferring infected neurospheres 
immediately into growth factor free culture conditions produced a reduced number 
TH expressing cells. This has also been described by others showing that infection of 
differentiated precursor cells with Nurrl expressing constructs did not have any 
inductive effects (Kim et al., 2003a). To study if TH expressing cells have been 
generated de novo or if TH is upregulated in post-mitotic neural cell types, Nurrl 
infected cortical neurospheres were BrdU pulse labelled during the first 24 hours after 
infection.
Immunocytochemical staining (Figure 5-16) confirmed that most of the TH 
expressing cells had incorporated BrdU and have therefore been generated from a 
proliferating precursor cell population. Differentiation into post-mitotic cell types 
appeared to occur after induction of TH expression in the cells. However, TH 
induction was not completely abolished when cell proliferation was inhibited in the 
presence of Ara-C (20/xM) from the day of Nurrl infection (data not shown). This
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suggests that proliferation conditions during the infection phase are beneficial but not 
essential for Nurrl-mediated TH induction.
Nurrl-induced TH positive cells exhibited two distinct morphologies: (i) TH positive 
cells often arranged in clusters of mainly rounded cells with short processes (Figure
5-16) and (ii) as single TH positive cells with large cell body bearing usually 2-3 
processes. However, the cell morphology of TH expressing cells did not resemble 
those of dopaminergic neurons generated from primary progenitor cultures. Indeed it 
was found by immunocytochemical staining that most of the TH expressing cells did 
not co-label with the neuronal marker TuJl. Instead the majority of the TH expressing 
cells double labelled with nestin, some strongly while others revealed only a weak 
immunoreactivity for the neurofilament marker (Figure 5-16). Thus, the TH 
expressing cells may still be immature and longer differentiation periods may be 
necessary to acquire a fully mature neuronal cell fate. Antibody incompatibility did 
not allow double labelling for TH and GFAP.
Other studies have shown that ascorbic acid during culture period after Nurrl 
transduction can significantly increase the number of TH positive cells (Kim et al., 
2003a). TH expression of Nurrl infected cortical neurospheres that were 
differentiated in the presence or absence of ascorbic acid (200/xM) was quantified by 
western blot analysis (Figure 5-16). TH expression was significantly upregulated in 
the presence of ascorbic acid. These data suggest that AA acts in additive fashion on 
the Nurrl-induced generation of TH positive cells.
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Figure 5-16: Characterization o f N urrl-induced TH expressing cells. (I) BrdU pulse labelling 
(0.2pM for 12h) revealed a high number o f de novo generated TH expressing cells. (II) 
Immunocytochemical staining of N urrl infected ctxNS showed TH expressing cells (Alexa 546, 
red) often occurring in clusters (A, arrow). However, only a few of the TH expressing cells co­
label with the neuronal marker T u Jl (Alexa 488, green) (B, arrow). M ost o f the cells show low 
reactivity for nestin (C, D arrow). (I ll)  Incubation with AA o f ct*NS infected with RL1+/Nurrl 
further increases TH expression as shown by western blot analysis.
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5.3.5 Unaltered behavioural impairment of virally delivered ShhN and FGF2 in
6-OHDA lesioned animals
Effects of recombinant ShhN protein on behaviour improvement has previously been 
tested in 6-OHDA (Tsuboi and Shults, 2002) and MPP+ (Dass et al., 2002) animal 
models of Parkinson’s disease. Tsuboi and Shults showed that repeated striatal 
administration of ShhN prior to injection of 6-OHDA into the striatum could reduce 
apomorphine and amphetamine induced rotations comparable to the effects of GDNF 
used as positive control in that study (Tsuboi and Shults, 2002). Surprisingly, only 
low concentrations of recombinant ShhN had a beneficial effect on behavioural 
impairment while high concentrations did not significantly decrease drug-induced 
rotations. Behavioural improvement was accompanied by an increased density of TH 
fibers in the respective groups but did not preserve the loss of dopaminergic neurons 
in the substantia nigra. As mentioned in the previous chapter, Shh appears to play a 
continuous role in the stem cell niche of the adult SVZ. While removal of Shh 
signalling significantly reduced the number of neural progenitors in the postnatal SVZ 
(Machold et al., 2003), striatal administration of ShhN protein increased the 
transcription levels of its receptor, patched, in the SVZ. However, this was without 
altering the proliferation or differentiation of SVZ precursor cells (Charytoniuk et al.,
2002). These studies support the idea that the Shh signalling pathway may be 
activated in vivo in the adult rodent SVZ.
In order to establish if ShhN and FGF2 can improve behavioural impairment in 6- 
OHDA lesioned animals the effects of virally delivered factors was established. By 
delivering the FGF2 expressing virus it was intended to increase proliferation of 
endogenous precursor cells residing in the SVZ as has been demonstrated e.g. by 
intrastriatal administration of TGF-a (Fallon et al., 2000). With respect to a potential 
role of ShhN on the adult neural stem cell niche, it was anticipated that a combination 
of proliferating signals (FGF2) and inductive/differentiation clues (ShhN) may reduce 
behavioural impairment in this animal model of PD.
297
A severe depletion of dopaminergic neurons was induced unilaterally by injection of 
free base 6-OHDA (12.5fig) into the medial forebrain bundle. This acute chemical 
lesion resulted in a profound loss of dopaminergic neuron cell bodies in the substantia 
nigra and of their axons projecting into the striatum (Figure 5-17B). The loss of 
dopaminergic neurons was measured by apomorphine induced rotation behaviour 
using an automatic Rotorat™ system (Med Associates Inc.) to determine the number 
of fully completed contralateral rotations assessed over a 30min period after drug 
administration (0.5mg apomorphine per kg, s.c.). Animals rotating with more than 5 
tums/min have more than 80% of the dopaminergic neurons lost (Ungerstedt, 1971b) 
and were selected for the experiment. As the rotational impairment varied over the 
first weeks after the 6-OHDA injection, rotational behaviour was determined every 
two weeks over a period of six weeks until animals showed stable rotational 
behaviour. Animals were grouped such that each group contained the same number of 
animals with increased rotations (more than 8 rotations/min) and animals with less 
profound degeneration (between 5 and 8 rotations/min). Each group (n=8 animals) 
performed the same number of total rotations/min prior to viral injection. 5xl05PFU 
of viral vectors were injected into the striatum ipsilateral to the 6-OHDA lesion. 
Groups were injected either with FGF2 expressing vector (1764/27-/4-/pR19FGF2), 
the ShhN expressing construct (1764/27-/4-pR19ShhN), a mixture of FGF2 and ShhN 
expressing vectors or with control virus expressing LacZ (1764/27-/4-pR19LacZ). 
Apomorphine induced rotational behaviour was determined every two weeks over a 
total period of 12 weeks (Figure 5-17).
None of the groups showed a significant improvement (p>0.05 compared to 1764/27- 
/4-pR19LacZ) in behavioral impairment over the tested period. Although 
administration with ShhN expressing vectors decreased the number of rotations within 
the first two weeks after virus injection, the trend was not maintained but actually 
reversed twelve weeks after inoculation. Analysis of the rotational behaviour of single 
animals rather than the entire group also did not reveal any potential beneficial effects 
of the administrated viral vectors.
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Figure 5-17: Effects o f virally delivered FGF2 and ShhN on rotational behaviour after 6- 
OHDA lesion. (A) In the animal model o f PD an acute lesion o f the nigrostriatal pathway was 
induced by injection o f 6-OHDA into the medial forebrain bundle. Apom orphine induced 
rotational behaviour was monitored with an autom atic Rotorat® system. (B) 
Im munohistochem ical staining for TH shows depletion o f dopam inergic neurons in the SN. 
(C) Apom orphine induced rotational behaviour o f 6-OHDA lesioned animals after 
intrastriatal injections o f highly disabled 1764/27-/4- expressing FGF2, ShhN, FGF2 and 
ShhN or LacZ. No im provem ent o f rotational im pairment was observed.
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The experimental rationale was tested by injecting viral vectors expressing glial 
derived neurotrophic factor (GDNF) (1764/27-/4-pR19GDNF) into the striatum of 6- 
OHDA lesioned animals four weeks after depletion of the nigrostriatal pathway 
(Figure 5-18). GDNF has been well established to improve behavioural impairment in 
this animal model by administration either prior or post 6-OHDA lesion (reviewed by 
Bjorklund et al., 2000). Indeed a significant improvement in apomorphine induced 
contralateral rotational behaviour was observed with the GDNF expressing vector two 
weeks after virus injection (p<0.05 vs. LacZ expressing vector in two-paired t test; 
n=6 animals). However, the improvement decreased over time and was less prominent 
6 weeks post virus administration.
Intrastriatal delivery of FGF2 expressing virus was also tested for any ability to 
increase cell proliferation. Unlesioned animals were either injected with 1764/27-/4- 
pR19FGF2 or 1764/27-/4-pR19LacZ (n=4 animals per treatment) and BrdU 
(lOOmg/kg; i.p.) over a period of six consecutive days. Immunohistochemical staining 
revealed an increased number of BrdU positive cells in the striatum of FGF2 injected 
animals, but no profound increase in control animals. The striatum of the FGF2 group 
also contained a large number of nestin positive cells. Interestingly, a significantly 
increased number of BrdU positive and nestin positive cells were also found in the 
substantia nigra of FGF2 injected animals. BrdU positive cells were only observed 
ipsilateral to the injection site and not in the control group injected with LacZ 
expressing vector. It has previously been shown that the less disabled vector used in 
this experiment efficiently expresses transgenes in the substantia nigra after 
intrastriatal injections (Lilley et al., 2001). Retrograde transport of the virus into the 
cell body of dopaminergic neurons after infection of striatal terminals make this 
vector particularly amenable for gene delivery to the substantia nigra. Hence, 
overexpression of FGF2 in the substantia nigra may have induced cell proliferation in 
this region. However, immunohistochemical doublestaining for BrdU and GFAP, 
nestin or TuJl failed to identify the antigenic character of the generated cells.
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5.4 Discussion
In an attempt to examine the roles of selected factors on the induction of TH 
expressing dopaminergic phenotypes from neural precursor cells, disabled HSV-1 
were constructed delivering FGF2, FGF8, ShhN and Nurrl, respectively. Under 
defined, serum-free conditions their function was studied in two in vitro cell models, 
glial deprived neural progenitor cultures or glial containing neurosphere cultures. 
Selected vectors were tested in an animal model of Parkinson’s disease.
Virally expressed FGF2 and FGF8 maintain progenitor cells in a proliferative state
Virally delivered FGF2 and FGF8 were expressed, posttranslationally modified and 
bioactive as demonstrated by inducing differentiation of PC 12 cells. In neural 
progenitor cells the virally delivered factors induced proliferation of the otherwise 
post-mitotic neuronal cell population and FGF8 additionally exerted survival effects 
on primary midbrain dopaminergic neurons. The neurotrophic effects of FGF8 on 
primary mesencephalic progenitor cultures further confirmed data presented in the 
previous chapter suggesting selective effects on dopamine neurons generated from 
neurospheres. However, virally delivered FGF2 did not increase the number of 
dopaminergic neurons as previously demonstrated by others suggesting increased 
proliferation of E l2 dopamine neuroblasts (Bouvier and Mytilineou, 1995) and 
survival of E l5 primary dopaminergic neurons (Engele, 1998a). Daadi and Weiss
(1999) even suggested inductive effects on de novo generation of dopaminergic 
neurons from E14 cortical and striatal progenitor cells mediated by FGF2. However, 
with 0.31% of the total striatal cell population expressing TH this appears to be a 
rather rare event and significant TH expression in cortical and striatal progenitor cells 
could only be induced by synergistic effects of FGF with media conditioned by 
astrocytes. Further the synergistic effects of FGF2 and the conditioned media (CM) 
depended on the time point of availability as supplementation 24 hours after plating 
did not exert significant TH induction (Daadi and Weiss, 1999). TH induction was not 
found in any of the forebrain cultures following delivery of FGF2 or FGF8. Since the 
chosen serum-free culture conditions did not support proliferation or differentiation of
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astrocytes, the inductive factors released by glia cells may simply not be present in the 
culture conditions. Indeed it was shown by immuncytochemistry that virally delivered 
FGF2 and FGF8 maintain a dividing population of undifferentiated, nestin positive 
cells but had no effects on gliogenesis. As the promoter constructs used in this study 
did not allow regulated gene expression, and transgene expression continued for 
extended periods in vitro, the infected cultures were sustained in this mitogenic state. 
Supplementation with glial conditioned media would be interesting, but was not 
carried out in the study.
Glial released factors may facilitate the TH induction by Nurrl
The molecular character of a potentially inductive glial derived factor(s) still remains 
unidentified. While a crucial role of these factors for the induction of a dopaminergic 
phenotype is undisputable, selective (survival) and/or instructive (differentiation) 
functions have been suggested: (i) BrdU/TH double labelling favored the idea of de 
novo generated dopaminergic neurons induced by the presence of CM in forebrain 
progenitor cultures (Daadi and Weiss, 1999) and Nurrl-expressing neural stem cell 
lines (Wagner et al., 1999). Testing different mitogens and morphogens the inductive 
effects of CM could not be mimicked in the mentioned studies, (ii) Survival effects on 
midbrain dopaminergic neurons were facilitated by CM from forebrain and midbrain 
glial cultures (Engele and Bohn, 1991; Engele, 1998b), independent from the 
embryonic stage from which the CM was generated (Pei et al., 2003), and were also 
achieved by co-cultures of mesencephalic cultures with striatal 0-2A progenitor cells 
(Takeshima et al., 1994a) or type-1 astrocytes (Takeshima et al., 1994b).
Factors released from glial cells may also explain the observed different inductive 
effects on TH expression of Nurrl delivering vectors. Infection of forebrain and 
midbrain progenitor cells that have proven to lack a significant number of astrocytes 
did not induce TH, while neurosphere cultures from the same neurogenic regions 
demonstrated ectopic TH expression after delivery of Nurrl. These finding are in 
agreement with other reports demonstrating that Nurrl failed to induce TH expression 
in cortical progenitor cells that had been differentiated for four days prior to 
transfection (Kim et al., 2003a). However, the authors argue that this is due to the
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post-mitotic state of the cultures and that DA-inducing effect of Nurrl requires 
precursor proliferation.
With respect to work presented here, it was found that CNS progenitors 
were mitotic active at least within the first three days, and BrdU labelling revealed 
that about 10% (mesencephalic) to 30% (cortical) of the progenitor cells were 
proliferating despite the lack of exogenous growth factors. In a preliminary 
experiment, inhibition of cell division by addition of Ara-C did not abolish the Nurrl 
mediated inductive effects in cortical and striatal neurosphere cultures. Therefore, it 
does not appear that the lack of proliferative conditions is the main reason for the 
failure of TH induction but that factors not present in progenitor cultures but released 
in neurosphere cultures explain this discrepancy. Interestingly, most of the TH 
expressing cells did not co-label with the neuronal marker TuJl. Other groups have 
proposed that Nurrl solely enhances the expression of TH without accompanying 
neural differentiation (Sakurada et al., 1999) by direct activation of the TH gene 
promoter (Iwawaki et al., 2000). Kim et al (2003) also found that only a minority of 
Nurrl-induced TH positive cells acquire neuronal characteristics (12% co-label with 
MAP2 and 23% with TuJl). Longer or enforced differentiation did not affect the 
number of TH positive cells expressing neuronal markers. However, co-localization 
with GFAP was also not detected (Kim et al., 2003a). It is also intriguing that the cell 
morphology of TH expressing cortical and striatal progenitor cells is very distinctive 
as compared to that observed in primary derived mesencephalic dopaminergic 
neurons. Nurrl-induced TH expressing cells appeared to have less and shorter 
processes with spinal shaped cell bodies. Overall it appears that the TH expressing 
cells did not have the characteristics of bona fide dopaminergic neurons or may 
alternatively be immature dopaminergic neurons as proposed by others (Kim et al., 
2003a). In fact, some of the Nurrl-transduced TH positive cells were demonstrated to 
incorporate BrdU and to be nestin positive suggesting precursor status.
Virally delivered ShhN is not sufficient to induce dopaminergic phenotypes
The inductive role of Shh on the development of midbrain dopaminergic neurons in 
vivo (Wang et al., 1995; Hynes et al., 1995a) is undisputable and has prompted many 
scientists to examine potential implication on TH expression in neural progenitor and
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neural stem cells in vitro. In primary mesencephalic cultures Shh has been suggested 
to be neurotrophic for the survival of dopaminergic neurons as high concentrations of 
the protein increased the number of TH expressing cells, confirmed by protective 
effects in MPP+ cytotoxicity studies and blocking experiments with Shh antibodies 
(Miao et al., 1997). BrdU incorporation assays did not support the idea that Shh 
induces a dopaminergic phenotype in mesencephalic progenitor cells (Miao et al., 
1997), as it has also been shown for forebrain (Daadi and Weiss, 1999; Stull and 
Iacovitti, 2001) and hippocampal (Sakurada et al., 1999) progenitor cells.
In this chapter it has been shown that virally delivered ShhN did not 
induce TH expression in cortical or striatal progenitor cells. However, neither did it 
exert neurotrophic effects on the survival of midbrain dopaminergic progenitors. 
Although expression and bioactivity of virally delivered ShhN have been validated, 
this result is not in agreement with other studies (Miao et al., 1997) and may be 
explained by insufficient expression levels as discussed. With respect to findings 
presented in the previous chapter showing an increase in TH expression when ShhN is 
added during expansion phase of E12 mesencephalic precursor cells, the proliferative 
state and the presence of other (glial released) factors may determine the observed 
effect. It has also been stated by others that “Shh may play an important role in the 
early patterning of proliferative precursors but may have an inhibitory effect on TH 
expression when expressed during the terminal stages of differentiation” (Sakurada et 
al., 1999) and that “Shh exerts its effects in vitro on the still dividing b-FGF 
stimulated neural precursors” (Volpicelli et al., 2004). Synergistic effects of ShhN and 
FGF8b on TH induction have been reported in vivo (Ye et al., 1998) and also for an 
immortalised mouse neural stem cell line (Kim et al., 2003c), but were not able to 
induce dopaminergic phenotypes in mouse striatal progenitor cells and human neural 
stem cell lines (Stull and Iacovitti, 2001). However, the situation is very different in 
embryonic stem cells as compelling evidence has proven inductive effects mediated 
by these factors to generate functional dopaminergic neurons (Lee et al., 2000; Kim et 
al., 2002; Lin and Rosenthal, 2003).
Overall, this chapter has demonstrated that the cell system used allows determination 
of the inductive effects of selective factors, such as FGF2, FGF8, ShhN or Nurrl. 
Neural precursor cells generated from the same neurogenic region and embryonic age
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showed very distinctive susceptibilities to such signals when maintained as primary 
neuronal and progenitor cultures compared to neurosphere cultures. This may result 
from the proliferative and differentiative state of the precursor cells, as well as from 
the release of factors conditioned by glial cells present or absent in the respective in 
vitro cell model.
Virally delivered FGF2 appeared to increase cell proliferation in vivo but neither 
FGF2 nor ShhN improved rotational impairment
The idea of stimulating endogenous stem cells of the SVZ to proliferate and 
differentiate in situ into neuronal cell types, thereby replacing lost or damaged 
dopaminergic neurons, is possibly the most challenging experimental approach to 
Parkinson’s disease therapy. On the other hand, limited scientific experience in 
studying functional replacement by using endogenous stem cells make experiments 
highly speculative and novel. A limited number of reports have described possible 
approaches to study endogenous neurogenesis in the substantia nigra. Fallon et al 
demonstrated that intrastriatal administration of TGFa; which activates the EGF 
receptor (EGFR) (Tropepe et al., 1997), induced a massive cell proliferation 
originating from the SVZ and leading to the mitogen source in 6-OHDA lesioned 
animals (Fallon et al., 2000). Signalling via EGF-R induces rapid proliferation of 
transit-amplifying C cells (Doetsch et al., 2002) and therefore the observed cell 
proliferation is likely to be attributable to increased amplification of type C cells. 
Adding to previous work on in vivo proliferative effects of TGFa (Craig et al., 1996; 
Tropepe et al., 1997), Fallon et al. showed that combination of an acute insult (6- 
OHDA lesion) and growth factor administration can guide precursor cells to the site 
of injury, and most notably is accompanied by the appearance of TH positive cells in 
the striatum and improvement of behaviour impairment. However, Fallon et al. did 
not quantify the number of generated TH positive neurons appearing in this ectopic 
position (striatum), and behavioural improvement is most likely not due to 
reconstitution of the nigrostriatal pathway. Zhao et al suggested the evidence of 
dopamine neurogenesis in the substantia nigra as a rare event that can be increased 
after injury based on confocal analysis of TH/BrdU double labelled cells (Zhao et al.,
2003). Using Dil-labelling Zhao et al proposed that the cells giving rise to
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dopaminergic neurons in the substantia nigra originate from the ventricular system in 
the midbrain and upon differentiation by unknown endogenous inducers, integrate 
into the basal ganglia circuitry. However, using a similar experimental approach as 
Zhao et al. the generation of new dopaminergic neurons in the adult substantia nigra 
was not evident in other studies (Frielingsdorf et al., 2004).
In work performed prior to publication of these reports the potential effects of virally 
delivered ShhN and FGF2 on behavioural recovery in a rat model of Parkinson’s 
disease was examined. To avoid neuroprotective effects of ShhN (Miao et al., 1997) 
transgene expressing vectors (FGF2 and ShhN) were injected after depletion of the 
nigrostriatal pathway with 6-OHDA. Further, gene delivery was performed six weeks 
after the toxic insult when apomorphine induced rotational behaviour was stable and 
depletion had become fully established. Medial forebrain bundle lesions with 6- 
OHDA resulted in an almost entire denervation compared to partial striatal lesions 
(Deumens et al., 2002). With respect to this complete unilateral destruction of the 
dopamine pathway no recovery effects were observed resulting from virally delivered 
ShhN and FGF2. The insult might have been too severe to generate enough dopamine 
releasing cells in order to achieve recovery. However, viral delivery of GDNF into 6- 
OHDA lesioned animals did show significant (p<0.05; n=6 animals two weeks after 
virus injection) improvement in rotational behaviour.
Interestingly, an increased number of BrdU positive cells was found in the striatum 
and substantia nigra of FGF2 injected animals. Although a ridge of migrating cells 
was not observed as Fallon et al described by injecting TGFa, the anterior SVZ 
appeared thickened and contained more BrdU positive cells than contralateral to the 
injection site or in LacZ injected animals. Therefore the proliferated cells may have 
been derived from stem cells lining the ventricular system giving rise to possibly 
rapidly dividing type C cells migrating to other regions of the forebrain and midbrain. 
However, it has proven difficult to identify the antigenic identiy of the generated 
cells. Although an increased number of nestin positive cells was detected in the 
striatum and the substantia nigra, antibodies used at that time of the study did not 
allow convincing co-labelling with BrdU immunohistochemistry. The high number of 
BrdU labelled cells found in the substantia nigra after FGF2 delivery was surprising.
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The cells may have originated from stem cells lining the ventricle system dorsal of the 
substantia nigra (Zhao et al., 2003) or residing within the substantia nigra (Lie et al., 
2002). Co-labelling of BrdU and TH did not reveal any evidence of de novo generated 
dopaminergic neurons in this study which is in agreement with a recent report 
(Frielingsdorf et al., 2004). Interestingly, Lie et al. demonstrated that progenitor cells 
residing in the substantia nigra can give rise to all neural cell types when isolated and 
propagated in vitro but do not generate neurons in vivo (Lie et al., 2002). 
Controversially, Zhao et al. propose unknown endogenous signals inducing 
differentiation of precursors into TH expressing neurons while Lie et al. discussing 
repressive signals in the substantia nigra inhibiting neurogenesis in this region. 
Species differences (Zhao et al. were using mice while Lie at al. were using rats) have 
been suggested to explain this dilemma (Zhao et al., 2003) and could also be 
considered for the missing differentiation of proliferated cells in this rat study.
Overall, the experiments have shown that although cell proliferation in the substantia 
nigra can be induced by virally delivered FGF2, virally delivered ShhN alone or in 
combination with FGF2 appear insufficient to recover dopamine function in the 
animal model used. Considering recent findings that Shh does have an impact in the 
adult SVZ (Charytoniuk et al., 2002; Machold et al., 2003), and that neurogenesis 
might be possible in the denervated striatum and substantia nigra (Fallon et al., 2000; 
Zhao et al., 2003), it might be wise to combine Shh with other factors, such as Nurrl 
or FGF8. From an experimental perspective it could be beneficial to enhance 
precursor proliferation prior to delivery of differentiative signals. As we are at the 
very beginning of the understanding of the mechanisms of endogenous stem cell 
behaviour, future findings will hopefully reveal the factors inducing or repressing 
neurogenesis in the adult substantia nigra.
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F i n a l  C o n c l u s i o n
The adult mammalian brain cannot regenerate. This is an old dogma that needs 
correcting in light of recent findings that neurogenesis is not restricted to the 
developing nervous system, but also occurs in the adult brain. The expansion and 
controlled conversion of neural stem cells into dopaminergic neurons has potential 
use for in vivo and ex vivo approaches in the treatment of Parkinson’s disease. 
However, methods by which precursor cells might be differentiated into a 
dopaminergic phenotype are unknown. An understanding of the natural differentiation 
stimuli may help to develop systems for the controlled generation of dopaminergic 
neurons in high yields. With progress in the development of replication deficient 
viruses, vector systems have become available to deliver the genetic information 
required for the possible induction of a dopaminergic phenotype. For this purpose 
various viral vector systems have been used, but no reports have previously 
thoroughly studied the use of HSV-1. However, HSV-1 has advantages compared to 
other viral vectors as a potential gene delivery system for neural precursor cells as the 
lack of chromosomal integration avoids the possible disruption of the host genes and 
the establishment of a latency-like state upon infection allows long-term transgene 
expression without clearance of virally infected cells by the host immune system.
The work presented in this thesis aimed to investigate the potential use of HSV-1 
based vectors for the delivery of transgenes to neural precursor cells of the CNS. 
Replication disabled HSV-1 vectors were used to deliver genes encoding factors that 
play important roles in the development of dopaminergic neurons. Their role for the 
induction of a dopaminergic phenotype from neural precursor cells was studied.
Chapter 3 demonstrated that disabled HSV-1 vectors can be used to deliver genes of 
interest to neural precursor cells. However, efficiency of gene delivery depended on 
the disablement of the vector and the cell system used. Highly disabled vectors 
resulted in insufficient transgene expression in primary neuronal and neural 
progenitor cultures, but efficient reporter gene expression in neural precursor cells 
expanded as neurosphere cultures. The integrity of the neural precursor cells, e.g. 
multipotency and self-renewal capacity, were not affected by viral transduction. Less 
disabled vectors expressing ICP27 and ICP34.5 gave stronger reporter gene 
expression in primary neural and neurosphere cultures, but on the expense of an
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increased neuronal cell loss in these models most likely due to expression of toxic 
viral gene products. Finally it was shown that replication-deficient HSV-1 also 
delivered transgenes to cells within the stem cell niche in vivo. Thus, future 
applications to alter the behaviour of these cells in situ may become possible.
Chapter 4 revealed that FGF8 is sufficient as mitogen for the expansion of neural 
precursor cells in vitro. Most notably FGF8 increased the number of dopamine 
neuroblasts and/or existing primary dopaminergic neurons. This was, however, most 
likely not due to inductive or proliferative effects, but due to enhanced survival. 
Interestingly, results from this and the following chapter indicated that FGF8 
expanded or infected neurospheres tended to generate an increased number of 
oligodendrocytes. Although this phenomenon has not further been investigated, it 
would be interesting to consider in future studies.
In chapter 5 replication-deficient HSV-1 vectors were constructed expressing factors 
known to be involved in dopamine neurogenesis from embryonic precursor cells 
during development in vivo and from embryonic stem cells in vitro. Summarising the 
results of this and the previous chapter regarding dopamine neurogenesis, it was 
found that none of the factors induced the de novo generation of dopaminergic 
neurons from neural precursor cells. Although FGF8 had survival effects on dopamine 
neurons and neuroblasts, and Nurrl induced ectopic TH expression in precursor cells, 
the tested factors were not sufficient to generate new neurons with a midbrain 
dopaminergic phenotype. Interestingly, the inductive effects of Nurrl on TH 
expression appeared to require the presence of glial cells or molecules released from 
these cells. Obviously, therefore, other factors are required to act synergistically with 
Nurrl or the morphogens Shh and FGF8 on the conversion of a multipotent precursor 
cell into a dopaminergic neuron., but these remain to be identified.
A general limitiation encountered with the use of mesencephalic derived neurospheres 
is the low number of neurons generated from this region compared to striatal or 
cortical precursor cells. As shown in this study as well as by others (Ostenfeld et al., 
2002a), continuously expanded mesencephalic neurospheres mainly produce glial cell 
types upon differentiation. The lack of pro-neuronal signals may partly be responsible
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for the limited generation of dopaminergic neurons from this region. Future 
approaches could involve the delivery of pro-neuronal genes, such as neurogenin (Ma 
et al., 1996; Sun et al., 2001), to direct the fate of mesencephalic precursor cells into a 
neuronal phenotype prior to differentiation into dopamine neurons. However, since 
this approach would require a stable expression of the transcription factor over 
multiple passages of the precursor cells, integrative viral vectors may be more suitable 
than HSV-1.
The results generated lead to a fundamental concern. How similar is neurogenesis 
occuring in embryos to that occurring in in vitro cell models or in the adult CNS? 
Precursor cells maintained in culture, and the cell source of new neurons in the adult 
CNS, are unlikely to be direct counterparts of the neuroepithelial cells that generate 
dopaminergic neurons in the embryo. However, cell types retained in the 
neuroepithelium of the adult nervous system have similarities to embryonic 
neuroepethelial cells from which they are derived (reviewed in Alvarez-Buylla et al., 
2001). It is even more intriguing that morphogens, such as Shh, Noggin, and BMPs, 
that are so critical to neurogenesis in the embryo, also appear to play a role in the 
adult neurogenic stem cell niches (reviewed in Alvarez-Buylla and Lim, 2004). It will 
be the challenge of future work to unveil the mechanisms to activate this cascade of 
morphogenic factors that may be involved in the de novo generation of neurons in the 
adult CNS.
The results presented in this thesis have identified disabled HSV-1 capable of gene 
delivery to neural precursor cells in vitro and in vivo. Various factors were tested for 
their potential to convert neural precursor cells into a dopaminergic phenotype, but 
only virally delivered Nurrl induced the expression of the dopaminergic marker 
tyrosine hydroxylase. Future experiments may reveal if other factors are sufficient for 
the de novo generation of dopaminergic neurons from foetal neural precursor cells.
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A .l Sequence of basic fibroblast growth factor (FGF2)
Sequence file name:
Plasmid:
Squencing primer:
According Genebank accession number:
A031000 C05H 2SP6 03 5 .ab 1.1
pGemTbFGF
SP6
M22427
TTTTNAGNGACCCATCCAACGCGTTGGGAGCTCTCCCATATGGTCGACCTG
CAGGCGGCCGCGAATTCACTAGTGATTCGTAAAGCTTGATTCCATGGCTG
CCGGCAGCATCACTTCGCTTCCCGCACTGCCGGAGGACGGCGGCGGCGCC
TTCCCACCCGGCCACTTCAAGGATCCCAAGCGGCTCTACTGCAAGAACGG
CGGCTTCTTCCTGCGCATCCATCCAGACGGCCGCGTGGACGGCGTCCGGG
AGAAGAGCGACCCACACGTCAAACTACAGCTCCAAGCAGAAGAGAGAGG
AGTTGTGTCCATCAAGGGAGTGTGTGCGAACCGGTACCTGGCTATGAAGG
AAGATGGACGGCTGCTGGCTTCTAAGTGTGTTACAGAAGAGTGTTTCTTCT
TTGAACGCCTGGAGTCCAATAACTACAACACTTACCGGTCACGGAAATAC
TCCAGTTGGTATGTGGCACTGAAACGAACTGGGCAGTATAAACTCGGATC
CAAAACGGGGCCTGGACAGAAGGCCATACTGTTTCTTCCAATGTCTGCTA
AGAGCTGACTCTCTTTAGACACTGTCACTCTCAGGGAATCTCGAGTACGA
ATCGAATTCCCGCGGCCGCCATGGCGGCCGGGAGCATGCGACGTCGGGCC
C AATTCGCCCTAT AGT G AGTCGT ATT AC AATTN ACTGGCCGTNGTTTT AC A
ACGTCNGTGACTGGGAAAACCCCTGGCGTTCCCAACTTAAATCNNCTTGC
ANCACATNCCCCTTTCGCCAGNTGGCGT
Appendix 1: Sequence o f rat basic fribroblast growth factor (bFGF or FGF2) for SP6 primers. In 
red idicating the start codon, in blue the stop codon. Underlined is part o f the prim er sequence 
used for the PCR reaction. The sequence was also confirmed using reverse sequence with T7 
primers but the result was not illustrated here.
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A.2 Sequence of rat aminoterminal sonic hedgehog (ShhN)
Sequence file name: 
Plasmid:
Squencing primer:
B 170300 G 0 6 B H 6 S P 6 0 5 1 .abl
pGemTShhN
SP6
According Genebank accession number: L27340 and NM 017221
NNNTNGGGAACNCNCCCCCCGCTNTTGGGGGGGAACNCCNCCNNCCGNC
CNGCAGGCGGCCGCGAATNCTTTTGTGGGGCGGGGNAANCCCATTCCGCA
CCAGCTCGCGCACAGACCGGCGCGGGGACGGCTCGCAAGTCCTCAGGTTC
CGCGGACGAGATGCTGCTGCTGCTGGCCAGATGTTTTCTGGTGGCCCTTGC
TTCCTCGCTGCTGGTGTGCCCCGGACTGGCCTGTGGGCCCGGCAGGGGGTT
TGGAAAGAGGCGGCACCCCAAAAAGCTGACCCCTTTAGCCGTAAAGCAGT
TT ATCCCC AACGT AGCCG AG AAGACCCT AGGGGCC AGCGGCCGAT AT GAA
GGGAAGATCACAAGAAACTCCGAACGATTTAAGGAACTCACCCCCAATTA
C AACCCCG AC ATC AT ATTT AAGG AT G AGG AAAAC ACTGG AGC AG ACCGGC
TGATGACTCAGAGGTGCAAAGACAAGTTAAATGCCTTGGCCATCTCCGTG
ATGAACCAGTGGCCTGGAGTGAAGCTTCGAGTGACTGAGGGCTGGGATGA
GGACGCCATCATTCAGAGGAGTCTCTACACTATGAGGGTCGAGCAGTGGA
CATCACCACGTCTGACAGGGACCGCAGCAAGTATGGCATGCTGGCTCGCC
TGGCTGTGGAGGCTGGCTTCGACTGGGTCTACTATGAATCCAAAGCTCAC
ATCCACTGCTCTGTGAAAGCAGAGAACTCCGTGGCGGCCAAATCTGACGG
CTGAAAAAAAAANAAAANA
Appendix 2: Sequence of rat aminoterminal sonic hedgehog (ShhN) for SP6 primers. In red 
idicating the start codon, in blue the stop codon. Turquoise codons indicate silent m utations and 
the green codon a polymorphism for rat ShhN in agreement with the sequence published in the 
Genebank accession number NM _017221. Underlined is part o f the prim er sequence used for the 
PCR reaction. The sequence was also confirmed using reverse sequence with T7 primers but the 
result was not illustrated here.
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A.3 Sequence of rat Nurrl
Sequence file names:
Plasmid:
Squencing primer:
According Genebank accession number:
A 16 0 5 0 0 G 10B H 7P7 083 .ab 1.1 
A090600_E05_BH5P5_038.abl. 1 
A130400_E02_BH1 l_018.abl 
B170300_B06_BHlT7_048.abl 
pGemTNurrl
T7, SP6, gene specific as described in
2 .2.11
U72345
CTCTNTTNGGGAACTTCGCCCCCCGCTTTTGGGGGGCAACNCCGGCCNCG
GGAATNNGNNTNAGCTTTCGGCTGTTNCCATGCCTTGTGTTCAGGCGCAGT
ATGGGTCCTCGCCTCAAGGAGCCAGCCCCGCTTCTCAGAGCTACAGTTAC
CACTCTTCGGGAGAATACAGCTCCGATTTCTTAACTCCAGAGTTTGTCAAG
TTTAGCATGGACCTCACCAACACTGAAATTACTGCCACCACTTCTCTCCCC
AGCTTCAGTACCTTTATGGACAACTACAGCACAGGCTACGACGTCAAGCC
ACCTTGCTTGTACCAAATGCCCCTGTCCGGACAGCAGTCCTCCATTAAGGT
AGAAGACATTCAGATGCACAACTACCAGCAACACAGCCACCTGCCCCCTC
AGTCCGAGGAGATGATGCCACACAGCGGGTCGGTTTACTACAAGCCCTCT
TCGCCCCCGACACCCAGCACCCCGGGCTTCCAGGTGCAGCATAGCCCGAT
GTGGGACGATCCGGGCTCCCTTCACAACTTCCACCAGAACTACGTGGCCA
CTACGCATATGATCGAGCAGAGGAAGACACCTGTCTCCCGCCTTTCACTCT
TCTCCTTTAAGCAGTCGCCCCCGGGCACTCCTGTGTCTAGCTGCCAGATGC
GCTTTGACGGGCCTCTGCACGTCCCCATGAACCCGGAGCCCGCGGGCAGC
CACCACGTAGTGGATGGGCAGACCTTCGCCGTGCCCAATCCCATTCGCAA
GCCGGCATCCATGGGCTTCCCGGGCCTGCAGATCGGCCACGCGTCGCAGT
TGCTTGACACGCAGGTGCCCTCGCCGCCGTCCCGGGGCTCTCCCTCCAATG
AGGGTCTGTGCGCTGTTTGCGGTGACAACGCGGCCTGTCAGCATTACGGT
GTTCGCACTTGTGAGGGCTGCAAAGGTTTCTTTAAGCGCACGGTGCAAAA
AAACGCGAAATATGTGTGTTTAGCAAATAAAAATTGCCCAGTGGATAAGC
GCCGCCGAAATCGTTGTCAGTACTGTCGGTTTCAGAAGTGCCTGGCTGTTG
GGATGGTTAAAGAAGTGGTTCGCACGGACAGTTTAAAAGGCCGGAGAGG
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TCGTCTACCCTCAAAACCGAAGAGCCCACAGGATCCCTCTCCCCCCTCACC
TCCGGTGAGTCTGATCAGTGCCCTCGTCAGAGCCCACGTCGACTCCAATCC
GGCAATGACCAGCCTGGACTATTCCAGGTTCCAGGCAAACCCTGACTATC
AGATGAGTGGAGATGATACTCAACATATCCAGCAGTTCTACGATCTCCTG
ACTGGCTCTATGGAGATCATCAGAGGGTGGGCAGAGAAGATTCCTGGCTT
TGCTGACCTGCCCAAAGCCGATCAGGACCTGCTTTTTGAATCAGCTTTCTT
AGAATTATTTGTTCTACGCTTAGCATACAGGTCCAACCCAGTGGAGGGTA
AACTCATCTTTTGCAATGGGGTGGTCCTGCACAGGTTGCAATGCGTGCGTG
GCTTTGGGGAATGGATTGATTCCATTGTTGAATTCTCCTCCAACTTGCAGA
ATATGAACATCGACATTTCTGCCTTCTCCTGCATTGCTGCCCTGGCTATGG
TCACAGAGAGACACGGGCTCAAGGAACCCAAGAGAGTGGAAGAGCTACA
AAACAAAATTGTAAATTGTCTTAAAGACCATGTGACTTTCAATAATGGGG
GATTGAACCGACCCAACTACCTGTCCAAACTGTTGGGGAAGCTCCCAGAA
CTTCGCACCCTTTGCACACAGGGGCTCCAGCGCATTTTCTACCTGAAATTG
GAAGACTTGGTACCACCACCAGCAATAATTGACAAACTTTTCCTGGACAC
CTTACCTTTCTAAGACTTTCTCCCATGCACGTCTCGAGTACGAATCACTAG
TGAATTCGCGGCCGCCTGCAGGTCGAC
Appendix 3: Sequence of rat N urrl. In red idicating the start codon, in blue the stop codon. 
Turquoise codon indicates silent m utation. Underlined is part o f the prim er sequence used for the 
PCR reaction. The sequence was also confirm ed using reverse sequence primers but the result 
was not illustrated here.
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